CHIMERIC ANTIGEN RECEPTORS TARGETING CANCER

FIELD OF INVENTION

Provided herein are chimeric antigen receptors for treating cancers.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING

Accompanying this filing is a Sequence Listing entitled “00130-015US2.xml”, having 6,742,076 bytes of data, machine formatted on IBM-PC, MS-Windows operating system. The sequence listing was created on Nov. 30, 2023. The sequence listing is hereby incorporated herein by reference in its entirety for all purposes.

BACKGROUND

All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.

Adoptive T-cell immunotherapy has risen to the forefront of treatment approaches for cancer. T cells can be engineered to express the genes of chimeric antigen receptors (CARs) that recognize tumor associated antigens. CARs are synthetic immune-receptors, which can redirect T cells to selectively kill tumor cells. The general premise for their use in cancer immunotherapy is to rapidly generate tumor-targeted T cells, bypassing the barriers and incremental kinetics of active immunization and thereby act as ‘living drugs’. Unlike the physiologic T-cell receptor (TCR), which engages HLA-peptide complexes, CARs engage molecules that do not require peptide processing or HLA expression to be recognized. CARs therefore recognize antigen on any HLA background, in contrast to TCRs, which need to be matched to the haplotype of the patient. Furthermore, CARs can target tumor cells that have down-regulated HLA expression or proteasomal antigen processing, two mechanisms that contribute to tumor escape from TCR-mediated immunity. Another feature of the broad applicability of CARs is their ability to bind not only to proteins but also to carbohydrate and glycolipid structures, again expanding the range of potential targets.

Initial first-generation CARs were constructed through the fusion of a scFv (single chain fragment variable)-based antigen binding domain to an inert CD8 transmembrane domain, linked to a cytoplasmic signaling domain derived from the CD3-ξ or Fc receptor γ chains (FIG. 1).

Although CD3-ξ chain aggregation is sufficient to enable lytic activity of T-cells, they failed to elicit a robust cytokine response, including interleukin-2 (IL-2), and support T-cell expansion upon repeated exposure to antigen. For optimal activation and proliferation, T cells require both T-cell receptor engagement and signaling, as well as costimulatory signaling through costimulatory receptors (i.e., CD28, 4-1BB, OX-40) on T cells binding to cognate ligands (i.e., CD80/86, 4-1BBL, OX-40L) expressed either by the targeted tumor cell or the antigen-presenting cells. To overcome the lack of T-cell co-stimulation, first generation CARs were further modified by incorporating the cytoplasmic signaling domains of T-cell costimulatory receptors. These second-generation CARs (FIG. 1) enhanced signaling strength and persistence of the modified T cells, leading to superior antitumor activity. But, which second-generation CAR is the best is not known and each one has their own strengths and weakness. For example, in clinics the 4-1BB design appears to favor persistence, with CD19-CAR T cells detectable out to at least 6 months in a majority of patients, whereas the CD28 costimulatory domain containing CD19 CAR T cells were typically undetectable beyond 3 months, but less severe cytokine release syndrome (CRS) and a lower CD19-negative relapse rate were observed using the CD28-based CAR T cells.

Despite the success with CAR-T cells, there are several limitation to this approach. In majority of patients who respond to engineered CAR T cells, excessive release of proinflammatory cytokines causes symptoms that include fevers, hypotension, hypoxemia, cardiac dysfunction, kidney failure and electrolyte abnormalities, collectively termed as “Cytokine release syndrome” (CRS). In some cases, CAR therapy can lead to neurologic symptoms including tremor, seizures and can be fatal. Strategies to counteract CRS and neurological complications include immunosuppressive agents (e.g., steroids) and Tocilizumab, a monoclonal antibody against IL-6 receptor. However, these strategies are not uniformly successful. The instant invention provides novel approaches to control the activity of CAR-T cells so as to prevent and/or treat the above complications.

The CAR constructs in current clinical use are artificial in design as they represent fusion of several different proteins. In particular, inclusion of costimulatory domain in the CAR construct results in non-physiological signaling through the receptor, which in turn could contribute to their toxicity. Some CARs show tonic antigen-independent signaling, which leads to unrestrained cellular activation, eventually resulting in apoptosis, excessive cytokine release independent of cognate antigens, and immunologic exhaustion. Frigault et al demonstrated that expression of some CARs containing CD28 and CD3z tandem signaling domains leads to constitutive activation and proliferation of the transduced primary human T cells which was related to inferior in vivo efficacy (Frigault et al., Cancer immunology research 3:356-67, 2015). One mechanism that was found to result in the phenotype of CARs with continuous T-cell proliferation was high density of CARs at the cell surface (Frigault et al., Cancer immunology research 3:356-67, 2015). Long et al demonstrated that early T cell exhaustion is a primary factor limiting the antitumor efficacy of CAR-expressing T cells and that CAR structure has a central role in predisposing CAR T cells to chronic activation and exhaustion (Long et al., Nat Med 21:581-90, 2015). They showed that tonic CAR CD3-z phosphorylation, triggered by antigen-independent clustering of CAR single-chain variable fragments, can induce early exhaustion of CAR T cells that limits antitumor efficacy (Long et al., Nat Med 21:581-90, 2015). Thus, there is a need for improving the CAR design to achieve long term persistence of CAR modified T cells without the risk of excessive toxicity, such as CRS.

Most CAR constructs in current clinical trials are based on murine monoclonal antibodies. Immunogenicity of these murine monoclonal antibodies based construct has been also postulated to limit their in vivo persistence and efficacy. This problem can be overcome with the use of CAR constructs described herein that are based on human or humanized antibodies.

The polyclonal nature of the immune response is key to its success in controlling various infections. In contrast, the current CAR therapies generally rely on targeting of a single antigen and/or single epitope of a single antigen. Loss of the targeted antigen or the targeted epitope is a frequent cause of failure of the current CAR therapies. To overcome this limitation, the instant invention provides CAR against multiple antigens and against multiple epitopes of a single antigen. These CARs can be used in suitable combinations to provide a polyclonal adaptive immune response for the prevention or treatment of diseases, such as cancer, infectious diseases, autoimmune diseases, allergic diseases and degenerative diseases.

CD19 is an attractive target for immunotherapy because it is uniformly expressed by the vast majority of B-cell malignancies, it is not expressed by normal non-hematopoietic tissues, and among hematopoietic cells, it is only expressed by B-lineage lymphoid cells. Early experiments demonstrated that anti-CD19 CARs could activate T cells in a CD19-specific manner. T cells genetically modified to express these CARs could kill CD19⁺ primary leukemia cells in vitro and eliminate CD19⁺ target cells in murine xenograft models. Even though, initial clinical results with first-generation CD19-targeted CAR-modified T cells were disappointing, T cells engineered to express second-generation CARs have demonstrated impressive clinical efficacy with significant improvements in patient outcomes for a number of B-cell malignancies, the notable being the dramatic clinical responses observed in patients with relapsed B-cell ALL.

Anti-CD19 CART therapy as proof-of-concept has been successful in part due to the tissue restriction of CD19 to B cells and by the clinical tolerability of prolonged B-cell depletion. However, in other settings, CART-based targeting of antigens expressed at low levels by normal tissues has led to significant toxicities. The paucity of well-characterized, truly tumor-specific surface antigens in myeloid malignancies, such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndrome MDS, has necessitated consideration of CAR-T tumor-targeting strategies that may also affect normal tissues, such as bone marrow.

SUMMARY

The following embodiments and aspects thereof are described and illustrated in conjunction with systems, compositions and methods which are meant to be exemplary and illustrative, not limiting in scope.

In certain embodiments, the present invention provides compositions comprising genetically engineered effector cells (such as NK cells and T cells) that include polynucleotides that encode chimeric antigen receptors that can be used on adoptive cell therapy for treatment of cancer, infectious, autoimmune and degenerative diseases.

In some embodiments, provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising an antigen specific domain (ASD), an extracellular hinge or spacer region (HR), a transmembrane domain (TMD), a costimulatory domain (CSD) and intracellular signaling domain (ISD), wherein the antigen binding domain targets any one or more of the targets set forth in Table 21. In one embodiment, the CAR targets CD19 and comprises the V_Land V_Hof Bu12 described in Table 21 and set forth in SEQ ID NO: 1470 and SEQ ID NO: 3215. In one embodiment, the CAR targets CD19 and comprises the V_Land V_Hof MM described in Table 21 and set forth in SEQ ID NO: 1471 and SEQ ID NO: 3216.

In some embodiments, provided herein are polynucleotides encoding any of conventional CARs (Table 1) and backbones 1-62 (Table 2), wherein each backbone comprises a conventional CAR component (Table 1) and one or more accessory modules as shown in Table 2. In some embodiments, the conventional CAR component and the one or more accessory components of each backbone are encoded by a single polynucleotide molecule. In some embodiments, the conventional CAR component is encoded by a first polynucleotide molecule and the one or more accessory modules are encoded by a second polynucleotide molecule. In some embodiments, backbones comprising a conventional CAR component and more than one accessory module, the first polynucleotide molecule encodes the conventional CAR component, a second polynucleotide molecule encodes the first accessory molecule and a third polynucleotide molecule encodes the second accessory molecule. For example, backbone 1 comprising conventional CAR I and K13-vFLIP may be encoded by a single polynucleotide molecule or by two polynucleotide molecules, wherein the first polynucleotide molecule encodes the conventional CAR I and the second polynucleotide molecule encodes K13-vFLIP. In various embodiments, the polynucleotide molecules encoding the CAR component of the conventional CARs I to III (Table 1) or the backbones (Table 2) described herein encodes one or more antigen specific domains. In some embodiments, the antigen specific domain comprises one or more V_L(or vL) fragments. In some embodiments, the antigen specific domain comprises one or more V_H(or vH) fragments. In some embodiments, the antigen specific domain comprises one or more scFVs (or scFvs) specific to the antigens on target cells such as cancer cells. In some embodiments, the antigen specific domain comprises one or more Fv fragments. In some embodiments, the antigen specific domain comprises one or more Fab fragments. In some embodiments, the antigen specific domain comprises one or more (Fab′)2 fragments. In some embodiments, the antigen specific domain comprises one or more single domain antibodies (SDAB). In some embodiments, the antigen specific domain comprises one or more camelid V_HH(or vHH) domains. In some embodiments, the antigen specific domain comprises one or more non-immunoglobulin scaffold such as a DARPIN, an affibody, an affilin, an adnectin, an affitin, an obodies, a repebody, a fynomer, an alphabody, an avimer, an atrimer, a centyrin, a pronectin, an anticalin, a kunitz domain, an Armadillo repeat protein, an autoantigen, a receptor or a ligand. In some embodiments, the antigen specific domain comprises one or more ligands.

Also provided herein are polypeptides encoded by the polynucleotides described herein. In various embodiments, polypeptides encoded by the polynucleotide molecule encoding the CAR component of the conventional CARs I to III (Table 1) or the backbones (Table 2) described herein encodes one or more antigen specific domains. In some embodiments, the antigen specific domain comprises one or more V_L(or vL) fragments. In some embodiments, the antigen specific domain comprises one or more VH (or vH) fragments. In some embodiments, the antigen specific domain comprises one or more scFVs specific to the antigens on target cells such as cancer cells. In some embodiments, the antigen specific domain comprises one or more Fv fragments. In some embodiments, the antigen specific domain comprises one or more Fab fragments. In some embodiments, the antigen specific domain comprises one or more (Fab′)2 fragments. In some embodiments, the antigen specific domain comprises one or more single domain antibodies (SDAB). In some embodiments, the antigen specific domain comprises one or more camelid VHH (vHH) domains. In some embodiments, the antigen specific domain comprises one or more Fv fragments. In some embodiments, the antigen specific domain comprises one or more non-immunoglobulin scaffold such as a DARPIN, an affibody, an affilin, an adnectin, an affitin, an obodies, a repebody, a fynomer, an alphabody, an avimer, an atrimer, a centyrin, a pronectin, an anticalin, a kunitz domain, an Armadillo repeat protein, an autoantigen, a receptor or a ligand. In some embodiments, the antigen specific domain comprises one or more ligands.

Further provided herein are one or more vectors comprising nucleic acids encoding any of conventional CARS I to III (Table 1) or backbones 1-62 (Table 2). In some embodiments, all the components of each backbone are encoded by a single vector. In some embodiments, each component of the backbone is encoded by a different vector. For examples, a backbone comprising a conventional CAR component and a single accessory module, a first vector comprises polynucleotides encoding the conventional CAR component and a second vector comprises polynucleotides encoding the accessory module. For example, a backbone comprising a conventional CAR component and a more than one accessory module, a first vector comprises polynucleotides encoding the conventional CAR component and a second vector comprises polynucleotides encoding the accessory modules. Alternately, a first vector comprises polynucleotides encoding the conventional CAR component, a second vector comprises polynucleotides encoding the first accessory module and a third vector comprises polynucleotides encoding the second accessory module. In various embodiments, the vectors encoding the polynucleotide molecule encoding the CAR component of the conventional CARs I to III or the backbones described herein encodes one or more antigen specific domains. In some embodiments, the antigen specific domain comprises one or more V_Lfragments. In some embodiments, the antigen specific domain comprises one or more V_Hfragments. In some embodiments, the antigen specific domain comprises one or more scFVs specific to the antigens on target cells such as cancer cells. In some embodiments, the antigen specific domain comprises one or more Fv fragments. In some embodiments, the antigen specific domain comprises one or more Fab fragments. In some embodiments, the antigen specific domain comprises one or more (Fab′)2 fragments. In some embodiments, the antigen specific domain comprises one or more single domain antibodies (SDAB). In some embodiments, the antigen specific domain comprises one or more camelid V_HHdomains. In some embodiments, the antigen specific domain comprises one or more Fv fragments. In some embodiments, the antigen specific domain comprises one or more non-immunoglobulin scaffold such as a DARPIN, an affibody, an affilin, an adnectin, an affitin, an obodies, a repebody, a fynomer, an alphabody, an avimer, an atrimer, a centyrin, a pronectin, an anticalin, a kunitz domain, an Armadillo repeat protein, an autoantigen, a receptor or a ligand. In some embodiments, the antigen specific domain comprises one or more ligand.

Further provided herein are genetically modified cells comprising vectors encoding polynucleotides encoding the conventional CARs I to III or backbones 1-62 described herein, wherein the CARs of the conventional CARs I to III or the backbones comprise antigen specific domains as described herein. In various embodiments, the genetically modified cells target antigen on target cells such as cancer cells via the V_Lfragments, V_Hfragments, VHH domains, scFvs, Fv fragments, Fab fragments, (Fab′)2 fragments, single domain antibody (SDAB) fragments, and/or non-immunoglobulin scaffold each of which are encoded by the antigen specific domains.

In some embodiments, the antigen specific domains of the CARs comprise one or more V_Lfragments. In exemplary embodiments, the one or more V_Lfragments are described in Table 4. In some embodiments, the polynucleotides encoding the one more V_Lfragments comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOs: 11-249. In some embodiments, the polypeptides encoding the one more V_Lfragments comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOS: 1785-2023 or sequences with 80-99% identity to sequences set forth in any one or more of SEQ ID NOS: 1785-2023 or sequences with 80-99% identity in the three complementarity determining regions (CDRs) to the sequences set forth in any one or more of SEQ ID NOS: 1785-2023 or sequences that bind to the same target antigens or the same epitopes on the target antigens as the sequences set forth in any one or more of SEQ ID NOS: 1785-2023. In some embodiments, the antigen specific domains of the CARs comprise one or more V_Hfragments. In exemplary embodiments, the one or more V_Hfragments are described in Table 6. In some embodiments, the polynucleotides encoding the one more V_Hfragments comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOS: 259-498. In some embodiments, the polypeptides encoding the one more V_Hfragments comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOS: 2028-2268 or sequences with 80-99% identity to sequences set forth in any one or more of SEQ ID NOS: 2028-2268 or sequences with 80-99% identity in the three complementarity determining regions (CDRs) to the sequences set forth in any one or more of SEQ ID NOS: 2028-2268 or sequences that bind to the same target antigens or the same epitopes on the target antigens as the sequences set forth in any one or more of SEQ ID NOS:2028-2268.

In some embodiments, the antigen specific domains of the CARs comprise one or more nanobodies (V_HHdomains). In exemplary embodiments, the one or more V_HHdomains are described in Table 7. In some embodiments, the polynucleotides encoding the one more V_HHfragments comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOS: 499-523. In some embodiments, the polypeptides encoding the one more V_HHfragments comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOS: 2269-2293 or sequences with 80-99% identity to sequences set forth in any one or more of SEQ ID NOS: 2269-2293 or sequences with 80-99% identity in the three complementarity determining regions (CDRs) to sequences set forth in any one or more of SEQ ID NOS: 2269-2293 or sequences that bind to the same target antigens or the same epitopes on the target antigens as the sequences set forth in any one or more of SEQ ID NOS: 2269-2293.

In some embodiments, the antigen specific domains of the CARs comprise one or more non-immunoglobulin antigen binding scaffolds. In exemplary embodiments, the one or more non-immunoglobulin antigen binding scaffolds are described in Table 8. In some embodiments, the polynucleotides encoding the one more non-immunoglobulin antigen binding scaffolds comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOS: 524-528. In some embodiments, the polypeptides encoding the one more non-immunoglobulin antigen binding scaffolds comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOS: 2294-2298 or sequences with 80-99% identity to sequences set forth in any one or more of SEQ ID NOS:2294-2298 or sequences that bind to the same target antigens or the same epitopes on the target antigens as the sequences set forth in any one or more of SEQ ID NOS: 2269-2293.

In some embodiments, the antigen specific domains of the CARs comprise one or more ligands. In exemplary embodiments, the ligands are described in Table 10. In some embodiments, the polynucleotides encoding the one more ligands comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOS: 553-563. In some embodiments, the polypeptides encoding the one more ligand binding domains comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOS: 2323-2333 or sequences with 80-99% identity to sequences set forth in any one or more of SEQ ID NOS: 2323-2333 or sequences that bind to the same target antigens or the same epitopes on the target antigens as the sequences set forth in any one or more of SEQ ID NOS: 2323-2333.

In some embodiments, the antigen specific domains of the CARs comprise one or more scFvs. In exemplary embodiments, the scFv fragments are described in Table 11. In some embodiments, the polynucleotides encoding the one more scFv fragments comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOS: 564-798. In some embodiments, the polynucleotides encoding the one more scFv fragments comprise, consist of or consist essentially of sequences that encode for polypeptide sequences set forth in any one or more of SEQ ID NOS: 2334-2568 or that encode for polypeptide sequences with 80-99% identity in the six complementarity determining regions (CDRs) to sequences set forth in any one or more of SEQ ID NOS: 2334-2568 or that encode for polypeptide sequences that bind to the same target antigens or the same epitopes on the target antigens as the sequences set forth in any one or more of SEQ ID NOS: 2334-2568. In some embodiments, the polypeptides encoding the one more scFv fragments comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOS: 2334-2568 or sequences with 80-99% identity to sequences set forth in any one or more of SEQ ID NOS: 2334-2568 or sequences with 80-99% identity in the six complementarity determining regions (CDRs) to sequences set forth in any one or more of SEQ ID NOS: 2334-2568 or sequences that bind to the same target antigens or the same epitopes on the target antigens as the sequences set forth in any one or more of SEQ ID NOS: 2334-2568.

In some embodiments, provided herein are polynucleotides encoding conventional CAR (Table 1) and any of backbones 1-62 as described herein in Table 2, wherein each backbone comprises a conventional CAR component (Table 1) and one or more accessory modules as shown in Table 2. In some embodiments, the conventional CAR component and the one or more accessory components of each backbone are encoded by a single polynucleotide molecule. In some embodiments, the conventional CAR component is encoded by a first polynucleotide molecule and the one or more accessory modules are encoded by a second polynucleotide molecule. In some embodiments, backbones comprising a conventional CAR component and more than one accessory module, the first polynucleotide molecule encodes the conventional CAR component, a second polynucleotide molecule encodes the first accessory molecule and a third polynucleotide molecule encodes the second accessory molecule.

In some embodiments, provided herein are polypeptides encoding conventional CAR (Table 1) and any of backbones 1-62 as described herein in Table 2, wherein each backbone comprises a conventional CAR component (Table 1) and one or more accessory modules as shown in Table 2. In some embodiments, the polypeptide encoding the conventional CAR component and the one or more accessory module components of each backbone are encoded by a single polynucleotide molecule. In some embodiments, the polypeptide encoding the conventional CAR component is encoded by a first polynucleotide molecule and the one or more accessory modules are encoded by a second polynucleotide molecule. In some embodiments, the polypeptide encoding the conventional CAR component and the one or more accessory module components of each backbone are encoded by a single polypeptide molecule. In some embodiments, the polypeptide encoding the conventional CAR component is encoded by a first polypeptide molecule and the one or more accessory modules are encoded by a second or more polypeptide molecules. In some embodiments, backbones comprising a conventional CAR component and more than one accessory module, the first polynucleotide molecule encodes the conventional CAR component, a second polynucleotide molecule encodes the first accessory molecule and a third polynucleotide molecule encodes the second accessory molecule. In some embodiments, backbones comprising a conventional CAR component and more than one accessory module, the first polypeptide molecule encodes the conventional CAR component, a second polypeptide molecule encodes the first accessory molecule and a third polypeptide molecule encodes the second accessory molecule.

In some embodiments, the polynucleotides encoding the one more accessory module comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOS: 850-904. In some embodiments, the polynucleotides encoding the one more accessory module comprise, consist of or consist essentially of sequences that encode for polypeptide sequences as set forth in any one or more of SEQ ID NOS: 2613-2667 or encode for polypeptide sequences with 70-99% identity to sequences set forth in any one or more of SEQ ID NOS: 2613-2667. In some embodiments, the polypeptides encoding the one more accessory modules comprise, consist of or consist essentially of sequences set forth in any one or more of SEQ ID NOS: 2613-2667 or sequences with 70-99% identity to sequences set forth in any one or more of SEQ ID NOS: 2613-2667.

In exemplary embodiments, nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets antigens of interest are described in Table 19. The sequences of nucleic acid fragments encoding backbone-1 comprising conventional CAR I and K13-vFLIP and targeting antigens of interest as described in Table 19 are set forth in SEQ ID NOs: 927-1196. The sequences of polypeptides encoding backbone-1 comprising conventional CAR I and K13-vFLIP and targeting antigens of interest as described in Table 19 are set forth in SEQ ID NOs: 2672-2941. The nucleic acid sequences in SEQ ID NOs: 927-1196 and polypeptide sequences in SEQ ID NOs: 2672-2941 also encode for a puromycin acetyl transferase (PuroR) fragment, which fragment can be used to select cells but is not essential for the function of the CAR.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym1 (Table 19). In exemplary embodiments, the sequence of nucleic acid fragment targeting Lym1 is set forth in SEQ ID NO: 1109. In exemplary embodiments, the sequence of isolated polypeptide fragment targeting Lym1 is set forth in SEQ ID NO: 2854. In some embodiments, the scFv fragment targeting Lym1 is described in Table 11 and set forth in SEQ ID NO: 723 and SEQ ID NO: 2493. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym1. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym1. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym1.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym2 (Table 19). In exemplary embodiments, sequence of the isolated nucleic acid fragment targeting Lym2 is set forth in SEQ ID NO: 1110. In exemplary embodiments, the sequence of isolated polypeptide targeting Lym2 is set forth in SEQ ID NO: 2855. In some embodiments, the scFv fragment targeting Lym2 is described in Table 11 and set forth in SEQ ID NO: 724 and SEQ ID NO: 2494. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym2. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym2. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym2.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets GRP-78 (Table 19). In exemplary embodiments, sequence of the isolated nucleic acid targeting GRP-78 is set forth in SEQ ID NO: 1078. In exemplary embodiments, sequence of the polypeptide targeting GRP-78 is set forth in SEQ ID NO: 2823. In some embodiments, the scFv fragment targeting GRP-78 is described in Table 11 and set forth in SEQ ID NO: 703 and SEQ ID NO: 2473. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets GRP-78. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets GRP-78. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets GRP-78.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD79b (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting CD79b are set forth in SEQ ID NOs: 995-996. In exemplary embodiments, the sequences of the polypeptide fragments targeting CD79b are set forth in SEQ ID NO: 2740-2741. In some embodiments, the scFv fragment targeting CD79b is described in Table 11 and set forth in SEQ ID NO: 628 and SEQ ID NO: 2398. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD79b. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD79b. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD79b.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets ALK (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting ALK are set forth in SEQ ID NOs: 946-947. In exemplary embodiments, the sequences of the polypeptide fragments targeting ALK are set forth in SEQ ID NO: 2691-2692. In some embodiments, the scFv fragments targeting ALK are described in Table 11 and set forth in SEQ ID NO: 582-583 and SEQ ID NO: 2352-2353. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets ALK. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets ALK. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets ALK.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets BCMA (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting BCMA are set forth in SEQ ID NOs: 951-957. In exemplary embodiments, the sequences of the polypeptide fragments targeting BCMA are set forth in SEQ ID NO: 2696-2702. In some embodiments, the scFv fragments targeting BCMA are described in Table 11 and set forth in SEQ ID NO: 586-592 and SEQ ID NO: 2356-2362. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets BCMA. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets BCMA. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets BCMA.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD20 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting CD20 are set forth in SEQ ID NOs: 964-976. In exemplary embodiments, the sequences of the polypeptide fragments targeting CD20 are set forth in SEQ ID NO: 2709-2721. In some embodiments, the scFv fragments targeting CD20 are described in Table 11 and set forth in SEQ ID NO: 596-597; 599-610 and SEQ ID NO: 2366-2367; 2369-2380. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD20. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD20. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD20.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD22 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting CD22 are set forth in SEQ ID NOs: 977-980 and SEQ ID NOs: 1192-1196. In exemplary embodiments, the sequences of the polypeptide fragments targeting CD22 are set forth in SEQ ID NOs: 2722-2725 and SEQ ID NOs: 2937-2941. In some embodiments, the scFv fragments targeting CD22 are described in Table 11 and set forth in SEQ ID NO: 598, 611-613 and SEQ ID NO: 2368, 2381-2384. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD22. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD22. Also provided herein are genetically-engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD22.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD30 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting CD30 are set forth in SEQ ID NOs: 981-982. In exemplary embodiments, the sequences of the polypeptide fragments targeting CD30 are set forth in SEQ ID NOs: 2726-2727. In some embodiments, the scFv fragments targeting CD30 are described in Table 11 and set forth in SEQ ID NO: 614-615 and SEQ ID NO: 2384-2385. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD30. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD30. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD30.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD32 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragment targeting CD32 is set forth in SEQ ID NO: 983. In exemplary embodiments, the sequence of the polypeptide fragments targeting CD32 is set forth in SEQ ID NO: 2728 In some embodiments, the scFv fragment targeting CD32 is described in Table 11 and set forth in SEQ ID NO: 616 and SEQ ID NO: 2386. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD32. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD32. Also provided herein are genetically-engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD32.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD33 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting CD33 are set forth in SEQ ID NOs: 984-991. In exemplary embodiments, the sequences of the polypeptide fragments targeting CD33 are set forth in SEQ ID NOs: 2729-2736. In some embodiments, the scFv fragments targeting CD33 are described in Table 11 and set forth in SEQ ID NO: 617-624 and SEQ ID NO: 2387-2394. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD33. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD33. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD33.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD123 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting CD123 are set forth in SEQ ID NOs: 998-1010. In exemplary embodiments, the sequences of the polypeptide fragments targeting CD123 are set forth in SEQ ID NOs: 2743-2755. In some embodiments, the scFv fragments targeting CD123 are described in Table 11 and set forth in SEQ ID NO: 630-642 and SEQ ID NO: 2400-2412. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD123. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD123. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD123.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD138 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragment targeting CD138 is set forth in SEQ ID NO: 1011. In exemplary embodiments, the sequence of the polypeptide fragments targeting CD138 is set forth in SEQ ID NO: 2756 In some embodiments, the scFv fragment targeting CD138 is described in Table 11 and set forth in SEQ ID NOs: 643 and 2413. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD138. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD138. Also provided herein are genetically-engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD138.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CLL1 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting CLL1 are set forth in SEQ ID NOs: 1024-1029. In exemplary embodiments, the sequences of the polypeptide fragments targeting CLL1 are set forth in SEQ ID NOs:2769-2774. In some embodiments, the scFv fragments targeting CLL1 are described in Table 11 and set forth in SEQ ID NO: 655-660 and SEQ ID NO: 2425-2430. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CLL1. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CLL1. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CLL1.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CS1 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting CS1 are set forth in SEQ ID NOs: 1031-1039. In exemplary embodiments, the sequences of the polypeptide fragments targeting CS1 are set forth in SEQ ID NOs:2776-2784. In some embodiments, the scFv fragments targeting CS1 are described in Table 11 and set forth in SEQ ID NO: 662-670 and SEQ ID NO: 2432-2440. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CS1. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD79b. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CS1.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets DLL3 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting DLL3 are set forth in SEQ ID NOs: 1044-1045. In exemplary embodiments, the sequences of the polypeptide fragments targeting DLL3 are set forth in SEQ ID NOs: 2789-2790. In some embodiments, the scFv fragments targeting DLL3 are described in Table 11 and set forth in SEQ ID NO: 673-674 and SEQ ID NO: 2443-2444. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets DLL3. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets DLL3. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets DLL3.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets GPRC5D (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting GPRC5D are set forth in SEQ ID NOs: 1070-1073. In exemplary embodiments, the sequences of the polypeptide fragments targeting GPRC5D are set forth in SEQ ID NOs: 2815-2818. In some embodiments, the scFv fragments targeting GPRC5D are described in Table 11 and set forth in SEQ ID NO: 695-674 and SEQ ID NO: 2465-2468. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets GPRC5D. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets GPRC5D. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets GPRC5D.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets HIV1-envelop glycoprotein gp120 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting HIV1-envelop glycoprotein gp120 are set forth in SEQ ID NOs: 959, 1089-1092. In exemplary embodiments, the sequences of the polypeptide fragments targeting HIV1-envelop glycoprotein gp120 are set forth in SEQ ID NOs: 2704, 2834-2837. In some embodiments, the scFv fragments targeting HIV1-envelop glycoprotein gp120 are described in Table 11 and set forth in SEQ ID NO: 581, 705-708 and SEQ ID NO: 2351, 2475-2478. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets HIV1-envelop glycoprotein gp120. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets HIV1-envelop glycoprotein gp120. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets HIV1-envelop glycoprotein gp120.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets IL11Ra (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragment targeting IL11Ra is set forth in SEQ ID NO: 1099. In exemplary embodiments, the sequence of the polypeptide fragments targeting IL11Ra is set forth in SEQ ID NO: 2844 In some embodiments, the scFv fragments targeting IL11Ra is described in Table 11 and set forth in SEQ ID NOs: 715 and 2485. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets IL11Ra. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets IL11Ra. Also provided herein are genetically-engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets IL11Ra.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets LAMP1 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting LAMP1 are set forth in SEQ ID NOs: 1104-1105. In exemplary embodiments, the sequences of the polypeptide fragments targeting LAMP1 are set forth in SEQ ID NOs: 2849-2850. In some embodiments, the scFv fragments targeting LAMP1 are described in Table 11 and set forth in SEQ ID NO: 719-720 and SEQ ID NO: 2489-2490. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets LAMP1. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets LAMP1. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets LAMP1.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets NY-BR1 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragment targeting NY-BR1 is set forth in SEQ ID NO: 1131. In exemplary embodiments, the sequence of the polypeptide fragments targeting NY-BR1 is set forth in SEQ ID NO: 2876 In some embodiments, the scFv fragments targeting NY-BR1 are described in Table 11 and set forth in SEQ ID NOs: 742 and 2512. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets NY-BR1. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets NY-BR1. Also provided herein are genetically-engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets NY-BR1.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TROP2 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting TROP2 are set forth in SEQ ID NOs: 1165-1166. In exemplary embodiments, the sequences of the polypeptide fragments targeting TROP2 are set forth in SEQ ID NOs: 2910⁻²⁹¹¹. In some embodiments, the scFv fragments targeting TROP2 are described in Table 11 and set forth in SEQ ID NO: 774-775 and SEQ ID NO: 2544-2545. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TROP2. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TROP2. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TROP2.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TSHR (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting TSHR are set forth in SEQ ID NOs: 1167-1170. In exemplary embodiments, the sequences of the polypeptide fragments targeting TSHR are set forth in SEQ ID NOs: 2912-2914. In some embodiments, the scFv fragments targeting TSHR are described in Table 11 and set forth in SEQ ID NO: 776-778 and SEQ ID NO: 2546-2548. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TSHR. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TSHR. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TSHR.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TSLPR (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragment targeting TSLPR is set forth in SEQ ID NO: 1171. In exemplary embodiments, the sequence of the polypeptide fragment targeting TSLPR is set forth in SEQ ID NO: 2916 In some embodiments, the scFv fragment targeting TSLPR is described in Table 11 and set forth in SEQ ID NOs: 779 and 2549. Also provided herein is a polypeptide encoded by a nucleic acid fragment encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TSLPR. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TSLPR. Also provided herein are genetically-engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TSLPR.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CDH19 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting CDH19 are set forth in SEQ ID NO: 1019 and 1180. In exemplary embodiments, the sequences of the polypeptide fragments targeting CDH19 are set forth in SEQ ID NO: 2764 and 2925 In some embodiments, the scFv fragments targeting CDH19 are described in Table 11 and set forth in SEQ ID NOs: 651, 788 and SEQ ID NOs: 2421 and 2558. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CDH19. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CDH19. Also provided herein are genetically-engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CDH19.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CDH6 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting CDH6 are set forth in SEQ ID NOs: 1017-1018. In exemplary embodiments, the sequences of the polypeptide fragments targeting CDH6 are set forth in SEQ ID NOs: 2761-2762. In some embodiments, the scFv fragments targeting CDH6 are described in Table 11 and set forth in SEQ ID NO: 648-649 and SEQ ID NO: 2418-2419. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CDH6. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CDH6. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CDH6.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD324 (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting CD324 are set forth in SEQ ID NOs: 1014-1015. In exemplary embodiments, the sequences of the polypeptide fragments targeting CD324 are set forth in SEQ ID NOs: 2759-2760. In some embodiments, the scFv fragments targeting CD324 are described in Table 11 and set forth in SEQ ID NO: 646-647 and SEQ ID NO: 2416-2417. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD324. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD324. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD324.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TCR gamma-delta (TCRgd) (Table 19). In exemplary embodiments, the sequence of the nucleic acid fragment targeting TCR gamma-delta (TCRgd) is set forth in SEQ ID NO: 1155. In exemplary embodiments, the sequence of the polypeptide fragments targeting TCR gamma-delta (TCRgd) is set forth in SEQ ID NO: 2900 In some embodiments, the scFv fragment targeting TCR gamma-delta (TCRgd) is described in Table 11 and set forth in SEQ ID NOs: 765 and SEQ ID NOs: 2535. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TCR gamma-delta (TCRgd). Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TCR gamma-delta (TCRgd). Also provided herein are genetically-engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TCR gamma-delta (TCRgd).

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TCRB1 (TCR beta 1 constant chain) (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting TCRB1 (TCR beta 1 constant chain) are set forth in SEQ ID NOs: 1151-1152. In exemplary embodiments, the sequences of the polypeptide fragments targeting TCRB1 (TCR beta 1 constant chain) are set forth in SEQ ID NOs: 2896-2897. In some embodiments, the scFv fragments targeting TCRB1 (TCR beta 1 constant chain) are described in Table 11 and set forth in SEQ ID NO: 761-762 and SEQ ID NO: 2531-2532. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TCRB1 (TCR beta 1 constant chain). Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TCRB1 (TCR beta 1 constant chain). Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TCRB1 (TCR beta 1 constant chain).

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TCRB2 (TCR beta 2 constant chain) (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting TCRB2 (TCR beta 2 constant chain) are set forth in SEQ ID NOs: 1153-1154. In exemplary embodiments, the sequences of the polypeptide fragments targeting TCRB2 (TCR beta 2 constant chain) are set forth in SEQ ID NOs: 2898-2899. In some embodiments, the scFv fragments targeting TCRB2 (TCR beta 2 constant chain) are described in Table 11 and set forth in SEQ ID NO: 763-764 and SEQ ID NO: 2533-2534. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TCRB2 (TCR beta 2 constant chain). Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TCRB2 (TCR beta 2 constant chain). Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets TCRB2 (TCR beta 2 constant chain).

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets LHR (Luteinizing hormone Receptor) (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting LHR (Luteinizing hormone Receptor) are set forth in SEQ ID NOs: 1182-1183. In exemplary embodiments, the sequences of the polypeptide fragments targeting LHR (Luteinizing hormone Receptor) are set forth in SEQ ID NOs: 2927-2928. In some embodiments, the scFv fragments targeting LHR (Luteinizing hormone Receptor) are described in Table 11 and set forth in SEQ ID NO: 790-791 and SEQ ID NO: 2560-2561. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets LHR (Luteinizing hormone Receptor). Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets LHR (Luteinizing hormone Receptor). Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets LHR (Luteinizing hormone Receptor).

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets Fc region of an immunoglobulin (Table 19). In exemplary embodiments, the sequences of the nucleic acid fragments targeting Fc region of an immunoglobulin are set forth in SEQ ID NOs: 961-962. In exemplary embodiments, the sequences of the polypeptide fragments targeting Fc region of an immunoglobulin are set forth in SEQ ID NOs: 2707-2708. In some embodiments, the receptor targeting Fc region of an immunoglobulin comprises, consists of or essentially consists of extracellular ligand-binding domain of CD16 (FCGR3A) or its variant V158 or its variant F158. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets Fc region of an immunoglobulin. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets Fc region of an immunoglobulin. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets Fc region of an immunoglobulin. The genetically engineered cells comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets Fc region of an immunoglobulin can be used to enhance antibody dependent cell mediated cytotoxicity and/or enhance antibody based immunotherapy, such as cancer immunotherapy, as described in US 2015/0139943A1.

In exemplary embodiments, nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets antigens of interest are described in Table 20. The sequences of nucleic acid fragments encoding backbone-32 comprising conventional CAR II and K13-vFLIP and targeting antigens of interest as described in Table 20 are set forth in SEQ ID NOs: 1197-1466. The sequences of polypeptides encoding backbone-32 comprising conventional CAR I and K13-vFLIP and targeting antigens of interest as described in Table 20 are set forth in SEQ ID NOs: 2942-3211. The nucleic acid sequences in SEQ ID NOs: 1197-1466 and polypeptide sequences in SEQ ID NOs: 2942-3211 also encode for a puromycin acetyl transferase (PuroR) fragment, which fragment can be used to select cells and is not essential for the function of the CAR.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD19 (Table 20). In exemplary embodiments, nucleic acid sequences of the V_L-V_Htargeting CD19 are set forth in SEQ ID NOs: 1197-1211. In exemplary embodiments, the polypeptide sequences of the V_L-V_Htargeting CD19 are set forth in SEQ ID NOs: 2942-2956. In some embodiments, the scFv fragments targeting CD19 are described in Table 11 and set forth in SEQ ID NOs: 564-577 and SEQ ID NOs: 2334-2347. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD19. Further provided herein are vectors encoding nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD19. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD19.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets MPL (Table 20). In exemplary embodiments, nucleic acid sequences of the V_L-V_Htargeting MPL are set forth in SEQ ID NOs: 1387-1394. In exemplary embodiments, the polypeptide sequences of the V_L-V_Htargeting MPL are set forth in SEQ ID NOs: 3132-3139. In some embodiments, the scFv fragments targeting MPL are described in Table 11 and set forth in SEQ ID NOs: 729-736 and SEQ ID NOs: 2499-2506. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets MPL. Further provided herein are vectors encoding nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets MPL. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets MPL.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym1 (Table 20). In exemplary embodiments, the nucleic acid sequence of the V_L-V_Htargeting Lym1 is set forth in SEQ ID NO: 1379. In exemplary embodiments, the polypeptide sequence of the V_L-V_Htargeting Lym1 is set forth in SEQ ID NO: 3124. In some embodiments, the scFv fragment targeting Lym1 is described in Table 11 and set forth in SEQ ID NO: 723 and SEQ ID NO: 2493. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym1. Further provided herein are vectors encoding nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym1. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym1.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym2 (Table 20). In exemplary embodiments, nucleic acid sequence of the V_L-V_Htargeting Lym2 is set forth in SEQ ID NO: 1380. In exemplary embodiments, the polypeptide sequence of the V_L-V_Htargeting Lym2 is set forth in SEQ ID NO: 3125. In some embodiments, the scFv fragment targeting Lym2 is described in Table 11 and set forth in SEQ ID NO: 724 and SEQ ID NO: 2494. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym2. Further provided herein are vectors encoding nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym2. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets Lym2.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-32 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets GRP-78 (Table 20). In exemplary embodiments, the nucleic acid sequence of the V_L-V_Htargeting GRP-78 is set forth in SEQ ID NO: 1348. In exemplary embodiments, the polypeptide sequence of the V_L-V_Htargeting GRP-78 is set forth in SEQ ID NO: 3093. In some embodiments, the scFv fragment targeting GRP-78 is described in Table 11 and set forth in SEQ ID NO: 703 and SEQ ID NO: 2473. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets GRP-78. Further provided herein are vectors encoding nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets GRP-78. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets GRP-78.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-32 comprising conventional CAR I and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD79b (Table 20). In exemplary embodiments, the nucleic acid sequence of the V_L-V_Htargeting CD79b are set forth in SEQ ID NO: 1381. In exemplary embodiments, the polypeptide sequence of the V_L-V_Htargeting CD79b is set forth in SEQ ID NO: 3126. In some embodiments, the scFv fragment targeting CD79b is described in Table 11 and set forth in SEQ ID NO: 628 and SEQ ID NO: 2398. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD79b. Further provided herein are vectors encoding nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD79b. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-32 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets CD79b.

In one embodiment, provided herein is an isolated nucleic acid encoding backbone-1 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets Fc region of an immunoglobulin (Table 20). In exemplary embodiments, the sequences of the nucleic acid fragments targeting Fc region of an immunoglobulin are set forth in SEQ ID NOs: 1232-1233. In exemplary embodiments, the sequences of the polypeptide fragments targeting Fc region of an immunoglobulin are set forth in SEQ ID NOs: 2977-2978. In some embodiments, the receptor targeting Fc region of an immunoglobulin comprises, consists of or essentially consists of extracellular ligand-binding domain of CD16 (FCGR3A) or its variant V158 or its variant F158. Also provided herein are polypeptides encoded by nucleic acids encoding backbone-1 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets Fc region of an immunoglobulin. Further provided herein are vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets Fc region of an immunoglobulin. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets Fc region of an immunoglobulin. The genetically engineered cells comprising vectors encoding nucleic acids encoding backbone-1 comprising conventional CAR II and K13-vFLIP, wherein the antigen specific domain of the CAR targets Fc region of an immunoglobulin can be used to enhance antibody dependent cell mediated cytotoxicity and/or enhance antibody based immunotherapy, such as cancer immunotherapy, as described in US 2015/0139943A1.

In exemplary embodiments, nucleic acids encode conventional CAR II wherein the antigen specific domain of the CAR targets antigens of interest (Table 21). The sequences of nucleic acid fragments encoding conventional CAR II and targeting antigens of interest as described in Table 21 are set forth in SEQ ID NOs: 1467-1730. The sequences of polypeptides comprising conventional CAR II and targeting antigens of interest as described in Table 21 are set forth in SEQ ID NOs: 3212-3475. The nucleic acid sequences in SEQ ID NOs: 1467-1730 and polypeptide sequences in SEQ ID NOs: 3212-3475 also encode for a puromycin acetyl transferase (PuroR) fragment, which fragment can be used to select cells and is not essential for the function of the CAR. Similarly, several CAR constructs described in Table 22 encode for PuroR or Enhanced Green Fluorescent Protein (EGFP), which are not essential for the function of these CAR constructs but may be used to select or enrich for cells expressing these CAR constructs.

In one embodiment, provided herein is an isolated nucleic acid encoding conventional CAR II, wherein the antigen specific domain of the CAR targets CD19 (Table 21). In exemplary embodiments, the sequences of isolated nucleic acid fragments targeting CD19 are set forth in SEQ ID NOs: 1470-1481, 1772. In exemplary embodiments, the sequences of isolated polypeptide targeting CD19 are set forth in SEQ ID NOs: 3215-3225, 3517. In some embodiments, the scFv fragments targeting CD19 are described in Table 11 and set forth in SEQ ID NOs: 566-577 and SEQ ID NOs: 2336-2347. Also provided herein are polypeptides encoded by nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets CD19. Further provided herein are vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets CD19. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets CD19.

In one embodiment, provided herein is an isolated nucleic acid encoding conventional CAR II, wherein the antigen specific domain of the CAR targets MPL or the Thrombopoietin Receptor (Table 21). In exemplary embodiments, the sequences of isolated nucleic acid fragments targeting MPL are set forth in SEQ ID NOs: 1657-1664, 1731-1737. In exemplary embodiments, the sequences of isolated polypeptide targeting MPL are set forth in SEQ ID NOs: 3402-3409, 3476-3484. In some embodiments, the scFv fragments targeting MPL are described in Table 11 and set forth in SEQ ID NOs: 729-736 and SEQ ID NOs: 2499-2506. Also provided herein are polypeptides encoded by nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets MPL. Further provided herein are vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets MPL. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets MPL.

In one embodiment, provided herein is an isolated nucleic acid encoding conventional CAR II, wherein the antigen specific domain of the CAR targets Lym1 (Table 21). In exemplary embodiments, the sequence of nucleic acid fragment targeting Lym1 is set forth in SEQ ID NO: 1649. In exemplary embodiments, the sequence of isolated polypeptide fragment targeting Lym1 is set forth in SEQ ID NO: 3394. In some embodiments, the scFv fragment targeting Lym1 is described in Table 11 and set forth in SEQ ID NO: 723 and SEQ ID NO: 2493. Also provided herein are polypeptides encoded by nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets Lym1. Further provided herein are vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets Lym1. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets Lym1.

In one embodiment, provided herein is an isolated nucleic acid encoding conventional CAR II, wherein the antigen specific domain of the CAR targets Lym2 (Table 21). In exemplary embodiments, sequence of the isolated nucleic acid fragment targeting Lym2 is set forth in SEQ ID NO: 1650. In exemplary embodiments, the sequence of isolated polypeptide targeting Lym2 is set forth in SEQ ID NO: 3395. In some embodiments, the scFv fragment targeting Lym2 is described in Table 11 and set forth in SEQ ID NO: 724 and SEQ ID NO: 2494. Also provided herein are polypeptides encoded by nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets Lym2. Further provided herein are vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets Lym2. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets Lym2.

In one embodiment, provided herein is an isolated nucleic acid encoding conventional CAR II, wherein the antigen specific domain of the CAR targets DLL3 (Table 21). In exemplary embodiments, the sequences of isolated nucleic acid fragments targeting DLL3 are set forth in SEQ ID NOs: 1314-1315. In exemplary embodiments, the sequences of isolated polypeptide targeting DLL3 are set forth in SEQ ID NOs: 3059-3060. In some embodiments, the scFv fragments targeting DLL3 are described in Table 11 and set forth in SEQ ID NOs: 673-674 and SEQ ID NOs: 2443-2444. Also provided herein are polypeptides encoded by nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets DLL3. Further provided herein are vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets DLL3. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets DLL3.

In one embodiment, provided herein is an isolated nucleic acid encoding conventional CAR II, wherein the antigen specific domain of the CAR targets CD324 (Table 21). In exemplary embodiments, the sequences of isolated nucleic acid fragments targeting CD324 are set forth in SEQ ID NOs: 1554-1555. In exemplary embodiments, the sequences of isolated polypeptide targeting CD324 are set forth in SEQ ID NOs: 3299-3300. In some embodiments, the scFv fragments targeting CD324 are described in Table 11 and set forth in SEQ ID NOs: 646-647 and SEQ ID NOs: 2416-2417. Also provided herein are polypeptides encoded by nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets CD324. Further provided herein are vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets CD324. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets CD324.

In one embodiment, provided herein is an isolated nucleic acid encoding conventional CAR II, wherein the antigen specific domain of the CAR targets CD276 (Table 21). In exemplary embodiments, the sequence of nucleic acid fragment targeting CD276 is set forth in SEQ ID NO: 1553. In exemplary embodiments, the sequence of isolated polypeptide fragment targeting CD276 is set forth in SEQ ID NO: 3298. In some embodiments, the scFv fragment targeting CD276 is described in Table 11 and set forth in SEQ ID NO: 645 and SEQ ID NO: 2415. Also provided herein are polypeptides encoded by nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets CD276. Further provided herein are vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets CD276. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets CD276.

In one embodiment, provided herein is an isolated nucleic acid encoding conventional CAR II, wherein the antigen specific domain of the CAR targets PTK7 (Table 21). In exemplary embodiments, the sequences of isolated nucleic acid fragments targeting PTK7 are set forth in SEQ ID NOs: 1683-1684. In exemplary embodiments, the sequences of isolated polypeptide targeting PTK7 are set forth in SEQ ID NOs: 3428-3429. In some embodiments, the scFv fragments targeting PTK7 are described in Table 11 and set forth in SEQ ID NOs: 753-754 and SEQ ID NOs:2523-2524. Also provided herein are polypeptides encoded by nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets PTK7. Further provided herein are vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets PTK7. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets PTK7.

In one embodiment, provided herein is an isolated nucleic acid encoding conventional CAR II, wherein the antigen specific domain of the CAR targets HIV1-envelop glycoprotein gp120 (Table 21). In exemplary embodiments, sequence of the isolated nucleic acid fragment targeting HIV1-envelop glycoprotein gp120 is set forth in SEQ ID NO: 1485. In exemplary embodiments, the sequence of isolated polypeptide targeting HIV1-envelop glycoprotein gp120 is set forth in SEQ ID NO: 3230. In some embodiments, the scFv fragment targeting HIV1-envelop glycoprotein gp120 is described in Table 11 and set forth in SEQ ID NO: 581 and SEQ ID NO: 2351. Also provided herein are polypeptides encoded by nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets HIV1-envelop glycoprotein gp120. Further provided herein are vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets HIV1-envelop glycoprotein gp120. Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets HIV1-envelop glycoprotein gp120.

In one embodiment, provided herein is an isolated nucleic acid encoding conventional CAR II, wherein the antigen specific domain of the CAR targets tyrosinase-derived peptides in association with MHC class I complex (Table 21). In exemplary embodiments, sequence of the isolated nucleic acid fragments targeting tyrosinase-derived peptides in association with MHC class I complex (HLA-A2) is set forth in SEQ ID NO: 1712-1714. In exemplary embodiments, the sequence of isolated polypeptides targeting tyrosinase-derived peptides in association with MHC class I complex (HLA-A2) is set forth in SEQ ID NO: 3457-3459. In some embodiments, the scFv fragments targeting tyrosinase-derived peptide in association with MHC class II (HLA-A2) complex is described in Table 11 and set forth in SEQ ID NO:780-782 and SEQ ID NO: 2550-2552. Also provided herein are polypeptides encoded by nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets tyrosinase-derived peptides in association with MHC class I complex (HLA-A2). Further provided herein are vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CARs target tyrosinase-derived peptides in association with MHC class I complex (HLA-A2). Also provided herein are genetically engineered cells (such as T cells, NK cells) comprising vectors encoding nucleic acids encoding conventional CAR II, wherein the antigen specific domain of the CAR targets target tyrosinase-derived peptides in association with MHC class I complex (HLA-A2). In exemplary embodiment, the sequence of the tyrosinase-derived peptide that is targeted by the CAR in association with MHC class I complex (HLA-A2) is-YMDGTMSQV-(SEQ ID NO:3563) (Table 23).

In some embodiments, provided herein are vectors comprising nucleic acid sequences encoding the conventional CARs or novel backbones (comprising conventional CARs and accessory modules) described herein. In exemplary embodiments, the vector is any of a DNA vector, an RNA vector, a plasmid, a lentivirus vector, an adenoviral vector or a retrovirus vector. In an embodiment, the vector is a lentivirus vector as described herein. In an embodiment, the vector is pLENTI-EF1α (SEQ ID NO: 905). In another embodiment, the vector is pLenti-EF1a-DWPRE (SEQ ID NO: 906). In another embodiment, the vector is MSCV-Bgl2-AvrII-Bam-EcoR1-Xho-BstB1-Mlu-Sal-ClaI.I03 (SEQ ID NO: 907). In another embodiment, the vector is a sleeping beauty transposon vector. In another embodiment, the sleeping beauty transposon vector is pSBbi-Pur (SEQ ID NO: 908). In one embodiment, the vector further comprises a promoter. Non-limiting examples of a promoter include from an EF-1 promoter, a CMV IE gene promoter, an EF-1α promoter, an ubiquitin C promoter, or a phosphoglycerate kinase (PGK) promoter. In one embodiment, the promoter is an EF-1 promoter (SEQ ID NO: 909). In one embodiment, the promoter is an inducible promoter that provides a molecular switch capable of turning on expression of the polynucleotide sequence encoding conventional CARs I to III and backbones 1-62 which it is operatively linked when such expression is desired, or turning off the expression when expression is not desired. Examples of inducible promoters include, but are not limited to a metallothionine inducible promoter, a glucocorticoid inducible promoter, a progesterone inducible promoter, and a tetracycline inducible promoter. RheoSwitch® system (Agarwal et al, 2012, AACR-NCI-EORTC international conference on Molecular Targets and Cancer Therapeutics) represents another transcriptional regulator platform for controlling the expression of conventional CARs and backbones 1-62 of the present invention. In one embodiment, a combinatorially activated T cell circuit can be engineered in which a synthetic Notch receptor for one antigen induces the expression of a conventional CAR or backbones 1-62 targeting a second antigen as described recently for controlling the activity of CARs (Roybal K T et al., Cell, 164:1-102016). In one embodiment, the vector is an in vitro transcription vector, (for example, a vector that transcribes RNA from a DNA molecule) described herein. In one embodiment, the nucleic acid sequence in the vector further comprises a poly(A) tail, e.g., a poly A tail described herein, e.g., comprising about 100-150 adenosine bases. For example, contemplated herein is a poly(A) tail comprising about 150 adenosine bases (SEQ ID NO: 922). In one embodiment, the nucleic acid sequence in the vector further comprises a 3′UTR, e.g., a 3′ UTR described herein, e.g., comprising at least one repeat of a 3′UTR derived from human beta-globulin.

In some embodiments, the vector comprising a nucleic acid sequence encoding a CAR may further comprise a nucleic acid sequence encoding one or more inhibitory molecules. Non-limiting examples of inhibitory molecules contemplated herein include: an inhKIR cytoplasmic domain; a transmembrane domain, e.g., a KIR transmembrane domain; and an inhibitor cytoplasmic domain, e.g., an ITIM domain, e.g., an inhKIR ITIM domain. An exemplary inhibitory molecule comprising the transmembrane and cytoplasmic domains of LAILR1 is represented by SEQ ID NOS: 849 and 2612. Inhibitory conventional CARs and backbones 1-62 targeting different antigens can be easily constructed by joining the scFv fragments described in Table 11 to the transmembrane and cytoplasmic domains of LAILR1 (SEQ ID NOS: 849 and 2612). Such inhibitory CARs can be expressed alone or in combination with the activating CARs, such as the CARs described in Tables 19-22.

In some embodiments, the ASD of the CARs described herein have a binding affinity (KD) of 10⁻⁴M to 10⁻⁸M, 10⁻⁵M to 10⁻⁷M, 10⁻⁶M or 10⁻⁷M, for the target antigen.

Also provided herein are genetically engineered cells e.g., an immune effector cell, (e.g., a population of cells, e.g., a population of immune effector cells) and/or a stem cell (e.g., a hematopoietic stem cell, a peripheral blood stem cell, a bone marrow derived stem cell, an immune stem cell, an induced pluripotent stem cell or iPSC) comprising nucleic acids, polypeptides or vectors as described herein.

In one embodiment, the cell is a human T cell. In some embodiments, the cell is an immune cell. Non-limiting examples of immune cells include T-cells and NK-cells. Further, non-limiting examples of T-cells include Tregs, CD8+ T cells, and CD4+ T cells. Immune cells, (e.g., T cells and NK cells) can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. T cells could be tissue resident gamma-delta T cells or tumor infiltrating lymphocytes (TILs), which can be cultured and expanded in vitro prior to and/or after the expression of the CARs and the novel backbones of this invention. In some embodiments, the cell is a mammalian cell. In some embodiment, the cell is a human cell. In some embodiments, the cell is a dog cell. In some embodiments, the cell is a monkey cell.

In one embodiment, the cell is a T cell and the T cell is deficient in one or more of endogenous T cell receptor chains. T cells stably lacking expression of a functional TCR according to the invention may be produced using a, variety of approaches such as use of Zn finger nucleases (ZFN), CRISP/Cas9 and shRNA targeting the endogenous T cell receptor chains. A non-limiting exemplary method relating to shRNAs is described in US 2012/0321667 A1. Another non-limiting exemplary method relating to eliminating endogenous TCR expression using ZFNs targeting constant regions of α and β chains of TCRs has been described (Torikai H et al., Blood 119:24, 2012).

In one embodiment, the cell is a stem cell and the stem cell is deficient in one or more of endogenous T cell receptor chains. In another embodiment, the cell is a stem cell in which one or more target antigens of the CAR have been deleted or mutated to a form that is no longer recognized by the CAR. In a non-limiting example, a CAR targeting CD19 is expressed in stem cells that have been made deficient in CD19 using CRISP/Cas9 or Zn finger nucleases so that the B cells produced by such stem cells are not eliminated by the T cells expressing the CD19-targeting CAR. In another non-limiting example, a CAR targeting CD19 is expressed in stem cells in which the endogenous CD19 gene has been mutated using CRISP/Cas9 or Zn finger nucleases to a form that is not targeted by CAR so that the B cells produced by such stem cells are not eliminated by the T cells expressing the CD19-targeting CAR. In another non-limiting example, the CAR is expressed in immune effector cells and the stem cells from an autologous or an allogeneic donor are genetically engineered to either lack the expression of the target antigen of the CAR or to express a mutated form of the target antigen of the CAR which is not recognized by the CAR. In another non-limiting example, a CAR targeting CD19 is expressed in T cells that are infused into a patient along with autologous or allogeneic hematopoietic stem cells that have been made deficient in CD19 using CRISP/Cas9 or Zn finger nucleases so that the B cells produced by such stem cells are not eliminated by the T cells expressing the CD19-targeting CAR. In another non-limiting example, a CAR targeting CD19 is expressed in T cells that are infused into a patient along with autologous or allogeneic hematopoietic stem cells in which the endogenous CD19 gene has been mutated using CRISP/Cas9 or Zn finger nucleases to a form that is not targeted by CAR so that the B cells produced by such stem cells are not eliminated by the T cells expressing the CD19-targeting CAR. In other non-limiting examples, CRISP/Cas9, Zn finger nucleases or siRNA/shRNA approaches are used to mutate or eliminate other endogenous antigens (e.g., MPL, CD33, CD123 etc.) in stem cells in subjects receiving CAR-T cells targeting these antigens for the treatment of specific diseases in which these antigens are expressed on disease-associated or disease-causing cells. In a non-limiting example, a CAR targeting MPL is expressed in stem cells that have been made deficient in MPL using CRISP/Cas9 or Zn finger nucleases so that the blood cells produced by such stem cells are not eliminated by the T cells expressing the MPL-targeting CAR. In another non-limiting example, a CAR targeting MPL (e.g., SEQ ID NO: 1657-1660) is expressed in stem cells in which the endogenous MPL gene has been mutated using CRISP/Cas9 or Zn finger nucleases to a form that is not targeted by MPL-directed CAR so that the blood cells produced by such stem cells are not eliminated by the T cells expressing the MPL-targeting CAR. In another non-limiting example, a CAR targeting MPL is expressed in T cells that are infused into a patient along with autologous or allogeneic hematopoietic stem cells in which the endogenous MPL gene has been mutated using CRISP/Cas9 or Zn finger nucleases to a form that is not targeted by CAR. In an exemplary embodiment the region of MPL gene that is targeted for mutation by CRISP/Cas9 or Zn finger nucleases to a form that is not targeted by MPL-directed CAR encodes for the peptide sequence-PWQDGPK-(SEQ ID NO:3564).

In various embodiments, the CARs target one, two, three, four or more antigens on the diseased-causing or disease-associated cells, such as the cancer cells. In some embodiments, the CARs comprising more than one ASD target the same antigen on the diseased-causing or disease-associated cells. In another embodiment, the CARs comprising more than one ASD target different antigens on the diseased-causing or disease-associated cells.

In some embodiments, the genetically engineered cells further comprise nucleic acids, polypeptides or vectors that encode accessory modules. In some embodiments, the accessory modules reduce or prevent toxicity associated with CARs. In some embodiments, the accessory modules are inhibitors of cytokines or chemokines, for examples, siRNA (either shRNA or Mir based shRNAs) against the involved cytokine and/or chemokine and are expressed from the same vector as the CAR. For example, any one or more of IL6, IL10 and IFNγ can be targeted. In some embodiments, the expression of the chemokine or cytokine can be blocked by expression of a blocking scFv fragment targeting the chemokine or cytokine or its receptor. Non-limiting examples of such accessory modules include IL6R-304-vHH (SEQ ID NOs: 884 and 2647), IGHSP2-IL6R-304-VHH-ALB8-V_HH(SEQ ID NOs: 886 and 2649), CD8SP2-PD1-4H1-scFv (SEQ ID NOs: 889 and 2652), CD8SP2-PD1-5C4-scFv CD8SP2-CTLA4-Ipilimumab-scFv (SEQ ID NOs: 891 and 2654), CD8SP2-PD1-4H1-Alb8-vHH (SEQ ID NOs: 892 and 2655), CD8SP2-PD1-5C4-Alb8-vHH (SEQ ID NOs: 893 and 2656), CD8SP2-CTLA4-Ipilimumab-Alb8-vHH (SEQ ID NOs: 894 and 2657), IgSP-IL6-19A-scFV (SEQ ID NOs: 899 and 2662), CD8SP2-sHVEM (SEQ ID NOs: 901 and 2664), CD8SP2-sHVEM-Alb8-vHH (SEQ ID NOs: 902 and 2665), hTERT (SEQ ID NOs: 903 and 2666), Heparinase (SEQ ID NOs: 904 and 2667), IL12F (SEQ ID NOs: 863 and 2626), 41BB-L (SEQ ID NOs: 864 2627), CD40L (SEQ ID NOs: 865 2628) and shRNA targeting Brd4 (SEQ ID NO: 919). An exemplary vector expressing H1 promoter-driven shRNA targeting Brd4 that can be used to clone the conventional CARs and novel backbones 1-62 of the invention is pLenti-EF1a-shRNA-BRD4-DWPRE (SEQ ID NO: 920). An exemplary CAR in backbone 1 coexpressing shRNA targeting Brd4 is pLenti-EF1a-CD8SP-FMC63-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC-H1-prom-shRNA-BRD4-DWPRE (SEQ ID NO: 921).

Capillary leak syndrome is another major complication of CARs. A natural plasmin digest product of fibrin, peptide BB15-42 (also called FX06), has been shown to significantly reduce vascular leak (Groger et al., PLoS ONE 4:e5391, 2009). FX06 peptide has been shown to block capillary leak. In some embodiments, as described herein, FX06 (SEQ ID NOs: 900 and 2663) can be coexpressed with the CARs described herein from the same vector to mitigate capillary leak associated with CAR therapy. The nucleic acid and protein sequences of an exemplary CAR co-expressing FX06 are represented by SEQ ID NOs: 1764 and 3509, respectively.

A limitation of the current technology for adoptive cellular therapy with T cells is the limited life span of genetically modified T cells, such as CAR-T cells, when infused into patients. To extend the life span of genetically-modified T cells, provided herein are vectors expressing CARs in conjunction with a number of viral and cellular proteins that stimulate the proliferation of T cells and/or to protect them from activation-induced cell death. The use of these proteins, however, is not limited to CAR-expressing T cells and they can be used to extend the life-span of any immune cells that are to be used for the purpose of adoptive immunotherapy, including but not limited to any T cell (e.g., autologous T cells or allogeneic T cells), T cell subsets (e.g., CD8, CD4, TILs), T cells directed against specific tumor antigens or infectious agents, T cells expressing an exogenous T cell receptor (i.e., TCR gene therapy), and T cells expressing a synthetic or chimeric T cell receptor. The DNA and protein sequences of several proteins that can promote the proliferation and survival of CAR-expressing T cells are provided in SEQ ID NOs; 862-882 and SEQ ID NOs: 2625-2645, respectively (Table 16). In exemplary embodiments, these proteins include any one or more of viral proteins K13-vFLIP (SEQ ID NOs: 866 and 2629) and MC159-vFLIP (SEQ ID NOs: 867 and 2630) as described herein. In further embodiments, these proteins include cFLIP-L/MRIT-alpha (SEQ ID NOs: 873 and 2636) and cFLIP-p22 (SEQ ID NOs: 874 and 2637). In further embodiments, these proteins include any one, two or more of Tax and Tax-mutants from human T cell leukemia/lymphoma virus (HTLV-1 and HTLV-2) (SEQ ID NOs: 875-877 and SEQ ID NOs: 2638-2640), Tio protein from herpes virus ateles, stpC Tip from Herpes virus Saimiri. The use of the viral and cellular proteins to promote the survival and proliferation of T cells, is however, not limited to CAR-expressing T cells. In further embodiment, these viral and cellular proteins can be used to promote the survival and proliferation of any T cell, including those expressing an exogenous T cell receptor or synthetic T cell receptor.

In one embodiment, the viral and cellular proteins that are known to stimulate the proliferation of T cells and/or to protect them from activation-induced cell death can be expressed in the CAR-expressing cells constitutively. In another embodiment, the viral and cellular proteins that are known to stimulate the proliferation of T cells and/or to protect them from activation-induced cell death can be expressed in the CAR-expressing cells in an inducible manner, for example, using an inducible promoter. Examples of inducible promoters include, but are not limited to a metallothionine inducible promoter, a glucocorticoid inducible promoter, a progesterone inducible promoter, and a tetracycline inducible promoter. RheoSwitch® system represents another transcriptional regulator platform for controlling the expression of CAR of the present invention (Agarwal et al, 2012, AACR-NCI-EORTC international conference on Molecular Targets and Cancer Therapeutics). In another embodiment, the activity of the viral and cellular proteins that are known to stimulate the proliferation of T cells and/or to protect them from activation-induced cell death is controlled by expressing them in fusion with a dimerization domain. Non-limiting examples of dimerization domains include FKBP (SEQ ID NOs: 857-858 and SEQ ID NOs: 2620 and 2621), FKBPx2 (SEQ ID NOs: 859 and 2622) and Myr-FKBP. Non-limiting examples of several viral and cellular proteins in fusion with FKBP domains are provided in SEQ ID NOs: 878-882 and SEQ ID NOs: 2641 to 2645 (Table 16). The DNA and protein sequences of exemplary CAR constructs coexpressing a viral protein in fusion with FKBP dimerization domain(s) are provided in SEQ ID NOs: 1755 to 1758 and SEQ ID NOs: 3500 to 3503.

Further, a Src inhibitor can be used to prevent and/or treat the toxicity associated with the administration of CAR-expressing cells. In some embodiments, the Src inhibitors are particularly useful for the treatment of cytokine release syndrome and neurological complications associated with the use of genetically modified T cells (e.g., T cells expressing CAR or exogenous TCR or chimeric TCR),Bispecific T cell engagers (BiTE) and DARTs (Dual Affinity Re-targeting proteins).

Also provided herein are methods for treating a disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nucleic acid encoding one or more conventional CARs I to III, a therapeutically effective amount of a nucleic acid encoding one or more CARs and at least one accessory module (backbones 1-62), a therapeutically effective amount of polypeptide encoded by the nucleic acid encoding one or more conventional CARs I to III, a therapeutically effective amount of polypeptide encoded by the nucleic acid encoding one or more CARs and at least one accessory module (backbones 1-62), a therapeutically effective amount of genetically modified cells, as described herein, comprising nucleic acid encoding one or more conventional CARs I to III, or a therapeutically effective amount of genetically modified cells, as described herein, comprising nucleic acid encoding one or more conventional CARs and at least one accessory module (backbones 1-62), as described herein. In one embodiment, the nucleic acids, polypeptides, vectors and genetically modified cells comprise a conventional CAR II. In one embodiment, the nucleic acids, polypeptides, vectors and genetically modified cells comprise backbone-1, comprising a conventional CAR I and K13-vFLIP. In one embodiment, the nucleic acids, polypeptides, vectors and genetically modified cells comprise backbone-32, comprising a conventional CAR II and K13-vFLIP. In one embodiment, the disease treated or prevented by CAR is a cancer. In other embodiments, the diseases treated or prevented by CARs are infectious diseases, allergic diseases, autoimmune diseases, a degenerative diseases, or a combination thereof.

In one embodiment, provided herein is a method for treating, inhibiting, reducing the severity of, preventing metastasis of and/or reducing the relapse of a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of genetically modified cells comprising nucleic acid encoding one or more conventional CARs. In one embodiment, the genetically modified cells comprise vectors encoding a conventional CAR II as described herein. In one embodiment, provided herein is a method for treating, inhibiting, reducing the severity of, preventing metastasis of and/or reducing the relapse of cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of genetically modified cells comprising nucleic acid encoding one or more CARs and at least one accessory module (backbones 1-62). In one embodiment, the genetically modified cells comprise vectors encoding backbone-1, comprising a conventional CAR I and K13-vFLIP as described herein. In one embodiment, the genetically modified cells comprise vectors encoding backbone-32, comprising a conventional CAR II and K13-vFLIP as described herein. In some embodiments, the vectors encoding CARs target two, three or more antigens on cancer cells. In one embodiment, the disease treated or prevented by administration of genetically modified cells comprising nucleic acid encoding one or more CARs is a cancer. In other embodiments, the diseases treated or prevented by administration of genetically modified cells comprising nucleic acid encoding one or more CARs are infectious disease, allergic diseases, autoimmune diseases, a degenerative diseases, or combination thereof.

In exemplary embodiments, the cancer is any of colon cancer, rectal cancer, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine, cancer of the esophagus, melanoma, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of childhood, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, primary effusion lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers, combinations of said cancers, and metastatic lesions of said cancers.

Also provided herein are methods for treating, inhibiting, reducing the severity of, preventing metastasis of and/or reducing the relapse of hematological cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of genetically modified cells, as described herein, wherein the genetically modified cells comprise vectors encoding backbone-1, comprising conventional CAR I and K13-vFLIP or vectors encoding backbone-32, comprising CAR II and K13-vFLIP. In one embodiment, the ASD of the CAR targets MPL. In exemplary embodiments, conventional CAR II targeting MPL are described in Table 21 and 22 and comprise nucleic acid sequences set forth in SEQ ID NOs: 1657-1664 and 1731-1739 and comprise polypeptide sequences set forth in SEQ ID NOs: 3402-3409 and 3476-3484. In exemplary embodiments, conventional CAR I targeting MPL and coexpressing K13-vFLIP (backbone 1) are described in Table 19 and comprise nucleic acid sequences set forth in SEQ ID NOs: 1117-1124 and 1747 and comprise polypeptide sequences set forth in SEQ ID NOs: 2862-2869 and 3492. In exemplary embodiments, conventional CAR II targeting MPL and coexpressing K13-vFLIP (backbone 32) are described in Tables 20 and 22 and comprise nucleic acid sequences set forth in SEQ ID NOs: 1387-1394 and 1747 and comprise polypeptide sequences set forth in SEQ ID NOs: 3132-3139 and 3492. Non-limiting examples of hematological cancers treated or prevented by administration of cells expressing CARs targeting MPL include acute myeloid leukemia, chronic myeloid leukemia and myelodysplastic syndrome.

Also provided herein are methods for treating, inhibiting, reducing the severity of, preventing metastasis of and/or reducing the relapse of cancers expressing CD19 (e.g., B cell acute lymphocytic leukemia (B-ALL), chronic lymphocytic leukemia, diffuse large cell lymphoma, indolent lymphoma) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of genetically modified cells, as described herein, wherein the genetically modified cells comprise vectors encoding a conventional CAR II targeting CD19 as described herein.

Also provided herein are methods for treating, inhibiting, reducing the severity of, preventing metastasis of and/or reducing the relapse of a CD19 expressing cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of genetically modified cells, as described herein, wherein the genetically modified cells comprise vectors encoding backbone-1, comprising conventional CAR I targeting CD19 and K13-vFLIP or vectors encoding backbone-32, comprising CAR II targeting CD19 and K13-vFLIP. In exemplary embodiments, conventional CAR II targeting CD19 are described in Table 21 and comprise nucleic acid sequences set forth in SEQ ID NOs: 1470-1480 and comprise polypeptide sequences set forth in SEQ ID NOs: 3215-3225. In exemplary embodiments, conventional CAR I targeting CD19 and coexpressing K13-vFLIP (backbone 1) are described in Table 19 and comprise nucleic acid sequences set forth in SEQ ID NOs: 927-941 and comprise polypeptide sequences set forth in SEQ ID NOs: 2672-2686. In exemplary embodiments, conventional CAR II targeting CD19 and coexpressing K13-vFLIP (backbone 32) are described in Tables 20 and 22 and comprise nucleic acid sequences set forth in SEQ ID NOs: 1197-1211 and 1759 and comprise polypeptide sequences set forth in SEQ ID NOs: 2942-2956 and 3504.

Also provided herein are methods for treating, inhibiting, reducing the severity of, preventing metastasis of and/or reducing the relapse of GRP-78 expressing cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of genetically modified cells, as described herein, wherein the genetically modified cells comprise vectors encoding backbone-1, comprising conventional CAR I and K13-vFLIP or vectors encoding backbone-32, comprising CAR II and K13-vFLIP. In one embodiment, the ASD of the CAR targets GRP-78. In exemplary embodiments, CARs targeting GRP-78 and accessory modules are described in Table 22 and comprise nucleic acid sequence set forth in SEQ ID NOs: 1771 and 1775 and comprise polypeptide sequence set forth in SEQ ID NO: 3516 and 3520.

In various embodiments, additional antigen targets, CAR constructs and accessory modules for use with the instant invention will be apparent to a person of skill in the art. Exemplary embodiments are set forth in Tables 2-22.

In some embodiments, the therapeutically effective amount of the genetically modified cells is administered at a dosage of 10⁴to 10⁹cells/kg body weight, in some instances 10⁵to 10⁶cells/kg body weight, including all integer values within those ranges. T cell compositions may also be administered multiple times at these dosages. The cells can be administered by using infusion techniques that are commonly known in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319:1676, 1988). The cells can be administered by injection into the site of the lesion (e.g., intra-tumoral injection).

In some embodiments, the therapeutic methods described herein further comprise administering to the subject, sequentially or simultaneously, existing therapies. Examples of existing cancer treatment include, but are not limited to, active surveillance, observation, surgical intervention, chemotherapy, immunotherapy, radiation therapy (such as external beam radiation, stereotactic radiosurgery (gamma knife), and fractionated stereotactic radiotherapy (FSR)), focal therapy, systemic therapy, vaccine therapies, viral therapies, molecular targeted therapies, or combinations thereof.

In some embodiments, the therapeutic methods described herein further comprise administering to the subject, sequentially or simultaneously, any one or more of a kinase inhibitor, a BTK inhibitor, an mTOR inhibitor, a MNK inhibitor, BRD4 inhibitor or a dual PI3K/mTOR inhibitor, or combinations thereof.

In one embodiment, the kinase inhibitor is a Src family kinase inhibitor, such as dasatinib.

In one embodiment, the kinase inhibitor is a CDK4 inhibitor, such as CDK4/6 inhibitors, selected from ribociclib, abemaciclib and palbociclib.

In one embodiment, the kinase inhibitor is an mTOR inhibitor, for example, rapamycin, a rapamycin analog, OSI-027. The mTOR inhibitor can be, for example, an mTORC1 inhibitor and/or an mTORC2 inhibitor.

In one embodiment, the kinase inhibitor is a MNK inhibitor, for example, 4-amino-5-(4-fluoroanilino)-pyrazolo [3,4-d] pyrimidine. The MNK inhibitor can be, for example, an inhibitor of MNK1a, MNK1b, MNK2a and/or MNK2b. The dual P13K/mTOR inhibitor can be, e.g., PF-04695102.

In one embodiment, the inhibitor is a Brd4 inhibitor selected from JQ1, MS417, OTXO15, LY 303511 and Brd4 inhibitor as described in US 20140256706 A1 and any analogs thereof.

In one embodiment of the methods described herein, the kinase inhibitor is a CDK4 inhibitor, e.g., palbociclib (PD0332991), and the palbociclib is administered at a dose of about 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg (e.g., 75 mg, 100 mg or 125 mg) daily for a period of time, e.g., daily for 14-21 days of a 28 day cycle, or daily for 7-12 days of a 21 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of palbociclib are administered.

In one embodiment of the methods described herein, the kinase inhibitor is a BTK inhibitor selected from ibrutinib (PCI-32765); GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224: CC-292; ONO-4059; CNX-774; and LFM-A113. In one embodiment, the BTK inhibitor does not reduce or inhibit the kinase activity of interleukin-2-inducible kinase (ITK), and is selected from GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; and LFM-A13. In one embodiment of the methods or uses described herein, the kinase inhibitor is a BTK inhibitor, e.g., ibrutinib (PCI-32765), and the ibrutinib is administered at a dose of about 250 mg, 300 mg, 350 mg, 400 mg, 420 mg, 440 mg, 460 mg, 480 mg, 500 mg, 520 mg, 540 mg, 560 mg, 580 mg, 600 mg (e.g., 250 mg, 420 mg or 560 mg) daily for a period of time, e.g., daily for 21 day cycle, or daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of ibrutinib are administered,

In one embodiment of the methods or uses described herein, the kinase inhibitor is a BTK inhibitor that does not inhibit the kinase activity of ITK, e.g., RN-486, and RN-486 is administered at a dose of about 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg (e.g., 150 mg, 200 mg or 250 mg) daily for a period of time, e.g., daily a 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, or more cycles of RN-486 are administered.

In one embodiment of the methods described herein, the kinase inhibitor is an mTOR inhibitor selected from temsirolimus; ridaforolimus (1R,2R,4S)-4-[(2R)-2 [(1R,9S,12S.15R.16E,18R,19R,21R, 23S24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15, 17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-1 1,36-dioxa-4-azatricyclo[30.3.1.0] hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate, also known as AP23573 and MK8669; everolimus (RAD001); rapamycin (AY22989); simapimod; (5-{2,4-bis[(35″)-3-methylmorpholin-4-yl]pyrido[2,3-(i]pyrimidin-7-yl}-2-methoxyphenyl)methanol (AZD8055); 2-amino-8-[iran5-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-mnethoxy-3-pyridinyl)-4-methyl-pyrido[2,3-J]pyrimidin-7(8H)-one (PF04691502); and N²-[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]burtyl]-L-arginylglycyl-L-a-aspartyiL-serine-, inner salt (SF1126); and XL765.

In one embodiment of the methods or uses described herein, the kinase inhibitor is an mTOR inhibitor, e.g., rapamycin, and the rapamycin is administered at a dose of about 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg (e.g., 6 mg) daily for a period of time, e.g., daily for 21 day cycle, or daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of rapamycin are administered. In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g., everolimus and the everolimus is administered at a dose of about 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg (e.g., 10 mg) daily for a period of time, e.g., daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of everolimus are administered.

Also provided herein are methods for preparing genetically engineered cells comprising transfecting the cells with vectors comprising nucleic acid encoding the conventional CARs or the CARs on novel backbones described herein. In some embodiments, the cells are immune effector cells, such as human T cells or human NK cells, or stem cells that give rise to immune effector cells. In some embodiments, the cells are autologous human T cells or autologous human NK cells or autologous human stem cells. In some embodiments, the cells are allogeneic human T cells or allogeneic human NK cells or allogeneic human stem cells.

In one embodiment, the method for preparing the genetically modified cells comprise obtaining a population of cells and depleting the cells of the CD25+T regulatory cells, for example by using antibodies specific to CD25. Methods for depleting CD25+T regulatory cells from the population of cells will be apparent to a person of skill in the art. In some embodiments, the Treg depleted cells comprise less than 30%, 20%, 10%, 5% or less Treg cells. In some embodiments, the vectors encoding the CARs described herein are transfected into Treg depleted cells.

In some embodiments, prior to transfection, the Treg depleted cells are further depleted of cells which express checkpoint inhibitors. The checkpoint inhibitor may be any one or more of PD-1, LAG-3, TIM3, B7-H1, CD160, P1H, 2B4, CEACAM (e.g., CEACAM-1, CEACAM-3, and/or CEACAM-5), TIGIT, CTLA-4, BTLA, and LAIR1. In some embodiments, the cells comprise less than comprise less than 30%, 20%, 10%, 5% or less cells that express checkpoint inhibitors. In some embodiments, the vectors encoding the CARs described herein are transfected into Treg depleted and checkpoint inhibitor depleted cells.

In some embodiments, methods for preparing the genetically modified cells comprise obtaining a population of cells and selecting cells that express any one or more of CD3, CD28, CD4, CD8, CD45RA, and/or CD45RO. In certain embodiments, the population of immune effector cells provided are CD3+ and/or CD28+.

In one embodiment, the method for preparing the genetically modified cells comprise obtaining a population of cells and enriching for the CD25+T regulatory cells, for example by using antibodies specific to CD25. Methods for enriching CD25+T regulatory cells from the population of cells will be apparent to a person of skill in the art. In some embodiments, the Treg enriched cells comprise less than 30%, 20%, 10%, 5% or less non-Treg cells. In some embodiments, the vectors encoding the CARs described herein are transfected into Treg-enriched cells. Treg enriched cells expressing a CAR may be used to induced tolerance to antigen targeted by the CAR.

In some embodiments, the method further comprises expanding the population of cells after the vectors comprising nucleic acids encoding the CARs described herein have been transfected into the cells. In embodiments, the population of cells is expanded for a period of 8 days or less. In certain embodiments, the population of cells is expanded in culture for 5 days, and the resulting cells are more potent than the same cells expanded in culture for 9 days under the same culture conditions. In other embodiments, the population of cells is expanded in culture for 5 days show at least a one, two, three or four fold increase in cell doublings upon antigen stimulation as compared to the same cells expanded in culture for 9 days under the same culture conditions. In some embodiments, the population of cells is expanded in an appropriate media that includes one or more interleukins that result in at least a 200-fold, 250-fold, 300-fold, or 350-fold increase in cells over a 14 day expansion period, as measured by flow cytometry.

In various embodiments, the expanded cells comprise one or more CARs as described herein. In some embodiments, the expanded cells comprise one CAR with one, two, three or more ASDs. In some embodiments, the expanded cells further comprise accessory modules and therapeutic controls as described herein.

Provided herein is a cell comprising nucleic acids encoding a chimeric antigen receptor (CAR) and one or more of signaling proteins selected from K13-vFLIP, MC159-vFLIP, cFLIP-L, cFLIP-p22, HTLV1-Tax and HTLV2-Tax, wherein the CAR comprises an a) extracellular antigen specific domain, b)a transmembrane domain and c) an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM); wherein c) is located at the C-terminus of the chimeric receptor. In some embodiments, the CAR further comprises one or more co-stimulatory domains.

Also provided herein is a cell comprising nucleic acids encoding a chimeric antigen receptor (CAR) and K13-vFLIP signaling protein, wherein the CAR comprises an a) extracellular antigen specific domain, b) a transmembrane domain and c) an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM); wherein c) is located at the C-terminus of the chimeric receptor. In some embodiments, the CAR further comprises one or more co-stimulatory domains.

Also provided herein is a cell comprising nucleic acids encoding a chimeric antigen receptor (CAR) and MC159-vFLIP signaling protein, wherein the CAR comprises an a) extracellular antigen specific domain, b) a transmembrane domain and c) an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM); wherein c) is located at the C-terminus of the chimeric receptor. In some embodiments, the CAR further comprises one or more co-stimulatory domains.

In some embodiment, the cell described herein further comprises nucleic acids encoding MC159-vFLIP signaling protein.

In some embodiments, the cell further comprises nucleic acids encoding scFvs targeting IL6 and/or IL6 receptor alpha. In some embodiments, the cell further comprises nucleic acid encoding peptide FX06 so as to mitigate capillary leak associated with CAR therapy. In some embodiments, the signaling protein is expressed in fusion with one or more copies of FKBP domain. In some embodiments, the activity of the signaling protein is controlled post-translationally by dimerization of the FKBP domain in the presence of a dimerizing agent. In some embodiments, the dimerizing agent is AP20187.

In an exemplary embodiment, wherein the antigen specific domain of the CAR targets MPL. In some embodiments, the antigen specific domain targets two antigens, wherein the two antigens are MPL and CD123.

In some embodiments, the antigen specific domain of the CAR targets CD19, CD23, Lym1, Lym2, CLEC5A, CDH179b, FLT3, GCC, Muc1, CSF2RA, GFRa4, CD32, IL11Ra, IL13Ra, NYBR1, SLea, CD200R, TGFBetaR2, CD276, TROP2, LAMP1, PTK7, DLL3, CDH1, CDH6, CDH17, CDH19, TSHR and tyrosinase.

In some embodiments, the antigen specific domain of the CAR targets MPL and comprises one or more scFv fragments selected from 161 (SEQ ID NO: 2500 and 2501), 175 (SEQ ID NO: 2499), 178 (SEQ ID NO: 2503), 111 (SEQ ID NO: 2502), AB317 (SEQ ID NO: 2404), 12E10 (SEQ ID NO: 2505) or huVB22Bw5 (SEQ ID NO: 2506) or ligands selected from extracellular receptor binding domains of hTPO (SEQ ID NO: 2323) or mTPO (SEQ ID NO: 2323).

In some embodiments, the antigen specific domain of the CAR targets CD19 and comprises one or more scFv fragments selected from CD19Bu12 or CD19MM.

In one embodiment, the cell is a T-lymphocyte (T-cell). In another embodiment, the cell is a Natural Killer (NK) cell.

Also provided herein are nucleic acids comprising a first polynucleotide encoding the CAR of claim and a second polynucleotide encoding the K13-vFLIP signaling protein. In some embodiments, the nucleic acids further comprise a third polynucleotide encoding the MC159-vFLIP signaling protein. Also provided herein are polypeptides encoded by the nucleic acids described herein and vectors encoding the nucleic acids described herein.

Further provided herein is a pharmaceutical composition comprising the cells described herein, the nucleic acids described herein, the polypeptides encoded by the nucleic acids described herein or vectors comprising the nucleic acids described herein, and a pharmaceutically acceptable carrier.

In some embodiments, provided herein is a method for treating a MPL-expressing cancer comprising administering to the subject, a therapeutically effective amount of the cell described herein, wherein the CAR targets MPL. In some embodiments, the cancer is a blood cancer, wherein the blood cancer is any one or more of acute myeloid leukemia, chronic myeloid leukemia, myelodyplastic syndrome, lymphoma, multiple myeloma and acute lymphocytic leukemia. In some embodiments, the method further comprises administering to the subject a tyrosine kinase inhibitor, wherein the inhibitor inhibits the Src family of kinases. In some embodiments, the inhibitor inhibits Lck. In some embodiments, the inhibitor is any one or more of Dasatinib, Ponatinib or A-770041.

BRIEF DESCRIPTION OF THE DRAWINGS

Exemplary embodiments are illustrated in referenced figures. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than restrictive.

FIG. 1 depicts, in accordance with various embodiments of the invention, three generations of CARs. Depiction of first, second, and third generation chimeric antigen receptors with the scFv segments in green and the various TCR signaling components in red, blue and yellow (Casucci, Monica and Attilio Bondanza (2011). Journal of Cancer. 2: 378-382)

FIG. 2A-FIG. 2D depict, in accordance with various embodiments of the invention, FIG. 2A: MPL gene expression in normal tissues. MPL has very restricted expression in normal tissues; FIG. 2B: MPL gene expression in 542 patient samples of Acute Myeloid Leukemia. MPL is expressed in most AML samples; FIG. 2C: MPL gene expression in 206 samples of Myelodysplastic syndrome (MDS). MPL is expressed in most MDS samples. FIG. 2D: MPL gene expression in 76 samples of CML. MPL is expressed in most CML samples.

FIG. 3A-FIG. 3B depict, in accordance with various embodiments of the invention, strong binding with 161-GGSG-NLuc-AcV5 was observed on HEL.92.1.7-Gluc-vector cells suggesting significant expression of MPL endogenously.

FIG. 4A-FIG. 4B depicts in accordance with various embodiments of the invention, NLuc assay to measure expression of CAR in 293FT cells. The untransfected 293FT cells, and those transfected with CAR CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467] and CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658] CAR were incubated with FLAG-CD19-ECD-GGSG-NLuc-AcV5[SEQ ID NO: 926] and MPL-ECD-GGSG-NLuc-AcV5[SEQ ID NO: 925] supernatants as described in material and methods section followed by washing with PBS and measurement of NLuc activity by Coeleoentrazine (CTZ; Nanolight) diluted in PBS. Luminescence was quantified using a BioTek plate reader. Data represents mean values of triplicate wells+/−standard deviation (SD).

FIG. 5 depicts, in accordance with various embodiments of the invention, modest binding of MPL-ECD-GGSG-NLuc-AcV5 to 293FT cells transfected with hTPO-(1-187)-Myc-CD28z-T2A-PAC(031915-U04)[SEQ ID NO:1738] and mTPO-(1-187)-Myc-CD28z-T2A-PAC(031915-V03)[SEQ ID NO:1739] constructs and strong binding to 293FT cells transfected with CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658] construct as compared to untransfected cells or cells that had been transfected with control CAR construct.

FIG. 6 depicts, in accordance with various embodiments of the invention, expression of MPL CARs on the surface of T cells as determined by increased EGFP fluorescence and increased staining with APC-Myc as compared to the uninfected T cells (UI).

FIG. 7 depicts in accordance with various embodiments, of the invention, strong binding of T cells expressing CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658], CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-Q04)[SEQ ID NO:1733], and CD8SP-MPL-VB22Bw4-(vL-vH)-Myc-CD28z-T2A-PAC(031615-B06)[SEQ ID NO:3536] CARs and modest binding of T cells expressing CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731], CD8SP-AB317-(vL-vH)-Myc-CD28z-T2A-PAC(031615-T04)[SEQ ID NO:1735] and CD8SP-12E10-(vL-vH)-Myc-CD28z-T2A-PAC(031615-S03)[SEQ ID NO:1736] to MPL-GGSG-NLuc AcV5 supernatant as measured by NLuc assay. SEQ ID NO. 925 comprises MPL-ECD-GGSG-Nluc-AcV5. SEQ ID NO.: 926 comprises FLAG-CD19-ECD-GGSG-NLuc-AcV5. SEQ ID NO: 1734 comprises CD8SP-178-(vL-vH)-Myc-CD28z-T2A-PAC(031615-R04). SEQ ID NO: 3534 comprises CD8SP-4C3-(vL-vH)-Myc-CD28z-T2A-Pac(031615-W05).

FIG. 8 depicts, in accordance with various embodiments of the invention, increase in GLuc activity following co-culture with T cells expressing MPL-specific CD8SP-161-(vL-vH)-Myc-CD8TM-BBz-T2A-EGFP(090814-C03)[SEQ ID NO:1732] as compared to the uninfected T cells indicating lysis of target cells by the different MPL-CAR-T cells.

FIG. 9 depicts, in accordance with various embodiments of the invention, increased killing of HEL-GLuc cells by CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658] CAR expressing PBMC as compared to FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467] PBMC or uninfected PBMC.

FIG. 10 depicts, in accordance with an embodiment of the invention, increased killing of HEL-GLuc cells by CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-Q04)[SEQ ID NO:1733] CAR expressing PBMC as compared to uninfected PBMC.

FIG. 11 depicts, in accordance with an embodiments of the invention, increase in GLuc activity, indicating lysis of target cells, following co-culture with T cells expressing MPL-specific CARs, which was stronger with CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731], CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-Q04)[SEQ ID NO:1733], and CD8SP-AB317-(vL-vH)-Myc-CD28z-T2A-PAC(031615-T04)[SEQ ID NO:1735] constructs and modest with CD8SP-178-(vL-vH)-Myc-CD28z-T2A-PAC(031615-R04)[SEQ ID NO:1734] construct as compared to the uninfected T cells.

FIG. 12 depicts, in accordance with various embodiments of the invention, increase in GLuc activity, indicating lysis of target cells, following co-culture with T cells expressing MPL-specific CARs, which was stronger with CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731], CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-Q04)[SEQ ID NO:1733], CD8SP-AB317-(vL-vH)-Myc-CD28z-T2A-PAC(031615-T04)[SEQ ID NO:1735], and CD8SP-12E10-(vL-vH)-Myc-CD28z-T2A-PAC(031615-S03)[SEQ ID NO:1736] constructs and modest with CD8SP-178-(vL-vH)-Myc-CD28z-T2A-PAC(031615-R04)[SEQ ID NO:1734] and CD8SP-VB22Bw4-(vL-vH)-Myc-CD28z-T2A-PAC(031615-B06)[SEQ ID NO:3536] constructs as compared to the uninfected T cells.

FIG. 13 depicts, in accordance with an embodiment of the invention, increase in GLuc activity, indicating lysis of target cells, following co-culture with NK92MI cells expressing MPL-specific CD8SP-161-(vL-vH)-Myc-CD8TM-BBz-T2A-EGFP(090814-C03)[SEQ ID NO:1732] CAR.

FIG. 14 depicts, in accordance with an embodiment of the invention, increase in GLuc activity, indicating lysis of target cells, following co-culture with NK92MI cells expressing MPL-specific CARs.

FIG. 15 depicts, in accordance with an embodiment of the invention, increased secretion of TNFα upon coculture of T cells expressing CAR targeting MPL with HEL cells as compared to uninfected T cells used as controls.

FIG. 16 depicts, in accordance with an embodiment of the invention, that the median survival of mice given CD8SP-161-(vL-vH)-Myc-CD8TM-BBz-T2A-EGFP(090814-C03)[SEQ ID NO:1732] expressing NK92MI cells was 31.5 days, which was significantly higher than mice given unmodified NK92MI cells (28.5 days; p=0.03) or those given NK92MI cells expressing a control CD8SP-4C3-(vL-vH)-Myc-BBz-T2A-EGFP(100814-K06)[SEQ ID NO:3537] CAR (28 days; p=0.04).

FIG. 17 depicts, in accordance with an embodiment of the invention, increased expression of the different CD19 CARs (shown with grey lines) on the surface of T cells as determined by staining with APC-Myc as compared to the uninfected T cells (UI; shown with dotted lines). Constructs depicted include CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467]; CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470]; CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471]; CD8SP-KSHV-4C3-(vL-vH)-Myc-BBz-T2A-PAC(042315-N01)[SEQ ID NO:1643].

FIG. 18 depicts, in accordance with various embodiments of the invention, strong binding of Jurkats expressing CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470], CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471] and CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467] CAR constructs to FLAG-CD19-ECD-GGSG-NLuc-AcV5 [SEQ ID NO:2671] supernatant, while no significant binding was observed on parental cells or those expressing the CD8SP-KSHV-4C3-(vL-vH)-Myc-BBz-T2A-PAC(042315-N01)[SEQ ID NO:1643] control CAR.

FIG. 19 depicts, in accordance with various embodiments of the invention, strong binding of T cells expressing CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470], CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471] and CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467] CAR constructs to FLAG-CD19-ECD-GGSG-NLuc-AcV5 [SEQ ID NO:2671] supernatant, while no significant binding was observed on parental cells or those expressing CD8SP-KSHV-4C3-(vL-vH)-Myc-BBz-T2A-PAC(042315-N01)[SEQ ID NO:1643] control CAR.

FIG. 20 depicts, in accordance with various embodiments of the invention, increase in GLuc activity, indicating lysis of RAJI target cells, following co-culture with T cells expressing CD19-specific CARs as compared to uninfected T cells (T-UI) or those expressing the control CAR 4C3. Constructs depicted include CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467]; CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471]; CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470]; CD8SP-KSHV-4C3-(vL-vH)-Myc-BBz-T2A-PAC(042315-N01)[SEQ ID NO:1643]; (−) indicates CAR-transduced T cells were used without puromycin selection; (+) indicates CAR-transduced T cells were used with puromycin selection.

FIG. 21 depicts, in accordance with various embodiments of the invention, increase in GLuc activity, indicating lysis of RAJI target cells, following co-culture with T cells expressing CD19-specific CARs as compared to uninfected T cells (T-UI) or those expressing the control CAR 4C3. Constructs depicted include CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467]; CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471]; CD8SP-KSHV-4C3-(vL-vH)-Myc-BBz-T2A-PAC(042315-N01)[SEQ ID NO:1643]; (−) indicates CAR-transduced T cells were used without puromycin selection; (+) indicates CAR-transduced T cells were used with puromycin selection.

FIG. 22 depicts, in accordance with various embodiments of the invention, the survival of mice in specific groups.

FIG. 23A-C depicts, in accordance with various embodiments of the invention, increased staining with FITC-FLAG antibody in K13-expressing T cells as compared to uninfected T cells. K13 immortalized T cells are CD8+/CD4−(49%), CD8−/CD4+(21%) and CD8+/CD4+(29%).

FIG. 24 depicts, in accordance with various embodiments of the invention, that CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467], and CD8SP-FMC63-(vL-vH)-Myc-BBz-P2A-K13-Flag-T2A-PAC(111014-Y11)[SEQ ID NO:1197] expressing T-cells that have been selected with puromycin induce specific lysis of RS411 cells as measured by Gluc assay.

FIG. 25 depicts, in accordance with various embodiments of the invention, increase in GLuc activity, indicating lysis of target cells, following co-culture with T cells expressing CD19-specific CARs as compared to uninfected T cells (T-UI) or those expressing the control CAR 4C3.

FIG. 26 depicts, in accordance with various embodiments of the invention, confirms that incorporation of K13, MC159 or HTLV2-Tax (Tax2) does not negatively impact the killing ability of CARs with or without the presence of 41BB costimulatory domain.

FIG. 27 depicts, in accordance with various embodiments of the invention, that the T cells expressing CAR constructs that co-expressed MC159 and HTLV2-Tax continue to exert cytotoxicity after 2 months in culture while the T cells expressing the constructs lacking MC159 and HTLV2-Tax lost this ability.

FIG. 28A-FIG. 28B depict, in accordance with various embodiments of the invention, treatment with AP20187 led to increase in K13- and HTLV2-Tax RS mutant-induced NF-κB-Luc activity in all constructs in which K13 and HTLV2-Tax mutant were expressed in fusion with FKBP. Constructs depicted in FIG. 28A include FKBPX2-K13[SEQ ID NO: 879]; CD8SP-FMC63(vL-vH)-Myc-z-P2A-FKBP-K13-FLAG-T2A-EGFP(112614-B06)[SEQ ID NO:1755]; CD8SP-161-(vL-vH)-Myc-BBz-P2A-FKBP-K13-Flag-T2A-EGFP(112614-E05)[SEQ ID NO:1744]; CD8SP-FMC63(vL-vH)-Myc-z-P2A-FKBPx2-K13-FLAG-T2A-EGFP(120314-J03)[SEQ ID NO:1756]; and CD8SP-FMC63(vL-vH)-Myc-z-P2A-Myr-FKBPx2-K13-FLAG-T2A-EGFP(120314-N07)[SEQ ID NO:1757]. Constructs depicted in FIG. 28B include CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-FKBPx2-FLAG-TAX2U2RS-T2A-eGFP-M03(012315-03)[SEQ ID NO:3539]; and CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-FKBPx2-HTLV2-Tax-RS-T2A-EGFP(012315-001)[SEQ ID NO:1758].

FIG. 29A-FIG. 29B depict, in accordance with various embodiments of the invention, activation of K13-mediated NF-κB activity by addition of AP20187 does not adversely affect cell killing induced by the CAR constructs that coexpress FKBP-K13. Construct depicted in FIG. 29A include CD8SP-FMC63(vL-vH)-Myc-z-P2A-FKBP-K13-FLAG-T2A-PAC(112316-S06)[SEQ ID NO:1770]. Construct depicted in FIG. 29B include CD8SP-161-(vL-vH)-Myc-z-P2A-FKBP-K13-FLAG-T2A-PAC(112916-U06)[SEQ ID NO: 1741].

FIG. 30A-FIG. 30B depict, in accordance with various embodiments of the invention, induction of target cell death by different MPL-directed and CD32-directed CAR constructs that coexpress K13, MC159, HTLV2-Tax or HTLV2-Tax RS mutant.

FIG. 31 depicts, in accordance with various embodiments of the invention, induction of PC3-target cell death by a TROP2-directed conventional CAR I construct that coexpresses K13.

FIG. 32A-FIG. 32B depict, in accordance with various embodiments of the invention, induction of target cell death by different LAMP1-directed CAR constructs that coexpress K13,

FIG. 33 depicts, in accordance with various embodiments of the invention, that activation of K13 signaling in T cells expressing the FKBP-K13 fusion protein by addition of AP20187 compound does not adversely affect activation of CAR-induced NFAT signaling.

FIG. 34 depicts, in accordance with various embodiments of the invention, NF-κB reporter activity by wild-type K13 and various K13 mutants.

FIG. 35 depict, in accordance with various embodiments of the invention, shows inhibition of CAR CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471]-induced cell death by 50 nM and 100 nM Dasatinib, while Imatinib has no effect.

FIG. 36A-B depict, in accordance with various embodiments of the invention, increase in GLuc activity following co-culture with T cells expressing CD19-specific CARs CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467] (FIG. 36A) and CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471](FIG. 36B) as compared to the uninfected T cells (T-UI) indicating lysis of target cells by the different CD19-CAR-T cells and its inhibition by Dasatinib and Ponatinib at the indicated doses.

FIG. 37 depict, in accordance with various embodiments of the invention, that Dasatinib effectively blocks killing of RAJI-GLuc cells by T cells expressing the CD8SP-CD22-m971-(vL-vH)-Myc-BBz-T2A-PAC(091515-A02)[SEQ ID NO:1519] CAR as determined by GLuc assay.

FIG. 38A-FIG. 38B depict, in accordance with various embodiments of the invention, that FIG. 38A: Dasatinib blocks NK92 cells mediated death of K562 cells as determined by Gluc assay and FIG. 38B: Dasatinib blocks death of RAJI-GLuc cells by CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-EGFP(070814-D06)[SEQ ID NO:3535] expressing NK92MI cells as determined by Gluc assay.

FIG. 39A-FIG. 39B depict, in accordance with various embodiments of the invention, that FIG. 39A: treatment with Blinatumomab in the presence of T cells result in strong induction of death of RAJI-GLuc cells which is effectively blocked by 100 nM Dasatinib and FIG. 39B: that co-culture of RAJI-GLuc cells with Blinatumomab in the presence of T cells result in strong induction of IFNγ production which is effectively blocked by 100 nM Dasatinib.

FIG. 40A-FIG. 40C depict, in accordance with various embodiments of the invention, FIG. 40A shows no significant toxic effect of the various drugs on RAJI-pLenti-Gluc cells that had not been co-cultured with CAR T cells. FIG. 40B shows mild to modest inhibition of CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470] CAR-T cells-induced death of RAJI-pLenti-GLuc cells by Ruxolitinib, Fosatamatinib and Alisertib as compared to cells treated with media (Med) alone (FIG. 40A). Dasatinib was used as a positive control. FIG. 40C shows that the above compounds have only a minimal effect on Blinatumomab induced cell death mediated by T cells at the indicated concentrations.

FIG. 41A-FIG. 41C depict, in accordance with various embodiments of the invention, FIG. 41A shows the release of Gluc in cells treated with the indicated drugs in the presence of media alone without any CAR-T cells. FIG. 41B shows near complete inhibition of CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470] CAR-T cells-induced death of RAJI-pLenti-GLuc cells by A-770041 at 100 nM and 200 nM while Saracatinib had no significant effect. Avasimibe had no significant effect on CAR-T cells induced cell death at 100 nM but completely blocked it at 1 PM. FIG. 41C shows that treatment with 100 nM A770041 partially blocked cell death induced by combination of Blinatumomab with T cells while treatment with 200 nM A770041 led to complete inhibition.

FIG. 42A-FIG. 42B depict, in accordance with various embodiments of the invention, that coculturing of Jurkat cells expressing CD8SP-FMC63(vL-vH)-BBz-P2A-IgHSP-IL6R-M83(vL-vH)-Flag-T2A-PAC(011315-K04)[SEQ ID NO:1763] with RAJI cells led to increase in EGFP expression as compared to cells that had not been exposed to RAJI cells (FIG. 42A). This indicates activation of NFAT signaling. No increase in EGFP expression was observed in parental Jurkats (J-N-G-P) without or with culturing with RAJI (FIG. 42B).

DETAILED DESCRIPTION

All references cited herein are incorporated by reference in their entirety as though fully set forth. Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Allen et al., Remington: The Science and Practice of Pharmacy 22^nded., Pharmaceutical Press (Sep. 15, 2012); Hornyak et al., Introduction to Nanoscience and Nanotechnology, CRC Press (2008); Singleton and Sainsbury, Dictionary ofMicrobiology and Molecular Biology 3^rded., revised ed., J. Wiley & Sons (New York, NY 2006); Smith, March's Advanced Organic Chemistry Reactions, Mechanisms and Structure 7^thed., J. Wiley & Sons (New York, NY 2013); Singleton, Dictionary of DNA and Genome Technology 3^rded., Wiley-Blackwell (Nov. 28, 2012); and Green and Sambrook, Molecular Cloning: A Laboratory Manual 4th ed., Cold Spring Harbor Laboratory Press (Cold Spring Harbor, N Y 2012), provide one skilled in the art with a general guide to many of the terms used in the present application. For references on how to prepare antibodies, see Greenfield, Antibodies A Laboratory Manual 2^nded., Cold Spring Harbor Press (Cold Spring Harbor NY, 2013); Kohler and Milstein, Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion, Eur. J. Immunol. 1976 July, 6(7):511-9; Queen and Selick, Humanized immunoglobulins, U.S. Pat. No. 5,585,089 (1996 December); and Riechmann et al., Reshaping human antibodiesfor therapy, Nature 1988 Mar. 24, 332(6162):323-7.

One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Other features and advantages of the invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings, which illustrate, by way of example, various features of embodiments of the invention. Indeed, the present invention is in no way limited to the methods and materials described. For convenience, certain terms employed herein, in the specification, examples and appended claims are collected here.

Unless stated otherwise, or implicit from context, the following terms and phrases include the meanings provided below. Unless explicitly stated otherwise, or apparent from context, the terms and phrases below do not exclude the meaning that the term or phrase has acquired in the art to which it pertains. The definitions are provided to aid in describing particular embodiments, and are not intended to limit the claimed invention, because the scope of the invention is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

Chimeric antigen receptors (CAR) are artificial T cell receptors that are under investigation as a therapy for cancer, using a technique called adoptive cell transfer. Hematopoietic cells are removed from a patient and modified so that they express receptors that recognize proteins that are specific to the particular form of cancer. The cells, which can then recognize and kill the cancer cells, are reintroduced into the patient. CAR targeting the human CD19 antigen have shown impressive activity against B cell lineage human blood cancers, such as Acute Lymphocytic Leukemia, chronic lymphocytic leukemia and lymphoma and are under commercial development by several companies. However, there is a need to develop CAR targeting antigens that are expressed on non-lymphoid cells. This invention pertains to CARs targeting several such antigens.

Definitions

As used herein the term “comprising” or “comprises” is used in reference to compositions, methods, and respective component(s) thereof, that are useful to an embodiment, yet open to the inclusion of unspecified elements, whether useful or not. It will be understood by those within the art that, in general, terms used herein are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.).

Unless stated otherwise, the terms “a” and “an” and “the” and similar references used in the context of describing a particular embodiment of the application (especially in the context of claims) can be construed to cover both the singular and the plural. The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (for example, “such as”) provided with respect to certain embodiments herein is intended merely to better illuminate the application and does not pose a limitation on the scope of the application otherwise claimed. The abbreviation, “e.g.” is derived from the Latin exempli gratia, and is used herein to indicate a non-limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example.” No language in the specification should be construed as indicating any non-claimed element essential to the practice of the application.

As used herein, the term “about” refers to a measurable value such as an amount, a time duration, and the like, and encompasses variations of ±20%, ±10%, ±5%, ±1%, ±0.5% or ±0.1% from the specified value.

“Chimeric antigen receptor” or “CAR” or “CARs” as used herein refers to engineered receptors, which graft an antigen specificity onto cells (for example T cells such as naïve T cells, central memory T cells, effector memory T cells or combination thereof). CARs are also known as artificial T-cell receptors, chimeric T-cell receptors or chimeric immunoreceptors. In various embodiments, CARs are recombinant polypeptides comprising an antigen-specific domain (ASD), a hinge region (HR), a transmembrane domain (TMD), co-stimulatory domain (CSD) and an intracellular signaling domain (ISD).

“Antigen-specific domain” (ASD) refers to the portion of the CAR that specifically binds the antigen on the target cell. In some embodiments, the ASD of the CARs comprising any of the backbones described herein comprises an antibody or a functional equivalent thereof or a fragment thereof or a derivative thereof. The targeting regions may comprise full length heavy chain, Fab fragments, single chain Fv (scFv) fragments, divalent single chain antibodies or diabodies, each of which are specific to the target antigen. There are, however, numerous alternatives, such as linked cytokines (which leads to recognition of cells bearing the cytokine receptor), affibodies, ligand binding domains from naturally occurring receptors, soluble protein/peptide ligand for a receptor (for example on a tumor cell), peptides, and vaccines to prompt an immune response, which may each be used in various embodiments of the invention. In some embodiments, almost any molecule that binds a given antigen with high affinity can be used as an ASD, as will be appreciated by those of skill in the art. In some embodiments, the ASD comprises T cell receptors (TCRs) or portions thereof. In exemplary embodiments, nucleic acids encoding ASDs comprising scFVs are set forth herein in SEQ ID NOs: 564-798.

“Hinge region” (HR) as used herein refers to the hydrophilic region which is between the ASD and the TMD. The hinge regions include but are not limited to Fc fragments of antibodies or fragments or derivatives thereof, hinge regions of antibodies or fragments or derivatives thereof, CH2 regions of antibodies, CH3 regions of antibodies, artificial spacer sequences or combinations thereof. Examples of hinge regions include but are not limited to CD8a hinge, and artificial spacers made of polypeptides which may be as small as, for example, Gly3 or CH1 and CH3 domains of IgGs (such as human IgG4). In some embodiments, the hinge region is any one or more of (i) a hinge, CH2 and CH3 regions of IgG4, (ii) a hinge region of IgG4, (iii) a hinge and CH2 of IgG4, (iv) a hinge region of CD8a, (v) a hinge, CH2 and CH3 regions of IgG1, (vi) a hinge region of IgG1 or (vi) a hinge and CH2 region of IgG1. Other hinge regions will be apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.

“Transmembrane domain” (TMD) as used herein refers to the region of the CAR which crosses the plasma membrane. The transmembrane domain of the CAR of the invention is the transmembrane region of a transmembrane protein (for example Type I transmembrane proteins), an artificial hydrophobic sequence or a combination thereof. Other transmembrane domains will be apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention. In some embodiments, the TMD encoded CAR comprising any of the backbones described herein comprises a transmembrane domain selected from the transmembrane domain of an alpha, beta or zeta chain of a T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRFl), CD160, CD19, IL2R beta, IL2R gamma, IL7R a, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1(CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAMI, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMFI, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG/Cbp, NKp44, NKp30, NKp46, NKG2D, and/or NKG2C.

“Co-stimulatory domain” (CSD) as used herein refers to the portion of the CAR comprising any of the backbones described herein which enhances the proliferation, survival and/or development of memory cells. The CARs of the invention may comprise one or more co-stimulatory domains. Each co-stimulatory domain comprises the costimulatory domain of any one or more of, for example, members of the TNFR superfamily, CD28, CD137 (4-1BB), CD134 (OX40), Dap10, CD27, CD2, CD5, ICAM-1, LFA-1(CD11a/CD18), Lck, TNFR-I, TNFR-II, Fas, CD30, CD40 or combinations thereof. Other co-stimulatory domains (e.g., from other proteins) will be apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.

“Intracellular signaling domain” (ISD) or “cytoplasmic domain” as used herein refers to the portion of the CAR comprising any of the backbones described herein which transduces the effector function signal and directs the cell to perform its specialized function. Examples of domains that transduce the effector function signal include but are not limited to the z chain of the T-cell receptor complex or any of its homologs (e.g., h chain, FceR1g and b chains, MB1 (Iga) chain, B29 (Igb) chain, etc.), human CD3 zeta chain, CD3 polypeptides (D, d and e), syk family tyrosine kinases (Syk, ZAP 70, etc.), src family tyrosine kinases (Lck, Fyn, Lyn, etc.) and other molecules involved in T-cell transduction, such as CD2, CD5 and CD28. Other intracellular signaling domains will be apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.

“Linker” (L) or “linker domain” or “linker region” as used herein refer to an oligo- or polypeptide region from about 1 to 100 amino acids in length, which links together any of the domains/regions of the CAR of the invention. Linkers may be composed of flexible residues like glycine and serine so that the adjacent protein domains are free to move relative to one another. Longer linkers may be used when it is desirable to ensure that two adjacent domains do not sterically interfere with one another. Linkers may be cleavable or non-cleavable. Examples of cleavable linkers include 2A linkers (for example T2A), 2A-like linkers or functional equivalents thereof and combinations thereof. In some embodiments, the linkers include the picornaviral 2A-like linker, CHYSEL sequences of porcine teschovirus (P2A), Thosea asigna virus (T2A) or combinations, variants and functional equivalents thereof. In other embodiments, the linker sequences may comprise Asp-Val/Ile-Glu-X-Asn-Pro-Gly(2A)-Pro^(2B)motif (SEQ ID NO:3572), which results in cleavage between the 2A glycine and the 2B proline. The nucleic sequences of several exemplary cleavable linkers are provided in SEQ ID NO: 831 to SEQ ID NO: 836 and amino acid sequences of several exemplary linkers are provide in SEQ ID NO: 2598 to SEQ ID NO: 2602. Other linkers will be apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention. In an embodiment, a Ser-Gly-Ser-Gly (SGSG) motif (SEQ ID NOs: 837-838 and SEQ ID NO: 2603) is also added upstream of the cleavable linker sequences to enhance the efficiency of cleavage. A potential drawback of the cleavable linkers is the possibility that the small 2A tag left at the end of the N-terminal protein may affect protein function or contribute to the antigenicity of the proteins. To overcome this limitation, in some embodiments, a furine cleavage site (RAKR) (SEQ ID NO: 839-841 and SEQ ID NO: 2604) is added upstream of the SGSG (SEQ ID NO:2:837-838 and SEQ ID NO:2603) motifs to facilitate cleavage of the residual 2A peptide following translation.

“Effector function” refers to the specialized function of a differentiated cell. Effector function of a T-cell, for example, may be cytolytic activity or helper activity including the secretion of cytokines.

“Enhancer”, as used herein, denotes sequence elements that augment, improve or ameliorate transcription of a nucleic acid sequence irrespective of its location and orientation in relation to the nucleic acid sequence to be expressed. An enhancer may enhance transcription from a single promoter or simultaneously from more than one promoter. As long as this functionality of improving transcription is retained or substantially retained (e.g., at least 70%, at least 80%, at least 90% or at least 95% of wild-type activity, that is, activity of a full-length sequence), any truncated, mutated or otherwise modified variants of a wild-type enhancer sequence are also within the above definition.

“Accessory module” or “accessory modules” as used herein refers to an element that is co-expressed with a CAR to increase, decrease, regulate or modify the expression or activity of a CAR or CAR-expressing cells. In exemplary embodiments, accessory modules include but are not limited to examples described in Table 16. In one embodiment, the accessory module comprises K13-vFLIP (Table 16). In another embodiment, the accessory module comprises MC159-vFLIP (Table 16). In a further embodiment, the accessory module comprises an FKBP((FK506 binding protein)-fusion protein, such as FKBP-K13, in which whose activity can be controlled by the administration of a dimerizer molecule (Table 16).

“Switch domain,” or a “dimerization domain” as used herein, typically refers to a polypeptide-based entity, that, in the presence of a dimerization molecule, associates with another switch domain. The association results in a functional coupling of a first entity linked to, e.g., fused to, a first switch domain, and a second entity linked to, e.g., fused to, a second switch domain. A first and second switch domain are collectively referred to as a dimerization switch. In embodiments, the first and second switch domains are the same as one another, e.g., they are polypeptides having the same primary amino acid sequence, and are referred to collectively as a homodimerization switch. In embodiments, the switch is intracellular. In embodiments, the switch domain is a polypeptide-based entity, e.g., FKBP (FK506 binding protein), and the dimerization molecule is small molecule, e.g., AP20187.

“Dimerization molecule,” as that term is used herein refers to a molecule that promotes the association of a first switch domain with a second switch domain. In embodiments, the dimerization molecule does not naturally occur in the subject, or does not occur in concentrations that would result in significant dimerization. In embodiments, the dimerization molecule is a small molecule, e.g., rapamycin or a rapalogue, e.g., RAD001 or AP20187.

“Therapeutic Controls” as used herein refers to an element used for controlling the activity of a CAR expressing cell. In some embodiments, therapeutic controls for controlling the activity of the CAR expressing cells of the invention comprise any one or more of truncated epidermal growth factor receptor (tEGFR), truncated epidermal growth factor receptor viii (tEGFRviii), truncated CD30 (tCD30), truncated BCMA (tBCMA), truncated CD19 (tCD19), thymidine kinase, cytosine deaminase, nitroreductase, xanthine-guanine phosphoribosyl transferase, human caspase 8, human caspase 9, inducible caspase 9, purine nucleoside phosphorylase, linamarase/linamarin/glucose oxidase, deoxyribonucleoside kinase, horseradish peroxidase (HRP)/indole-3-acetic (IAA), Gamma-glutamylcysteine synthetase, CD20/alphaCD20, CD34/thymidine kinase chimera, dox-dependent caspase-2, mutant thymidine kinase (HSV-TKSR39), AP1903/Fas system, a chimeric cytokine receptor (CCR), a selection marker, and combinations thereof. The nucleic acid sequences of several therapeutic controls are provided in SEQ ID NO: 850 to SEQ ID NO: 856 and SEQ ID NO: 883 (Table 16).

“Disease targeted by genetically modified cells” as used herein encompasses the targeting of any cell involved in any manner in any disease by the genetically modified cells of the invention, irrespective of whether the genetically modified cells target diseased cells or healthy cells to effectuate a therapeutically beneficial result. The genetically modified cells include but are not limited to genetically modified T-cells, NK cells, hematopoietic stem cells, pluripotent embryonic stem cells or embryonic stem cells. The genetically modified cells express the conventional CARs and novel backbones containing conventional CARs with accessory modules of the invention, which CARs may target any of the antigens expressed on the surface of target cells. Examples of antigens which may be targeted include but are not limited to antigens expressed on B-cells; antigens expressed on carcinomas, sarcomas, lymphomas, leukemia, germ cell tumors, and blastomas; antigens expressed on various immune cells; and antigens expressed on cells associated with various hematologic diseases, autoimmune diseases, and/or inflammatory diseases. Other antigens that may be targeted will be apparent to those of skill in the art and may be targeted by the CARs of the invention in connection with alternate embodiments thereof.

“Co-express” as used herein refers to simultaneous expression of two or more genes. Genes may be nucleic acids encoding, for example, a single protein or a chimeric protein as a single polypeptide chain. In one embodiment, simultaneous expression includes a single vector encoding a CAR and proteins that modulate an immune response. In another embodiment, simultaneous expression includes a first vector that encodes the CAR and a second vector that encodes one or more proteins that modulate an immune response.

“Autologous” cells as used herein refers to cells derived from the same individual as to whom the cells are later to be re-administered into.

“Genetically modified cells”, “redirected cells”, “genetically engineered cells” or “modified cells” as used herein refer to cells that express the CAR of the invention. In some embodiments, the genetically modified cells comprise vectors that encode a CAR. In some embodiments, the genetically modified cells comprise vectors that encode a CAR and one or more accessory molecules in the same vector. In some embodiments, the genetically modified cells comprise a first vector that encodes a CAR and a second vector that encodes the accessory molecule. In some embodiments, the genetically modified cells comprise a first vector that encodes a CAR and a second vector that encodes more than one accessory molecule. In some embodiments, the genetically modified cells comprise a first vector that encodes a CAR and a second vector that encodes the first accessory molecule and a third vector that encodes a second accessory molecule.

As used herein, the term “backbone” refers to the specific combination of conventional CARs (Table 1) and accessory modules as described in Table 2. In exemplary embodiments, specific combinations of CARs and accessory modules which comprise various backbones are described in Table 2. In one embodiment, the CAR and the accessory module are encoded by a single nucleic acid molecule. In another embodiment, the CAR is encoded by the first nucleic acid molecule and the accessory module is encoded by a second nucleic acid molecule. In some embodiments, the accessory module is encoded by more than one nucleic acid molecule, depending on the number of components in the accessory modules.

“Immune cell” as used herein refers to the cells of the mammalian immune system including but not limited to antigen presenting cells, B-cells, basophils, cytotoxic T-cells, dendritic cells, eosinophils, granulocytes, helper T-cells, leukocytes, lymphocytes, macrophages, mast cells, memory cells, monocytes, natural killer cells, neutrophils, phagocytes, plasma cells and T-cells.

The term “immune effector function” of the CAR-containing cell refers to any of the activities shown by the CAR-expressing cell upon stimulation by a stimulatory molecule. Examples of immune effector function, e.g., in a CAR-T cell, include cytolytic activity and helper activity, including the secretion of cytokines.

“Immune effector cell” as used herein refers to the T cells and natural killer (NK) cells.

“Immune response” as used herein refers to immunities including but not limited to innate immunity, humoral immunity, cellular immunity, immunity, inflammatory response, acquired (adaptive) immunity, autoimmunity and/or overactive immunity.

As used herein, “CD4 lymphocytes” refer to lymphocytes that express CD4, i.e., lymphocytes that are CD4+. CD4 lymphocytes may be T cells that express CD4.

The terms “T-cell” and “T-lymphocyte” are interchangeable and used synonymously herein. Examples include but are not limited to naïve T cells, central memory T cells, effector memory T cells or combinations thereof.

As used herein, the term “antibody” refers to an intact immunoglobulin or to a monoclonal or polyclonal antigen-binding fragment with the Fc (crystallizable fragment) region or FcRn binding fragment of the Fc region, referred to herein as the “Fc fragment” or “Fc domain”. Antigen-binding fragments may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding fragments include, inter alia, Fab, Fab′, F(ab′)2, Fv, dAb, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), single domain antibodies, chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide. The Fc domain includes portions of two heavy chains contributing to two or three classes of the antibody. The Fc domain may be produced by recombinant DNA techniques or by enzymatic (e.g. papain cleavage) or via chemical cleavage of intact antibodies.

The term “antibody fragment,” as used herein, refer to a protein fragment that comprises only a portion of an intact antibody, generally including an antigen binding site of the intact antibody and thus retaining the ability to bind antigen. Examples of antibody fragments encompassed by the present definition include: (i) the Fab fragment, having VL, CL, VH and CH1 domains; (ii) the Fab′ fragment, which is a Fab fragment having one or more cysteine residues at the C-terminus of the CH1 domain; (iii) the Fd fragment having VH and CH1 domains; (iv) the Fd′ fragment having VH and CH1 domains and one or more cysteine residues at the C-terminus of the CH1 domain; (v) the Fv fragment having the VL and VH domains of a single arm of an antibody; (vi) the dAb fragment (Ward et al., Nature 341, 544-546 (1989)) which consists of a VH domain; (vii) isolated CDR regions; (viii) F(ab′)2 fragments, a bivalent fragment including two Fab′ fragments linked by a disulphide bridge at the hinge region; (ix) single chain antibody molecules (e.g., single chain Fv; scFv) (Bird et al., Science 242:423-426 (1988); and Huston et al., PNAS (USA) 85:5879-5883 (1988)); (x) “diabodies” with two antigen binding sites, comprising a heavy chain variable domain (V_H) connected to a light chain variable domain (VL) in the same polypeptide chain (see, e.g., EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); (xi) “linear antibodies” comprising a pair of tandem Fd segments (VH-CH1-VH-CH1) which, together with complementary light chain polypeptides, form a pair of antigen binding regions (Zapata et al. Protein Eng. 8(10):1057-1062 (1995); and U.S. Pat. No. 5,641,870).

“Single chain variable fragment”, “single-chain antibody variable fragments” or “scFv” antibodies as used herein refer to forms of antibodies comprising the variable regions of only the heavy (V_H) and light (V_L) chains, connected by a linker peptide. The scFvs are capable of being expressed as a single chain polypeptide. The scFvs retain the specificity of the intact antibody from which it is derived. The light and heavy chains may be in any order, for example, V_H-linker-V_Lor V_L-linker-V_H, so long as the specificity of the scFv to the target antigen is retained.

“Complementarity determining region” (CDR) as used herein refers to the amino acid sequences within the variable regions of antibodies which regions confer specificity and binding affinity. In general, there are three CDRs in each of the light chain variable regions (LCDR1, LCDR2 and LCDR3) and three CDRs in each of the heavy chain variable regions (HCD1, HCDr2 and HCDR3). The boundaries of the CDRs may be determined using methods well known in the art including the “Kabat” numbering scheme and/or “Chothia” number scheme (Kabat et al. Sequences of Proteins of Immunological Interest, 5^thEd. Public Health Services, National Institutes of Health, Bethesda, MD; Al-Lazikani et al., (1997) JMB 273,927-948).

As used herein, the term “specific binding” means the contact between an antibody and an antigen with a binding affinity of at least 10⁻⁶M. In certain aspects, antibodies bind with affinities of at least about 10⁻⁷M, and preferably 10⁻⁸M, 10⁻⁹M, 10⁻¹⁰M, 10⁻¹¹M, or 10⁻¹²M.

“Binds the same epitope as” means the ability of an antibody, scFv, antigen specific domain of a CAR or other binding agent to bind to a target and having the same epitope as the exemplified antibody, scFv, antigen specific domain of a CAR or other binding agent. As an example, the epitopes of the exemplified antibody, scFv, or other binding agent and other antibodies can be determined using standard epitope mapping techniques. Epitope mapping techniques, well known in the art include Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, New Jersey. For example, linear epitopes may be determined by e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports. Such techniques are known in the art and described in, e.g., U.S. Pat. No. 4,708,871; Geysen et al, (1984) Proc. Natl. Acad. Sci. USA 8:3998-4002; Geysen et al, (1985) Proc. Natl. Acad. Sci. USA 82:78-182; Geysen et al, (1986) Mol. Immunol. 23: 709-715. Similarly, conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., hydrogen/deuterium exchange, x-ray crystallography and two-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols, supra. Antigenic regions of proteins can also be identified using standard antigenicity and hydropathy plots, such as those calculated using, e.g., the Omiga version 1.0 software program available from the Oxford Molecular Group. This computer program employs the Hopp/Woods method, Hopp et al, (1981) Proc. Natl. Acad. Sci USA 78:3824-3828; for determining antigenicity profiles, and the Kyte-Doolittle technique, Kyte et al, (1982) J. Mol. Bioi. 157: 1 05-132; for hydropathy plots (FROM MORPHOSYS CD19 patent WO 2013/024097). To determine if selected monoclonal antibodies against a target (e.g., CD19) bind to unique epitopes, each antibody can be biotinylated using commercially available reagents (Pierce, Rockford, Ill.). Competition studies using unlabeled monoclonal antibodies and biotinylated monoclonal antibodies can be performed using CD19-extracellular domain coated-ELISA plates as described above. Biotinylated mAb binding can be detected with a strep-avidin-alkaline phosphatase probe.

The epitope recognized by a CAR can be also determined from the epitope recognized by the scFv comprising the CAR. For example, since the antigen specific domain of the CAR CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC (SEQ ID NO: 1658 and SEQ ID NO: 3403) targeting MPL is comprised of scFv MPL-161-(vL-vH) (SEQ ID NO: 730 and SEQ ID NO: 2500), it is expected that the CAR would target the same epitope as the scFv and the parental antibody from which the scFv is derived. The epitopes recognized by several scFv and/or their parental antibodies used in the construction of the CARs and backbones of this invention are known in the art. Alternatively, the epitope targeted by a CAR (including the CARs that are present as parat of backbones) can be determined by generating a series of mutants of its target antigen and testing the ability of the mutants to bind to the CAR-expressing cells. As an example, the epitope recognized by the CAR CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC (SEQ ID NO: 1658 and SEQ ID NO: 3403) targeting MPL can be determined by generating a panel of mutants of the MPL-ECD-GGSG-Nluc-AcV5 fusion construct (SEQ ID NO: 925 and SEQ ID NO: 2670). The mutant constructs would be transfected into a suitable cell line (e.g., 293FT cells) and the supernatant containing the fusion protein collected and assayed for NLuc activity to assure that the different mutant MPL-ECD-GGSG-Nluc-AcV5 fusion proteins are being secreted in the supernatant. Subsequently, the fusion proteins would be tested for their ability to bind to cells (e.g., Jurkat cells or T cells) expressing the CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC (SEQ ID NO: 1658 and SEQ ID NO: 3403) CAR construct. The mutant that fails to bind to the CAR-expressing cells is a candidate for containing the epitope targeted by the MPL-specific CAR. An alternate approach to determine the epitope recognized by a particular CAR could include a functional competitive assay with different test antibodies. For example, T cells expressing the CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC (SEQ ID NO: 1658 and SEQ ID NO: 3403) CAR would be co-cultured with a cell line expressing MPL (e.g., HEL cells) in the absence and presence of increasing concentrations of different test MPL antibodies. In case the epitope recognized by a test MPL antibody overlaps with the epitope recognized by the CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC (SEQ ID NO: 1658 and SEQ ID NO: 3403) CAR, then the test antibody would be expected to block target-cell killing and cytokine production induced by T cells expressing the CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC (SEQ ID NO: 1658 and SEQ ID NO: 3403) CAR in a dose-dependent manner. A non-specific antibody of the same isotype as the test antibody would be included as a control and would be expected to have no effect on the target-cell killing and cytokine production induced by T cells expressing the CAR. Similarly, a specific CAR can be expressed in Jurkat-NFAT-EGFP cells and the ability of a test antibody to block EGFP induction by the CAR-expressing Jurkat-NFAT-GFP cells upon coculture with a target cell line can be used to determine whether the epitope recognized by the test antibody overlaps with the epitope recognized by the said CAR.

“Therapeutic agents” as used herein refers to agents that are used to, for example, treat, inhibit, prevent, mitigate the effects of, reduce the severity of, reduce the likelihood of developing, slow the progression of and/or cure, a disease. Diseases targeted by the therapeutic agents include but are not limited to infectious diseases, carcinomas, sarcomas, lymphomas, leukemia, germ cell tumors, blastomas, antigens expressed on various immune cells, and antigens expressed on cells associated with various hematologic diseases, and/or inflammatory diseases.

“Cancer” and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. The term “cancer” is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. Examples of solid tumors include malignancies, e.g., sarcomas, adenocarcinomas, and carcinomas, of the various organ systems, such as those affecting liver, lung, breast, lymphoid, gastrointestinal (e.g., colon), genitourinary tract (e.g., renal, urothelial cells), prostate and pharynx. Adenocarcinomas include malignancies such as most colon cancers, rectal cancer, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus. In one embodiment, the cancer is a melanoma, e.g., an advanced stage melanoma. Metastatic lesions of the aforementioned cancers can also be treated or prevented using the methods and compositions of the invention. Examples of other cancers that can be treated include bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin Disease, non-Hodgkin lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers. Treatment of metastatic cancers, e.g., metastatic cancers that express PD-L1 (Iwai et al. (2005) Int. Immunol. 17:133-144) can be effected using the antibody molecules described herein.

“Polynucleotide” as used herein includes but is not limited to DNA, RNA, cDNA (complementary DNA), mRNA (messenger RNA), rRNA (ribosomal RNA), shRNA (small hairpin RNA), snRNA (small nuclear RNA), snoRNA (short nucleolar RNA), miRNA (microRNA), genomic DNA, synthetic DNA, synthetic RNA, and/or tRNA.

It is to be inferred without explicit recitation and unless otherwise intended, that when the present disclosure relates to a polypeptide, protein, polynucleotide, antibody or fragment thereof, an equivalent or a biologically equivalent of such is intended within the scope of this disclosure. As used herein, the term “biological equivalent thereof” is intended to be synonymous with “equivalent thereof” when referring to a reference protein, antibody or fragment thereof, polypeptide or nucleic acid, intends those having minimal homology while still maintaining desired structure or functionality. Unless specifically recited herein, it is contemplated that any of the above also includes equivalents thereof. For example, an equivalent intends at least about 70% homology or identity, or at least 80% homology or identity and alternatively, or at least about 85%, or alternatively at least about 90%, or alternatively at least about 95%, or alternatively at least 98% percent homology or identity and exhibits substantially equivalent biological activity to the reference protein, polypeptide, antibody or fragment thereof or nucleic acid. Alternatively, when referring to polynucleotides, an equivalent thereof is a polynucleotide that hybridizes under stringent conditions to the reference polynucleotide or its complement. Alternatively, when referring to polypeptides or proteins, an equivalent thereof is an expressed polypeptide or protein from a polynucleotide that hybridizes under stringent conditions to the polynucleotide or its complement that encodes the reference polypeptide or protein.

A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) having a certain percentage (for example, 80%, 85%, 90%, or 95%) of “sequence identity” to another sequence means that, when aligned, that percentage of bases (or amino acids) are the same in comparing the two sequences. The alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in Current Protocols in Molecular Biology (Ausubel et al., eds. 1987) Supplement 30, section 7.7.18, Table 7.7.1. Preferably, default parameters are used for alignment. A preferred alignment program is BLAST, using default parameters. In particular, preferred programs are BLASTN and BLASTP, using the following default parameters: Genetic code=standard; filter=none; strand=both; cutoff=60; expect=10; Matrix=BLOSUM62; Descriptions=50 sequences; sort by=HIGH SCORE; Databases=non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank CDS translations+SwissProtein+SPupdate+PIR. Details of these programs can be found at the following Internet address: ncbi.nlm.nih.gov/cgi-bin/BLAST.

The term “isolated” as used herein refers to molecules or biologicals or cellular materials being substantially free from other materials. In one aspect, the term “isolated” refers to nucleic acid, such as DNA or RNA, or protein or polypeptide (e.g., an antibody or derivative thereof), or cell or cellular organelle, or tissue or organ, separated from other DNAs or RNAs, or proteins or polypeptides, or cells or cellular organelles, or tissues or organs, respectively, that are present in the natural source. The term “isolated” also refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Moreover, an “isolated nucleic acid” is meant to include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state. The term “isolated” is also used herein to refer to polypeptides which are isolated from other cellular proteins and is meant to encompass both purified and recombinant polypeptides. The term “isolated” is also used herein to refer to cells or tissues that are isolated from other cells or tissues and is meant to encompass both, cultured and engineered cells or tissues.

“Naked DNA” as used herein refers to DNA encoding a CAR cloned in a suitable expression vector in proper orientation for expression. Viral vectors which may be used include but are not limited SIN lentiviral vectors, retroviral vectors, foamy virus vectors, adeno-associated virus (AAV) vectors, hybrid vectors and/or plasmid transposons (for example sleeping beauty transposon system) or integrase based vector systems. Other vectors that may be used in connection with alternate embodiments of the invention will be apparent to those of skill in the art.

“Target cell” as used herein refers to cells which are involved in a disease and can be targeted by the genetically modified cells of the invention (including but not limited to genetically modified T-cells, NK cells, hematopoietic stem cells, pluripotent stem cells, and embryonic stem cells). Other target cells will be apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.

“Vector”, “cloning vector” and “expression vector” as used herein refer to the vehicle by which a polynucleotide sequence (e.g. a foreign gene) can be introduced into a host cell, so as to transform the host and promote expression (e.g. transcription and translation) of the introduced sequence. Vectors include plasmids, phages, viruses, etc.

The term “functional” when used in conjunction with “derivative” or “variant” or “fragment” refers to a polypeptide which possess a biological activity that is substantially similar to a biological activity of the entity or molecule of which it is a derivative or variant or fragment thereof.

As used herein, the term “administering,” refers to the placement an agent as disclosed herein into a subject by a method or route which results in at least partial localization of the agents at a desired site.

“Beneficial results” may include, but are in no way limited to, lessening or alleviating the severity of the disease condition, preventing the disease condition from worsening, curing the disease condition, preventing the disease condition from developing, lowering the chances of a patient developing the disease condition and prolonging a patient's life or life expectancy. As non-limiting examples, “beneficial results” or “desired results” may be alleviation of one or more symptom(s), diminishment of extent of the deficit, stabilized (i.e., not worsening) state of cancer progression, delay or slowing of metastasis or invasiveness, and amelioration or palliation of symptoms associated with the cancer.

As used herein, the terms “treat,” “treatment,” “treating,” or “amelioration” refer to therapeutic treatments, wherein the object is to reverse, alleviate, ameliorate, inhibit, slow down or stop the progression or severity of a condition associated with, a disease or disorder. The term “treating” includes reducing or alleviating at least one adverse effect or symptom of a condition, disease or disorder, such as cancer. Treatment is generally “effective” if one or more symptoms or clinical markers are reduced. Alternatively, treatment is “effective” if the progression of a disease is reduced or halted. That is, “treatment” includes not just the improvement of symptoms or markers, but also a cessation of at least slowing of progress or worsening of symptoms that would be expected in absence of treatment. Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. The term “treatment” of a disease also includes providing relief from the symptoms or side-effects of the disease (including palliative treatment). In some embodiments, treatment of cancer includes decreasing tumor volume, decreasing the number of cancer cells, inhibiting cancer metastases, increasing life expectancy, decreasing cancer cell proliferation, decreasing cancer cell survival, or amelioration of various physiological symptoms associated with the cancerous condition.

“Conditions” and “disease conditions,” as used herein may include, cancers, tumors or infectious diseases. In exemplary embodiments, the conditions include but are in no way limited to any form of malignant neoplastic cell proliferative disorders or diseases. In exemplary embodiments, conditions include any one or more of kidney cancer, melanoma, prostate cancer, breast cancer, glioblastoma, lung cancer, colon cancer, or bladder cancer.

The term “effective amount” or “therapeutically effective amount” as used herein refers to the amount of a pharmaceutical composition comprising one or more peptides as disclosed herein or a mutant, variant, analog or derivative thereof, to decrease at least one or more symptom of the disease or disorder, and relates to a sufficient amount of pharmacological composition to provide the desired effect. The phrase “therapeutically effective amount” as used herein means a sufficient amount of the composition to treat a disorder, at a reasonable benefit/risk ratio applicable to any medical treatment.

A therapeutically or prophylactically significant reduction in a symptom is, e.g. at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 125%, at least about 150% or more in a measured parameter as compared to a control or non-treated subject or the state of the subject prior to administering the oligopeptides described herein. Measured or measurable parameters include clinically detectable markers of disease, for example, elevated or depressed levels of a biological marker, as well as parameters related to a clinically accepted scale of symptoms or markers for diabetes. It will be understood, however, that the total daily usage of the compositions and formulations as disclosed herein will be decided by the attending physician within the scope of sound medical judgment. The exact amount required will vary depending on factors such as the type of disease being treated, gender, age, and weight of the subject.

The phrase “first line” or “second line” or “third line” refers to the order of treatment received by a patient. First line therapy regimens are treatments given first, whereas second or third line therapy are given after the first line therapy or after the second line therapy, respectively. The National Cancer Institute defines first line therapy as “the first treatment for a disease or condition. In patients with cancer, primary treatment can be surgery, chemotherapy, radiation therapy, or a combination of these therapies. First line therapy is also referred to those skilled in the art as “primary therapy and primary treatment.” See National Cancer Institute website at www.cancer.gov, last visited on May 1, 2008. Typically, a patient is given a subsequent chemotherapy regimen because the patient did not show a positive clinical or sub-clinical response to the first line therapy or the first line therapy has stopped.

“Mammal” as used herein refers to any member of the class Mammalia, including, without limitation, humans and nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be included within the scope of this term.

Chimeric Antigen Receptors

Provided herein are compositions comprising a CAR and an accessory module and method of using same to treat diseases, including cancer. As described herein, specific combinations of conventional CARs (Table 1) and accessory modules as described in Table 2 define a ‘backbone’ (Table 2).

TABLE 1

Conventional CAR architectures. First generation conventional

CARs (Conventional CAR I) have an intracellular signaling (ISD)

domain (e.g. CD3z) and no costimulatory domain. Second generation

conventional CARs (Conventional CAR 2 or CAR II) have one

costimulatory domain (e.g. 41BB or CD28) and an intracellular

signaling (ISD) domain (e.g. CD3z). Third generation conventional CARs

(Conventional CAR 3 or CAR III) have two costimulatory domains (e.g.

41BB and CD28) and an intracellular signaling (ISD) domain (e.g. CD3z).

Table 1 Conventional CAR Architectures

1
Conventional CAR 1
ASD
HR
TMD
ISD

(CAR I)

2
Conventional CAR 2
ASD
HR
TMD
CSD
ISD

(CAR II)

3
Conventional CAR 3
ASD
HR
TMD
CSD-I
CSD-II
ISD

(CAR III)

TABLE 2

Exemplary Backbones

Accessory Module

SEQ ID
SEQ ID

Backbone No.
CAR Component
NAME
(DNA)
(PRT)

Backbone 1
Conventional CAR I
K13-vFLIP
866
2629

Backbone 2
Conventional CAR I
MC159-vFLIP
867
2630

Backbone 3
Conventional CAR I
MC160-vFLIP
868
2631

Backbone 4
Conventional CAR I
E8-vFLIP
869
2632

Backbone 5
Conventional CAR I
Herpesvirus-saimiri-vFLIP
870
2633

Backbone 6
Conventional CAR I
Mecaca-vFLIP
871
2634

Backbone 7
Conventional CAR I
BHV-vFLIP
872
2635

Backbone 8
Conventional CAR I
cFLIP-L/MRIT-alpha
873
2636

Backbone 9
Conventional CAR I
cFLIP-p22
874
2637

Backbone 10
Conventional CAR I
HTLV1-TAX
875
2638

Backbone 11
Conventional CAR I
HTLV2-TAX
876
2639

Backbone 12
Conventional CAR I
HTLV2-TAX-RS
877
2640

Backbone 13
Conventional CAR I
FKBP-K13
878
2641

Backbone 14
Conventional CAR I
FKBPX2-K13
879
2642

Backbone 15
Conventional CAR I
Myr-FKBPx2-K13
880
2643

Backbone 16
Conventional CAR I
FKBPx2-HTLV2-Tax-RS
881
2644

Backbone 17
Conventional CAR I
FKBPx2-Flag-HTLV2-Tax-RS
882
2645

Backbone 18
Conventional CAR I
IL6R-304-vHH
884
2647

Backbone 19
Conventional CAR I
IGHSP2-IL6R-304-VHH-ALB8-VHH
886
2649

Backbone 20
Conventional CAR I
IgSP-IL6-19A-scFV
899
2662

Backbone 21
Conventional CAR I
IgSP-Fx06
900
2663

Backbone 22
Conventional CAR I
CD8SP2-PD1-4H1-scFv
889
2652

Backbone 23
Conventional CAR I
CD8SP2-PD1-5C4-scFv
890
2653

Backbone 24
Conventional CAR I
CD8SP2-CTLA4-Ipilimumab-scFv
891
2654

Backbone 25
Conventional CAR I
CD8SP2-PD1-4H1-Alb8-vHH
892
2655

Backbone 26
Conventional CAR I
CD8SP2-PD1-5C4-Alb8-vHH
893
2656

Backbone 27
Conventional CAR I
CD8SP2-CTLA4-Ipilimumab-Alb8-vHH
894
2657

Backbone 28
Conventional CAR I
CD8SP2-sHVEM-Alb8-vHH
902
2665

Backbone 29
Conventional CAR I
tCD19
855
2618

Backbone 30
Conventional CAR I
tBCMA
856
2619

Backbone 31
Conventional CAR I
CNB30
852
2615

Backbone 32
Conventional CAR II
K13-vFLIP
866
2629

Backbone 33
Conventional CAR II
MC159-vFLIP
867
2630

Backbone 34
Conventional CAR II
MC160-vFLIP
868
2631

Backbone 35
Conventional CAR II
E8-vFLIP
869
2632

Backbone 36
Conventional CAR II
Herpesvirus-saimiri-vFLIP
870
2633

Backbone 37
Conventional CAR II
Mecaca-vFLIP
871
2634

Backbone 38
Conventional CAR II
BHV-vFLIP
872
2635

Backbone 39
Conventional CAR II
cFLIP-L/MRIT-alpha
873
2636

Backbone 40
Conventional CAR II
cFLIP-p22
874
2637

Backbone 41
Conventional CAR II
HTLV1-TAX
875
2638

Backbone 42
Conventional CAR II
HTLV2-TAX
876
2639

Backbone 43
Conventional CAR II
HTLV2-TAX-RS
877
2640

Backbone 44
Conventional CAR II
FKBP-K13
878
2641

Backbone 45
Conventional CAR II
FKBPX2-K13
879
2642

Backbone 46
Conventional CAR II
Myr-FKBPx2-K13
880
2643

Backbone 47
Conventional CAR II
FKBPx2-HTLV2-Tax-RS
881
2644

Backbone 48
Conventional CAR II
FKBPx2-Flag-HTLV2-Tax-RS
882
2645

Backbone 49
Conventional CAR II
IL6R-304-vHH
884
2647

Backbone 50
Conventional CAR II
IGHSP2-IL6R-304-VHH-ALB8-VHH
886
2649

Backbone 51
Conventional CAR II
IgSP-IL6-19A-scFV
899
2662

Backbone 52
Conventional CAR II
IgSP-Fx06
900
2663

Backbone 53
Conventional CAR II
CD8SP2-PD1-4H1-scFv
889
2652

Backbone 54
Conventional CAR II
CD8SP2-PD1-5C4-scFv
890
2653

Backbone 55
Conventional CAR II
CD8SP2-CTLA4-Ipilimumab-scFv
891
2654

Backbone 56
Conventional CAR II
CD8SP2-PD1-4H1-Alb8-vHH
892
2655

Backbone 57
Conventional CAR II
CD8SP2-PD1-5C4-Alb8-vHH
893
2656

Backbone 58
Conventional CAR II
CD8SP2-CTLA4-Ipilimumab-Alb8-vHH
894
2657

Backbone 59
Conventional CAR II
CD8SP2-sHVEM-Alb8-vHH
902
2665

Backbone 60
Conventional CAR II
tCD19
855
2618

Backbone 61
Conventional CAR II
tBCMA
856
2619

Backbone 62
Conventional CAR II
CNB30
852
2615

Exemplary embodiments of the CAR components are described in Tables 1-6,8, 11, and 15.

As described herein, the various backbones comprise a CAR component and accessory modules. Exemplary embodiments of the accessory modules are described in Table 16.

In some embodiments, the compositions comprise nucleic acids encoding conventional CARs I-III (Table 1), wherein the antigen specific domain of the CAR targets one or more specific antigens as described in Tables 21 and 22. In some embodiments, the compositions comprise nucleic acids encoding any one or more of backbones 1-62 (Table 2) where the antigen specific domain of the encoded CAR targets one or more specific antigens as described herein and in Tables 19, 20 and 22. In some embodiments, the compositions comprise nucleic acids encoding backbone-1, wherein the antigen specific domain of the CAR in backbone-1 targets one or more cancer specific antigens as described herein and in Table 19 and 22. In some embodiments, the compositions comprise nucleic acids encoding backbone-2, wherein the antigen specific domain of the CAR in backbone-2 targets one or more cancer specific antigens as described herein. In some embodiments, the compositions comprise nucleic acids encoding backbone-32, wherein the antigen specific domain of the CAR in backbone-32 targets one or more cancer specific antigens as described herein and in Table 20 and 22. In some embodiments, the compositions comprise nucleic acids encoding backbone-33, wherein the antigen specific domain of the CAR in backbone-33 targets one or more cancer specific antigens as described herein. In various embodiments, the nucleic acids are used in the treatment of cancer. In some embodiments, the nucleic acids encoding the CAR component of the backbones described herein comprise more than one antigen specific domain wherein each of the antigen specific domains are contiguous and in the same reading frame as the other antigen specific domains in the same CAR.

In some embodiments, the compositions comprise polypeptides encoded by nucleic acids encoding any conventional CARs 1-III, wherein the antigen specific domain of the CAR targets one or more specific antigens as described herein and in Tables 21 and 22. In some embodiments, the compositions comprise polypeptides encoded by nucleic acids encoding any one or more of backbones 1-62 (Table 2) where the antigen specific domain of the encoded CAR targets one or more specific antigens as described herein and in Tables 20 to 22. In some embodiments, the compositions comprise polypeptides encoded by nucleic acids encoding backbone-1, wherein the antigen specific domain of the CAR in backbone-1 targets one or more cancer specific antigens as described herein and in Table 19 and 22. In some embodiments, the compositions comprise polypeptides encoded by nucleic acids encoding backbone-2, wherein the antigen specific domain of the CAR in backbone-2 targets one or more cancer specific antigens as described herein. In some embodiments, the compositions comprise nucleic acids encoding backbone-32, wherein the antigen specific domain of the CAR in backbone-32 targets one or more cancer specific antigens as described herein and in Table 20 and 22. In some embodiments, the compositions comprise nucleic acids encoding backbone-33, wherein the antigen specific domain of the CAR in backbone-33 targets one or more cancer specific antigens as described herein. In various embodiments, the polypeptides are used in the treatment of cancer. In some embodiments, polypeptides encoded by the nucleic acids encoding the CAR component of the backbones described herein comprise more than one antigen specific domain wherein each of the antigen specific domains are contiguous and in the same reading frame as the other antigen specific domains in the same CAR.

In some embodiments, the compositions comprise vectors comprising nucleic acids encoding any of conventional CARs I-III, wherein the antigen specific domain of the CAR targets one or more cancer specific antigens as described herein and in Tables 21 and 22. In some embodiments, the compositions comprise vectors comprising nucleic acids encoding any one or more of backbones 1-62 (Table 2) where the antigen specific domain of the encoded CAR targets one or more specific antigens as described herein and in Tables 20 to 22. In some embodiments, the compositions comprise vectors encoding nucleic acids encoding backbone-1, wherein the antigen specific domain of the CAR in backbone-1 targets one or more cancer specific antigens as described herein and in Tables 19 and 22. In some embodiments, the compositions comprise vectors encoding nucleic acids encoding backbone-2, wherein the antigen specific domain of the CAR in backbone-2 targets one or more cancer specific antigens as described herein. In some embodiments, the compositions comprise vectors encoding nucleic acids encoding backbone-32, wherein the antigen specific domain of the CAR in backbone-32 targets one or more cancer specific antigens as described herein. In some embodiments, the compositions comprise vectors encoding nucleic acids encoding backbone-33, wherein the antigen specific domain of the CAR in backbone-33 targets one or more cancer specific antigens as described herein. In various embodiments, the vectors are used in the treatment of cancer. In some embodiments, vectors comprising nucleic acids encoding the conventional CARs I to III or CAR component of the backbones described herein comprise more than one antigen specific domain wherein each of the antigen specific domains are contiguous and in the same reading frame as the other antigen specific domains in the same CAR.

In some embodiments, the compositions comprise genetically modified cells which include vectors comprising nucleic acids encoding any one or more of conventional CARs I to III or backbones 1-62 (Table 2) where the antigen specific domain of the encoded CAR targets one or more specific antigens as described herein and in Tables 19 to 22. In some embodiments, the compositions comprise genetically modified cells which include vectors encoding nucleic acids encoding conventional CARs I to III, wherein the antigen specific domain of the CAR targets one or more cancer specific antigens as described herein and in Tables 19 and 22. In some embodiments, the compositions comprise genetically modified cells which include vectors encoding nucleic acids encoding backbone-1, wherein the antigen specific domain of the CAR in backbone-1 targets one or more cancer specific antigens as described herein. In some embodiments, the compositions comprise genetically modified cells which include vectors encoding nucleic acids encoding backbone-2, wherein the antigen specific domain of the CAR in backbone-2 targets one or more cancer specific antigens as described herein. In some embodiments, the compositions comprise genetically modified cells which include vectors encoding nucleic acids encoding backbone-32, wherein the antigen specific domain of the CAR in backbone-32 targets one or more cancer specific antigens as described herein. In some embodiments, the compositions comprise genetically modified cells which include vectors encoding nucleic acids encoding backbone-33, wherein the antigen specific domain of the CAR in backbone-33 targets one or more cancer specific antigens as described herein. In various embodiments, the genetically modified cells are used in treatment of cancer. In some embodiments, the genetically modified cells targets more than one antigen on a cancer cell.

In various embodiments, the isolated nucleic acid molecules encoding the CAR components of the backbones described herein, encode one, two, three or more antigen specific domains.

In various embodiments, the isolated nucleic acid molecules encoding the CAR components of the backbones described herein, encode one, two, three or more co-stimulatory domains.

In various embodiments, the isolated nucleic acid molecules encoding the CAR components of the backbones described herein, encode one, two, three or more intracellular signaling domain.

The nucleic acid sequences encoding for the desired components of the CARs and accessory modules described herein can be obtained using recombinant methods known in the art, such as, for example by screening libraries from cells expressing the nucleic acid molecule, by deriving the nucleic acid molecule from a vector known to include the same, or by isolating directly from cells and tissues containing the same, using standard techniques. Alternatively, the nucleic acid of interest can be produced synthetically, rather than cloned. In exemplary embodiments, the nucleic acid sequences encoding for the desired components of the CARs and accessory modules described herein are described in Tables 3-22.

In some embodiments, the genetically modified cells described herein that express the CARs and accessory components described herein also express agents that reduce toxicity of CARs. In exemplary embodiments, such agents are set forth in Table 16. In exemplary embodiments, such agents include but are not limited to any one, two, three or more of scFv against IL-6 (for example, SEQ ID NO: 899), a camelid vHH against IL-6 receptor alpha (for example, SEQ ID NO: 884), a bispecific camelid vHH targeting IL-6 receptor alpha and albumin (SEQ ID NO: 886), Fx06 peptide (SEQ ID NO: 900), or combinations thereof.

In some embodiments, the genetically modified cells described herein that express the CARs and accessory components described herein also express agents that enhance the activity of CARs. In exemplary embodiments, such agents are set forth in Table 16. In exemplary embodiments, such agents include but are not limited to any one, two, three or more of hTERT (SEQ ID NO: 903), heparinase (SEQ ID NO: 904), soluble HVEM (SEQ ID NO: 901), a fusion protein containing soluble HVEM and a camelid vHH targeting albumin (SEQ ID NO: 902), scFvs targeting PD1 (SEQ ID NOs: 889 and 890), scFv targeting CTLA4 (SEQ ID NO: 894), bispecific proteins targeting PD1 and albumin (SEQ ID NO: 892 and 893), bispecific proteins targeting CTLA4 and albumin (SEQ ID NO: 894) or combinations thereof. The rationale for targeting albumin in the bispecific proteins is to extend the half-lives of the scFvs and vHH fragments which are otherwise rapidly cleared by the kidneys due to their relatively small size.

In specific embodiments, exemplary constructs containing backbone-1, which comprises a conventional CAR I containing a CD3z activation domain and coexpresses a K13-vFLIP accessory module, are set forth in Table 19.

In specific embodiments, exemplary constructs containing backbone-32, which comprises a conventional CAR II containing a 41BB costimulatory domain, a CD3z activation domain and coexpresses a K13-vFLIP accessory module, are set forth in Table 20.

In specific embodiments, exemplary conventional CAR II constructs containing a 41BB costimulatory domain and a CD3z activation domain are described in Table 21.

In specific embodiments, exemplary CAR constructs in various embodiments of the inventions are described in Table 22.

Antigen Specific Domain

The compositions comprising various backbones as described herein comprise CARs which comprise one or more ASD that binds specifically to a cancer associated antigen as described herein. The sequences of the ASD are contiguous with and in the same reading frame as a nucleic acid sequence encoding the remainder of the CAR.

In one embodiment, each antigen specific region comprises the full-length IgG heavy chain (specific for the target antigen) having the V_H, CH1, hinge, and the CH2 and CH3 (Fc) Ig domains, if the V_Hdomain alone is sufficient to confer antigen-specificity (“single-domain antibodies”). The full length IgG heavy chain may be linked to the co-stimulatory domain and the intracellular signaling domain via the appropriate transmembrane domain. If both, the V_Hand the V_Ldomains, are necessary to generate a fully active antigen-specific targeting region, the V_H-containing CAR and the full-length lambda light chain (IgL) are both introduced into the cells to generate an active antigen-specific targeting region.

In some embodiments, the antigen specific domain of the encoded CAR molecule comprises an antibody, an antibody fragment, an scFv, a Fv, a Fab, a (Fab′)₂, a single domain antibody (SDAB), a VH or VL domain, or a camelid VHH domain. In some embodiments, the antigen binding domain of the CAR is a scFv antibody fragment that is humanized compared to the murine sequence of the scFv from which it is derived.

In some instances, scFvs can be prepared according to methods known in the art (for example, Bird et al., (1988) Science 242:423-426 and Huston et al., (1988) Proc.Natl. Acad. Sci. USA 85:5879-5883). ScFv molecules can be produced by linking V_Hand V_Lregions together using flexible polypeptide linkers. The scFv molecules comprise a linker (e.g., a Ser-Gly linker) with an optimized length and/or amino acid composition. The linker length can greatly affect how the variable regions of a scFv fold and interact. For example, if a short polypeptide linker is employed (for example, between 5-10 amino acids) intrachain folding is prevented. Interchain folding is also required to bring the two variable regions together to form a functional epitope binding site. For examples of linker orientation and size see, e.g., Hollinger et al. 1993 Proc Natl Acad. Sci. U.S.A. 90:6444-6448, U.S. Patent Application Publication Nos. 2005/0100543, 2005/0175606, 2007/0014794, and PCT publication Nos. WO2006/020258 and WO2007/024715, is incorporated herein by reference.

An scFv can comprise a linker of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, or more amino acid residues between its V_Land V_Hregions. The linker sequence may comprise any naturally occurring amino acid. In some embodiments, the linker sequence comprises amino acids glycine and serine. In another embodiment, the linker sequence comprises sets of glycine and serine repeats such as (Gly4Ser)n, where n is a positive integer equal to or greater than 1 (SEQ ID NO:252, SEQ ID NO:253). In one embodiment, the linker can be (Gly4Ser)3 (SEQ ID NO:254, SEQ ID NO:254) or (Gly4Ser)3 (SEQ ID NO:250-SEQ ID NO:255). Variation in the linker length may retain or enhance activity, giving rise to superior efficacy in activity studies.

In another aspect, the antigen binding domain is a T cell receptor (“TCR”), or a fragment thereof, for example, a single chain TCR (scTCR). Methods to make such TCRs are known in the art. See, e.g., Willemsen R A et al, Gene Therapy 7: 1369-1377 (2000); Zhang T et al, Cancer Gene Ther 11: 487-496 (2004); Aggen et al, Gene Ther. 19(4):365-74 (2012) (references are incorporated herein by its entirety). For example, scTCR can be engineered that contains the Vα and vβ genes from a T cell clone linked by a linker (e.g., a flexible peptide). This approach is very useful to cancer associated target that itself is intracellular, however, a fragment of such antigen (peptide) is presented on the surface of the cancer cells by MHC

In one embodiment, the antigen specific domain comprises one, two or all three heavy chain (hc) CDRs, hcCDR1, hcCDR2 and hcCDR3 of an antibody listed herein, and/or one, two or all three light chain (lc) CDRs, lcCDR1, lcCDR2 and lcCDR3 of an antibody listed herein.

In another embodiment, the antigen specific domain comprises a humanized antibody or an antibody fragment. In some aspects, a non-human antibody is humanized, where specific sequences or regions of the antibody are modified to increase similarity to an antibody naturally produced in a human or fragment thereof. In one aspect, the antigen binding domain is humanized. A humanized antibody can be produced using a variety of techniques known in the art, including but not limited to, CDR-grafting (see, e.g., European Patent No. EP 239,400; International Publication No. WO 91/09967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089, each of which is incorporated herein in its entirety by reference), veneering or resurfacing (see, e.g., European Patent Nos. EP 592,106 and EP 519,596; Padlan, 1991, Molecular Immunology, 28(4/5):489-498; Studnicka et al., 1994, Protein Engineering, 7(6):805-814; and Roguska et al., 1994, PNAS, 91:969-973, each of which is incorporated herein by its entirety by reference), chain shuffling (see, e.g., U.S. Pat. No. 5,565,332, which is incorporated herein in its entirety by reference), and techniques disclosed in, e.g., U.S. Patent Application Publication No. US2005/0042664, U.S. Patent Application Publication No. US2005/0048617, U.S. Pat. Nos. 6,407,213, 5,766,886, International Publication No. WO 9317105, Tan et al., J. Immunol., 169:1119-25 (2002), Caldas et al., Protein Eng., 13(5):353-60 (2000), Morea et al., Methods, 20(3):267-79 (2000), Baca et al., J. Biol. Chem., 272(16): 10678-84 (1997), Roguska et al., Protein Eng., 9(10):895-904 (1996), Couto et al., Cancer Res., 55 (23 Supp):5973s-5977s (1995), Couto et al., Cancer Res., 55(8): 1717-22 (1995), Sandhu J S, Gene, 150(2):409-10 (1994), and Pedersen et al., J. Mol. Biol., 235(3):959-73 (1994), each of which is incorporated herein in its entirety by reference. In some embodiments, the portion of a CAR composition of the invention that comprises an antibody fragment is humanized with retention of high affinity for the target antigen and other favorable biological properties

In some embodiments, the antigen specific domain is a T cell receptor specific for the target antigen or a fragment of the T cell receptor, wherein the fragment retains the specificity for the target antigen.

In some embodiments, the antigen specific domain of a CAR described herein is a scFv antibody fragment. In some embodiments, the antigen specific scFv antibody fragments are functional in that they bind the same antigen with the same or comparable affinity as the IgG antibody from which it is derived. In other embodiments, the antibody fragment has a lower binding affinity to the antigen compared to the antibody from which it is derived but is functional in that it provides a biological response described herein. In one embodiment, the CAR molecule comprises an antibody fragment that has a binding affinity KD of 10⁻⁴M to 10⁻⁸M, 10⁻⁵M to 10⁻⁷M, 10⁻⁶M or 10⁻⁸M, for the target antigen.

In some embodiments, antigen specific domain of a CAR described herein binds to a MHC presented peptide. Normally, peptides derived from endogenous proteins fill the pockets of Major histocompatibility complex (MHC) class I molecules, and are recognized by T cell receptors (TCRs) on CD8+T lymphocytes. The MHC class I complexes are constitutively expressed by all nucleated cells. In cancer, virus-specific and/or tumor-specific peptide/MHC complexes represent a unique class of cell surface targets for immunotherapy. TCR-like antibodies targeting peptides derived from viral or tumor antigens in the context of human leukocyte antigen (HLA)-A1 or HLA-A2 have been described (see, e.g., Sastry et al., J Viral. 2011 85(5):1935-1942; Sergeeva et al., Blood, 2011117(16):4262-4272; Verma et al., J Immunol 2010 184(4):2156-2165; Willemsen et al., Gene Ther 20018(21):1601-1608; Dao et al., Sci Transl Med 2013 5(176):176ra33; Tassev et al., Cancer Gene Ther 2012 19(2):84-100). For example, TCR-like antibody can be identified from screening a library, such as a human scFv phage displayed library. Exemplary CARs that are based on TCR-like antibodies targeting WT1 in association with HLA-A2 are represented by SEQ ID NO: 1176 to SEQ ID NO: 1179. In the instant invention, CARs were generated using antigen binding domain derived from TCR like antibodies against several HLA-A2 restricted intracellular peptides. The target protein antigens, the peptide fragment and the sequence of the peptide are shown in Table 23.

In some embodiments, when the CARs comprising functional fragments of antibodies (including scFv fragments) described herein bind the target antigen, a biological response is induced such as activation of an immune response, inhibition of signal-transduction originating from its target antigen, inhibition of kinase activity, and the like, as will be understood by a skilled artisan.

In some embodiments, the antigens specific for disease which may be targeted by the CARs when expressed alone or with the accessory modules as described herein include but are not limited to any one or more of CD19, CD22, CD23, MPL, CD123, CD32, CD138, CD200R, CD276, CD324, CD30, CD32, FcRH5, CD99, Tissue Factor, amyloid, Fc region of an immunoglobulin, CD171, CS-1, CLL-1 (CLECL1), CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, IL11Ra, Mesothelin, PSCA, VEGFR2, Lewis Y, CD24, PDGFR-beta, PRSS21, SSEA-4, CD20, Folate receptor alpha, ERBB2 (Her2/neu), MUC1, EGFR, NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gp100, bcr-abl, tyrosinase, EphA2, Fucosyl GM1, sLea, GM3, TGS5, HMWMAA, o-acetyl-GD2, Folate receptor beta, TEM1/CD248, TEM7R, CLDN6, TSHR, TCR-beta1 constant chain, TCR beta2 constant chain, TCR gamma-delta, GPRC5D, CXORF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, legumain, HPV E6, E7, HTLV1-Tax, KSHV K8.1 protein, EBB gp350, HIV1-envelop glycoprotein gp120, MAGE-A1, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p⁵³, p⁵³mutant, prostein, survivin and telomerase, PCTA-1/Galectin 8, MelanA/MART1, Ras mutant, hTERT, DLL3, TROP2, PTK7, GCC, AFP, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, Androgen receptor, Cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, FITC, Leutenizing hormone receptor (LHR), Follicle stimulating hormone receptor (FSHR), Chorionic Gonadotropin Hormone receptor (CGHR), CCR4, GD3, SLAMF6, SLAMF4, FITC, Leutenizing hormone receptor (LHR), Follicle stimulating hormone receptor (FSHR), Chorionic Gonadotropin Hormone receptor (CGHR), CCR4, GD3, SLAMF6, SLAMF4, or combinations thereof.

In some embodiments, the antigens specific for a disease which may be targeted by the CARs when expressed alone or with the accessory modules as described herein include but are not limited to any one or more of 4-1BB, 5T4, adenocarcinoma antigen, alpha-fetoprotein, BAFF, B-lymphoma cell, C242 antigen, CA-125, carbonic anhydrase 9 (CA-IX), C-MET, CCR4, CD152, CD19, CD20, CD200, CD22, CD221, CD23 (IgE receptor), CD28, CD30 (TNFRSF8), CD33, CD4, CD40, CD44 v6, CD51, CD52, CD56, CD74, CD80, CD123, CEA, CNT0888, CTLA-4, DR5, EGFR, EpCAM, CD3, FAP, fibronectin extra domain-B, folate receptor 1, GD2, GD3 ganglioside, glycoprotein 75, GPNMB, HER2/neu, HGF, human scatter factor receptor kinase, IGF-1 receptor, IGF-I, IgG1, L1-CAM, IL-13, IL-6, insulin-like growth factor I receptor, integrin α5β1, integrin αvβ3, LAMP1, MORAb-009, MS4A1, MUC1, mucin CanAg, N-glycolylneuraminic acid, NPC-1C, PDGF-R a, PDL192, phosphatidylserine, prostatic carcinoma cells, RANKL, RON, ROR1, SCH 900105, SDC1, SLAMF7, TAG-72, tenascin C, TGF beta 2, TGF-β, TRAIL-R1, TRAIL-R2, tumor antigen CTAA16.88, VEGF-A, VEGFR-1, VEGFR2, vimentin or combinations thereof. Other antigens specific for cancer will be apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.

In some embodiments, the antigens specific for cancer which may be targeted by the CARs when expressed alone or with the accessory modules as described herein include but are not limited to any one or more of MPL, CD19, FLT3, GRP-78, CD79b, Ly-1, Lym2, CD23, CD179b, CDH1, CDH6, CDH19, CDH17, DLL3, PTK7, TROP2, TIM1, LAMP1 or combinations thereof. In some embodiments, the antigen specific domains of the CARs specific for MPL, CD19, FLT3, GRP-78, CD79b, Lym1, Lym2, CD23, CDH1, CDH6, CDH19, CDH17, DLL3, PTK7, TROP2, TIM1, LAMP1 comprise scFv sequences set forth in Table 11.

A CAR when used alone or with accessory modules as described herein can comprise an antigen binding domain (e.g., antibody or antibody fragment) that binds to a disease-supporting antigen (e.g., a disease-supporting antigen as described herein). In some embodiments, the disease-supporting antigen is an antigen present on cells that support the survival and proliferation of disease causing cells. In some embodiments, the disease-supporting antigen is an antigen present on a stromal cell or a myeloid-derived suppressor cell (MDSC). Stromal cells can secrete growth factors and cytokines to promote cell proliferation in the microenvironment. MDSC cells can block T cell proliferation and activation. Without wishing to be bound by theory, in some embodiments, the CAR-expressing cells destroy the disease-supporting cells, thereby indirectly blocking growth or survival of disease causing cells.

In embodiments, the stromal cell antigen is selected from one or more of: bone marrow stromal cell antigen 2 (BST2), fibroblast activation protein (FAP) and tenascin. In an embodiment, the FAP-specific antibody is, competes for binding with, or has the same CDRs as, sibrotuzumab. In embodiments, the MDSC antigen is selected from one or more of: CD33, CD11b, C14, CD15, and CD66b. Accordingly, in some embodiments, the disease supporting antigen is selected from one or more of: bone marrow stromal cell antigen 2 (BST2), fibroblast activation protein (FAP) or tenascin, CD33, CD11b, C14, CD15, and CD66b.

In a further embodiment, each antigen specific region of the CAR may comprise a divalent (or bivalent) single-chain variable fragment (di-scFvs, bi-scFvs). In CARs comprising di-scFVs, two scFvs specific for each antigen are linked together by producing a single peptide chain with two V_Hand two V_Lregions, yielding tandem scFvs. (Xiong, Cheng-Yi; Natarajan, A; Shi, XB; Denardo, GL; Denardo, SJ (2006). “Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding”. Protein Engineering Design and Selection 19 (8): 359-367; Kufer, Peter; Lutterbiise, Ralf; Baeuerle, Patrick A. (2004). “A revival of bispecific antibodies”. Trends in Biotechnology 22 (5): 238-244). CARs comprising at least two antigen-specific targeting regions would express two scFvs specific for each of the two antigens. The resulting ASD is joined to the co-stimulatory domain and the intracellular signaling domain via a hinge region and a transmembrane domain. Alternatively, CARs comprising two antigen specific targeting regions would express two vHH specific for each of the two antigens or two epitopes of the same antigen. Exemplary CARs targeting two antigens are represented by SEQ ID NOs: 1042, 1043, 1049, 1050 and 1087.

In an additional embodiment, each ASD of the CAR comprises a diabody. In a diabody, the scFvs are created with linker peptides that are too short for the two variable regions to fold together, driving the scFvs to dimerize. Still shorter linkers (one or two amino acids) lead to the formation of trimers, the so-called triabodies or tribodies. Tetrabodies may also be used.

In some embodiments, the ASD of the CAR comprises V_Lfragments as described in Table 4.

In some embodiments, the ASD of the CAR comprises V_Hfragments as described in Table 6.

In some embodiments, the ASD of the CAR comprises V_HHfragments (nanobodies) as described in Table 7.

In some embodiments, the ASD of the CAR comprises affibodies as described in Table 8.

In some embodiments, the ASD of the CAR comprises ligands as describes in Table 10.

In some embodiments, the ASD of the CAR comprises scFv fragments as describes in Table 11.

In one embodiment, an antigen specific domain of a CAR against a target antigen is an antigen binding portion, e.g., CDRs, of vL and vH fragments targeting this antigen as shown in Tables 4 and 6, respectively.

In one embodiment, an antigen specific domain of a CAR against a target antigen is an antigen binding portion, e.g., CDRs, of vHH fragments targeting this antigen as shown in Table 7.

In one embodiment, an antigen specific domain of a CAR against a target antigen is an antigen binding portion of a non-immunoglobulin scaffold targeting this antigen as shown in Table 8.

In one embodiment, an antigen specific domain of a CAR against a target antigen is an antigen binding portion of a receptor known to bind this target antigen.

In one embodiment, an antigen binding specific domain of a CAR against a target antigen is an antigen binding portion of a ligand known to bind this target antigen.

In one embodiment, an antigen specific domain of a CAR against a target antigen is an antigen binding portion, e.g., CDRs, of vL and vH fragments of a scFV targeting this antigen as shown in Table 11.

In another embodiment, the invention provides CARs that bind to the same epitope on the different targets described in Tables 19-22 as any of the CARs of the invention (i.e., CARs that have the ability to cross-compete for binding to the different targets with any of the CARs of the invention). In some embodiments, the antigen specific domains of these CARs could be derived from vL fragments, vH fragments or scFv fragments of antibodies. In some embodiments, the reference antibodies for cross-competition studies to determine the target-epitope recognized by a CAR of the invention described in Tables 19-22 are scFvs having sequences as shown in SEQ ID NOs: 2334-2568 (Table 11). In an exemplary embodiment, the reference scFv FMC63(vL-vH) represented by SEQ ID NO: 2334 can be used in cross-competition studies to determine the target-epitope recognized by FMC63-based conventional CARs and backbones of the invention (SEQ ID NOs:2672, 2942, 3212, 3495-3515) described in Tables 19-22. In some embodiments, the reference vHH fragments for cross-competition studies to determine the target-epitope recognized by a CAR of the invention described in Tables 19-22 are vHH fragments having sequences as shown in SEQ ID NOs: 2269-2293 (Table 7). In some embodiments, the reference non-immunoglobulin antigen binding scaffolds for cross-competition studies for cross-competition studies to determine the target-epitope recognized by a CAR of the invention described in Tables 19-22 are non-immunoglobulin antigen binding scaffolds having sequences as shown in SEQ ID NOs: 2294-2298 (Table 8). ). In some embodiments, the reference ligands for cross-competition studies to determine the target-epitope recognized by a CAR of the invention described in Tables 19-22 are ligands having sequences as shown in SEQ ID NOs: 2323-2333 (Table 10). In some embodiments, the reference CARs for cross-competition studies against different targets are CARs having sequences as shown in SEQ ID NOs: 2672-2941 (Table 19).

In an embodiment, the reference antibodies for cross-competition studies to determine the target-epitopes recognized by the MPL-targeting CARs of the invention (e.g., SEQ ID NOs: 1117-1125) are antibodies mAb-1.6, mAb-1.111, mAb-1.75, mAb-1.78, mAb-1.169, and mAb-1.36 described in patent application US 2012/0269814 A1.

In an embodiment, the reference scFvs for cross-competition studies to determine the target-epitopes recognized by the MPL-targeting CARs of the invention (e.g., SEQ ID NOs: 1117-1125) are scFvs having sequences as shown in SEQ ID NOs: 2499-2506 (Table 11).

In an embodiment, the reference ligands for cross-competition studies to determine the target-epitopes recognized by the MPL-targeting CARs of the invention (e.g., SEQ ID NOs: 1117-1125) are ligands having sequences as shown in SEQ ID NOs: 2323-2324 (Table 10).

In an embodiment, the reference CARs for cross-competition studies to determine the target-epitopes recognized by the MPL-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 1117-1125 and 1164 (Table 19).

In the preferred embodiment, an MPL-targeting CAR of the invention binds to an MPL-epitope corresponding to or overlapping with the peptide sequence-PWQDGPK-(SEQ ID NO:3564).

In an embodiment, the reference scFvs for cross-competition studies to determine the target-epitopes recognized by the CD19-targeting CARs of the invention (e.g., SEQ ID NOs: 930-941) are scFvs having sequences as shown in SEQ ID NOs: 2336-2347 (Table 11).

In an embodiment, the reference CARs for cross-competition studies to determine the target-epitopes recognized by the CD19-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 930-941 (Table 19).

In an embodiment, the reference scFvs for cross-competition studies to determine the target-epitopes recognized by the CD20-targeting CARs of the invention (e.g., SEQ ID NOs: 964-977) are scFvs having sequences as shown in SEQ ID NOs: 2366-2380 (Table 11).

In an embodiment, the reference CARs for cross-competition studies to determine the target-epitopes recognized by the CD20-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 964-977 (Table 19).

In the preferred embodiment, the CD20-targeting CARs of the invention bind to the epitopes corresponding to one or more of the sequences-PAGIYAPI-(SEQ ID NO:3565), -FLKMESLNFIRAHTP-(SEQ ID NO:3566), -HFLKMESLNFIRAHTPY-(SEQ ID NO:3567), -YNAEPANPSEKNSPSTQY-(SEQ ID NO:3568), -YNAEPANPSEKNSPST-(SEQ ID NO:3569) and-YNCEPANPSEKNSP-(SEQ ID NO:3570).

In an embodiment, the reference scFvs for cross-competition studies against DLL3-targeting CARs of the invention (e.g., SEQ ID NOs: 1044-1045) are scFvs having sequences as shown in SEQ ID NOs: 2443-2444 (Table 11).

In an embodiment, the reference CARs for cross-competition studies against DLL3-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 1044-1045 (Table 19).

In an embodiment, the reference scFvs for cross-competition studies against LAMP1-targeting CARs of the invention (e.g., SEQ ID NOs: 1104-1105) are scFvs having sequences as shown in SEQ ID NOs: 2489-2490 (Table 11).

In an embodiment, the reference CARs for cross-competition studies against LAMP1-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 1104-1105 (Table 19).

In an embodiment, the reference scFvs for cross-competition studies against TROP2-targeting CARs of the invention (e.g., SEQ ID NOs: 2910⁻²⁹¹¹) are scFvs having sequences as shown in SEQ ID NOs: 2544-2545 (Table 11).

In an embodiment, the reference CARs for cross-competition studies against TROP2-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 2910-2911 (Table 19).

In an embodiment, the reference scFvs for cross-competition studies against PTK7-targeting CARs of the invention (e.g., SEQ ID NOs: 1143-1144) are scFvs having sequences as shown in SEQ ID NOs: 2523-2524 (Table 11).

In an embodiment, the reference CARs for cross-competition studies against PTK7-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 1143-1144 (Table 19).

In an embodiment, the reference scFv for cross-competition studies against a CD23-targeting CAR (e.g., SEQ ID NO: 2932) is a scFv having sequence as shown in SEQ ID NO: 2565 (Table 11).

In an embodiment, the reference CAR for cross-competition studies against a CD23-targeting CAR of the invention is a CAR having sequences as shown in SEQ ID NO: 2932 (Table 19).

In an embodiment, the reference scFvs for cross-competition studies against a TCR-gamma-delta-targeting CAR (e.g., SEQ ID NO: 1155) is a scFv having sequence as shown in SEQ ID NO: 2535 (Table 11).

In an embodiment, the reference CAR for cross-competition studies against TCR-gamma-delta-targeting-targeting CAR of the invention is a CAR having sequences as shown in SEQ ID NO: 1155 (Table 19).

In an embodiment, the reference scFvs for cross-competition studies against CDH6-targeting CARs of the invention (e.g., SEQ ID NOs: 1016-1017) are scFvs having sequences as shown in SEQ ID NOs: 2418-2419 (Table 11).

In an embodiment, the reference CARs for cross-competition studies against CDH6-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 1016-1017 (Table 19).

In an embodiment, the reference scFvs for cross-competition studies against CDH19-targeting CARs of the invention (e.g., SEQ ID NOs: 1019 and 1180) are scFvs having sequences as shown in SEQ ID NOs: 2421 and 2558 (Table 11).

In an embodiment, the reference CARs for cross-competition studies against CDH19-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 1019 and 1180 (Table 19).

In an embodiment, the reference scFvs for cross-competition studies against CD324-targeting CARs of the invention (e.g., SEQ ID NOs: 1014-1015) are scFvs having sequences as shown in SEQ ID NOs: 2416-2417 (Table 11).

In an embodiment, the reference CARs for cross-competition studies against CD324-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 1014-1015 (Table 19).

In an embodiment, the reference scFv for cross-competition studies against a CD276-targeting CAR (e.g., SEQ ID NO: 2578) is a scFv having sequence as shown in SEQ ID NO: 2415 (Table 11).

In an embodiment, the reference CAR for cross-competition studies against a CD276-targeting CARs of the invention is a CAR having sequences as shown in SEQ ID NO: 2578 (Table 19).

In an embodiment, the reference scFvs for cross-competition studies against GFRa4-targeting CARs of the invention (e.g., SEQ ID NOs: 1066-1067) are scFvs having sequences as shown in SEQ ID NOs: 2461-2462 (Table 11).

In an embodiment, the reference CARs for cross-competition studies against GFRa4-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 1066-1067 (Table 19).

In an embodiment, the reference scFvs for cross-competition studies against CSF2RA-targeting CARs of the invention (e.g., SEQ ID NOs: 1040-1041) are scFvs having sequences as shown in SEQ ID NOs: 2441-2442 (Table 11).

In an embodiment, the reference CARs for cross-competition studies against CSF2RA-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 1040-1041 (Table 19).

In an embodiment, the reference scFvs for cross-competition studies against B7H4-targeting CARs of the invention (e.g., SEQ ID NOs: 2929-2930) are scFvs having sequences as shown in SEQ ID NOs: 2562-2563 (Table 11).

In an embodiment, the reference CARs for cross-competition studies against B7H4-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 2929-2930 (Table 19).

In an embodiment, the reference scFv for cross-competition studies against a NY-BR1-targeting CAR (e.g., SEQ ID NO: 1131) is a scFv having sequence as shown in SEQ ID NO: 2512 (Table 11).

In an embodiment, the reference CAR for cross-competition studies against a NY-BR1-targeting CARs of the invention is a CAR having sequences as shown in SEQ ID NO: 1131 (Table 19).

In an embodiment, the reference scFv for cross-competition studies against a CD200R-targeting CAR (e.g., SEQ ID NO: 1190) is a scFv having sequence as shown in SEQ ID NO: 2568 (Table 11).

In an embodiment, the reference CAR for cross-competition studies against a CD200R-targeting CARs of the invention is a CAR having sequences as shown in SEQ ID NO: 1190 (Table 19).

In an embodiment, the reference scFv for cross-competition studies against a HIV1-envelop glycoprotein gp120-targeting CAR (e.g., SEQ ID NO: 945) is a scFv having sequence as shown in SEQ ID NO: 2512 (Table 11).

In an embodiment, the reference CAR for cross-competition studies against a HIV1-envelop glycoprotein gp120-targeting CAR of the invention is a CAR having sequences as shown in SEQ ID NO: 945 (Table 19).

In an embodiment, the reference ligand for cross-competition studies against a TSHR-targeting CAR (e.g., SEQ ID NOs: 1167) is a ligand having sequences as shown in SEQ ID NO: (Table 11).

In an embodiment, the reference scFvs for cross-competition studies against TSHR-targeting CARs of the invention (e.g., SEQ ID NOs: 1168-1170) are scFvs having sequences as shown in SEQ ID NOs: 2333 (Table 10).

In an embodiment, the reference CARs for cross-competition studies against TSHR-targeting CARs of the invention are CARs having sequences as shown in SEQ ID NOs: 1167-1170 (Table 19).

In some embodiment, the CARs targeting gp100, MART, Tyrosinase, hTERT, MUC1, CMV-pp65, HTLV1-Tax, HIV1-gag, NY-ESO, WT1, AFP, HPV-16-E7, PR1 bind to target peptides shown in Table 23 in complex with MHC class I (HLA-A2). Linkers

In some embodiments, two or more functional domains of the CARs as described herein, are separated by one or more linkers. Linkers are oligo- or polypeptides region from about 1 to 100 amino acids in length, that link together any of the domains/regions of the CAR of the invention. In some embodiments, the linkers may be for example, 5-12 amino acids in length, 5-15 amino acids in length or 5 to 20 amino acids in length. Linkers may be composed of flexible residues like glycine and serine so that the adjacent protein domains are free to move relative to one another. Longer linkers, for example those longer than 100 amino acids, may be used in connection with alternate embodiments of the invention, and may be selected to, for example, ensure that two adjacent domains do not sterically interfere with one another. In exemplary embodiments, linkers are described in SEQ ID NOs: 250-258 (Tables 5).

Hinge Region

In some embodiments, the CARs (which form part of the backbones) described herein comprise a hinge region between the antigen specific domain and the transmembrane domain. In some embodiments, the hinge region comprises any one or more of human CD8a or an Fc fragment of an antibody or a functional equivalent, fragment or derivative thereof, a hinge region of human CD8a or an antibody or a functional equivalent, fragment or derivative thereof, a CH2 region of an antibody, a CH3 region of an antibody, an artificial spacer sequence and combinations thereof. In exemplary embodiments, the hinge region comprises any one or more of (i) a hinge, CH2 and CH3 region of IgG4, (ii) a hinge region of IgG4, (iii) a hinge and CH2 region of IgG4, (iv) a hinge region of CD8a, (v) a hinge, CH2 and CH3 region of IgG1, (vi) a hinge region of IgG1, (vi) a hinge and CH2 region of IgG1, or (vii) combinations thereof.

Transmembrane Domain

As described herein, the CARs (which form part of the backbones) described herein comprise a transmembrane domain. The transmembrane domain may comprise the transmembrane sequence from any protein which has a transmembrane domain, including any of the type I, type II or type III transmembrane proteins. The transmembrane domain of the CAR of the invention may also comprise an artificial hydrophobic sequence. The transmembrane domains of the CARs described herein may be selected so that the transmembrane domain do not dimerize. In some embodiments, the TMD encoded CAR comprising any of the backbones described herein comprises a transmembrane domain selected from the transmembrane domain of an alpha, beta or zeta chain of a T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRFl), CD160, CD19, IL2R beta, IL2R gamma, IL7R a, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1(CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAMI, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CDIOO (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMFI, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG/Cbp, NKp44, NKp30, NKp46, NKG2D, and/or NKG2C

A transmembrane domain can include one or more additional amino acids adjacent to the transmembrane region, e.g., one or more amino acid associated with the extracellular region of the protein from which the transmembrane was derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the extracellular region) and/or one or more additional amino acids associated with the intracellular region of the protein from which the transmembrane protein is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the intracellular region). In one aspect, the transmembrane domain is contiguous with one of the other domains of the CAR. In one embodiment, the transmembrane domain may be from the same protein that the signaling domain, costimulatory domain or the hinge domain is derived from. In another aspect, the transmembrane domain is not derived from the same protein that any other domain of the CAR is derived from.

Intracellular Signaling Domain of Chimeric Antigen Receptors

As described herein, the CARs (which form part of the backbones) described herein comprise an intracellular signaling domain. This domain may be cytoplasmic and may transduce the effector function signal and direct the cell to perform its specialized function. Examples of intracellular signaling domains include, but are not limited to, ξ chain of the T-cell receptor or any of its homologs (e.g., η chain, FcεR1γ and R chains, MB1 (Igα) chain, B29 (Igβ) chain, etc.), CD3 polypeptides (Δ, δ and ε), syk family tyrosine kinases (Syk, ZAP 70, etc.), src family tyrosine kinases (Lck, Fyn, Lyn, etc.) and other molecules involved in T-cell transduction, such as CD2, CD5 and CD28. Specifically, the intracellular signaling domain may be human CD3 zeta chain, FcγRIII, FcεRI, cytoplasmic tails of Fc receptors, immunoreceptor tyrosine-based activation motif (ITAM) bearing cytoplasmic receptors or combinations thereof. Additional intracellular signaling domains will be apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention. In some embodiments, the intracellular signaling domain comprises a signaling domain of one or more of a human CD3 zeta chain, FcgRIII, FceRI, a cytoplasmic tail of a Fc receptor, an immunoreceptor tyrosine-based activation motif (ITAM) bearing cytoplasmic receptors, and combinations thereof.

Co-Stimulatory Domain

As described herein, the CARs (which form part of the backbones) described herein comprise a co-stimulatory domain. In exemplary embodiments, the co-stimulatory domain comprises a signaling domain from any one or more of CD28, CD137 (4-1BB), CD134 (OX40), Dap10, CD27, CD2, CD5, ICAM-1, LFA-1, Lck, TNFR-I, TNFR-II, Fas, CD30, CD40 and combinations thereof.

Cleavable Linkers

Cleavable linkers as described herein include 2A linkers (for example T2A), 2A-like linkers or functional equivalents thereof and combinations thereof. In some embodiments, the linkers include the picornaviral 2A-like linker, CHYSEL sequences of porcine teschovirus (P2A), Thosea asigna virus (T2A) or combinations, variants and functional equivalents thereof. In other embodiments, the linker sequences may comprise Asp-Val/Ile-Glu-X-Asn-Pro-Gly^(2A)-Pro^(2B)(SEQ ID NO:3572) motif, which results in cleavage between the 2A glycine and the 2B proline. The nucleic sequences of several exemplary cleavable linkers are provided in SEQ ID NO: 831 to SEQ ID NO: 836 and amino acid sequences of several exemplary linkers are provided in SEQ ID NO: 2598 to SEQ ID NO: 2602. Other linkers will be apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention. In an embodiment, a Ser-Gly-Ser-Gly (SGSG) motif (SEQ ID NOs: 837-838 and SEQ ID NO: 2603) is also added upstream of the cleavable linker sequences to enhance the efficiency of cleavage. A potential drawback of the cleavable linkers is the possibility that the small 2A tag left at the end of the N-terminal protein may affect protein function or contribute to the antigenicity of the proteins. To overcome this limitation, in some embodiments, a furine cleavage site (RAKR) (SEQ ID NO: 839-841 and SEQ ID NO: 2604) is added upstream of the SGSG motifs (SEQ ID NO:837-838 and SEQ ID NO:3603) to facilitate cleavage of the residual 2A peptide following translation. In an embodiment, cleavable linkers are placed between the polypeptide encoding the CAR and the polypeptide encoding the accessory modules. The cleavage at the site of cleavable linker results in separation of the two polypeptides.

Accessory Modules

“Accessory modules” as used herein refer to agents that enhance, reduce or modify the activity of T cells expressing the CARs or reduce toxicity associated with CARs so that the therapeutic response of the CARs is enhanced.

In some embodiments, vectors comprising polynucleotides encoding CARs further comprise polynucleotides encoding viral and cellular signaling proteins which (i) extend the life span of T cells expressing the CARs, (ii) stimulate T cell proliferation and/or (iii) protect T cells expressing the CARs from apoptosis. In exemplary embodiments, such proteins include but are not limited to vFLIP-K13 from Kaposi's sarcoma associated herpes virus (SEQ ID NO: 866), MC159 from molluscum contagiosum virus (SEQ ID NO: 867), cFLIP-L/MRITα (SEQ ID NO: 873), cFLIP-p22 (SEQ ID NO: 874) and Tax from human T cell leukemia/lymphoma virus (HTLV-1 and HTLV-2) (SEQ ID NOs: 875 and SEQ ID NO: 876) and Tax-RS mutant from HTLV-2 (SEQ ID NO: 877).

In one embodiment, vectors encoding CARs further encode vFLIP-K13. In another embodiment, vectors encoding CARs further encode MC159. In another embodiment, vectors encoding CARs further encode HTLV1-Tax. In another embodiment, vectors encoding CARs further encode HTLV2-Tax. In another embodiment, vectors encoding CARs further encode cFLIP-L/MRITα.

In some embodiments, the accessory molecules are encoded by vectors that are distinct from the vectors encoding by the CARs described herein. In some embodiments, effector cells comprising vectors encoding CARs also comprise vectors encoding accessory molecules.

In some embodiments, vectors comprising polynucleotides encoding CARs further express accessory molecule vFLIP MC160 from molluscum contagiosum virus, vFLIP E8 from equine herpes virus 2, vFLIP from human herpes virus saimiri, vFLIP from bovine herpes virus (BHV) 4, vFLIP from mecaca herpes virus and/or full length or N-terminal fragment of human cellular FLICE inhibitory protein (cFLIP-L/MRITα or cFLIP-p22). (Table 16).

In some embodiments, vectors comprising polynucleotides encoding CARs further comprise polynucleotides encoding siRNA or scFv specific for cytokines. In exemplary embodiments, the cytokines are any one or more of IL-10, IL-6, IFNγ or combinations thereof. In some embodiment, the CARs are co-expressed with a secreted bispecific antibody fragment that binds to IL6 receptor a and human serum albumin. In some embodiment, the CARs are co-expressed with a secreted scFv fragment that binds to IL6. In some embodiments, the CARs are coexpressed with the peptide FX06 so as to mitigate capillary leak associated with CAR therapy.

In further embodiments, vectors comprising polynucleotides encoding CARs further comprise polynucleotides encoding siRNA or a nuclease targeting the endogenous TCR-α, TCR-β, TCR-γ, TCR-delta, CD3gamma, CD3zeta, CD3epsilon, CD3-delta.

In further embodiments, vectors comprising polynucleotides encoding CARs further comprise polynucleotides encoding a selectable marker. In exemplary embodiment, the selectable marker can encode a drug resistance gene, such as gene that confers resistance to puromycin or calcineurin inhibitors (e.g. CNB30; SEQ ID NO: 852). In some embodiment, the selectable marker may encode for extracellular and transmembrane domains of human CD30, CD20, CD19 (SEQ ID NO: 854), BCMA (SEQ ID NO: 855), EGFR (SEQ ID NO: 853), CD34, or any protein or protein fragment that is expressed on cell surface and can be recognized by an antibody that can be used to eliminate cells expressing its target antigen. In an exemplary embodiment, cetuximab, an anti-EGFR monoclonal is used to eliminate CAR-expressing cells of the invention which coexpress a truncated EGFR (SEQ ID NO: 853). The selectable marker(s) can be used to enrich for cells expressing the CAR, to select for cells that express high levels of CAR and/or to reduce the clonal diversity of the cells expressing the CAR. In further embodiments, polynucleotides encoding CARs may encode for epitope tags that are expressed on the extracellular domain of the CARs and can be used to enrich for cells expressing the CAR, to select for cells that express high levels of CAR and/or to reduce the clonal diversity of the cells expressing the CAR. Non-limiting examples of such tags are provided in SEQ ID NOs: 553-563 and 3526-3530 (Table 12). Reducing the clonal diversity of allogeneic T cells expressing the CARs will in turn lead to reduced incidence of Graft versus Host Disease (GVHD), thereby allowing the use of allogeneic T cells for CAR-T cell therapy.

Polynucleotides and Polypeptides

Provided herein are one or more polypeptides encoded by one or more nucleic acid molecules encoding conventional CARs I to III or any one or more of backbones 1-62 described herein (Table 2).

Also provided herein are one or more polypeptides encoded by one or more nucleic acid molecules encoding conventional CARs I to III. In some embodiments, the antigen-specific domain of the CARs is specific to one, two, three or more antigens on target cells, such as cancer cells. As described herein, each component of the CAR is contiguous and in the same reading frame with each other components of the CAR. In some embodiments, in the CAR comprising backbone comprises more than one antigen specific domain, each of the antigen specific domains are contiguous and in the same reading frame as the other antigen specific domains in the same CAR.

Also provided herein are one or more polypeptides encoded by one or more nucleic acid molecules encoding backbone-1 comprising conventional CAR I and K13-vFLIP as described herein. In some embodiments, the antigen-specific domain of the CAR comprising backbone-1 is specific to one, two, three or more antigens on target cells, such as cancer cells. As described herein, each component of the CAR is contiguous and in the same reading frame with each other components of the CAR comprising backbone-1. In some embodiments, in the CAR comprising backbone-1 comprises more than one antigen specific domain, each of the antigen specific domains are contiguous and in the same reading frame as the other antigen specific domains in the same CAR.

Also provided herein are one or more polypeptides encoded by one or more nucleic acid molecules encoding backbone-32 which comprises conventional CAR II and K13-vFLIP as described herein. In some embodiments, the antigen-specific domain of the CAR comprising backbone-32 is specific to one, two, three or more antigens on target cells, such as cancer cells. As described herein, each component of the CAR is contiguous and in the same reading frame with each other components of the CAR. In some embodiments, in the CAR comprising backbone-32 comprises more than one antigen specific domain, each of the antigen specific domains are contiguous and in the same reading frame as the other antigen specific domains in the same CAR.

In various embodiments, the polypeptides encoded by the nucleic acid molecules encoding CARs which are part of conventional CARs I to III or part of the backbones described herein, such as backbone-1, backbone-2, backbone-32 or backbone-33, comprise two, three or more antigen specific domains.

In various embodiments, the polypeptides encoded by the nucleic acid molecules encoding CARs which are part of the backbones described herein, such as backbone-1, backbone-2, backbone-32 or backbone-33, comprise one, two, three or more viral and/or cellular signaling proteins.

The nucleic acid sequences encoding for the desired components of the CARs described herein can be obtained using recombinant methods known in the art, such as, for example by screening libraries from cells expressing the nucleic acid molecule, by deriving the nucleic acid molecule from a vector known to include the same, or by isolating directly from cells and tissues containing the same, using standard techniques. Alternatively, the nucleic acid of interest can be produced synthetically, rather than cloned.

In one embodiment, an antigen specific domain of a CAR against a target antigen is an antigen binding portion, e.g., CDRs, of vHH fragments targeting this antigen as shown in Table 7.

In one embodiment, an antigen specific domain of a CAR against a target antigen is an antigen binding portion of a non-immunoglobulin scaffold targeting this antigen as shown in Table 8.

In one embodiment, an antigen specific domain of a CAR against a target antigen is an antigen binding portion of a receptor known to bind this target antigen.

In one embodiment, an antigen binding specific domain of a CAR against a target antigen is an antigen binding portion of a ligand known to bind this target antigen.

In some embodiments, provided herein are polypeptides encoded by the nucleic acid molecules encoding CARs which are part of the conventional CARs I to III or are part of the backbones described herein, such as backbone-1, backbone-2, backbone-32 or backbone-33, wherein the antigen-specific domain of the CARs is specific to the thrombopoietin receptor, MPL.

In some embodiments, provided herein are polypeptides encoded by the nucleic acid molecules encoding CARs which are part of the conventional CARs I to III or are part of backbones described herein, such as backbone-1, backbone-2, backbone-32 or backbone-33, wherein the antigen-specific domain of the CARs is specific to Fc portion of an antibody (i.e. Ig Fc). An exemplary CAR with the antigen-specific domain specific to Ig Fc is represented by SEQ ID NO: 2708 and contains the extracellular domain of CD16-V158 as the antigen specific domain.

In some embodiments, the nucleic acid molecule encoding the CARs and/or accessory molecules described herein is provided as a messenger RNA (mRNA) transcript. In another embodiment, the nucleic acid molecule encoding the CARs and/or accessory molecules described herein is provided as a DNA construct.

Also provided herein are vectors comprising the polynucleotides described herein. In some embodiments, the vectors are viral vectors. Examples of viral vectors include but are not limited to retrovirus, an adenovirus, an adeno-associated virus, a lentivirus, a pox virus, a herpes virus vector or a sleeping beauty transposon vector. In various embodiments, the present invention includes retroviral and lentiviral vector constructs expressing the CAR and the accessory molecules that can be directly transduced into a cell.

The present invention also includes an RNA construct that can be directly transfected into a cell. A method for generating mRNA for use in transfection involves in vitro transcription (IVT) of a template with specially designed primers, followed by polyA addition, to produce a construct containing 3′ and 5′ untranslated sequence (“UTR”) (e.g., a 3′ and/or 5′ UTR described herein), a 5′ cap (e.g., a 5′ cap described herein) and/or Internal Ribosome Entry Site (IRES) (e.g., an IRES described herein), the nucleic acid to be expressed, and a polyA tail, typically 50-2000 bases in length (SEQ ID NO:922). RNA so produced can efficiently transfect different kinds of cells. In one embodiment, the template includes sequences for the CAR. In an embodiment, an RNA CAR vector is transduced into a cell, e.g., a T cell or a NK cell, by electroporation. In another embodiment, an RNA CAR vector is transduced into a cell, e.g., a T cell or a NK cell, by causing transient perturbations in cell membrane using a microfluidic device as described in patent application WO 2013/059343 A1 (PCT/US2012/060646). The polynucleotide sequences coding for the desired molecules can be obtained using recombinant methods known in the art, for example by screening libraries from cells expressing the gene, by deriving the gene from a vector known to include the same, or by isolating directly from cells and tissues containing the same, using standard techniques. Alternatively, the gene of interest can be produced synthetically, rather than cloned.

The present invention also provides vectors in which a DNA encoding the CARs of the present invention is inserted. Vectors derived from retroviruses such as the lentivirus are suitable tools to achieve long-term gene transfer since they allow long-term, stable integration of a transgene and its propagation in daughter cells. Lentiviral vectors have the added advantage over vectors derived from onco-retroviruses such as murine leukemia viruses in that they can transduce non-proliferating cells, such as hepatocytes. They also have the added advantage of low immunogenicity. Exemplary lentiviral vectors are provided in SEQ ID NOs: 905-906. A retroviral vector may also be, e.g., a gammaretroviral vector. A gammaretroviral vector may include, e.g., a promoter, a packaging signal (W), a primer binding site (PBS), one or more (e.g., two) long terminal repeats (LTR), and a transgene of interest, e.g., a gene encoding a CAR. A gammaretroviral vector may lack viral structural gens such as gag, pol, and env. Exemplary gammaretroviral vectors include Murine Leukemia Virus (MLV), Spleen-Focus Forming Virus (SFFV), and Myeloproliferative Sarcoma Virus (MPSV), and vectors derived therefrom. Other gammaretroviral vectors are described, e.g., in Tobias Maetzig et al., “Gammaretroviral Vectors: Biology, Technology and Application” Viruses. 2011 June; 3(6): 677-713. An exemplary retroviral vector is provided in SEQ ID NO: 907. In another embodiment, the vector comprising the nucleic acid encoding the desired CAR of the invention is an adenoviral vector (A5/35).

The expression of natural or synthetic nucleic acids encoding CARs is typically achieved by operably linking a nucleic acid encoding the CAR polypeptide or portions thereof to a promoter, and incorporating the construct into an expression vector. The vectors can be suitable for replication and integration eukaryotes. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the desired nucleic acid sequence. The expression constructs of the present invention may also be used for nucleic acid immunization and gene therapy, using standard gene delivery protocols. Methods for gene delivery are known in the art. See, e.g., U.S. Pat. Nos. 5,399,346, 5,580,859, 5,589,466, incorporated by reference herein in their entireties.

Cloning and expression methods will be apparent to a person of skill in the art and may be as described in WO 2015/142675; Sambrook et al., 2012, MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1-4, Cold Spring Harbor Press, NY; June et al. 2009 Nature Reviews Immunology 9.10: 704-716; WO 01/96584; WO 01/29058; U.S. Pat. No. 6,326,193, the contents of each of which are herein incorporated by reference in their entirety as though set forth herein.

Physical methods for introducing polynucleotides of into host cells such as calcium phosphate transfection and the like are well known in the art and will be apparent to a person of skill in the art. In exemplary embodiments, such methods are set forth in Sambrook et al., 2012, MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1-4, Cold Spring Harbor Press, NY); U.S. Pat. Nos. 5,350,674 and 5,585,362, the contents of each of which are herein incorporated by reference in their entirety as though set forth herein. In another embodiment, a CAR vector is transduced into a cell, e.g., a T cell or a NK cell, by causing transient perturbations in cell membrane using a microfluidic device as described in patent application WO 2013/059343 A1 (PCT/US2012/060646) and in Ding X et al, Nat. Biomed. Eng. 1, 0039 (2017) the contents of each of which are herein incorporated by reference in their entirety as though set forth herein.

Genetically Engineered Cells

In various embodiments, the cells for modifications with CARs described herein, including T cells or NK cells may be obtained from a subject desiring therapy. T cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. T cells could be tissue resident gamma-delta T cells, which can be cultured and expanded in vitro prior to expression of the CAR.

In one aspect, the invention provides a number of chimeric antigen receptors (CAR) comprising an antigen binding domain (e.g., antibody or antibody fragment, TCR or TCR fragment) engineered for specific binding to a disease-associated antigen, e.g., a tumor antigen described herein. In one aspect, the invention provides an immune effector cell (e.g., T cell, NK cell) engineered to express a CAR, wherein the engineered immune effector cell exhibits a therapeutic property. In one aspect, the invention provides an immune effector cell (e.g., T cell, NK cell) engineered to express a CAR, wherein the engineered immune effector cell exhibits an anticancer property. In one aspect, a cell is transformed with the CAR and the CAR is expressed on the cell surface. In some embodiments, the cell (e.g., T cell, NK cell) is transduced with a viral vector encoding a CAR. In some embodiments, the viral vector is a retroviral vector. In some embodiments, the viral vector is a lentiviral vector. In some such embodiments, the cell may stably express the CAR. In another embodiment, the cell (e.g., T cell, NK cell) is transfected with a nucleic acid, e.g., mRNA, cDNA, DNA, encoding a CAR. In some such embodiments, the cell may transiently express the CAR.

The present invention provides immune effector cells (e.g., T cells, NK cells) that are engineered to contain one or more CARs that direct the immune effector cells to diseased cells or disease-associated cells, such as cancer cells. This is achieved through an antigen binding domain on the CAR that is specific for a cancer associated antigen. There are two classes of cancer associated antigens (tumor antigens) that can be targeted by the CARs of the instant invention: (1) cancer associated antigens that are expressed on the surface of cancer cells; and (2) cancer associated antigens that itself is intracellular, however, a fragment of such antigen (peptide) is presented on the surface of the cancer cells by MHC (major histocompatibility complex).

Furthermore, the present invention provides CARs and CAR-expressing cells and their use in medicaments or methods for treating, among other diseases, cancer or any malignancy or autoimmune diseases or infectious disease or degenerative disease or allergic disease involving cells or tissues which express a tumor antigen or disease associated antigen as described herein.

In one aspect, the invention provides an immune effector cell (e.g., T cell, NK cell) engineered to express a chimeric antigen receptor (CAR), wherein the engineered immune effector cell exhibits an anti-disease property, such as antitumor property. A preferred antigen is a cancer associated antigen (i.e., tumor antigen) described herein. In one aspect, the antigen binding domain of the CAR comprises a partially humanized antibody fragment. In one aspect, the antigen binding domain of the CAR comprises a partially humanized scFv. Accordingly, the invention provides CARs that comprises a humanized antigen binding domain and is engineered into a cell, e.g., a T cell or a NK cell, and methods of their use for adoptive therapy.

Further provided herein are genetically engineered cells, comprising the polynucleotides and/or the chimeric antigen receptors described herein. In some embodiments, the cell is a T-lymphocyte (T-cell). In some embodiment the cell is a naïve T cells, a central memory T cells, an effector memory T cell, a regulatory T cell (Treg) or a combination thereof. In some embodiments, the cell is a natural killer (NK) cell, a hematopoietic stem cell (HSC), an embryonic stem cell, or a pluripotent stem cell. Genetically engineered cells which may comprise and express the CARs of the invention include, but are not limited to, T-lymphocytes (T-cells), naïve T cells (TN), memory T cells (for example, central memory T cells (TCM), effector memory cells (TEM)), natural killer cells, hematopoietic stem cells and/or pluripotent embryonic/induced stem cells capable of giving rise to therapeutically relevant progeny. In an embodiment, the genetically engineered cells are autologous cells. In an embodiment, the genetically engineered cells are allogeneic cells. By way of example, individual T-cells of the invention may be CD4+/CD8−, CD4−/CD8+, CD4−/CD8− or CD4+/CD8+. The T-cells may be a mixed population of CD4+/CD8− and CD4−/CD8+ cells or a population of a single clone. CD4+ T-cells of the invention may produce IL-2, IFNγ, TNFα and other T-cell effector cytokines when co-cultured in vitro with cells expressing the target antigens (for example CD20+ and/or CD19+ tumor cells). CD8+ T-cells of the invention may lyse antigen-specific target cells when co-cultured in vitro with the target cells. In some embodiments, T cells may be any one or more of CD45RA+CD62L+naïve cells, CD45RO+CD62L+ central memory cells, CD62L-effector memory cells or a combination thereof (Berger et al., Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol 2009 21(2)224-232). Genetically modified cells may be produced by stably transfecting cells with DNA encoding the CAR of the invention.

Various methods produce stable transfectants which express the CARs of the invention. In one embodiment, a method of stably transfecting and re-directing cells is by electroporation using naked DNA. By using naked DNA, the time required to produce redirected cells may be significantly reduced. Additional methods to genetically engineer cells using naked DNA encoding the CAR of the invention include but are not limited to chemical transformation methods (e.g., using calcium phosphate, dendrimers, liposomes and/or cationic polymers), non-chemical transformation methods (e.g., electroporation, optical transformation, gene electrotransfer, transient perturbation in cell membranes and/or hydrodynamic delivery) and/or particle-based methods (e.g., impalefection, using a gene gun and/or magnetofection). The transfected cells demonstrating presence of a single integrated un-rearranged vector and expression of the CAR may be expanded ex vivo. In one embodiment, the cells selected for ex vivo expansion are CD8+ and demonstrates the capacity to specifically recognize and lyse antigen-specific target cells.

Viral transduction methods may also be used to generate redirected cells which express the CAR of the invention. Cell types that may be used to generate genetically modified cells expressing the CAR of the invention include but are not limited to T-lymphocytes (T-cells), natural killer cells, hematopoietic stem cells and/or pluripotent embryonic/induced stem cells capable of giving rise to therapeutically relevant progeny.

Stimulation of the T-cells by an antigen under proper conditions results in proliferation (expansion) of the cells and/or production of IL-2. The cells comprising the CAR of the invention will expand in number in response to the binding of one or more antigens to the antigen-specific targeting regions of the CAR. The invention also provides a method of making and expanding cells expressing a CAR. The method comprises transfecting or transducing the cells with the vector expressing the CAR and stimulating the cells with cells expressing the target antigens, recombinant target antigens, or an antibody to the receptor to cause the cells to proliferate, so as to make and expand T-cells. In an embodiment, the cells may be any one or more of T-lymphocytes (T-cells), natural killer (NK) cells, hematopoietic stem cells (HSCs) or pluripotent embryonic/induced stem cells capable of giving rise to therapeutically relevant progeny.

In some embodiments, genetically engineered cells described herein express the various backbones described herein, wherein the CAR component of the backbone determines target specificity based on the antigen specific domain of the CAR.

In one embodiment, the genetically engineered cells comprise nucleic acid molecules encoding conventional CARs I to III or conventional CARs I to III which are part of the backbones described herein, such as backbone-1, backbone-2, backbone-32 or backbone-33, wherein the antigen-specific domain of the CARs is specific to MPL.

In various embodiments, the genetically engineered cells comprise nucleic acid molecules encoding conventional CARs I to III or conventional CARs I to III which are part of the backbones described herein, such as backbone-1, backbone-2, backbone-32 or backbone-33, wherein the antigen specific domain targets antigen described in Tables 4, 7, 8, 11, 19, 20, 21 or 22.

Immune effector cells such as T cells and NK cells comprising CARs and/or enhancers as described herein may be activated and expanded generally using methods as described, for example, in U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005.

Therapeutic Methods

Provided herein are methods for treating a disease associated with expression of a disease-associated antigen or a cancer associated antigen.

In one embodiment, provided herein are methods for treating a disease in a subject in need thereof by administering to the subject a therapeutically effective amount of genetically modified cells described herein (such as T cells, NK cells) that are engineered to express an antigen-specific CAR alone or an antigen specific CAR and an accessory molecule, wherein the antigen is a disease specific antigen as described herein, and wherein the disease causing or disease-associated cells express the said disease-specific antigen.

In one embodiment, provided herein are methods for treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of genetically modified cells described herein (such as T cells, NK cells) that are engineered to express an antigen-specific CAR alone or an antigen specific CAR and an accessory molecule, wherein the antigen is a cancer specific antigen as described herein, and wherein the cancer cells express the said tumor antigen.

In one embodiment, the cancer specific antigen is expressed on both normal cells and cancers cells, but is expressed at lower levels on normal cells. In one embodiment, the method further comprises selecting a CAR that binds the cancer specific antigen of interest with an affinity that allows the antigen specific CAR to bind and kill the cancer cells. In some embodiments, the antigen specific CAR kills cancer cells but kills less than 30%, 25%, 20%, 15%, 10%, 5% or less of the normal cells expressing the cancer antigen. In exemplary embodiments, the percentage of cells killed by the antigen specific CARs may be determined using the cell death assays described herein.

In some embodiment, the present invention provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the genetically modified cells (e.g., T cells, NK cells) that are engineered to express conventional CARs I to III, wherein the ASD of the CARs is specific to the antigen that is expressed on cancer cells (for example, the antigen is expressed at lower levels on normal cells relative to cancer cells).

In some embodiment, the present invention provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the genetically modified cells (e.g., T cells, NK cells) that are engineered to express backbone-1 comprising the conventional CARs I and the accessory module 1K13-vFLIP, wherein the ASD of the CARs is specific to the antigen that is expressed on cancer cells (for example, the antigen is expressed at lower levels on normal cells relative to cancer cells).

In some embodiment, the present invention provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the genetically modified cells (e.g., T cells, NK cells) that are engineered to comprising backbone-2 comprising the conventional CARs I and the accessory module MCl59-vFLIP, wherein the ASD of the CARs is specific to the antigen that is expressed on cancer cells (for example, the antigen is expressed at lower levels on normal cells relative to cancer cells).

In some embodiment, the present invention provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the genetically modified cells (e.g., T cells, NK cells) that are engineered to comprising backbone-3²comprising the conventional CAR 11 and the accessory module K13-vFLIP, wherein the ASD of the CARs is specific to the antigen that is expressed on cancer cells (for example, the antigen is expressed at lower levels on normal cells relative to cancer cells).

In some embodiment, the present invention provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the genetically modified cells (e.g., T cells, NK cells) that are engineered to comprising backbone-33 comprising the conventional CAR II and the accessory module MC159-vFLIP, wherein the ASD of the CARs is specific to the antigen that is expressed on cancer cells (for example, the antigen is expressed at lower levels on normal cells relative to cancer cells).

In exemplary embodiments, the antigens that may be targeted for the therapeutic methods described herein include but are not limited to any one, two, three, four or more of: CD19; CD123; CD22; CD23, CD30; CD32, CD99; Tissue Factor; MPL; CD171; CS-1 (also referred to as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant III (EGFRvIII); ganglioside G2 ((G2); ganglioside GD3(aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); TNF receptor family member B cell maturation (BCMA); Tn antigen ((Tn Ag) or (GalNAca-Ser/Thr)); prostate-specific membrane antigen (PSMA); Receptor tyrosine kinase-like orphan receptor 1 (ROR 1); Fms-Like Tyrosine Kinase 3 (FLT3); Tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; Carcinoembryonic antigen (CEA); Epithelial cell adhesion molecule (1CAM); 13713 (C_D276); KIT (CD1117); Interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); Mesothelin; Interleukin 11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); Protease Serine 21 (Testisin or PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis(Y) antigen; CD24; Platelet-derived growth factor receptor beta (PDGFR-beta); Stage-specific enbryonic antigen-4 (SSEA-4); CD20; Folate receptor alpha; Receptor tyrosine-protein kinase ERBB2 (Her2/neu); Mucin 1, cell surface associated (MUC); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); Prostase; prostatic acid phosphatase (PAP); elongation factor 2 mutated (ELF2M); Ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAFX); Proteasome (Prosome, Macropain) Subunit, Beta Type, 9 (LMP2); glycoprotein 100 (gp100); oncogene fusion protein consisting of breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog 1 (Abl) (her-abl); tyrosinase; ephrin type-A receptor 2 (EphA2); Fucosyl GM1; sialyl Lewis adhesion molecule (sle); ganglioside GM3 (aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); transglutaminase 5 (TGS5); high molecular weight-melanoma-associated antigen (HMWMAA); o-acetyl-GD¹2 ganglioside (OAcGD2); Folate receptor beta; tumor endothelial marker 1 (TEM1/CD248); tumor endothelial marker 7-related (TENM7R); claudin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lyphoma kinase (ALK; Polysialic acid; placenta-specific 1 (PLAC1); hexasaccharide portion of globoH glycoceramide (GloboH); mammary gland differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); Hepatitis A virus cellular receptor 1 (HAVCR1); adrenoceptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); Olfactory receptor 51 E2 (OR51E2); TCR Gamma Alternate Reading Frame Protein (TARP); Wilms tumor protein (WT1); Cancer/testis antigen 1 (NY-ESO-1); Cancer/testis antigen 2 (LAGE-1a); Melanoma-associated antigen 1 (MAGE-A1); ETS translocation-variant gene 6, located on chromosome 12p (ETV6-AM L); sperm protein 17 (SPA17); X Antigen Family, Member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutant; prostein; surviving; telomerase; prostate carcinoma tumor antigen-1 (PCTA-1 or Galectin 8), melanoma antigen recognized by T cells 1 (MelanA or MARTI); Rat sarcoma (Ras) mutant; human Telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (MLIAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-Acetyl glucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); Androgen receptor; Cyclin B1; v-mvc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN); Ras Homolog Family Member C (RhoC); Tyrosinase-related protein 2 (TRP-2); Cytochrome P450 1B11 (CYPIB1); CCCTC-Binding Factor (Zinc Finger Protein)-Like (BORIS or Brother of the Regulator of Imprinted Sites), Squamous Cell Carcinoma Antigen Recognized By T Cells 3 (SART3); Paired box protein Pax-5 (PAX5); proacrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint 2 (SSX2); Receptor for Advanced Glycation Endproducts (RAGE-1); renal ubiquitous 1 (RU1); renal ubiquitous 2 (RU2); legumain; human papilloma virus E6 (HPV E6); human papilloma virus E7 (HPV E7); intestinal carboxyl esterase; heat shock protein 70-2 mutated (mut hsp70-2); CD79a; CD79b; CD72; Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fe fragment of IgA receptor (FCAR or CD89); Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide 1 (IGLL1), PTK7, LAMP1, TROP2, Tim1 and HIV1-envelop glycoprotein gp120.

In exemplary embodiments, the antigens that may be targeted for the therapeutic methods described herein include but are not limited to any one, two, three, four or more of: TSHR, CD171, CS-1, CLL-1, GD3, Tn Ag, FLT3, CD38, CD44v6, B7H3, KIT, IL-13Ra2, IL-IIIRa, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-beta, SSEA-4, MUC1, EGFR, NCAM, CAIX, LMP2, EphA2, Fucosyl GM1, sLe, GM3, TGS5, HNMWMAA, o-acetyl-GD2, Folate receptor beta, TEM1/CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a. ALK, Polysialic acid, PLAC1, GloboH, NY-IR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, N1AD-CT-2, Fos-related antigen 1, p53 mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, Androgen receptor, Cyclin B1, MYCN, RhoC, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, CD79a, CD79b, CD72, LAIR1, FC AR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1.

In exemplary embodiments, the antigens that may be targeted for the therapeutic methods described herein include but are not limited to any one, two, three, four or more of: WT-1, hTERT, PRAME, HMMR/Rhamm, PR1, CG1, CD33, Cyclin-A1, NY-ESO-1, MAGE, HA-1, ACC1, T4A, LB-LY75-IK, BCR-ABL, FLT3-ITD, B-cell receptor idiotype, HTLV-I Tax protein, CD19, Lewis Y, CD22 and ROR1.

In exemplary embodiments, the antigens that may be targeted for the therapeutic methods described herein include but are not limited to any one, two, three, four or more of the targets described in Tables 4, 7, 8, 11, 19, 20, 21 or 22.

In one embodiment, the present invention provides methods of treating cancer by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express conventional CARs I to III or backbones (for example, backbone-1, backbone-2, backbone-32 or backbone-33) specific to MPL, wherein the cancer cells express MPL. In one embodiment, the cancer to be treated is acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. In one embodiment, the antigen specific domain of the MPL specific CAR comprises V_Lfragments as described in SEQ ID NOs: 180-187, V_Hfragments as described in SEQ ID NOs: 427-434 and/or scFV as described in SEQ ID NOS: 729-736. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the immune effector cells described herein.

In one embodiment, the present invention provides methods of treating cancer, autoimmune or allergic disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express conventional CARs I to III or backbones (for example, backbone-1, backbone-2, backbone-32 or backbone-33) specific to CD19, wherein the cancer cells express CD19. In one embodiment, the cancer to be treated is acute lymphoblastic leukemia, chronic lymphocytic leukemia, B cell malignancy, non-Hodgkins lymphoma, diffuse large 13-cell lymphoma, mantle cell lymphoma, or, multiple myeloma. In one embodiment, the antigen specific domain of the CD19 specific CAR comprises V_Lfragments as described in SEQ ID NOs: 40-55, V_Hfragments as described in SEQ ID NOs: 288-303 and/or scFV as described in SEQ ID NOs: 564-577. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the immune effector cells described herein.

In one embodiment, the present invention provides methods of treating cancer by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express backbones (for example, backbone-1, backbone-2, backbone-32 or backbone-33) specific to GRP-78, wherein the cancer cells express GRP-78. In one embodiment, the cancer to be treated is breast cancer. In one embodiment, when the immune effector cells expressing the GRP-78 CAR also expresses an MPL CAR, the cancer to be treated is acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, myelodysplastic syndrome or multiple myeloma. In one embodiment, the antigen specific domain of the GRP-78 specific CAR comprises scFV as described in SEQ ID NO: 703. In one embodiment, the antigen specific domain of the MPL specific CAR comprises V_Lfragments as described in SEQ 1D NOs: 180-187, V_Hfragments as described in SEQ ID NOs: 427-434 and/or scFV as described in SEQ ID NOs: 729-736. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the immune effector cells described herein.

In one embodiment, the present invention provides methods of treating cancer, autoimmune or allergic disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express backbones (for example, backbone-1, backbone-2, backbone-32 or backbone-33) specific to CD79b, wherein the cancer cells express CD79b. In one embodiment, the cancer to be treated is acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, myelodysplastic syndrome or multiple myeloma. In one embodiment, the antigen specific domain of the CD79b specific CAR comprises V_Lfragments as described in SEQ ID NOs: 92-93, V_Hfragments as described in SEQ ID NOs: 340-341 and/or scFV as described in SEQ ID NO: 628. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib. Ponatinib and/or A-770041, concurrently or sequentially with the immune effector cells described herein.

In one embodiment, the present invention provides methods of treating cancer, autoimmune or allergic disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express conventional CARs I to III or backbones (for example, backbone-1, backbone-2, backbone-32 or backbone-33) specific to ROR-1 (Receptor tyrosine kinase-like orphan receptor 1), wherein the disease associated or disease causing cells express ROR-1.In some embodiments, cancer to be treated is chronic lymphocytic leukemia or solid organ tumors. In one embodiment, the antigen specific domain of the ROR-1 specific CAR comprises V_Hfragments as described in SEQ ID NOs: 454-455 and/or scFV as described in SEQ ID NO: 755-756. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the immune effector cells described herein.

In one embodiment, the present invention provides methods of treating cancer, autoimmune or allergic a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express backbones (for example, backbone-1, backbone-2, backbone-32 or backbone-33) specific to Lym-1. In one embodiment, the cancer to be treated or prevented is a B cell malignancy. In one embodiment, the antigen specific domain of the Lym-1 specific CAR comprises V_Lfragments as described in SEQ ID NO: 175, V_Hfragments as described in SEQ ID NO: 421 and/or scFV as described in SEQ ID NO: 723. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the immune effector cells described herein.

In one embodiment, the present invention provides methods of treating cancer, autoimmune or allergic disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express conventional CAR I to III or backbones (for example, backbone-1, backbone-2, backbone-32 or backbone-33) specific to Lym-2. In some embodiments, the cancer to be treated is blood cancer, ovarian cancer, prostate cancer or pancreatic tumors. In one embodiment, the antigen specific domain of the Lym-2 specific CAR comprises V_Lfragments as described in SEQ ID NO: 176, V_Hfragments as described in SEQ ID NO: 422 and/or scFV as described in SEQ ID NO: 724. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a CD123-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express CD123. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is AML or myelodysplastic syndrome (MDS). In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a CD22-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express CD22. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is B cell malignancies. In one embodiment, the disease to be treated or prevented is an immune disease or allergic disease. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a CD23-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express CD23. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is B cell malignancies. In one embodiment, the disease to be treated or prevented is an immune disease or allergic disease. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a CS-1-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express CS-1. In one embodiment, the disease to be treated or prevented is an immune disease or allergic disease. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is a plasma cell malignancy or multiple myeloma or primary effusion lymphoma. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a BCMA-CAR, wherein the disease causing or disease associated cells express BCMA. In one embodiment, the disease to be treated or prevented is an immune disease or allergic disease. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is a plasma cell malignancy or multiple myeloma or primary effusion lymphoma. In one embodiment, the disease to be treated or prevented is an immune disease. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib. Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a CLL-1-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express CLL-1. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is AML or MDS. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a CD30-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express CD30. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is lymphoma or leukemia. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a CD33-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express CD33. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is AML or MDS. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a IL-13Ra2-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express IL-13Ra2. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is glioblastoma. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a IL-11Ra-CAR, wherein the disease causing or disease associated cells express IL-11Ra. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is osteosarcoma. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express CD20-CAR, wherein the disease causing or disease associated cells express CD20. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is a B cell malignancy, such as chronic lymphocytic leukemia, acute lymphocytic leukemia, diffuse large cell lymphoma, follicular lymphoma or mantle cell lymphoma. In one embodiment, the disease to be treated or prevented is an immune disease or allergic disease. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express folate receptor alpha-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express folate receptor alpha. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is ovarian cancer, NSCLC, endometrial cancer, renal cancer, or other solid tumors. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express TSHR-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express TSHR (Thyroid Stimulating Hormone Receptor). In one embodiment, the disease to be treated or prevented is cancer. In one embodiment, the cancer to be treated or prevented is thyroid cancer, or multiple myeloma or T cell leukemia or T cell lymphoma. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express GPRC5D-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express GPRC5D. In one embodiment, the disease to be treated or prevented is cancer, immune or allergic disease. In one embodiment, the cancer to be treated or prevented is a plasma cell disorder, multiple myeloma or primary effusion lymphoma. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express ALK-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express ALK. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is a NSCLC, ALCL (anaplastic large cell lymphoma), IMT (inflammatory myofibroblastic tumor), or neuroblastoma. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a HAVCR1-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express HAVCR1. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is renal cancer. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a WT1/MHC I complex-specific CAR, wherein the disease causing or disease associated cells express WT1 in association with MHC class I complex. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is AML or myeloma. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a NY-ESO-1/MHC 1 complex-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express NY-ESO-1 in association with MHC class I complex. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is myeloma. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express PTK7-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express PTK7. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is melanoma, lung cancer or ovarian cancer. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express DLL3-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express DLL3. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is melanoma, lung cancer or ovarian cancer. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express GCC-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express GCC. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is gastrointestinal cancer. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express CCR4-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express CCR4. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is T cell leukemia or lymphoma. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express CDH1/CD324-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express CDH1/CD324. In one embodiment, the disease to be treated or prevented is a cancer. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express CD200R-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express CD200R. In one embodiment, the disease to be treated or prevented is a cancer. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express a CDH19-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express CDH19. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is a solid tumor. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express a CDH17-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express CDH17. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is a solid tumor. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express a CDH6-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express CDH6. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is a solid tumor. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib. Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express a GFRa4-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express GFRa4. In one embodiment, the disease to be treated or prevented is a cancer. In one embodiment, the cancer to be treated or prevented is a thyroid medullary cancer. In some embodiments, the activity of CAR-T cells may be controlled using Dasatinib, Ponatinib and/or A-770041, concurrently or sequentially with the administration of immune effector cells described herein.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express TCRB1-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express TCRB1 (T cell receptor Beta1 constant chain). In one embodiment, the disease to be treated or prevented is a cancer or immune disease. In one embodiment, the cancer to be treated or prevented is T cell leukemia or T cell lymphoma. In one embodiment, the immune disorder to be treated or prevented is multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis, inflammatory Bowel Disease, Diabetes Mellitus, Graft vs host disease or autoimmune Thyroiditis.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express TCRB2-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express TCRB2 (T cell receptor Beta2 constant chain). In one embodiment, the disease to be treated or prevented is a cancer or immune disorder. In one embodiment, the cancer to be treated or prevented is T cell leukemia or T cell lymphoma. In one embodiment, the immune disorder to be treated or prevented is multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis, inflammatory Bowel Disease, Diabetes Mellitus, Graft vs host disease or autoimmune Thyroiditis.

In one aspect, the present invention provides methods of treating or preventing a disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express T cell receptor gamma-delta-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells express T cell receptor gamma-delta. In one embodiment, the disease to be treated or prevented is a cancer or immune disorder. In one embodiment, the cancer to be treated or prevented is T cell leukemia or T cell lymphoma. In one embodiment, the immune disorder to be treated or prevented is multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, diabetes mellitus, Graft vs host disease or autoimmune Thyroiditis.

In one aspect, the present invention provides methods of treating or preventing CMV (Cytomegalovirus) infection or associated disease by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express CMV-specific CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells are infected with CMV. In one aspect the CMV CAR and backbones are directed against the CMV pp65 protein. In one aspect, the CMV-associated disease is pneumonia, colitis or meningoencephalitis.

In one aspect, the present invention provides methods of treating or preventing EBB infection or diseases associated with EBB infection by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express an EBB-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells are infected with EBB. In one aspect the EBB-specific CARs and backbones are directed against the EBB EBNA3c protein. In one aspect, the EBB-specific CARs and backbones comprise a broadly neutralizing antibody against EBB. In one aspect, the EBB-associated disease is lymphoma.

In one aspect, the present invention provides methods of treating or preventing KSHV infection or diseases associated with KSHV infection by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express an KSHV-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells are infected with KSHV. In one aspect, the KSHV associated disease is Kaposi's sarcoma or primary effusion lymphoma or multicentric castleman's disease.

In one aspect, the present invention provides methods of treating or preventing HTLV1 infection or diseases associated with HTLV1 infection by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express HTLV1-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells are infected with HTLV1. In one aspect, the HTLV1-specific conventional CAR or backbones target HTLV1 Tax protein/MHC class I complex. In one aspect, the HTLV1 disease is human T cell leukemia or lymphoma.

In one aspect, the present invention provides methods of treating or preventing Influenza A infection or diseases associated with Influenza A infection by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express InfluenzaA-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33), wherein the disease causing or disease associated cells are infected with Influenza A. In one aspect, the InfluenzaA-specific conventional CAR or backbones comprise antigen binding domains derived from a broadly neutralizing antibody against Influenza A hemagglutinin (HA), such as MEDI8852.

In one aspect, the present invention provides methods of treating or preventing a cancer, infection, autoimmune or allergic diseases by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a universal conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33) encoding CD16V158 or a deletion- or point-mutant fragment thereof along with an antibody or an antibody fragment that binds to the CD16 domain of the CAR through its Fc region and on an antigen expressed on the disease associated cells through its variable (vL and/or vH) regions. In one aspect the disease associated cell is a cancer cell, an infected cell, or a plasma cell or a B cell or a T cell.

In one aspect, the present invention provides methods of treating or preventing a cancer, infection, autoimmune or allergic diseases by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) or stem cells that can give rise to immune effector cells that are engineered to express a FITC-specific conventional CAR or backbones 1-62 (for example, backbone-1, backbone-2, backbone-32 or backbone-33) along with a FITC-labeled antibody or an antibody fragment that binds to an antigen expressed on the disease associated cells. In one aspect the disease associated cell is a cancer cell, an infected cell, or a plasma cell or a B cell or a T cell.

Exemplary cancers whose growth can be inhibited include cancers typically responsive to immunotherapy. Non-limiting examples of cancers for treatment include melanoma (e.g., metastatic malignant melanoma), renal cancer (e.g. clear cell carcinoma), prostate cancer (e.g. hormone refractory prostate adenocarcinoma), breast cancer, colon cancer and lung cancer (e.g. non-small cell lung cancer). Additionally, refractory or recurrent malignancies can be treated using the molecules described herein.

In exemplary embodiments, cancers treated by the methods described herein include solid tumors such as sarcomas, adenocarcinomas, and carcinomas, of the various organ systems, such as those affecting liver, lung, breast, lymphoid, gastrointestinal (e.g., colon), genitourinary tract (e.g., renal, urothelial cells), prostate and pharynx. Adenocarcinomas include malignancies such as most colon cancers, rectal cancer, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus. In one embodiment, the cancer is a melanoma, e.g., an advanced stage melanoma. Metastatic lesions of the aforementioned cancers can also be treated or prevented using the methods and compositions of the invention.

Examples of other cancers that can be treated include bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin Disease, non-Hodgkin lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers. Treatment of metastatic cancers, e.g., metastatic cancers that express PD-L1 (Iwai et al. (2005) Int. Immunol. 17:133-144) can be effected using the antibody molecules described herein. Further a disease associated with a cancer associate antigen as described herein expression include, but not limited to, e.g., atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases associated with expression of a cancer associate antigen as described herein. In some embodiments, a CAR-expressing T cell or NK cell as described herein reduces the quantity, number, amount or percentage of cells and/or cancer cells by at least 25%, at least 30%, at least 40%, at least 50%, at least 65%, at least 75%, at least 85%, at least 95%, or at least 99% in a subject with hematological cancer or another cancer associated with a cancer associated antigen as described herein, expressing cells relative to a negative control. In one embodiment, the subject is a human.

In one embodiment, the present invention provides methods of treating hematological cancer by providing to the subject in need thereof genetically modified cells (e.g., T cells, NK cells) that are engineered to express the conventional CARs or backbones comprising antigen specific CARs specific to thrombopoietin receptor (MPL). In some embodiments, the hematological cancers include chronic myelogenous leukemia (CML), Acute Myeloid Leukemia and Myelodysplastic syndrome. In some embodiments, a cancer that can be treated using the compositions and methods of the present invention is multiple myeloma. Multiple myeloma is a cancer of the blood, characterized by accumulation of a plasma cell clone in the bone marrow. Current therapies for multiple myeloma include, but are not limited to, treatment with lenalidomide, which is an analog of thalidomide. Lenalidomide has activities which include anti-tumor activity, angiogenesis inhibition, and immunomodulation. Generally, myeloma cells are thought to be negative for a cancer associate antigen as described herein expression by flow cytometry. Thus, in some embodiments, a BCMA CAR (SEQ ID Nos: 951-957), may be used to target myeloma cells. In some embodiments, the CARs of the present invention therapy can be used in combination with one or more additional therapies, e.g., lenalidomide treatment.

In one aspect, the invention pertains to a method of inhibiting growth of a disease (e.g., cancer, autoimmune disease, infectious disease or allergic disease or a degenerative disease), comprising contacting the disease causing or disease associated cell with a genetically modified cell of the present invention expressing a conventional CAR or a CAR with accessory modules (i.e., backbones 1-62) such that the CAR-T is activated in response to the antigen and targets the disease causing or disease associated cell, wherein the growth of the disease causing or disease associated cell is inhibited. In one aspect, the invention pertains to a method of preventing a disease, comprising administering to a patient at risk of disease a CAR-expressing cell or a cell that is capable of generating a CAR-expressing cell of the present invention such that the CAR-T is activated in response to the antigen and targets the disease causing or disease associated cell, wherein the growth of the disease causing or disease associated cell is prevented. In one aspect the disease is a cancer, an infectious disease, an immune disease, an allergic disease, or a degenerative disease.

Embodiments of the instant invention includes a type of cellular therapy where effector cells (such as T cells and NK cells) or stem cells that can give rise to effector cells are genetically modified to express a CAR as described herein and the CAR-expressing T cell or NK cell is infused to a recipient in need thereof. The infused cell is able to kill tumor cells in the recipient. In various aspects, the immune effector cells (e.g., T cells, NK cells) administered to the patient, or their progeny, persist in the patient for at least four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, thirteen months, fourteen month, fifteen months, sixteen months, seventeen months, eighteen months, nineteen months, twenty months, twenty-one months, twenty-two months, twenty-three months, two years, three years, four years, or five years after administration of the T cell or NK cell to the patient.

The invention also includes a type of cellular therapy where immune effector cells (e.g., T cells, NK cells) are modified, e.g., by in vitro transcribed RNA, to transiently express a conventional CAR or a conventional CAR with accessory modules (e.g., backbones 1-62). T cells or NK cells are infused to a recipient in need thereof. The infused cells are able to kill disease associated cells (e.g., tumor cells or virally infected cells) in the recipient. Thus, in various aspects, the CAR-expressing immune effector cells (e.g., T cells, NK cells) persist for less than one month, e.g., three weeks, two weeks, one week, after administration of the T cell or NK cell to the patient.

The invention also includes a type of cellular therapy where stem cells (e.g., hematopoietic stem cell or lymphoid stem cells or embryonic stem cells, or induced pluripotent stem cells) that are capable of giving rise to immune effector cells (e.g., T cells or NK cells) are modified to express a conventional CAR or a conventional CAR with accessory modules (e.g., backbones 1-62) and are administered to a recipient in need thereof. The administered stem cells give rise to immune effector cells (e.g., T cells or NK cells) after transplantation into the recipient, which (i.e. the immune effector cells) are able to kill disease associated cells in the recipient. Thus, in various aspects, the immune effector cells (e.g., T cells. NK cells) that are produced in the patient after administration of CAR-expressing stein cells persist in the patient for at least one week, 2 weeks, 3 weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, thirteen months, fourteen month, fifteen months, sixteen months, seventeen months, eighteen months, nineteen months, twenty months, twenty-one months, twenty-two months, twenty three months, two years, three years, four years, five years, ten years or twenty years after administration of the genetically modified stem cells to the patient. The invention also includes a type of cellular therapy where stem cells that are capable of giving rise to immune effector cells (e.g., T cells or NK cells) are modified to express a conventional CAR or a conventional CAR with accessory modules (e.g. backbones 1-62) and are differentiated in vitro to generate immune effector cells that are infused to a recipient in need thereof. The infused immune effector cells (e.g., T cells or NK cells) after infusion into the recipient are able to kill disease associated cells in the recipient. Thus, in various aspects, the immune effector cells (e.g., T cells, NK cells) that are administered to the patient persist in the patient for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, one week, 2 weeks, 3 weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, thirteen months, fourteen month, fifteen months, sixteen months, seventeen months, eighteen months, nineteen months, twenty months, twenty-one months, twenty-two months, twenty three months, two years, three years, four years, five years, ten years or twenty years.

The invention also includes a type of cellular therapy where regulatory immune effector cells (e.g., TREG, or CD25+ T Cells) are modified to express a conventional CAR or a conventional CAR with accessory modules (e.g., backbones 1-62) targeting a specific antigen. Such CAR-TREG are administered to a patient to suppress immune response against the specific antigen. The CAR-TREG can be used to prevent and treat autoimmune diseases and to enhance immune tolerance.

The anti-tumor immunity response elicited by the CAR-modified immune effector cells (e.g., T cells, NK cells) may be an active or a passive immune response, or alternatively may be due to a direct vs indirect immune response. In one aspect, the CAR-transduced immune effector cells (e.g., T cells, NK cells) exhibit specific pro-inflammatory cytokine secretion and potent cytolytic activity in response to human diseased cells (e.g., cancer or infected cells) expressing the disease associate antigen as described herein, resist soluble disease associate antigen as described herein, mediate bystander killing and mediate regression of an established human disease, including cancer.

The invention also includes a type of cellular therapy where immune effector cells (e.g., T cells and NK cells) or stem cells that are capable of giving rise to immune effector cells (e.g., T cells or NK cells) are modified to express a conventional CAR or a conventional CAR with accessory modules (e.g., backbones 1-62) and are used ex vivo to purge the bone marrow or peripheral blood hematopoietic stem cells of disease-associated cells (e.g. cancer cells). As an example, T cells expressing a CD19-specific CAR are cocultured with bone marrow or peripheral blood stein cell sample taken from a patient with acute lymphocytic leukemia or non-Hodgkin lymphoma so as to kill off any leukemia or lymphoma cells present in the bone marrow or peripheral blood stem cell preparation. After a suitable duration of culture in vitro (ex vivo), which may range from a 6 hours to several days, the purged bone marrow and peripheral blood sample is used for autologous transplant in the patient.

Ex vivo expansion of hematopoietic stem and progenitor cells has been described in U.S. Pat. No. 5,199,942, and is incorporated herein by reference, and can be applied to the cells of the present invention. However, the present invention is not limited to any particular method of ex vivo expansion of the cells and other suitable methods known in the art can be utilized. Briefly, ex vivo culture and expansion of hematopoietic stem cells comprises: (1) collecting CD34+ hematopoietic stem and progenitor cells from a mammal from peripheral blood harvest or bone marrow explants; and (2) expanding such cells ex vivo. In addition to the cellular growth factors described in U.S. Pat. No. 5,199,942, other factors such as flt3-L, IL-1, IL-3 and c-kit ligand, can be used for culturing and expansion of the cells,

In addition to using a cell-based vaccine in terms of ex vivo immunization, the present invention also provides compositions and methods for in vivo immunization to elicit an immune response directed against an antigen in a patient.

In some embodiments, the fully-human CAR-modified genetically modified cells (such as T cells, NK cells) of the invention may be a type of vaccine for ex vivo immunization and/or in vivo therapy in a mammal (for example, human). With respect to ex vivo immunization, at least one of the following occurs in vitro prior to administering the cell into a mammal: i) expansion of the cells, ii) introducing a nucleic acid encoding a CAR to the cells or iii) cryopreservation of the cells. Ex vivo procedures are well known in the art, for example, as described in U.S. Pat. No. 5,199,942, incorporated herein by reference.

Further described herein are methods for controlling the activity of CAR-T cells and Bispecific T cell Engager (BiTE) (such as Blincyto or Blinatumomab) when administered to the patients. In some embodiment these methods can be used to control the side effects of CAR-T cells and BiTE, such as cytokine release syndrome, capillary leak syndrome and neurological complications. In majority of patients who respond to engineered CAR T cells and Blinatumomab, excessive release of proinflammatory cytokines causes symptoms that include fevers, hypotension, hypoxemia, cardiac dysfunction, kidney failure and electrolyte abnormalities, collectively termed as “Cytokine release syndrome” (CRS). A number of these patients require admission to intensive care units for pressure support and artificial ventilation. In significant number of cases, CAR T cells and Blinatumomab therapy can lead to neurologic symptoms including tremor, seizures and can be fatal. Although a number of treatment approaches, including steroids and an IL6 receptor antibody, are used for the treatment of these disorders, a number of patients are refractory to such therapies. The instant invention provides a novel method for the treatment and prevention of complications, such as cytokine release syndrome and neurological complications, of adoptive cellular therapies, including but not limited to CAR-T cell and Bispecific T cell engagers (BiTE). In some embodiment the method involves administration of inhibitors of tyrosine kinases, particularly Scr family kinase, and in particular Lck kinase. In one embodiment, the method involves administration of Dasatinib, an oral small molecule inhibitor of Abl and Src family tyrosine kinases (SFK), including p56Lck (Lck) (Lee K C et al, Leukemia (2010) 24, 896-900). Dasatinib has been previously shown to block antigen-specific effector T cell functions (Weichsel R et al, Clin Cancer Res 2008; 14(8), 2484). However, it has never been tested for the ability to block functions of CAR-T cells and Bispecific T cell engagers. CAR-expressing T cells have been detected in the cerebrospinal fluid (CSF) of patients suffering from neurological complications (Hu, Y et al, Journal of Hematology & Oncology 20169:70). A particularly important advantage of Dasatinib for the treatment and prevention of cytokine release syndrome and neurological complications caused by CAR-T cells and BiTE is its ability to cross the blood-brain barrier and achieve effective concentration in the brain when administered at clinically acceptable doses (Porkka K et al., Blood. 2008 Aug. 15; 112(4):1005-12). Therefore, Dasatinib is expected to block the effector functions, including cytokine release, of CAR-T cells that have crossed the blood brain barrier.

In one embodiment, the Src kinase inhibitor is administered to the patient after the administration of CAR-expressing cells to control or terminate the activity of CAR-expressing cells. In one embodiment, an Lck inhibitor is administered to the patient after the administration of CAR-expressing cells to control or terminate the activity of CAR-expressing cells. In one embodiment, Lck inhibitor is A-770041.

In one embodiment, Dasatinib is administered to the patient after the administration of CAR-expressing cells to control or terminate the activity of CAR-expressing cells. In one embodiment, dasatinib is administered orally at a dose of at least 10 mg/day, 20 mg/day, 40 mg/day, 60 mg/day, 70 mg/day, 90 mg/day, 100 mg/day, 140 mg/day, 180 mg/day, 210 mg/day, 250 mg/day or 280 mg/day.

In one embodiment, Ponatinib is administered to the patient after the administration of CAR-expressing cells to control or terminate the activity of CAR-expressing cells. In one embodiment, ponatinib is administered orally at a dose of at least 15 mg/day, 30 mg/day, 45 mg/day, 60 mg/day.

T lymphocytes have a limited replicative life span until they reach the terminally differentiated state and then enter into a replicative senescence phase due to progressive loss of telomeres with age. Human T lymphocytes display a limited life-span of about 30-50 population doublings when cultured in vitro.

Further contemplated herein are methods for promoting the survival and proliferation of peripheral blood mononuclear cells and T cells and preventing their replicative senescence to extend the life span of immune cells (e.g., lymphocytes and NK cells) for the purpose of adoptive cell therapy. The method entails ectopic expression of viral and cellular proteins that promote survival and proliferation and block activation induced cell death. The exemplary viral proteins suitable for this purpose include viral FLICE Inhibitory Protein (vFLIP) K13 encoded by the Kaposi's sarcoma associated herpesvirus (also known as human herpesvirus 8), MC159-vFLIP and MC160 vFLIP from the molluscum contagiosum virus (MCV), E8-vFLIP from the equine herpesvirus 2 (EHV2), bovine herpesvirus 4 encoded vFLIP (BHV-vFLIP), vFLIP encoded by herpesvirus mecaca, vFLIP encoded by herpesvirus saimiri and HTLV1-encoded Tax, HTLV2-encoded Tax and HTLV2-encoded Tax-RS mutant. Exemplary cellular proteins suitable for this purpose include cFLIP-L isoform or MRIT-α, cFLIP-p22 deletion mutant or MRIT-p22 (Bertin et al., Proc Natl Acad Sci USA 94:1172-6, 1997; Hu et al., J Biol Chem 272:9621-4, 1997; Thome et al., Nature 386:517-21, 1997). In some embodiments, the above viral and cellular proteins are expressed in the immune cells (e.g., T cells and NK cells) in their native state or carrying small epitope tags and are functionally active in a constitutive manner. In other embodiments, the above viral and cellular proteins are expressed in the immune cells (e.g., T cells and NK cells) in fusion with one or more copies of a switch domain (or a dimerization domain), such as FKBP (SEQ ID NOs: 2620 and 2621) and FKBPx2 (SEQ ID NO: 2622). In other embodiment, the FKBP or the FKBP-x2 domain may additionally carry an N-terminal myrisotylation (Myr) sequence to anchor the fusion proteins to the cell membrane. The sequence of an exemplary FKBPx2-K13 fusion protein carrying a Myr sequence is presented in SEQ ID NO: 2623. The fusion proteins carrying the switch domains are functionally inactive in their basal state but are activated upon addition of a dimerizer agent, such as AP20187.

In an embodiment, an immune effector cell, e.g., a T cell, ectopically expresses a viral or cellular signaling protein selected from the group of K13-vFLIP (SEQ ID NO: 2629), MC159-vFLIP (SEQ ID NO: 2630), MC160-vFLIP (SEQ ID NO: 2631), E8-vFLIP (SEQ ID NO: 2632), BHV-vFLIP (SEQ ID NO: 2635), mecaca vFLIP (SEQ ID NO: 2634), herpesvirus saimiri vFLIP (SEQ ID NO: 2633), cFLIP-L/MRITα (SEQ ID NO: 2636), cFLIP-p22 (SEQ ID NO: 2637), HTLV1-Tax (SEQ ID NO: 2638), HTLV2-Tax (SEQ ID NO: 2639), HTLV2-Tax-RS mutants (SEQ ID NO: 2640) or proteins with 70-99% identity to amino acid sequences of the above proteins (SEQ ID NOs: 2629 to 2640).

In an embodiment, an immune effector cell, e.g., a T cell, ectopically expresses a fusion protein containing one or more switch domains, e.g., FKBP (SEQ ID NO: 2620-2621), FKBPx2 (SEQ ID NO: 2622) or Myr-FKBP, and one or more viral or cellular signaling protein selected from the group of K13-vFLIP (SEQ ID NO: 2629), MC159-vFLIP (SEQ ID NO: 2630), MC160-vFLIP (SEQ ID NO: 2631), E8-vFLIP (SEQ ID NO: 2632), BHV-vFLIP (SEQ ID NO: 2635), mecaca vFLIP (SEQ ID NO: 2634), herpesvirus saimiri vFLIP (SEQ ID NO: 2633), cFLIP-L/MRITα (SEQ ID NO: 2636), cFLIP-p22 (SEQ ID NO: 2637), HTLV1-Tax (SEQ ID NO: 2638), HTLV2-Tax (SEQ ID NO: 2639), HTLV2-Tax-RS mutants (SEQ ID NO: 2640) or proteins with 70-99% identity to amino acid sequences of SEQ ID NOs: 2629 to 2640. Exemplary fusion proteins containing one or more switch domains and viral signaling proteins are represented by SEQ ID NOs: 2641-2645.

In some aspects, this disclosure provides a method of producing an immune effector cell suitable for adoptive cellular therapy, comprising contacting the cell with a nucleic acid encoding one or more of a viral or cellular signaling protein selected from the group of K13-vFLIP (SEQ ID NO: 2629), MC159-vFLIP (SEQ ID NO: 2630), MC160-vFLIP (SEQ ID NO: 2631), E8-vFLIP (SEQ ID NO: 2632), BHV-vFLIP (SEQ ID NO: 2635), mecaca vFLIP (SEQ ID NO: 2634), herpesvirus saimiri vFLIP (SEQ ID NO: 2633), cFLIP-L/MRITα (SEQ ID NO: 2636), cFLIP-p22 (SEQ ID NO: 2637), HTLV1-Tax (SEQ ID NO: 2638), HTLV2-Tax (SEQ ID NO: 2639), HTLV2-Tax-RS mutants (SEQ ID NO: 2640) or proteins with 70-99% identity to amino acid sequences of SEQ ID NOs: 2629 to 2640.

In some aspects, this disclosure provides a method of producing an immune effector cell suitable for adoptive cellular therapy, comprising contacting the cell with a nucleic acid encoding expresses a fusion protein containing one or more switch domains, e.g., FKBP (SEQ ID NO: 2620-2621), FKBPx2 (SEQ ID NO: 2622) or Myr-FKBP, and one or more viral or cellular signaling protein selected from the group of K13-vFLIP (SEQ ID NO: 2629), MC159-vFLIP (SEQ ID NO: 2630), MC160-vFLIP (SEQ ID NO: 2631), E8-vFLIP (SEQ ID NO: 2632), BHV-vFLIP (SEQ ID NO: 2635), mecaca vFLIP (SEQ ID NO: 2634), herpesvirus saimiri vFLIP (SEQ ID NO: 2633), cFLIP-L/MRITα (SEQ ID NO: 2636), cFLIP-p22 (SEQ ID NO: 2637), HTLV1-Tax (SEQ ID NO: 2638), HTLV2-Tax (SEQ ID NO: 2639), HTLV2-Tax-RS mutants (SEQ ID NO: 2640) or proteins with 70-99% identity to amino acid sequences of SEQ ID NOs: 2629 to 2640.

In an embodiment, the cell suitable for adoptive cell therapy expresses a natural or synthetic immune receptor. Exemplary such immune receptors include a chimeric antigen receptor (CAR), a T cell receptor (TCR), a chimeric T cell receptor (cTCR), a synthetic T cell receptor and a synthetic notch receptor. In an embodiment, the cell may be contacted with the nucleic acid encoding the viral and cellular signaling proteins before, simultaneous with, or after being contacted with a construct encoding a natural or synthetic immune receptor. In an embodiment, the cell may be contacted with the nucleic acid encoding the viral and cellular signaling proteins containing a switch or dimerization domain before, simultaneous with, or after being contacted with a construct encoding a natural or synthetic immune receptor.

In one aspect, the disclosure features a method of making a population of immune effector cells (e.g., T cells, NK cells). In an embodiment, the method comprises: providing a population of immune effector cells (e.g., T cells or NK cells), contacting the population of immune effector cells with a nucleic acid encoding an immune receptor (e.g., CAR, TCR, synthetic TCR) and contacting the population of immune effector cells with a nucleic acid encoding a viral or cellular signaling protein of SEQ ID NOs: 2629-2645, under conditions that allow for immune receptor and viral or cellular signaling protein co-expression.

In an embodiment, the nucleic acid encoding the viral or cellular signaling protein of SEQ ID NOs: 2629-2645 is DNA. In an embodiment, the nucleic acid encoding the viral or cellular signaling protein of SEQ ID NOs: 2629-2645 contains promoter capable of driving expression of the viral and cellular signaling proteins. In an embodiment, the nucleic acid encoding the viral or cellular signaling protein of SEQ ID NOs: 2629-2645 and the nucleic acid encoding the immune receptor is expressed from the same vector. In an embodiment, the nucleic acid encoding the viral or cellular signaling protein of SEQ ID NOs: 2629-2645 and the nucleic acid encoding the immune receptor is expressed from separate vectors. In an embodiment, the nucleic acid encoding the viral or cellular signaling protein of SEQ ID NOs: 2629-2645 (subunit 1) and the nucleic acid encoding the immune receptor (subunit 2) is expressed from the same polynucleotide fragment containing an internal ribosomal entry site (IRES) that allows the translation of the second subunit. In an embodiment, the nucleic acid encoding the viral or cellular signaling protein of SEQ ID NOs: 2629-2645 (subunit 1) and the nucleic acid encoding the immune receptor (subunit 2) is expressed from a single polynucleotide fragment that encodes and the different subunits are separated by a cleavable linker (e.g., SEQ ID NOs: 831-836).

In an embodiment, the nucleic acid encoding the viral or cellular signaling protein of SEQ ID NOs: 2629-2645 is an in vitro transcribed RNA. In an embodiment, the viral or cellular signaling protein of SEQ ID NOs: 2629-2645 (subunit 1) and the immune receptor (subunit 2) is expressed from the same RNA containing an internal ribosomal entry site (IRES) that allows the translation of the second subunit. In an embodiment, the viral or cellular signaling protein of SEQ ID NOs: 2629-2645 (subunit 1) and the immune receptor (subunit 2) is expressed from a single RNA and the different subunits are separated by cleavable linkers (e.g., SEQ ID NOs: 831-836).

Combination Therapies

Therapeutic methods described herein comprise using compositions comprising genetically modified cells comprising nucleic acids encoding CARs described herein. In various embodiments, the therapeutic methods described herein may be combined with existing therapies and agents. The therapeutic compositions described herein, comprising genetically modified cells comprising nucleic acids encoding the CARs described herein, are administered to the subject with at least one additional known therapy or therapeutic agent. In some embodiments, the compositions described herein and the additional therapy or therapeutic agents are administered sequentially. In some embodiments, the compositions described herein and the additional therapy or therapeutic agents are administered simultaneously. The optimum order of administering the compositions described herein and the existing therapies will be apparent to a person of skill in the art, such as a physician.

A CAR-expressing cell described herein and the at least one additional therapeutic agent can be administered simultaneously, in the same or in separate compositions, or sequentially. For sequential administration, the CAR-expressing cell described herein can be administered first, and the additional agent can be administered second, or the order of administration can be reversed.

Combinations therapies may be administered to the subject over the duration of the disease. Duration of the disease includes from diagnosis until conclusion of treatment, wherein the treatment results in reduction of symptoms and/or elimination of symptoms. In various embodiments, the effect of the two treatments can be partially additive, wholly additive, or greater than additive. The delivery can be such that an effect of the first treatment delivered is still detectable when the second is delivered.

The CAR therapy and/or other therapeutic agents, procedures or modalities can be administered during periods of active disorder, or during a period of remission or less active disease. The CAR therapy can be administered before the other treatment, concurrently with the treatment, post-treatment, or during remission of the disorder.

When administered in combination, the CAR therapy and the additional agent (e.g., second or third agent), or all, can be administered in an amount or dose that is higher, lower or the same than the amount or dosage of each agent used individually, e.g., as a monotherapy. In certain embodiments, the administered amount or dosage of the CAR therapy, the additional agent (e.g., second or third agent), or all, is lower (e.g., at least 20%, at least 30%, at least 40%, or at least 50%) than the amount or dosage of each agent used individually, e.g., as a monotherapy. In other embodiments, the amount or dosage of the CAR therapy, the additional agent (e.g., second or third agent), or all, that results in a desired effect (e.g., treatment of cancer) is lower (e.g., at least 20%, at least 30%, at least 40%, or at least 50% lower) than the amount or dosage of each agent used individually, e.g., as a monotherapy, required to achieve the same therapeutic effect.

Further method aspects relate administering to the subject an effective amount of a cell, e.g., an immune effector cell, or a population thereof, each cell comprising a CAR molecule, optionally in combination with an agent that increases the efficacy and/or safety of the immune cell. In further aspects, the agent that increases the efficacy and/or safety of the immune cell is one or more of: (i) a protein phosphatase inhibitor; (ii) a kinase inhibitor; (iii) a cytokine; (iv) an inhibitor of an immune inhibitory molecule; or (v) an agent that decreases the level or activity of a TREG cell; vi) an agent that increase the proliferation and/or persistence of CAR-modified cells vii) a chemokine viii) an agent that increases the expression of CAR ix) an agent that allows regulation of the expression or activity of CAR x) an agent that allows control over the survival and/or persistence of CAR-modified cells xi) an agent that controls the side effects of CAR-modified cells xii) a Brd4 inhibitor xiii) an agent that delivers a therapeutic (e.g. sHVEM) or prophylactic agent to the site of the disease xiv) an agent that increases the expression of the target antigen against which CAR is directed; xv) an adenosine A2a receptor antagonist

In some embodiments, a the genetically modified cells described herein may be used in a treatment regimen in combination with surgery, chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludarabine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and irradiation, peptide vaccine, such as that described in Izumoto et al. 2008 J Neurosurg 108:963-971. In one embodiment, a CAR-expressing cell described herein can be used in combination with a chemotherapeutic agent. Exemplary chemotherapeutic agents include an anthracycline (e.g., doxorubicin (e.g., liposomal doxorubicin)), a vinca alkaloid (e.g., vinblastine, vincristine, vindesine, vinorelbine), an alkylating agent (e.g., cyclophosphamide, decarbazine, melphalan, ifosfamide, temozolomide), an immune cell antibody (e.g., alemtuzamab, gemtuzumab, rituximab, of atumumab, tosiumomab, brentuximab), an antimetabolite (including, e.g., folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors (e.g., fludarabine)), an mTOR inhibitor, a TNFR glucocorticoid induced TNFR related protein (GITR) agonist, a proteasome inhibitor (e.g., aclacinomycin A, gliotoxin or bortezomib), an immunomodulator such as thalidomide or a thalidomide derivative (e.g., lenalidomide).

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with cyclophosphamide and fludarabine.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with bendamustine and rituximab. In embodiments, the subject has CLL.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and/or a corticosteroid (e.g., prednisone). In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). In embodiments, the subject has diffuse large B-cell lymphoma (DLBCL).

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and/or rituximab. In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R). In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with dose adjusted EPOCH-R (DA-EPOCH-R). In embodiments, the subject has a B cell lymphoma, e.g., a Myc-rearranged aggressive B cell lymphoma.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with brentuximab. Brentuximab is an antibody-drug conjugate of anti-CD30 antibody and monomethyl auristatin E. In embodiments, the subject has Hodgkin's lymphoma (HL), e.g., relapsed or refractory HL. In embodiments, the subject comprises CD30+HL. In embodiments, the subject has undergone an autologous stem cell transplant (ASCT).

In some embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a CD20 inhibitor, e.g., an anti-CD20 antibody (e.g., an anti-CD20 mono- or bispecific antibody) or a fragment thereof.

In one embodiment, a CAR expressing cell described herein is administered to a subject in combination with an mTOR inhibitor, e.g., an mTOR inhibitor described herein, e.g., a rapalog such as everolimus. In one embodiment, the mTOR inhibitor is administered prior to the CAR-expressing cell. For example, in one embodiment, the mTOR inhibitor can be administered prior to apheresis of the cells. In one embodiment, the subject has CLL.

In one embodiment, a CAR-expressing cell described herein can be used in combination with a kinase inhibitor. In one embodiment, the kinase inhibitor is a CDK4 inhibitor, e.g., a CDK4 inhibitor described herein, e.g., a CD4/6 inhibitor, such as, e.g., 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, hydrochloride (also referred to as palbociclib or PD0332991). In one embodiment, the kinase inhibitor is a BTK inhibitor, e.g., a BTK inhibitor described herein, such as, e.g., ibrutinib. In some embodiments, ibrutinib is administered at a dosage of about 300-600 mg/day (e.g., about 300-350, 350-400, 400-450, 450-500, 500-550, or 550-600 mg/day, e.g., about 420 mg/day or about 560 mg/day), e.g., orally. In embodiments, the ibrutinib is administered at a dose of about 250 mg, 300 mg, 350 mg, 400 mg, 420 mg, 440 mg, 460 mg, 480 mg, 500 mg, 520 mg, 540 mg, 560 mg, 580 mg, 600 mg (e.g., 250 mg, 420 mg or 560 mg) daily for a period of time, e.g., daily for 21 day cycle, or daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of ibrutinib are administered. Without being bound by theory, it is thought that the addition of ibrutinib enhances the T cell proliferative response and may shift T cells from a T-helper-2 (Th2) to T-helper-1 (Th1) phenotype. Th1 and Th2 are phenotypes of helper T cells, with Th1 versus Th2 directing different immune response pathways. A Th1 phenotype is associated with proinflammatory responses, e.g., for killing cells, such as intracellular pathogens/viruses or cancerous cells, or perpetuating autoimmune responses. A Th2 phenotype is associated with eosinophil accumulation and anti-inflammatory responses. In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g., an mTOR inhibitor described herein, such as, e.g., rapamycin, a rapamycin analog, OSI-027. The mTOR inhibitor can be, e.g., an mTORC1 inhibitor and/or an mTORC2 inhibitor, e.g., an mTORC1 inhibitor and/or mTORC2 inhibitor described herein. In one embodiment, the kinase inhibitor is a MNK inhibitor, e.g., a MNK inhibitor described herein, such as, e.g., 4-amino-5-(4-fluoroanilino)-pyrazolo [3,4-d]pyrimidine. The MNK inhibitor can be, e.g., a MNK1a, MNK1b, MNK2a and/or MNK2b inhibitor. In one embodiment, the kinase inhibitor is a dual PI3K/mTOR inhibitor described herein, such as, e.g., PF-04695102. In one embodiment, the kinase inhibitor is a Src kinase inhibitor. In one embodiment, the kinase inhibitor is Dasatinib. In one embodiment, the Src kinase inhibitor is administered to the patient after the administration of CAR expressing cells to control or terminate the activity of CAR-expressing cells. In one embodiment, Dasatinib is administered to the patient after the administration of CAR expressing cells to control or terminate the activity of CAR-expressing cells. In one embodiment, dasatinib is administered orally at a dose of at least 10 mg/day, 20 mg/day, 40 mg/day, 60 mg/day, 70 mg/day, 90 mg/day, 100 mg/day, 140 mg/day, 180 mg/day or 210 mg/day.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with an anaplastic lymphoma kinase (ALK) inhibitor. Exemplary ALK kinases include but are not limited to crizotinib (Pfizer), ceritinib (Novartis), alectinib (Chugai), brigatinib (also called AP26113; Ariad), entrectinib (Ignyta), PF-06463922 (Pfizer), TSR-OIl (Tesaro) (see, e.g., Clinical Trial Identifier No. NCT02048488), CEP-37440 (Teva), and X-396 (Xcovery). In some embodiments, the subject has a solid cancer, e.g., a solid cancer described herein, e.g., lung cancer.

Drugs that inhibit either the calcium dependent phosphatase calcineurin (cyclosporine and FK506) or inhibit the p70S6 kinase that is important for growth factor induced signaling (rapamycin). (Liu et al., Cell66:807-815, 1991; Henderson et al., Immun. 73:316-321, 1991; Bierer et al., Curr. Opin. Immun. 5:763-773, 1993) can also be used. In a further aspect, the cell compositions of the present invention may be administered to a patient in conjunction with (e.g., before, simultaneously or following) bone marrow transplantation, T cell ablative therapy using chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, and/or antibodies such as OKT3 or CAMP ATH. In one aspect, the cell compositions of the present invention are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan. For example, in one embodiment, subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. In certain embodiments, following the transplant, subjects receive an infusion of the expanded immune cells of the present invention. In an additional embodiment, expanded cells are administered before or following surgery.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with an autologous stem cell transplant, an allogeneic stem cell transplant, an autologous bone marrow transplant or an allogeneic bone marrow transplant.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with microtransplant or HLA mismatched allogeneic cellular therapy (Guo M et al, J Clin Oncol. 2012 Nov. 20; 30(33):4084-90).

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with an indoleamine 2,3-dioxygenase (IDO) inhibitor.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a modulator of myeloid-derived suppressor cells (MDSCs). MDSCs accumulate in the periphery and at the tumor site of many solid tumors. These cells suppress T cell responses, thereby hindering the efficacy of CAR-expressing cell therapy. Without being bound by theory, it is thought that administration of a MDSC modulator enhances the efficacy of a CAR-expressing cell described herein. In an embodiment, the subject has a solid tumor, e.g., a solid tumor described herein, e.g., glioblastoma. Exemplary modulators of MDSCs include but are not limited to MCSllO and BLZ945. MCSllO is a monoclonal antibody (mAb) against macrophage colony-stimulating factor (M-CSF). See, e.g., Clinical Trial Identifier No. NCT00757757. BLZ945 is a small molecule inhibitor of colony stimulating factor 1 receptor (CSF1R). See, e.g., Pyonteck et al. Nat. Med. 19(2013):1264-72.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a Brd4 or BET (bromodomain and extra-terminal motif) inhibitor. BET protein BRD4 directly regulated expression of the transcription factor BATF in CD8+ T cells, which was associated with differentiation of T cells into an effector memory phenotype. JQ1, an inhibitor of bromodomain and extra-terminal motif (BET) proteins, maintained CD8+ T cells with functional properties of stem cell-like and central memory T cells. Exemplary Brd4 inhibitors that can be administered in combination with CAR-expressing cells include but are not limited to JQ1, MS417, OTXO15, LY 303511 and Brd4 inhibitor as described in US 20140256706 A1 and any analogs thereof.

In some embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a interleukin-15 (IL-15) polypeptide, a interleukin-15 receptor alpha (IL-15Ra) polypeptide, or a combination of both a IL-15 polypeptide and a IL-15Ra polypeptide e.g., hetiL-15 (Admune Therapeutics, LLC). hetiL-15 is a heterodimeric non-covalent complex of IL-15 and IL-15Ra. hetiL-15 is described in, e.g., U.S. Pat. No. 8,124,084, U.S. 2012/0177598, U.S. 2009/0082299, U.S. 2012/0141413, and U.S. 201110081311, incorporated herein by reference. In embodiments, het-IL-15 is administered subcutaneously. In embodiments, the subject has a cancer, e.g., solid cancer, e.g., melanoma or colon cancer. In embodiments, the subject has a metastatic cancer.

In one embodiment, the subject can be administered an agent which reduces or ameliorates a side effect associated with the administration of a CAR-expressing cell. Side effects associated with the administration of a CAR-expressing cell include, but are not limited to CRS, and hemophagocytic lymphohistiocytosis (HLH), also termed Macrophage Activation Syndrome (MAS). Symptoms of CRS include high fevers, nausea, transient hypotension, hypoxia, and the like. CRS may include clinical constitutional signs and symptoms such as fever, fatigue, anorexia, myalgias, arthalgias, nausea, vomiting, and headache. CRS may include clinical skin signs and symptoms such as rash. CRS may include clinical gastrointestinal signs and symptoms such as nausea, vomiting and diarrhea. CRS may include clinical respiratory signs and symptoms such as tachypnea and hypoxemia. CRS may include clinical cardiovascular signs and symptoms such as tachycardia, widened pulse pressure, hypotension, increased cardiac output (early) and potentially diminished cardiac output (late). CRS may include clinical coagulation signs and symptoms such as elevated d-dimer, hypofibrinogenemia with or without bleeding. CRS may include clinical renal signs and symptoms such as azotemia. CRS may include clinical hepatic signs and symptoms such as transaminitis and hyperbilirubinemia. CRS may include clinical neurologic signs and symptoms such as headache, mental status changes, confusion, delirium, word finding difficulty or frank aphasia, hallucinations, tremor, dymetria, altered gait, and seizures.

Accordingly, the methods described herein can comprise administering a CAR-expressing cell described herein to a subject and further administering one or more agents to manage elevated levels of a soluble factor resulting from treatment with a CAR-expressing cell. In one embodiment, the soluble factor elevated in the subject is one or more of IFN-γ, TNFa, IL-2 and IL-6. In an embodiment, the factor elevated in the subject is one or more of IL-1, GM-CSF, IL-10, IL-8, IL-5 and fraktalkine. Therefore, an agent administered to treat this side effect can be an agent that neutralizes one or more of these soluble factors. In one embodiment, the agent that neutralizes one or more of these soluble forms is an antibody or antigen binding fragment thereof. Examples of such agents include, but are not limited to a steroid (e.g., corticosteroid), Src inhibitors (e.g., Dasatinib) an inhibitor of TNFa, and an inhibitor of IL-6. An example of a TNFα inhibitor is an anti-TNFα antibody molecule such as, infliximab, adalimumab, certolizumab pegol, and golimumab. Another example of a TNFα inhibitor is a fusion protein such as entanercept. An example of an IL-6 inhibitor is an anti-IL-6 antibody molecule or an anti-IL-6 receptor antibody molecule such as tocilizumab (toe), sarilumab, elsilimomab, CNTO 328, ALD518/BMS-945429, CNTO 136, CPSI-2364, CDP6038, VX30, ARGX-109, FE301, and FM101. In one embodiment, the anti-IL-6 receptor antibody molecule is tocilizumab. In one embodiment, the IL-6 inhibitor is a camelid bispecific antibody that binds to IL6R and human serum albumin (e.g., IL6R-304-Alb8) (SEQ ID NO: 2649). An example of an IL-1R based inhibitor is anakinra. In one embodiment, an agent administered to treat the side effects of CAR-expressing cells is a Src inhibitor (e.g., Dasatinib). In one embodiment, an agent administered to treat the side effects of CAR-expressing cells is the Src inhibitor Dasatinib. In embodiments, Dasatinib is administered at a dose of about 10 mg/day to 240 mg/day (e.g., 10 mg/day, 20 mg/day, 40 mg/day, 50 mg/day, 70 mg/day, 80 mg/day, 100 mg/day, 110 mg/day, 120 mg/day, 140 mg/day, 180 mg/day, 210 mg/day, 240 mg/day or 300 mg/day).

In one embodiment, the subject can be administered an agent which enhances the activity of a CAR-expressing cell. For example, in one embodiment, the agent can be an agent which inhibits an inhibitory molecule. Inhibitory molecules, e.g., Programmed Death 1 (PD-1), can, in some embodiments, decrease the ability of a CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules include PD-1, PDL1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and TGFR beta. Inhibition of an inhibitory molecule, e.g., by inhibition at the DNA, RNA or protein level, can optimize a CAR-expressing cell performance. In embodiments, an inhibitory nucleic acid, e.g., an inhibitory nucleic acid, e.g., a dsRNA, e.g., an siRNA or shRNA, a clustered regularly interspaced short palindromic repeats (CRISPR), a transcription-activator like effector nuclease (TALEN), or a zinc finger endonuclease (ZFN), e.g., as described herein, can be used to inhibit expression of an inhibitory molecule in the CAR-expressing cell. In an embodiment the inhibitor is an shRNA. In an embodiment, the inhibitory molecule is inhibited within a CAR-expressing cell. In these embodiments, a dsRNA molecule that inhibits expression of the inhibitory molecule is linked to the nucleic acid that encodes a component, e.g., all of the components, of the CAR. In one embodiment, the inhibitor of an inhibitory signal can be, e.g., an antibody or antibody fragment that binds to an inhibitory molecule. For example, the agent can be an antibody or antibody fragment that binds to PD-1, PD-L1, PD-L2 or CTLA4 (e.g., ipilimumab (also referred to as MDX-010 and MDX-101, and marketed as Yervoy®; Bristol-Myers Squibb; Tremelimumab (IgG2 monoclonal antibody available from Pfizer, formerly known as ticilimumab, CP-675,206).). In an embodiment, the agent is an antibody or antibody fragment that binds to TIM3. In an embodiment, the agent is an antibody or antibody fragment that binds to CEACAM (CEACAM-1, CEACAM-3, and/or CEACAM-5). In an embodiment, the agent is an antibody or antibody fragment that binds to LAG3.

PD-1 is an inhibitory member of the CD28 family of receptors that also includes CD28, CTLA-4, ICOS, and BTLA. PD-1 is expressed on activated B cells, T cells and myeloid cells. Two ligands for PD-1, PD-L1 and PD-L2 have been shown to down regulate T cell activation upon binding to PD-1. PD-L1 is abundant in human cancers. Immune suppression can be reversed by inhibiting the local interaction of PD-1 with PD-L1. Antibodies, antibody fragments, and other inhibitors of PD-1, PD-L1 and PD-L2 are available in the art and may be used combination with a CAR of the present invention described herein. For example, nivolumab (also referred to as BMS-936558 or MDX1106; Bristol-Myers Squibb) is a fully human IgG4 monoclonal antibody which specifically blocks PD-1. Nivolumab (clone 5C4) and other human monoclonal antibodies that specifically bind to PD-1 are disclosed in U.S. Pat. No. 8,008,449 and WO2006/121168. Pidilizumab (CT-011; Cure Tech) is a humanized IgG1k monoclonal antibody that binds to PD-1. Pidilizumab and other humanized anti-PD-1 monoclonal antibodies are disclosed in WO2009/101611. Pembrolizumab (formerly known as lambrolizumab, and also referred to as MK03475; Merck) is a humanized IgG4 monoclonal antibody that binds to PD-1. Pembrolizumab and other humanized anti-PD-1 antibodies are disclosed in U.S. Pat. No. 8,354,509 and WO2009/114335. MEDI4736 (Medimmune) is a human monoclonal antibody that binds to PDL1, and inhibits interaction of the ligand with PDl. MDPL3280A (Genentech I Roche) is a human Fe optimized IgG1 monoclonal antibody that binds to PD-L1. MDPL3280A and other human monoclonal antibodies to PD-L1 are disclosed in U.S. Pat. No. 7,943,743 and U.S. Publication No.: 20120039906. In other embodiments, the agent that enhances the activity of a CAR-expressing cell is a CEACAM inhibitor (e.g., CEACAM-1, CEACAM-3, and/or CEACAM-5 inhibitor).

In one embodiment, the agent which enhances activity of a CAR-described herein is another agent that increases the expression of the target antigen against which the CAR is directed. The agents that can be administered to the subject receiving a CAR-expressing cell described herein include: Arsenic trioxide, ATRA (all-trans-retinoic acid), compounds 27, 40,49 of (Du et al, Blood; Prepublished online Oct. 12, 2016), IDH2 inhibitors (e.g., AG-221) or a combination thereof. In an embodiment, the agents are administered prior to, concurrently or after administration of CAR-expressing cells. In preferred embodiments these agents are administered prior to administration of CAR-expressing cells. In preferred embodiment, the CAR expressing cells that are administered with the above agents target a B cell antigen (e.g., CD19, CD20, or CD22 etc.).

In one embodiment, the agent which enhances activity of a CAR described herein is a soluble receptor. Soluble receptor that can be administered to the subject receiving a CAR-expressing cell described herein include: sHVEM (SEQ ID NO: 2664), sHVEM-Alb8-vHH fusion protein (SEQ ID NO: 2665), or a combination thereof. The soluble receptor can be administered once a day or more than once a day, e.g., twice a day, three times a day, or four times a day. The soluble receptor can be administered for more than one day, e.g. the soluble receptor is administered for 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks. For example, the soluble receptor is administered once a day for 7 days.

In one embodiment, the subject can be administered an agent which protects against the toxicity of a CAR-expressing cell on normal tissues. One of the limitations of CAR-T cell therapy could be toxicity on normal tissue. For example, CAR targeting CD19 could lead to long-term depletion of normal B cells, which also express CD19 antigen. In one embodiment, CD19 CAR-T cell therapy can be combined with knock-out or mutation of endogenous CD19 in normal hematopoietic stem cells. In one embodiment, the knock out or mutation of the endogenous CD19 is achieved using CRIPS/Cas9, Talons or other suitable gene editing methods which are known in the art. The epitope of CD19 bound by the CD19 CAR-T cells in current clinical use has been mapped to exon2-4. In one embodiment, missense or nonsense mutations are generated in exon 2 (or other suitable exons/regions that are recognized by CD19 targeted CAR T-cells) of autologous or allogeneic hematopoietic stem cells using CRISP/Cas9, Zn finger nucleases, Talons or other methods known in the art. In one embodiment, the subject is given CD19 CART cells infusion to control his/her disease and an autologous or allogeneic stem cell transplant using CD19 deleted/mutated hematopoietic stem cells. As the B cells that will originate from the modified stem cells will not be targeted by CD19-CAR-T cells, the patient will escape B cell aplasia which is a common side effect of CD19 CAR-T cells. In another embodiment, MPL CAR-T cell therapy is combined with knock-out or mutation of endogenous MPL in normal hematopoietic stem cells. In another embodiment, CD123 CAR-T cell therapy is combined with knock-out or mutation of endogenous CD123 in normal hematopoietic stem cells. In another embodiment, CD33 CAR-T cell therapy is combined with knock-out or mutation of endogenous CD33 in normal hematopoietic stem cells. In another embodiment, CD20 CAR-T cell therapy is combined with knock-out or mutation of endogenous CD20 in normal hematopoietic stem cells. In another embodiment, CD22 CAR-T cell therapy is combined with knock-out or mutation of endogenous CD22 in normal hematopoietic stem cells. In another embodiment, CS1 CAR-T cell therapy is combined with knock-out or mutation of endogenous CS1 in normal hematopoietic stem cells. In another embodiment, BCMA CAR-T cell therapy is combined with knock-out or mutation of endogenous BCMA in normal hematopoietic stem cells. In another embodiment, CD45 CAR-T cell therapy is combined with knock-out or mutation of endogenous CD45 in normal hematopoietic stem cells or immune effector cells (e.g., T cells or NK cells). Essentially, a similar approach could be used to mitigate the toxicity of CAR-T cells against normal tissue where the antigen targeted by the CAR is also expressed on normal hematopoietic stem cells or one of its progenies.

In another embodiment, CAR-T cell therapy is combined with knock-out or mutation of endogenous gene or protein targeted by the CAR in the immune effector cell (e.g., T cells or NK cells) or stem cells that give rise to immune effector cells. For example, since CD45 is expressed on all hematopoietic cells, CAR-T cells targeting CD45 would be difficult to generate as they would be killed off by neighboring CD45-CART cells. However, such cells can be generated if expression of CD45 CAR in T cells is combined with knock-down or deletion of endogenous CD45 in the T cells in which CD45 CAR is being expressed. Essentially a similar approach can be used to generate CAR targeting other antigens that are expressed on immune effector cells. Exemplary such antigens include, but are not limited to, CD5, TCRα, TCRβ1, TCRβ2, TCRγ, TCRδ, preTCRα and various receptors expressed on NK cells.

Cytokines that can be administered to the subject receiving a CAR-expressing cell described herein include: IL-2, IL-4, IL-7, IL-9, IL-15, IL-18, LIGHT, and IL-21, or a combination thereof. In preferred embodiments, the cytokine administered is IL-7, IL-15, or IL-21, IL12F, or a combination thereof. The cytokine can be administered once a day or more than once a day, e.g., twice a day, three times a day, or four times a day. The cytokine can be administered for more than one day, e.g. the cytokine is administered for 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks. For example, the cytokine is administered once a day for 7 days. Administration of the cytokine to the subject that has sub-optimal response to the CAR-expressing cell therapy improves CAR-expressing cell efficacy or anti-cancer activity. In a preferred embodiment, the cytokine administered after administration of CAR-expressing cells is IL-7.

In one embodiment, the agent which enhances activity of a CAR-expressing cell described herein is a Brd4 inhibitor or an siRNA or an shRNA targeting BRD4 as described in (Tolani, B et al., Oncogene, 29; 33(22):2928-37. PMID: 23792448)(Tolani, Gopalakrishnan, Punj, Matta, & Chaudhary, 2014).

Pharmaceutical Compositions

Also provided herein are pharmaceutical compositions comprising any one or more of the chimeric antigen receptors, the polynucleotides, the polypeptides, the vectors, the viruses, and/or the genetically engineered cells and/or chemical compounds described herein and a pharmaceutically acceptable carrier. Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. Compositions of the present invention are in one aspect formulated for intravenous administration.

Pharmaceutical compositions of the present invention may be administered in a manner appropriate to the disease to be treated. The quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient's disease, although appropriate dosages may be determined by clinical trials.

When a “therapeutically effective amount” is indicated, the precise amount of the compositions of the present invention to be administered can be determined by a physician with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (subject). It can generally be stated that a pharmaceutical composition comprising the genetically modified cells (T cells, NK cells) described herein may be administered at a dosage of 10⁴to 10⁹cells/kg body weight, in some instances 10⁵to 10⁶cells/kg body weight, including all integer values within those ranges. T cell compositions may also be administered multiple times at these dosages. The cells can be administered by using infusion techniques that are commonly known in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319:1676, 1988).

In some embodiments, it may be desired to administer activated genetically modified cells (T cells, NK cells) to a subject and then subsequently redraw blood (or have an apheresis performed), activate the genetically modified cells therefrom and reinfuse the patient with these activated and expanded genetically modified cells. This process can be carried out multiple times every few weeks. In certain aspects, immune effector cells (e.g., T cells, NK cells) can be activated from blood draws of from 10 cc to 400 cc. In certain aspects, immune effector cells e.g., T cells, NK cells) are activated from blood draws of 20 cc, 30 cc, 40 cc, 50 cc, 60 cc, 70 cc, 80 cc, 90 cc, or 100 cc.

“Pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and desirable, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. Such excipients may be solid, liquid, semisolid, or, in the case of an aerosol composition, gaseous.

In various embodiments, the pharmaceutical compositions according to the invention may be formulated for delivery via any route of administration. “Route of administration” may refer to any administration pathway known in the art, including but not limited to aerosol, nasal, oral, intravenous, intramuscular, intraperitoneal, inhalation, transmucosal, transdermal, parenteral, implantable pump, continuous infusion, topical application, capsules and/or injections.

The pharmaceutical compositions according to the invention can also contain any pharmaceutically acceptable carrier. “Pharmaceutically acceptable carrier” as used herein refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting a compound of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body. For example, the carrier may be a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, or a combination thereof. Each component of the carrier must be “pharmaceutically acceptable” in that it must be compatible with the other ingredients of the formulation. It must also be suitable for use in contact with any tissues or organs with which it may come in contact, meaning that it must not carry a risk of toxicity, irritation, allergic response, immunogenicity, or any other complication that excessively outweighs its therapeutic benefits.

The pharmaceutical compositions according to the invention can also be encapsulated, tableted or prepared in an emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, alcohols and water. Solid carriers include starch, lactose, calcium sulfate, dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax

The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulation, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms. When a liquid carrier is used, the preparation will be in the form of syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.

The pharmaceutical compositions according to the invention may be delivered in a therapeutically effective amount. The precise therapeutically effective amount is that amount of the composition that will yield the most effective results in terms of efficacy of treatment in a given subject. This amount will vary depending upon a variety of factors, including but not limited to the characteristics of the therapeutic compound (including activity, pharmacokinetics, pharmacodynamics, and bioavailability), the physiological condition of the subject (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication), the nature of the pharmaceutically acceptable carrier or carriers in the formulation, and the route of administration. One skilled in the clinical and pharmacological arts will be able to determine a therapeutically effective amount through routine experimentation, for instance, by monitoring a subject's response to administration of a compound and adjusting the dosage accordingly. For additional guidance, see Remington: The Science and Practice of Pharmacy (Gennaro ed. 20th edition, Williams & Wilkins PA, USA) (2000).

The administration of the subject compositions may be carried out in any convenient manner, including by aerosol inhalation, injection, transfusion, implantation or transplantation. The compositions described herein may be administered to a patient trans-arterially, subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous (i.v.) injection, or intraperitoneally. In one aspect, the T cell compositions of the present invention are administered to a patient by intradermal or subcutaneous injection. In one aspect, the T cell compositions of the present invention are administered by i. v. injection. The compositions of immune effector cells (e.g., T cells, NK cells) may be injected directly into a tumor, lymph node, or site of infection.

In a particular exemplary aspect, subjects may undergo leukapheresis, wherein leukocytes are collected, enriched, or depleted ex vivo to select and/or isolate the cells of interest, e.g., T cells. These T cell isolates may be expanded by methods known in the art and treated such that one or more CAR constructs of the invention may be introduced, thereby creating a CAR T cell of the invention. Subjects in need thereof may subsequently undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. In certain aspects, following or concurrent with the transplant, subjects receive an infusion of the expanded CAR T cells of the present invention. In an additional aspect, expanded cells are administered before or following surgery.

In one embodiment, the CAR is introduced into immune effector cells (e.g., T cells, NK cells), e.g., using in vitro transcription, and the subject (e.g., human) receives an initial administration of CAR immune effector cells (e.g., T cells, NK cells) of the invention, and one or more subsequent administrations of the CAR immune effector cells (e.g., T cells, NK cells) of the invention, wherein the one or more subsequent administrations are administered less than 15 days, e.g., 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 days after the previous administration. In one embodiment, more than one administration of the CAR immune effector cells (e.g., T cells, NK cells) of the invention are administered to the subject (e.g., human) per week, e.g., 2, 3, or 4 administrations of the CAR immune effector cells (e.g., T cells, NK cells) of the invention are administered per week. In one embodiment, the subject (e.g., human subject) receives more than one administration of the CAR immune effector cells (e.g., T cells, NK cells) per week (e.g., 2, 3 or 4 administrations per week) (also referred to herein as a cycle), followed by a week of no CAR immune effector cells (e.g., T cells, NK cells) administrations, and then one or more additional administration of the CAR immune effector cells (e.g., T cells, NK cells) (e.g., more than one administration of the CAR immune effector cells (e.g., T cells, NK cells) per week) is administered to the subject. In another embodiment, the subject (e.g., human subject) receives more than one cycle of CAR immune effector cells (e.g., T cells, NK cells), and the time between each cycle is less than 10, 9, 8, 7, 6, 5, 4, or 3 days. In one embodiment, the CAR immune effector cells (e.g., T cells, NK cells) are administered every other day for 3 administrations per week. In one embodiment, the CAR immune effector cells (e.g., T cells, NK cells) of the invention are administered for at least two, three, four, five, six, seven, eight or more weeks.

A potential issue that can arise in patients being treated using transiently expressing CAR immune effector cells (e.g., T cells, NK cells) (particularly with murine scFv bearing CAR-Ts) is anaphylaxis after multiple treatments.

Without being bound by this theory, it is believed that such an anaphylactic response might be caused by a patient developing humoral anti-CAR response, i.e., anti-CAR antibodies having an anti-IgE isotype. It is thought that a patient's antibody producing cells undergo a class switch from IgG isotype (that does not cause anaphylaxis) to IgE isotype when there is a ten to fourteen day break in exposure to antigen.

If a patient is at high risk of developing an anaphylactic response to CAR therapy or generating an IgE type CAR antibody response during the course of CAR therapy, then omalizumab (Xolair) can be administered before or during the CAR therapy.

If a patient is at high risk of generating an anti-CAR antibody response during the course of transient CAR therapy (such as those generated by RNA transductions), CART infusion breaks should not last more than ten to fourteen days.

Kits

Kits to practice the invention are also provided. For example, kits for treating a cancer in a subject, or making a CAR T cell that expresses one or more of the CARs disclosed herein. The kits may include a nucleic acid molecule or a polypeptide molecule encoding a CAR or a vector encoding a CAR along with a method to introduce the nucleic acid into the immune effector cells. The kit may include a virus comprising a nucleic acid encoding a CAR and chemicals, such as polybrene, to enhance the virus transduction. The kit may contain components for isolation of T cells for expressing a CAR. Alternatively, the kit may contain immune effector cells (e.g., T cells or NK cells) or stem cells expressing a CAR. More than one of the disclosed CAR can be included in the kit. The kit can include a container and a label or package insert on or associated with the container.

Suitable containers include, for example, bottles, vials, syringes, etc. The containers may be formed from a variety of materials such as glass or plastic. The container typically holds a composition including one or more of the nucleic acid molecules, viruses, vectors, T cells expressing a CAR. In several embodiments the container may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). A label or package insert indicates that the composition is used for treating the particular condition. The label or package insert typically will further include instructions for use of a disclosed nucleic acid molecules, CARs or T cells expressing a CAR, for example, in a method of treating or preventing a tumor or of making a CAR T cell. The package insert typically includes instructions customarily included in commercial packages of therapeutic products that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products. The instructional materials may be written, in an electronic form (such as a computer diskette or compact disk) or may be visual (such as video files). The kits may also include additional components to facilitate the particular application for which the kit is designed. Thus, for example, the kit may additionally contain means for measuring the expression of CAR on T cells or of determining the number or percentage of T cells that express the CAR or of determining the functionality of CART cells. The kits may additionally include buffers and other reagents routinely used for the practice of a particular method. Such kits and appropriate contents are well known to those of skill in the art.

TABLE 3

Exemplary signal peptides

NAME
SEQ ID (DNA)
SEQ ID (PRT)

CD8_Signal_Peptide
1
1781

CD8_Signal_Peptide
2
1781

CD8_Signal_Peptide
3
1781

CD8-SIGNAL-PEPTIDE
4
1781

IgH_Signal_Peptide
5
1782

IgH_Signal_Peptide
6
1782

IgH-Signal-Peptide
7
1782

IgH_Signal Peptide
8
1782

Amyloid-158-158-
9
1783

Signal-peptide

hCD19 Signal Peptide
10
1784

TABLE 4

Exemplary VL fragments

SEQ ID
SEQ ID

Target
(DNA)
(PRT)
NAME

AFP/MHC
11
1785
AFP-61-vL

class I complex

AFP/MHC
12
1786
AFP-76-vL

class I complex

AFP/MHC
13
1787
AFP-79-vL

class I complex

ALK
14
1788
Alk-48-vL

ALK
15
1789
Alk-58-vL

Amyloid
16
1790
Amyloid-158-vL

BCMA
17
1791
BCMA-ET-40-vL

BCMA
18
1792
BCMA-ET-54-vL

BCMA
19
1793
BCMA-huC12A3-vL

BCMA
20
1794
BCMA-J6M0-vL

BCMA
21
1795
BCMA-ET-03-vL

BCMA
22
1796
BCMA-huC11.D5.3L1H3-vL

BCMA
23
1797
BCMA-huC13-F12-vL

CCR4
24
1798
CCR4-humAb1567-vL

CD123
25
1799
CD123-CSL362-vL

CD123
26
1800
CD123-1172-vL

CD123
27
1801
CD123-DART-1-vL

CD123
28
1802
CD123-DART-2-vL

CD123
29
1803
CD123-I3RB18-vL

CD123
30
1804
CD123-hu3E3-vL

CD123
31
1805
CD123-9F6-vL

CD123
32
1806
CD123-I3RB2-vL

CD123
33
1807
CD123-1176-vL

CD123
34
1808
CD123-8B11-vL

CD123
35
1809
CD123-2B8-vL

CD123
36
1810
CD123-9D7-vL

CD123
37
1811
CD123-3B10-vL

CD138
38
1812
CD138-vL

CD179b
39
1813
CD179b-vL

CD19
40
1814
CD19-4G7-vL

CD19
41
1815
CD19Bu12-vL

CD19
42
1816
CD19MM-vL

CD19
43
1817
FMC63-vL

CD19
44
1818
FMC63-[2]-vL

CD19
45
1819
FMC63-[3]-vL

CD19
46
1820
huFMC63-11-vL

CD19
47
1821
CD19-MEDI-3649-vL

CD19
48
1822
CD19-Medrex-24D1-vL

CD19
49
1823
CD19-MOR0028-vL

CD19
50
1824
CD19-HD37-H2L1-vL

CD19
51
1825
CD19-huBly3-vL

CD19
52
1826
CD19-huSJ25C1-vL

CD19
53
1827
CD19-hB4-vL

CD19
54
1828
CD19-hu-mROO5-1-vL

CD19
55
1829
CD19-hA19-vL

CD20
56
1830
CD20-2F2-vL

CD20
57
1831
CD20-GA101-vL

CD20
58
1832
CD20-Leu16-vL

CD20
59
1833
CD20-11B8-vL

CD20
60
1834
CD20-2C6-vL

CD20
61
1835
CD20-2H7-vL

CD20
62
1836
CD20-hA20-vL

CD20
63
1837
CD20-BM-CA-1925-v4-vL

CD20
64
1838
CD20-Ubli-v4-vL

CD20
65
1839
CD20-2H7-vL

CD20
66
1840
CD20-h1F5-vL

CD20
67
1841
CD20-7D8-vL

CD20
68
1842
CD20-AME-33-vL

CD22
69
1843
CD22-h10F4-vL

CD22
70
1844
CD22-H22Rhov2ACDRKA-vL

CD22
71
1845
CD22m971-vL

CD276
72
1846
CD276-17-vL

CD30
73
1847
CD30-5F11-vL

CD30
74
1848
CD30-Ac10-vL

CD32
75
1849
CD32-Med9-vL

CD324
76
1850
CD324-hSC10-17-vL

CD324
77
1851
CD324-SC10-6-vL

CD33
78
1852
CD33-huMyc9-vL

CD33
79
1853
CD33-AF5-vL

CD33
80
1854
CD33-Boehr2800308-vL

CD33
81
1855
CD33-Him3-4-vL

CD33
82
1856
CD33-SGNh2H12-vL

CD33
83
1857
CD33-15G15-33-vL

CD33
84
1858
CD33-33H4-vL

CD33
85
1859
CD33-9C3-2-vL

CD34
86
1860
CD34-hu4C7-[2]-vL

CD34
87
1861
CD34-hu4C7-vL

CD44v6
88
1862
CD44v6-Biwa8-vL

CD5
89
1863
CD5-18-vL

CD5
90
1864
CD5-9-vL

CD70
91
1865
CD70-h1F6-vL

CD79b
92
1866
CD79b-2F2-vL

CD79b
93
1867
huMA79bv28-vL

CD99
94
1868
CD99-hu12E7-vL

CDH17
95
1869
CDH17-PTA001A4-vL

CDH19
96
1870
CDH19-16A4-vL

CDH6
97
1871
CDH6-NOV710-vL

CDH6
98
1872
CDH6-NOV712-vL

CLEC5A
99
1873
CLEC5A-3E12A2-vL

CLEC5A
100
1874
CLEC5A-8H8F5-vL

CLL1
101
1875
CLL1-M26-vL

CLL1
102
1876
CLL1-M32-vL

CLL1
103
1877
CLL1-21C9-L2H3-vL

CLL1
104
1878
CLL1-6E7L4H1e-vL

CLL1
105
1879
CLL1-hu1075-v1-vL

CLL1
106
1880
CLL1-hu1075-v2-vL

CMVpp65/
107
1881
CMVpp65-F5-vL

MHC class

I complex

CS1
108
1882
huLuc63-vL

CS1
109
1883
HuLuc64-[2]vL

CS1
110
1884
HuLuc64-vL

CS1
111
1885
Luc90-vL

CS1
112
1886
CS1-PDL241-vL

CS1
113
1887
CS1-Hu27A-vL

CS1
114
1888
CS1-ScHu34C3-vL

CS1
115
1889
CS1-Hu31-D2-vL

CS1
116
1890
CS1-Luc34-vL

CS1
117
1891
CS1-LucX2-vL

CSF2RA
118
1892
CSF2RA-Ab1-vL

CSF2RA
119
1893
CSF2RA-Ab6-vL

DLL3
120
1894
DLL3-hSC16-13-vL

DLL3
121
1895
DLL3-hSC16-56-vL

EBNA3c//
122
1896
EBNA3c-315-vL

MHC class

I complex

EGFR
123
1897
Cetuximab-vL

EGFR
124
1898
Nimotuzumab-vL

EGFRviii
125
1899
EGFRviii-139-vL

EGFRviii
126
1900
EGFRviii-2173-vL

EpCam1
127
1901
EpCam1-D5K5-vL

EpCam1
128
1902
Epcam1-MM1-vL

FITC
129
1903
FITC-vL

FITC
130
1904
FITC-4M-53-vL

FITC
131
1905
FITC-E2-vL

FLT3
132
1906
FLT3-NC7-vL

HIV1-envelop
133
1907
HIV1-N6-vL

glycoprotein

FR1 (Folate
134
1908
FR1-huMov19-vL

Receptor alpha)

GAD65/MHC
135
1909
GAD-G3H8-vL

class I complex

GD2
136
1910
GD2-hu14-18-vL

GD2
137
1911
GD2-hu3F8-vL

GD3
138
1912
GD3-KM-641-vL

GFRa4
139
1913
GFRa4-P4-10-2-vL

GFRa4
140
1914
GFRa4-P4-10-vL

GFRa4
141
1915
GFRAlpha4-P4-6-vL

GM1
142
1916
GM1-5B2-vL

GM1
143
1917
GM1-7E5-vL

gp100//
144
1918
gp100-G2D12-vL

MHC class

I complex

gp100//
145
1919
gp100-vL

MHC class

I complex

GPC3
146
1920
GPC3-4E5-vL

gpNMB
147
1921
gpNMB-115-vL

GPRC5D
148
1922
GPRC5D-ET150-18-vL

GPRC5D
149
1923
GPRC5D-ET150-5-vL

GPRC5D
150
1924
GPRC5D-ET150-1-vL

GPRC5D
151
1925
GPRC5D-ET150-2-vL

Her2
152
1926
Her2-Hu4D5-vL

HIV1-envelop
153
1927
HIV1-3BNC117-vL

glycoprotein

HIV1-gag (77-85)/
154
1928
HIV1-E5-vL

MHC class

I complex

HIV1-envelop
155
1929
HIV1-PGT-128-vL

glycoprotein

HIV1-envelop
156
1930
HIV1-VR-C01-vL

glycoprotein

HIV1-envelop
157
1931
HIV1-X5-vL

glycoprotein

HLA-A2
158
1932
HLA-A2-3PB2-vL

HMW-MAA
159
1933
HMW-MAA-hIND-vL

HPV16-E7/
160
1934
HPV16-7-8-vL

MHC class

I complex

HPV16-E7/
161
1935
HPV16-2-vL

MHC class

I complex

HTLV1-TAX/
162
1936
TAX-T3E3-vL

MHC class

I complex

HTLV1-TAX/
163
1937
TAX-T3F2-vL

MHC class

I complex

IL11Ra
164
1938
IL11Ra-8E2-vL

IL13Ra2
165
1939
IL13Ra2-hu107-vL

IL13Ra2
166
1940
IL13Ra2-Hu108-vL

IL6R
167
1941
IL6R-M83-vL

Influenza A HA
168
1942
FLU-MEDI-8852-vL

KSHV-gH
169
1943
YC15-vL

KSHV-K8.1
170
1944
4C3-vL

L1CAM
171
1945
L1CAM-9-3-HU3-vL

LAMP1
172
1946
LAMP1-humab1-2-vL

LAMP1
173
1947
LAMP1-Mb4-vL

LewisY
174
1948
LewisY-huS193-vL

Lym1
175
1949
Lym1-vL

Lym2
176
1950
Lym2-vL

MART1/
177
1951
MART1-CAG10-vL

MHC class

I complex

MART1/
178
1952
MART1-CLA12-vL

MHC class

I complex

Mesothelin
179
1953
Mesothelin-m912-vL

MPL
180
1954
MPL-111-vL

MPL
181
1955
MPL-161-HL-vL

MPL
182
1956
MPL-161-vL

MPL
183
1957
MPL-175-vL

MPL
184
1958
MPL-178-vL

MPL
185
1959
MPL-huVB22Bw5-vL

MPL
186
1960
MPL-12E10-vL

MPL
187
1961
MPL-AB317-vL

Muc1/MHC
188
1962
MUC1-D6-M3A1-vL

class I complex

Muc1/MHC
189
1963
Muc1-D6-M3B8-vL

class I complex

Muc16
190
1964
Muc16-4H11-vL

NKG2D
191
1965
NKG2D-MS-vL

NYBR1
192
1966
NYBR1-vL

NY-ESO/MHC
193
1967
NY-ESO-T1-vL

class I complex

PD1
194
1968
PD1-4H1-vL

PD1
195
1969
PD1-5C4-vL

PDL1
196
1970
PDL1-10A5-vL

PDL1
197
1971
PDL1-Atezoli-vL

PDL1
198
1972
PDL1-SP142-vL

PR1/MHC
199
1973
PR1-vL

class I complex

PSCA
200
1974
PSCA-Ha14-117-vL

PSCA
201
1975
PSCA-Ha14-121-vL

PSMA
202
1976
PSMA-006-vL

PSMA
203
1977
PSMA-J591-vL

PTK7
204
1978
PTK7-hSC6-23-vL

PTK7
205
1979
PTK7-SC6-10-2-vL

ROR1
206
1980
ROR1-4A5-vL

ROR1
207
1981
ROR1-4C10-vL

SLea
208
1982
SLea-5B1-vL

SLea
209
1983
SLea-7E3-vL

SSEA4
210
1984
SSEA4-vL

TCRB1
211
1985
TCRB1-E09-vL

TCRB1
212
1986
TCRB1-Jovi1-vL

TCRB2
213
1987
TCRB2-CP01-D05-vL

TCRB2
214
1988
TCRB2-CP01-E05-vL

TCR gamma-
215
1989
TCRgd-G5-4-vL

delta (TCRgd)

TERT/MHC
216
1990
TERT-3G3-T865-vL

class I complex

TERT/MHC
217
1991
TERT-4A9-T540-vL

class I complex

TF1
218
1992
TF1-98-vL

TGFBR2
219
1993
TGFBR2-Ab1-vL

TIM1
220
1994
TIM1-HVCR1-270-2-vL

TIM1
221
1995
Tim1HVCR1-ARD5-vL

TnAg
222
1996
TnAg-vL

Tn-Muc1
223
1997
Tn-Muc1-hu5E5-vL

TROP2
224
1998
TROP2-ARA47-HV3KV3-vL

TROP2
225
1999
TROP2-h7E6-SVG-vL

TSHR
226
2000
TSHR-5C9-vL

TSHR
227
2001
TSHR-K1-70-vL

TSHR
228
2002
TSHR-KB1-vL

TSLPR
229
2003
TSLPR-vL

Tyrosinase/MHC
230
2004
Tyro-B2-vL

class I complex

Tyrosinase/MHC
231
2005
Tyro-Mc1-vL

class I complex

Tyrosinase/MHC
232
2006
TA2-vL

class I complex

VEGFR3
233
2007
VEGFR3-Ab1-vL

WT1/MHC
234
2008
WT1-Ab13-vL

class I complex

WT1/MHC
235
2009
WT1-Ab15-vL

class I complex

WT1/MHC
236
2010
WT1-Ab1-vL

class I complex

WT1/MHC
237
2011
WT1-Ab5-vL

class I complex

EBV-gp350
238
2012
EBV-gp350-vL

CDH19
239
2013
CDH19-4B10-vL

Folate Receptor
240
2014
FRbeta-m923-vL

beta (FRbeta)

LHR
241
2015
LHR-8B7-vL

LHR
242
2016
LHR-5F4-21-vL

B7H4
243
2017
B7H4-hu22Cl0-vL

B7H4
244
2018
B7H4-hu1D11-vL

IgE
245
2019
IgE-omalizumab-vL

CD23
246
2020
CD23-p5E8-vL

GCC
247
2021
GCC-5F9-vL

GCC
248
2022
GCC-Ab229-vL

CD200R
249
2023
CD200R-huDx182-vL

TABLE 5

ExemplaryLinkers

SEQ ID
SEQ ID

NAME
(DNA)
(PRT)

(GGGGS)x3_LINKER
250
2024

(GGGGS)x3_Linker
251
2024

(Gly4Ser)x3_Linker
252
2024

(Gly4Ser)x3_Linker
253
2024

(GGGGS)x3-Linker
254
2024

(GGGGS)x3-Linker
255
2024

(GGSG)7_Linker
256
2025

(GGSG)7_Linker_2
257
2026

DDAKK_linker
258
2027

TABLE 6

Exemplary V_Hfragments

SEQ ID
SEQ ID

Target
(DNA)
(PRT)
CONSTRUCT NAME

AFP/MHC class I complex
259
2028
AFP-61-vH

AFP/MHC class I complex
260
2029
AFP-76-vH

AFP/MHC class I complex
261
2030
AFP-79-vH

ALK
262
2031
Alk-48-vH

ALK
263
2032
Alk-58-vH

Amyloid
264
2033
Amyloid-158-vH

BCMA
265
2034
BCMA-ET-40-vH

BCMA
266
2035
BCMA-ET-54-vH

BCMA
267
2036
BCMA-huC12A3-vH

BCMA
268
2037
BCMA-J6M0-vH

BCMA
269
2038
BCMA-ET-03-vH

BCMA
270
2039
BCMA-huC11.D5.3L1H3-vH

BCMA
271
2040
BCMA-huC13-F12-vH

CCR4
272
2041
CCR4-humAb1567-vH

CD123
273
2042
CD123-CSL362-vH

CD123
274
2043
CD123-1172-vH

CD123
275
2044
CD123-DART-1-vH

CD123
276
2045
CD123-DART-2-vH

CD123
277
2046
CD123-13RB18-vH

CD123
278
2047
CD123-hu3E3-vH

CD123
279
2048
CD123-9F6-vH

CD123
280
2049
CD123-I3RB2-vH

CD123
281
2050
CD123-1176-vH

CD123
282
2051
CD123-8B11-vH

CD123
283
2052
CD123-2B8-vH

CD123
284
2053
CD123-9D7-vH

CD123
285
2054
CD123-3B10-vH

CD138
286
2055
CD138-vH

CD179b
287
2056
CD179b-vH

CD19
288
2057
CD19-4G7-vH

CD19
289
2058
CD19Bu12-vH

CD19
290
2059
CD19Bu12-[2]-vH

CD19
291
2060
CD19MM-vH

CD19
292
2061
FMC63-vH

CD19
293
2062
FMC-63-vH

CD19
294
2063
huFMC63-11-vH

CD19
295
2064
CD19-MEDI-3649-vH

CD19
296
2065
CD19-Medrex-24D1-vH

CD19
297
2066
CD19-MOR0028-vH

CD19
298
2067
CD19-HD37-H2L1-vH

CD19
299
2068
CD19-huBly3-vH

CD19
300
2069
CD19-huSJ25C1-vH

CD19
301
2070
CD19-hB4-vH

CD19
302
2071
CD19-hu-mROO5-1-vH

CD19
303
2072
CD19-hA19-vH

CD20
304
2073
CD20-2F2-vH

CD20
305
2074
CD20-GA101-vH

CD20
306
2075
CD20-Leu16-vH

CD20
307
2076
CD20-11B8-vH

CD20
308
2077
CD20-2C6-vH

CD20
309
2078
CD20-2H7-vH

CD20
310
2079
CD20-hA20-vH

CD20
311
2080
CD20-BM-CA-1925-v4-vH

CD20
312
2081
CD20-Ubli-v4-vH

CD20
313
2082
CD20-2H7-vH

CD20
314
2083
CD20-h1F5-vH

CD20
315
2084
CD20-7D8-vH

CD20
316
2085
CD20-AME-33-vH

CD22
317
2086
CD22-h10F4-vH

CD22
318
2087
CD22-H22Rhov2ACDRKA-vH

CD22
319
2088
CD22m971-vH

CD276
320
2089
CD276-17-vH

CD30
321
2090
CD30-5F11-vH

CD30
322
2091
CD30-Ac10-vH

CD32
323
2092
CD32-Med9-vH

CD324
324
2093
CD324-hSC10-17-vH

CD324
325
2094
CD324-SC10-6-vH

CD33
326
2095
CD33-huMyc9-vH

CD33
327
2096
CD33-AF5-vH

CD33
328
2097
CD33-Boehr2800308-vH

CD33
329
2098
CD33-Him3-4-vH

CD33
330
2099
CD33-SGNh2H12-vH

CD33
331
2100
CD33-15G15-33-vH

CD33
332
2101
CD33-33H4-vH

CD33
333
2102
CD33-33H4-vH

CD33
334
2103
CD33-9C3-2-vH

CD34
335
2104
CD34-hu4C7-vH

CD44v6
336
2105
CD44v6-Biwa8-vH

CD5
337
2106
CD5-18-vH

CD5
338
2107
CD5-9-vH

CD70
339
2108
CD70-h1F6-vH

CD79b
340
2109
CD79b-2F2-vH

CD79b
341
2110
huMA79bv28-vH

CD99
342
2111
CD99-hu12E7-vH

CDH17
343
2112
CDH17-PTA001A4-vH

CDH19
344
2113
CDH19-16A4-vH

CDH6
345
2114
CDH6-NOV710-vH

CDH6
346
2115
CDH6-NOV712-vH

CLEC5A
347
2116
CLEC5A-3E12A2-vH

CLEC5A
348
2117
CLEC5A-8H8F5-vH

CLL1
349
2118
CLL1-M26-vH

CLL1
350
2119
CLL1-M32-vH

CLL1
351
2120
CLL1-21C9-L2H3-vH

CLL1
352
2121
CLL1-6E7L4H1e-vH

CLL1
353
2122
CLL1-hu1075-v1-vH

CLL1
354
2123
CLL1-hu1075-v2-vH

CMVpp65/MHC class I
355
2124
CMVpp65-F5-vH

complex

CS1
356
2125
huLuc63-vH

CS1
357
2126
HuLuc64-vH

CS1
358
2127
Luc90-vH

CS1
359
2128
CS1-PDL241-vH

CS1
360
2129
CS1-Hu27A-vH

CS1
361
2130
CS1-ScHu34C3-vH

CS1
362
2131
CS1-Hu31-D2-vH

CS1
363
2132
CS1-Luc34-vH

CS1
364
2133
CS1-LucX2-vH

CSF2RA
365
2134
CSF2RA-Ab1-vH

CSF2RA
366
2135
CSF2RA-Ab6-vH

DLL3
367
2136
DLL3-hSC16-13-vH

DLL3
368
2137
DLL3-hSC16-56-vH

EBNA3c/MHC class I
369
2138
EBNA3c-315-vH

complex

EGFR
370
2139
Cetuximab-vH

EGFR
371
2140
Nimotuzumab-vH

EGFRviii
372
2141
EGFRviii-139-vH

EGFRviii
373
2142
EGFRviii-2173-vH

EpCam1
374
2143
EpCam1-D5K5-vH

EpCam1
375
2144
Epcam1-MM1-vH

FITC
376
2145
FITC-vH

FITC
377
2146
FITC-4M-53-vH

FITC
378
2147
FITC-E2-vH

FLT3
379
2148
FLT3-NC7-vH

HIV1-envelop glycoprotein
380
2149
HIV1-N6-vH

FR1 (Folate Receptor alpha)
381
2150
FR1-huMov19-vH

GAD65/MHC class I complex
382
2151
GAD-G3H8-vH

GD2
383
2152
GD2-hu14-18-vH

GD2
384
2153
GD2-hu3F8-vH

GD3
385
2154
GD3-KM-641-vH

GFRa4
386
2155
GFRa4-P4-10-vH

GFRa4
387
2156
GFRAlpha4-P4-6-vH

GM1
388
2157
GM1-5B2-vH

GM1
389
2158
GM1-7E5-vH

gp100/MHC class I complex
390
2159
gp100-G2D12-vH

gp100/MHC class I complex
391
2160
gp100-vH

GPC3
392
2161
GPC3-4E5-vH

gpNMB
393
2162
gpNMB-115-vH

GPRC5D
394
2163
GPRC5D-ET150-18-vH

GPRC5D
395
2164
GPRC5D-ET150-5-vH

GPRC5D
396
2165
GPRC5D-ET150-1-vH

GPRC5D
397
2166
GPRC5D-ET150-2-vH

Her2
398
2167
Her2-Hu4D5-vH

HIV1-envelop glycoprotein
399
2168
HIV1-3BNC117-vH

HIV1-gag (77-85) MHC class I
400
2169
HIV1-E5-vH

complex HIV1-envelop

glycoprotein

HIV1-envelop glycoprotein
401
2170
HIV1-PGT-128-vH

HIV1-envelop glycoprotein
402
2171
HIV1-VR-C01-vH

HIV1-envelop glycoprotein
403
2172
HIV1-X5-vH

HLA-A2
404
2173
HLA-A2-3PB2-vH

HMW-MAA
405
2174
HMW-MAA-hIND-vH

HPV16-E7/MHC class I
406
2175
HPV16-7-8-vH

complex

HPV16-E7/MHC class I
407
2176
HPV16-2-vH

complex

HTLV1-TAX/MHC class I
408
2177
TAX-T3E3-vH

HTLV1-TAX/MHC class I
409
2178
TAX-T3F2-vH

IL11Ra
410
2179
IL11Ra-8E2-vH

IL13Ra2
411
2180
IL13Ra2-hu107-vH

IL13Ra2
412
2181
IL13Ra2-Hu108-vH

IL6R
413
2182
IL6R-M83-vH

Influenza A HA
414
2183
FLU-MEDI-8852-vH

KSHV-gH
415
2184
YC15-vH

KSHV-K8.1
416
2185
4C3-vH

L1CAM
417
2186
L1CAM-9-3-HU3-vH

LAMP1
418
2187
LAMP1-humab1-2-vH

LAMP1
419
2188
LAMP1-Mb4-vH

LewisY
420
2189
LewisY-huS193-vH

Lym1
421
2190
Lym1-vH

Lym2
422
2191
Lym2-vH

MART1/MHC class I complex
423
2192
MART1-CAG10-vH

MART1/MHC class I complex
424
2193
MART1-CLA12-vH

Mesothelin
425
2194
Mesothelin-m912-[2]-vH

Mesothelin
426
2195
Mesothelin-m912-vH

MPL
427
2196
MPL-111-vH

MPL
428
2197
MPL-161-HL-vH

MPL
429
2198
MPL-161-vH

MPL
430
2199
MPL-175-vH

MPL
431
2200
MPL-178-vH

MPL
432
2201
MPL-huVB22Bw5-vH

MPL
433
2202
MPL-12E10-vH

MPL
434
2203
MPL-AB317-vH

Muc 1/MHC class I complex
435
2204
MUC1-D6-M3A1-vH

Muc 1/MHC class I complex
436
2205
Muc1-D6-M3B8-vH

Muc16
437
2206
Muc16-4H11-vH

NKG2D
438
2207
NKG2D-MS-vH

NYBR1
439
2208
NYBR1-vH

NY-ESO/MHC class I
440
2209
NY-ESO-T1-vH

complex

NY-ESO/MHC class I
441
2210
NY-ESO-T2-vH

complex

PD1
442
2211
PD1-4H1-vH

PD1
443
2212
PD1-5C4-vH

PDL1
444
2213
PDL1-Atezoli-vH

PDL1
445
2214
PDL1-SP142-vH

PR1
446
2215
PR1-vH

PSCA
447
2216
PSCA-Ha14-117-vH

PSCA
448
2217
PSCA-Ha14-121-vH

PSMA
449
2218
PSMA-006-vH

PSMA
450
2219
PSMA-J591-vH

PTK7
451
2220
PTK7-hSC6-23-vH

PTK7
452
2221
PTK7-SC6-10-2-vH

ROR1
453
2222
ROR1-4A5-vH

ROR1
454
2223
ROR1-4C10-vH

SLea
455
2224
SLea-5B1-vH

SLea
456
2225
SLea-7E3-vH

SSEA4
457
2226
SSEA4-vH

TCRB1 (TCR-beta1 constant
458
2227
TCRB1-E09-vH

chain)

TCRB1
459
2228
TCRB1-Jovi1-vH

TCRB2 (TCR-beta2 constant
460
2229
TCRB2-CP01-D05-vH

chain)

TCRB2
461
2230
TCRB2-CP01-E05-vH

TCR gamma-delta (TCRgd)
462
2231
TCRgd-G5-4-vH

TERT/MHC class I complex
463
2232
TERT-3G3-T865-vH

TERT/MHC class I complex
464
2233
TERT-4A9-T540-vH

TF1(Tissue Factor 1)
465
2234
TF1-98-vH

TGFBR2
466
2235
TGFBR2-Ab1-vH

TIM1
467
2236
TIM1-HVCR1-270-2-vH

TIM1
468
2237
Tim1HVCR1-ARDS-vH

TnAg
469
2238
TnAg-vH

Tn-Muc1
470
2239
Tn-Muc1-hu5E5-vH

TROP2
471
2240
TROP2-ARA47-HV3KV3-vH

TROP2
472
2241
TROP2-h7E6-SVG-vH

TSHR (Thyrotropin receptor)
473
2242
TSHR-5C9-vH

TSHR
474
2243
TSHR-K1-70-vH

TSHR
475
2244
TSHR-KB1-vH

TSLPR (Thymic stromal
476
2245
TSLPR-vH

lymphopoietin receptor)

Tyrosinase/MHC class I
477
2246
Tyro-B2-vH

complex

Tyrosinase/MHC class I
478
2247
Tyro-Mc1-vH

complex

Tyrosinase/MHC class I
479
2248
TA2-vH

complex

VEGFR3
480
2249
VEGFR3-Ab1-vH

WT1/MHC class I complex
481
2250
WT1-Ab13-vH

WT1/MHC class I complex
482
2251
WT1-Ab15-vH

WT1/MHC class I complex
483
2252
WT1-Ab1-vH

WT1/MHC class I complex
484
2253
WT1-Ab5-[2]-vH

WT1/MHC class I complex
485
2254
WT1-Ab5-vH

EBV-gp350
486
2255
EBV-gp350-vH

CDH19
487
2256
CDH19-4B10-vH

Folate Receptor beta (FRbeta)
488
2257
FRbeta-m923-vH

LHR (Luteinizing hormone
489
2258
LHR-8B7-vH

Receptor)

LHR
490
2259
LHR-5F4-21-vH

B7H4
491
2260
B7H4-hu22Cl0-vH

B7H4
492
2261
B7H4-hu1D11-vH

IgE
493
2262
IgE-omalizumab-vH

CD23
494
2263
CD23-p5E8-vH

GCC (Guanylyl cyclase C)
495
2264
GCC-5F9-vH

GCC (Guanylyl cyclase C)
496
2265
GCC-Ab229-vH

CD200R
497
2266
CD200R-huDx182-vH

PDL1
498
2268
PDL1-10A5-vH

TABLE 7

Exemplary V_HHfragments (Nanobodies)

SEQ
ID
SEQ ID

Target
(DNA)
(PRT)
NAME

Her2
499
2269
Her2-2D3-vHH

Her2
500
2270
Her2-5F7-vHH

Her2
501
2271
Her2-47D5-vHH

Her3
502
2272
Her3-17B05So-vHH

Her3
503
2273
Her3-21F06-vHH

CEA
504
2274
CEA1-vHH

CEA
505
2275
CEA5-vHH

EGFR
506
2276
EGFR1-vHH

EGFR
507
2277
EGFR33-vHH

cMet
508
2278
cMET-171-vHH

CXCR4
509
2279
CXCR4-2-vHH

CXCR4
510
2280
CXCR4-1-vHH

Mesothelin
511
2281
SD1-vHH

Mesothelin
512
2282
SD2-vHH

Albumin
513
2283
Alb8-vHH

CD123
514
2284
CD123-1-vHH

CD123
515
2285
CD123-2-vHH

IL6R
516
2286
IL6R-304-vHH

EGFR &
517
2287
EGFR1-vHH-Gly-Ser-

CEA

Linker-CEA1-vHH

EGFR &
518
2288
EGFR33-vHH-Gly-Ser-

CEA

Linker-CEA5-vHH

Her2
519
2289
Her2-5F7-vHH-Gly-Ser-

Linker-Her2-47D5-vHH

Her2
520
2290
Her2-Hu4D5-vL-Gly-Ser-

Linker-Her2-Hu4D5-vH

Her3 & Her2
521
2291
Her3-17B05So-vHH-Gly-

Ser-Linker-Her2-2D3-vHH

cMet &
522
2292
cMET-171-vHH-Gly-Ser-

Her3

Linker-Her3-21F06-14-vHH

Mesothelin
523
2293
SD1-vHH-Gly-Ser-Linker-

SD2-vHH

TABLE 8

Exemplary non-immunoglobulin antigen

binding scaffolds (affibodies, darpins).

SEQ ID
SEQ ID

Target
(DNA)
(PRT)
NAME

Her2
524
2294
Her2-DARPIN-1

Her2
525
2295
Her2-DARPIN-2

Her3
526
2296
Her3-affi

Her2
527
2297
Her2-affi

EGFR
528
2298
EGFR-affi

TABLE 9

Exemplary receptor extracellular domain

SEQ ID
SEQ ID

(DNA)
(PRT)
NAME

529
2299
CD19-Extracellular-Domain-minus-signal-

peptide(61-867)

530
2300
MPL-Extracellular-Domain-with-signal-ptepide

531
2301
CD8-SP-PD1-opt-ECD

532
2302
PD1-opt-ECD-minus-signal-peptide

533
2303
PD1-ECD-with-native-Signal-Peptide

534
2304
CTLA4-opt-ECD with signal peptide

535
2305
CD138-SDC1-ECD

536
2306
Synth-CD123-ECD

537
2307
CDH1-ECD

538
2308
CD200R1L-ECD

539
2309
GPNMB-ECD

540
2310
PTK7-ECD

541
2311
CD33-ECD

542
2312
CD34-ECD

543
2313
EpCAM-ECD

544
2314
CLEC12A-ECD

545
2315
CD20-ECx2-ECD

546
2316
CD20-ECx1-ECD

547
2317
CD22-v5-ECD

548
2318
Thyroid Stimulating Hormone Receptor (TSHR)-

ECD

549
2319
EGFRviii-ECD

550
2320
BCMA-ECD

551
2321
SLAMF7-CS1-ECD

552
2322
NKG2D-ECD-minus-signal-peptide

TABLE 10

Exemplary ligands

SEQ ID
SEQ ID

(DNA)
(PRT)
NAME

553
2323
hTPO (1-187)

554
2324
mTPO(1-187)

555
2325
CGH-alpha-minus-Signal-Peptide

556
2326
CGH-beta-with-Signal-Peptide

557
2327
FSH-beta-minus-Signal-Peptide

558
2328
LH-beta-with-Signal-Peptide

559
2329
TSH-beta-with-Signal-Peptide

560
2330
SP-CGHb-Gly-Ser-Linker-CGHa

561
2331
CD8SP-FSHb-Gly-Ser-Linker-CGHa

562
2332
SP-LHb-Gly-Ser-Linker-CGHa

563
2333
SP-TSHb-Gly-Ser-Linker-CGHa

TABLE 11

Exemplary scFv fragments

Target
SEQ ID
SEQ ID
CONSTRUCT NAME

CD19
564
2334
FMC63-(vL-vH)

CD19
565
2335
huFMC63-11-(vL-vH)

CD19
566
2336
CD19Bu12-(vL-vH)

CD19
567
2337
CD19MM-(vL-vH)

CD19
568
2338
CD19-4G7-(vL-vH)

CD19
569
2339
CD19-MEDI-3649-(vL-vH)

CD19
570
2340
CD19-Medrex-24D1-(vL-vH)

CD19
571
2341
CD8SP-Ritx-CD19-MOR0028-(vL-vH)

CD19
572
2342
CD19-HD37-H2L1-(vL-vH)

CD19
573
2343
CD19-huBly3-(vL-vH)

CD19
574
2344
CD19-huSJ25C1-(vL-vH)

CD19
575
2345
CD8SP-Ritx-CD19-hB4-(vL-vH)

CD19
576
2346
CD19-hu-mROO5-1-(vL-vH)

CD19
577
2347
CD19-hA19-(vL-vH)

AFP/MHC class I complex
578
2348
AFP-61-(vL-vH)

AFP/MHC class I complex
579
2349
AFP-76-(vL-vH)

AFP/MHC class I complex
580
2350
AFP-79-(vL-vH)

HIV1-env
581
2351
HIV1-N6-(vL-vH)

ALK
582
2352
Alk-48-(vL-vH)

ALK
583
2353
Alk-58-(vL-vH)

Amyloid
584
2354
Amyloid-158-(vL-vH)

CD45
585
2355
BC8-CD45-(vL-vH)

BCMA
586
2356
BCMA-J6M0-(vL-vH)

BCMA
587
2357
BCMA-huC12A3-L3H3-(vL-vH)

BCMA
588
2358
BCMA-ET-40-(vL-vH)

BCMA
589
2359
BCMA-ET-54-(vL-vH)

BCMA
590
2360
BCMA-ET-03-(vL-vH)

BCMA
591
2361
BCMA-huC11.D5.3L1H3-(vL-vH)

BCMA
592
2362
BCMA-huC13-F12-(vL-vH)

CCR4
593
2363
CCR4-humAb1567-(vL-vH)

CD5
594
2364
CD5-9-(vL-vH)

CD5
595
2365
CD5-18-(vL-vH)

CD20
596
2366
CD20-2F2-(vL-vH)

CD20
597
2367
CD20-GA101-(vL-vH)

CD22
598
2368
CD22-h10F4v2-(vL-vH)

CD20
599
2369
CD20-Leu16-(vL-vH)

CD20
600
2370
CD20-11B8-(vL-vH)

CD20
601
2371
CD20-2C6-(vL-vH)

CD20
602
2372
CD20-2H7-(vL-vH)

CD20
603
2373
CD20-hA20-(vL-vH)

CD20
604
2374
CD20-BM-CA-1925-v4-(vL-vH)

CD20
605
2375
CD20-Ubli-v4-(vL-vH)

CD20
606
2376
CD20-2H7-(vL-vH)

CD20
607
2377
CD20-h1F5-(vL-vH)

CD20
608
2378
CD20-7D8-(vL-vH)

CD20
609
2379
CD20-7D8-(vL-GA-tag-vH)

CD20
610
2380
CD20-AME-33-(vL-vH)

CD22
611
2381
CD22-H22Rhov2ACDRKA-(vL-vH)

CD22
612
2382
CD22-m971-(vL-vH)

CD22
613
2383
CD22-m971-HL-(vH-vL)

CD30
614
2384
CD30-5F11-(vL-vH)

CD30
615
2385
CD30-Ac10-(vL-vH)

CD32
616
2386
CD32-Med9-(vL-vH)

CD33
617
2387
CD33-AF5-(vL-vH)

CD33
618
2388
CD33-huMyc9-(vL-vH)

CD33
619
2389
CD8SP-Ritx2-BC33-Boehr2800308-

CD33
620
2390
CD8SP-Ritx2-CD33-Him3-4-(vL-vH)

CD33
621
2391
CD33-SGNh2H12-(vL-vH)

CD33
622
2392
CD33-15G15-33-(vL-vH)

CD33
623
2393
CD33-33H4-(vL-vH)

CD33
624
2394
CD33-9C3-2-(vL-vH)

CD34
625
2395
CD34-hu4C7-(vL-vH)

CD44v6
626
2396
CD44v6-Biwa8-(vL-vH)

CD70
627
2397
CD70-h1F6-(vL-vH)

CD79b
628
2398
CD79b-2F2-(vL-vH)

CD99
629
2399
CD99-hu12E7-(vL-vH)

CD123
630
2400
CD123-CSL362-(vL-vH)

CD123
631
2401
CD123-1172-(vL-vH)

CD123
632
2402
CD123-DART1-1-(vL-vH)

CD123
633
2403
CD123-DART1-2-(vL-vH)

CD123
634
2404
CD123-I3RB18-(vL-vH)

CD123
635
2405
CD123-hu3E3-(vL-vH)

CD123
636
2406
CD123-9F6-(vL-vH)

CD123
637
2407
CD123-I3RB2-(vL-vH)

CD123
638
2408
CD123-1176-(vL-vH)

CD123
639
2409
CD8SP-Ritx2-CD123-8B11-(vL-vH)

CD123
640
2410
CD123-2B8-(vL-vH)

CD123
641
2411
CD123-9D7-(vL-vH)

CD123
642
2412
CD123-3B10-(vL-vH)

CD138
643
2413
CD138-(vL-vH)

CD179b
644
2414
CD179b-(vL-vH)

CD276
645
2415
CD276-17-(vL-vH)

CD324
646
2416
CD324-SC10-6-(vL-vH)

CD324
647
2417
CD324-hSC10-17-(vL-vH)

CDH6
648
2418
CDH6-NOV710-(vL-vH)

CDH6
649
2419
CDH6-NOV712-(vL-vH)

CDH17
650
2420
CDH17-PTA001A4-(vL-vH)

CDH19
651
2421
CDH19-16A4-(vL-vH)

EGFR
652
2422
Cetuximab-(vL-vH)

CLEC5A
653
2423
CLEC5A-8H8F5-(vL-vH)

CLEC5A
654
2424
CLEC5A-3E12A2-(vL-vH)

CLL1
655
2425
CLL1-M26-(vL-vH)

CLL1
656
2426
CLL1-M32-(vL-vH)

CLL1
657
2427
CLL1-21C9-L2H3-(vL-vH)

CLL1
658
2428
CLL1-6E7L4H1e-(vL-vH)

CLL1
659
2429
CLL1-hu1075-v1-(vL-vH)

CLL1
660
2430
CLL1-hu1075-v2-(vL-vH)

CMVpp65/MHC class I
661
2431
CMVpp65-F5-(vL-vH)

CS1
662
2432
CS1-huLuc63-(vL-vH)

CS1
663
2433
CS1-HuLuc64-(vL-vH)

CS1
664
2434
CS1-Luc90-(vL-vH)

CS1
665
2435
CS1-PDL241-(vL-vH)

CS1
666
2436
CS1-Hu27A-(vL-vH)

CS1
667
2437
CS1-ScHu34C3-(vL-vH)

CS1
668
2438
CS1-Hu31-D2-(vL-vH)

CS1
669
2439
CS1-Luc34-(vL-vH)

CS1
670
2440
CS1-LucX2-(vL-vH)

CSF2RA
671
2441
CSF2RA-Ab6-(vL-vH)

CSF2RA
672
2442
CSF2RA-Ab1-(vL-vH)

DLL3
673
2443
DLL3-hSC16-13-(vL-vH)

DLL3
674
2444
DLL3-hSC16-56-(vL-vH)

EBNA3c/MHC class I
675
2445
EBNA3c-315-(vL-vH)

EBV-gp350
676
2446
EBV-gp350-(vL-vH)

EGFRvIII
677
2447
EGFRvIII-139-(vL-vH)

EGFRvIII
678
2448
EGFRvIII-2173-(vH-vL)

EpCam1
679
2449
Epcam1-MM1-(vL-vH)

EpCam1
680
2450
Epcam1-D5K5-(vL-vH)

FLT3
681
2451
FLT3-NC7-(vL-vH)

FITC
682
2452
FITC-(vL-vH)

FITC
683
2453
FITC-4M-53-(vL-vH)

FITC
684
2454
FITC-E2-HL-(vH-vL)

Influenza A HA
685
2455
FLU-MEDI-8852-(vL-vH)

FR1 (Folate Receptor a)
686
2456
FR1-huMov19-(vL-vH)

GAD
687
2457
GAD-G3H8-(vL-vH)

GD2
688
2458
GD2-hu14-18-(vL-vH)

GD2
689
2459
GD2-hu3F8-(vL-vH)

GD3
690
2460
GD3-KM-641-(vL-vH)

GFRa4
691
2461
GFRAlpha4-P4-6-(vL-vH)

GFRa4
692
2462
GFRa4-P4-10-(vL-vH)

GM1
693
2463
GM1-5B2-(vL-vH)

GM1
694
2464
GM1-7E5-(vL-vH)

GPRC5D
695
2465
GPRC5D-ET150-5-(vL-vH)

GPRC5D
696
2466
GPRC5D-ET150-18-(vL-vH)

GPRC5D
697
2467
GPRC5D-ET150-1-(vL-vH)

GPRC5D
698
2468
GPRC5D-ET150-2-(vL-vH)

gp100/MHC class I
699
2469
gp100-(vL-vH)

gp100/MHC class I
700
2470
gp100-G2D12-(vL-vH)

GPC3
701
2471
GPC3-4E5-(vL-vH)

gpNMB
702
2472
gpNMB-115-(vL-vH)

GRP78
703
2473
GRP78-GC18-(vL-vH)

HIV-gag/MHC class I
704
2474
HIV1-E5-(vL-vH)

HIV1-env
705
2475
HIV1-3BNC117-(vL-vH)

HIV1-env
706
2476
HIV1-PGT-128-(vL-vH)

HIV1-env
707
2477
HIV1-VR-C01-(vL-vH)

HIV1-env
708
2478
HIV1-X5-(vL-vH)

HLA-A2
709
2479
HLA-A2-3PB2-(vL-vH)

HMW-MAA
710
2480
HMW-MAA-hIND-(vL-vH)

HPV16
711
2481
HPV16-7-8-(vL-vH)

HPV16
712
2482
HPV16-2-(vL-vH)

HTLV1-TAX/MHC class I
713
2483
HTLV-TAX-T3F2-(vL-vH)

HTLV1-TAX/MHC class I
714
2484
HTLV-TAX-T3E3-(vL-vH)

IL11Ra
715
2485
IL11Ra-8E2-Ts107-(vL-vH)

IL13Ra2
716
2486
IL13Ra2-hu107-(vL-vH)

IL13Ra2
717
2487
IL13Ra2-Hu108-(vL-vH)

KSHV-K8.1
718
2488
KSHV-4C3-(vL-vH)

LAMP1
719
2489
LAMP1-humab1-2-(vL-vH)

LAMP1
720
2490
LAMP1-Mb4-(vL-vH)

LewisY
721
2491
LewisY-huS193-(vL-vH)

L1CAM
722
2492
L1CAM-9-3-HU3-(vL-vH)

Lym1
723
2493
Lym1-(vL-vH)

Lym2
724
2494
Lym2-(vL-vH)

CD79b
725
2495
huMA79bv28-(vL-vH)

MART/MHC class I
726
2496
MART1-CAG10-(vL-vH)

MART/MHC class I
727
2497
MART1-CLA12-(vL-vH)

Mesothelin
728
2498
Mesothelin-m912-(vL-vH)

MPL
729
2499
MPL-175-(vL-vH)

MPL
730
2500
MPL-161-(vL-vH)

MPL
731
2501
MPL-161-HL-(vH-vL)

MPL
732
2502
MPL-111-(vL-vH)

MPL
733
2503
MPL-178-(vL-vH)

MPL
734
2504
MPL-AB317-(vL-vH)

MPL
735
2505
MPL-12E10-(vL-vH)

MPL
736
2506
MPL-huVB22Bw5-(vL-vH)

Muc 1/MHC class I complex
737
2507
Muc1-D6-M3B8-(vL-vH)

Muc 1/MHC class I complex
738
2508
MUC1-D6-M3A1-(vL-vH)

Muc16
739
2509
Muc16-4H11-(vL-vH)

EGFR
740
2510
Nimotuzumab-(vL-vH)

NKG2D
741
2511
NKG2D-MS-(vL-vH)

NYBR1
742
2512
NYBR1-(vL-vH)

NY-ESO/MHC class I
743
2513
NYESO-T1-(vL-vH)

NY-ESO/MHC class I
744
2514
NYESO-T2-(vL-vH)

PDL1
745
2515
PDL1-Atezoli-(vL-vH)

PDL1
746
2516
PDL1-SP142-(vL-vH)

PDL1
747
2517
PDL1-10A5-(vL-vH)

PSCA
748
2518
PSCA-Ha14-121-(vL-vH)

PSCA
749
2519
PSCA-Ha14-117-(vL-vH)

PR1/MHC class I complex
750
2520
PR1-(vL-vH)

PSMA
751
2521
PSMA-006-(vL-vH)

PSMA
752
2522
PSMA-J591-(vL-vH)

PTK7
753
2523
PTK7-hSC6-23-(vL-vH)

PTK7
754
2524
PTK7-SC6-10-2-(vL-vH)

ROR1
755
2525
ROR1-4A5-(vL-vH)

ROR1
756
2526
ROR1-4C10-(vL-vH)

Mesothelin
757
2527
SD1-14-1H-Gly-Ser-Linker-SD2-vHH

SLea
758
2528
SLea-7E3-(vL-vH)

SLea
759
2529
SLea-5B1-(vL-vH)

SSEA4
760
2530
SSEA4-(vL-vH)

TCRB 1
761
2531
TCRB1-CP01-E09-(vL-vH)

TCRB 1
762
2532
TCRB1-Jovi1-(vL-vH)

TCRB2
763
2533
TCRB2-CP01-D05-(vL-vH)

TCRB2
764
2534
TCRB2-CP01-E05-(vL-vH)

TCRgd
765
2535
TCRgd-G5-4-(vL-vH)

hTERT
766
2536
TERT-4A9-T540-(vL-vH)

hTERT
767
2537
TERT-3G3-T865-(vL-vH)

Tissue Factor-1
768
2538
TF1-98-(vL-vH)

TGFBR2
769
2539
TGFBR2-Ab1-(vL-vH)

TIM1
770
2540
TIM1-HVCR1-270-2-(vL-vH)

TIM1
771
2541
TIM1-HVCR1-ARD5-(vL-vH)

TnAg
772
2542
TnAg-(vL-vH)

Tn-Muc1
773
2543
TnMuc1-hu5E5-RHA8-RKA-2-(vL-vH)

TROP2
774
2544
TROP2-ARA47-HV3KV3-(vL-vH)

TROP2
775
2545
TROP2-h7E6-SVG-(vL-vH)

TSHR
776
2546
TSHR-K1-70-(vL-vH)

TSHR
777
2547
TSHR-KB1-(vL-vH)

TSHR
778
2548
TSHR-5C9-(vL-vH)

TSLPR
779
2549
TSLPR-(vL-vH)

Tyrosinase/MHC class I
780
2550
Tyros-B2-(vL-vH)

Tyrosinase/MHC class I
781
2551
Tyros-MC1-(vL-vH)

Tyrosinase/MHC class I
782
2552
Tyros-TA2-(vL-vH)

VEGFR3
783
2553
VEGFR3-Ab1-(vL-vH)

WT1/MHC class I complex
784
2554
WT1-Ab1-(vL-vH)

WT1/MHC class I complex
785
2555
WT1-Ab5-(vL-vH)

WT1/MHC class I complex
786
2556
WT1-Ab13-(vL-vH)

WT1/MHC class I complex
787
2557
WT1-Ab15-(vL-vH)

CDH19
788
2558
CDH19-4B10-(vL-vH)

Folate Receptor beta
789
2559
FRbeta-m923-(vL-vH)

LHR
790
2560
LHR-8B7-(vL-vH)

LHR
791
2561
LHR-5F4-21-(vL-vH)

B7H4
792
2562
B7H4-hu22C10-(vL-vH)

B7H4
793
2563
B7H4-hu1D11-(vL-vH)

IgE
794
2564
IgE-omalizumab-(vL-vH)

CD23
795
2565
CD23-p5E8-(vL-vH)

GCC
796
2566
GCC-5F9-(vL-vH)

GCC
797
2567
GCC-Ab229-(vL-vH)

CD200R
798
2568
CD200R-huDx182-(vL-vH)

TABLE 12

Epitope Tags

SEQ ID (DNA)
SEQ ID (PRT)
NAME

553
2569
Myc-TAG

554
2570
FLAG-TAG

555
2571
AcV5

556
2572
V5-TAG

557
2573
HA-TAG

558
2574
HIS-TAG

559
2575
AVI-TAG-delta-GSG

560
2576
StrepTagII

561
2577
4XFLAG-2xSTREP-8xHIS

562
2578
3xFLAG

563
2579
4xHA-Strep-8xHis

3526
3530
RITX-TAG

3527
3531
RITX2-TAG

3528
3532
RITX4-TAG

3529
3533
GA-TAG

TABLE 13

Exemplary reporter fragments

SEQ ID
SEQ ID

(DNA)
(PRT)
REPORTER NAME

813
2580
GLuc (Gaussia princeps Luc)

Minus Secretory Signal

814
2581
NLuc (NanoLuc)

815
2582
TLuc (TurboLuc16)

Minus Secretory Signal

816
2583
MLuc7-(Metrida longa) Luc

M43L/M110L

Variant Minus Secretory Signal

817
2584
LoLuc (Lucicutia ovaliformis Luc)

Minus Secretory Signal

818
2585
HtLuc (H.tanneri Luc)

Minus Secretory Signal

819
2586
PaLuc1 (Pleuromamma

abdominalis Luc)

minus Secretory Signal

820
2587
PaLuc2 (Pleuromamma

abdominalis Luc2)-minus

Secretory Signal

821
2588
MpLuc1[Metridia pacifica]

minus secretory signal

822
2589
McLuc1 [Metridia curticauda]

minus secretory signal

823
2590
MaLuc1 [Metridia asymmetrical]

minus secretory signal

824
2591
MoLuc1 [Metridia okhotensis]

minus secretory signal

825
2592
MoLuc2 [Metridia okhotensis]

minus secretory signal

826
2593
MLuc39 [Metridia longa]

minus secretory signal

827
2594
PsLuc1 [Pleuromamma scutullata]

minus secretory signal

828
2595
LoLuc 1-3 [Lucicutia ovaliformis]

minus secretory signal

829
2596
HtLuc2 [Heterorhabdus tanneri]

minus secretory signal

830
2597
Renilla Luc

TABLE 14

Exemplary cleavable linkers and furine cleavage site

SEQ ID
SEQ ID

NAME
(DNA)
(PRT)

F2A
831
2598

T2A
832
2599

T2A
833
2599

P2A
834
2600

P2a-variant
835
2601

E2A
836
2602

SGSG
837
2603

SGSG
838
2603

FURINE CLEAVAGE SITE
839
2604

FURINE CLEAVAGE SITE
840
2604

FURINE Cleavage Site
841
2604

TABLE 15

Exemplary CAR components

SEQ ID
SEQ ID

(DNA)
(Prt)
NAME

842
2605
hCD8-Hinge-TM

843
2606
hCD8-Hinge-TM-BBz

844
2607
hCD8TM-Hinge-BB

845
2608
4-1BB-cytosolic-domain

846
2609
CD3z-cytosolic-domain

847
2610
CD3z-cytosolic-domain

848
2611
CD28-Hinge-TM-

cytosolic-domain

849
2612
LAILR1-TM-CP

TABLE 16

Exemplary Therapeutic Controls,

Accessory modules and their components

SEQ ID
SEQ ID

(DNA)
(PRT)
NAME

850
2613
PuroR_Variant-(PAC)

851
2614
BlastR

852
2615
CNB30

853
2616
GMCSF-SP-tEGFR

854
2617
tEGFRviii

855
2618
tCD19

856
2619
tBCMA

857
2620
FKBP

858
2621
FKBP

859
2622
FKBPx2

860
2623
Myr-FKBPx2-K13

861
2624
MYR

862
2625
Myr-MYD88-CD40-Fv′-Fv

863
2626
IL12F

864
2627
41BB-L

865
2628
CD40L

866
2629
K13-vFLIP

867
2630
MC159-vFLIP

868
2631
MC160-vFLIP

869
2632
E8-vFLIP

870
2633
Herpesvirus-saimiri-vFLIP

871
2634
Mecaca-vFLIP

872
2635
BHV-vFLIP

873
2636
cFLIP-L/MRIT-alpha

874
2637
cFLIP-p22

875
2638
HTLV1-TAX

876
2639
HTLV2-TAX

877
2640
HTLV2-TAX-RS

878
2641
FKBP-K13

879
2642
FKBPX2-K13

880
2643
Myr-FKBPx2-K13

881
2644
FKBPx2-HTLV2-Tax-RS

882
2645
FKBPx2-Flag-HTLV2-Tax-RS

883
2646
icaspase-9

884
2647
IL6R-304-vHH

885
2648
Alb8-vHH

886
2649
IGHSP2-IL6R-304-VHH-ALB8-VHH

887
2650
IL6-19A-vL

888
2651
1L6-19A-vH

889
2652
CD8SP2-PD1-4H1-scFv

890
2653
CD8SP2-PD1-5C4-scFv

891
2654
CD8SP2-CTLA4-Ipilimumab-scFv

892
2655
CD8SP2-PD1-4H1-Alb8-vHH

893
2656
CD8SP2-PD1-5C4-Alb8-vHH

894
2657
CD8SP2-CTLA4-Ipilimumab-Alb8-vHH

895
2658
IL6-19A-vL

896
2659
1L6-19A-vH

897
2660
IL6R-M83-vL

898
2661
IL6R-M83-vH

899
2662
IgSP-IL6-19A-scFV

900
2663
IgSP-Fx06

901
2664
CD8SP2-sHVEM

902
2665
CD8SP2-sHVEM-Alb8-vHH

903
2666
hTERT

904
2667
Heparinase

TABLE 17

Exemplary vectors, components and polyA sequence

SEQ ID

(DNA)
NAME

905
pLenti-EF1a

906
pLenti-EF1a-DWPRE

907
MSCV-Bgl2-AvrII-Bam-EcoR1-Xho-

BstB1-Mlu-Sal-ClaI.I03

908
pSBbi-Pur

909
EF1alpha_(EF1a)_Promoter_Variant

910
T7

911
T3

912
MSCVhygro-GLuc-HA-G02

913
MSCVpac-GLUC-R03

914
pLENTI-NLuc-AcV5-Blasticidin-Pa08

915
pLENTI-TurboLuc-16-X3Flag-C04

916
pLenti-EF1a-Pac-T2A-Gluc-B07

917
MSCV-hygro-NLuc-AcV5-D07

918
pLENTI-Gluc-Flag-blast-B07

919
H1-shRNA-BRD4-4

920
pLenti-EF1a-shRNA-BRD4-DWPRE

921
pLenti-EF1a-CD8SP-FMC63-(vL-vH)-Myc-z-P2A-K13-

Flag-T2A-PAC-H1-prom-shRNA-BRD4-DWPRE

922
PolyA

TABLE 18

Exemplary GGS-Luc reporter proteins

SEQ ID
SEQ ID

(DNA)
(PRT)
NAME

923
2668
CD8SP-FMC63(vL-vH)-GGSG-NLuc-AcV5

924
2669
CD8SP-161-(vL-vH)-GGSG-NLuc-AcV5

925
2670
MPL-ECD-GGSG-Nluc-AcV5

926
2671
FLAG-CD19-ECD-GGSG-NLuc-AcV5

TABLE 19

Exemplary CAR constructs containing CD3z activation domain and coexpressing K13.

SEQ ID
SEQ ID

Target
Clone ID
(DNA)
(PRT)
CONSTRUCT NAME

CD19
111614-B05
927
2672
CD8SP-FMC63-(vL-vH)-Myc-z-P2A-

K13-Flag-T2A-PAC

CD19

928
2673
CD8SP-huFMC63-11-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD19

929
2674
CD8SP-huFMC63-11-N203Q-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD19

930
2675
CD8SP-CD19Bu12-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD19

931
2676
CD8SP-2-CD19MM-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD19

932
2677
CD8SP-CD19-4G7-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD19

933
2678
CD8SP-CD19-MEDI-3649-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD19

934
2679
CD8SP-CD19-Medrex-24D1-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD19

935
2680
CD8SP-Ritx-CD19-MOR0028-(vL-

vH)-Myc-z-P2A-K13-Flag-T2A-PAC

CD19

936
2681
CD8SP-CD19-HD37-H2L1-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD19

937
2682
CD8SP-CD19-huBly3-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD19

938
2683
CD8SP-CD19-huSJ25C1-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD19

939
2684
CD8SP-Ritx-CD19-hB4-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

CD19

940
2685
CD8SP-CD19-hu-mROO5-1-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD19

941
2686
CD8SP-CD19-hA19-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

AFP/MHC class I

942
2687
CD8SP-AFP-61-(vL-vH)-Myc-z-P2A-

complex

K13-Flag-T2A-PAC

AFP/MHC class I

943
2688
CD8SP-AFP-76-(vL-vH)-Myc-z-P2A-

complex

K13-Flag-T2A-PAC

AFP/MHC class I

944
2689
CD8SP-AFP-79-(vL-vH)-Myc-z-P2A-

complex

K13-Flag-T2A-PAC

HIV1-envelop

945
2690
CD8SP-HIV1-N6-(vL-vH)-Myc-z-

glycoprotein

P2A-K13-Flag-T2A-PAC

ALK (Anaplastic
051916-D04
946
2691
CD8SP-Alk-48-(vL-vH)-Myc-z-P2A-

Lymphoma Kinase)

K13-Flag-T2A-PAC

ALK (Anaplastic

947
2692
CD8SP-Alk-58-(vL-vH)-Myc-z-P2A-

Lymphoma Kinase)

K13-Flag-T2A-PAC

Amyloid

948
2693
SP-Amyloid-158-(vL-vH)-Myc-z-P2A-

K13-Flag-T2A-PAC

Biotin

949
2694
CD8SP-dc-Avidin-Myc-z-P2A-K13-

Flag-T2A-PAC

CD45

950
2695
CD8SP-BC8-CD45-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

BCMA

951
2696
CD8SP-BCMA-J6M0-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

BCMA

952
2697
CD8SP-BCMA-huC12A3-L3H3-(vL-

vH)-Myc-z-P2A-K13-Flag-T2A-PAC

BCMA

953
2698
CD8SP-BCMA-ET-40-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

BCMA

954
2699
CD8SP-BCMA-ET-54-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

BCMA

955
2700
CD8SP-BCMA-ET-03-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

BCMA

956
2701
CD8SP-BCMA-huC11.D5.3L1H3-(vL-

vH)-Myc-z-P2A-K13-Flag-T2A-PAC

BCMA

957
2702
CD8SP-BCMA-huC13-F12-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CCR4

958
2703
CD8SP-CCR4-humAb1567-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

HIV1-envelop
052615-G02
959
2704
CD8SP-CD4-ECD-Gly-Ser-Linker-DC-

glycoprotein

SIGN-Myc-z-P2A-K13-Flag-T2A-PAC

CD5

960
2705
CD8SP-CD5-9-(vL-vH)-Myc-z-P2A-

K13-Flag-T2A-PAC

CD5

961
2706
CD8SP-CD5-18-(vL-vH)-Myc-z-P2A-

K13-Flag-T2A-PAC

Ig Fc

962
2707
CD8SP-CD16A-V158-ECD-v2-Myc-z-

P2A-K13-Flag-T2A-PAC

Ig Fc
091015-Z07
963
2708
CD8SP-CD16A-V158-ECD-v1-Myc-z-

P2A-K13-Flag-T2A-PAC

CD20

964
2709
CD8SP-CD20-2F2-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD20

965
2710
CD8SP-CD20-GA101-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD20

966
2711
CD8SP-CD20-Leu16-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD20

967
2712
CD8SP-CD20-11B8-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD20

968
2713
CD8SP-CD20-2C6-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD20

969
2714
CD8SP-CD20-2H7-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD20

970
2715
CD8SP-CD20-hA20-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD20

971
2716
CD8SP-CD20-BM-CA-1925-v4-(vL-

vH)-Myc-z-P2A-K13-Flag-T2A-PAC

CD20

972
2717
CD8SP-CD20-Ubli-v4-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD20

973
2718
CD8SP-CD20-2H7-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD20

974
2719
CD8SP-CD20-h1F5-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD20

975
2720
CD8SP-CD20-7D8-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD20

976
2721
CD8SP-CD20-AME-33-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

CD22

977
2722
CD8SP-CD22-h10F4v2-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

CD22
050516-H05
978
2723
CD8SP-CD22-H22Rhov2ACDRKA-

(vL-vH)-Myc-z-P2A-K13-Flag-T2A-

PAC

CD22

979
2724
CD8SP-CD22-m971-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD22

980
2725
CD8SP-CD22-m971-HL-(vH-vL)-Myc-

z-P2A-K13-Flag-T2A-PAC

CD30
060616-H05
981
2726
CD8SP-CD30-5F11-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD30

982
2727
CD8SP-CD30-Ac10-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD32
060916-A02
983
2728
CD8SP-CD32-Med9-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD33

984
2729
CD8SP-CD33-AF5-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD33

985
2730
CD8SP-CD33-huMyc9-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

CD33

986
2731
CD8SP-CD33-Boehr2800308-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD33

987
2732
CD8SP-CD33-Him3-4-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD33

988
2733
CD8SP-CD33-SGNh2H12-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD33

989
2734
CD8SP-CD33-15G15-33-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD33

990
2735
CD8SP-CD33-33H4-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD33

991
2736
CD8SP-CD33-9C3-2-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD34
051616-I02
992
2737
CD8SP-CD34-hu4C7-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD44v6

993
2738
CD8SP-CD44v6-Biwa8-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

CD70

994
2739
CD8SP-CD70-h1F6-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD79b

995
2740
CD8SP-CD79b-2F2-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD79b

996
2741
CD8SP-huMA79bv28-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD99

997
2742
CD8SP-CD99-hu12E7-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD123

998
2743
CD8SP-CD123-CSL362-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

CD123

999
2744
CD8SP-CD123-1172-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD123

1000
2745
CD8SP-CD123-DART-1-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD123

1001
2746
CD8SP-CD123-DART-2-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD123

1002
2747
CD8SP-CD123-I3RB18-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

CD123

1003
2748
CD8SP-CD123-hu3E3-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD123

1004
2749
CD8SP-CD123-9F6-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD123

1005
2750
CD8SP-CD123-I3RB2-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD123

1006
2751
CD8SP-CD123-1176-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD123

1007
2752
CD8SP-Ritx2-CD123-8B11-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD123

1008
2753
CD8SP-CD123-2B8-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD123

1009
2754
CD8SP-CD123-9D7-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD123

1010
2755
CD8SP-CD123-3B10-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD138

1011
2756
CD8SP-CD138-(vL-vH)-Myc-z-P2A-

K13-Flag-T2A-PAC

CD179b
051716-N05
1012
2757
CD8SP-CD179b-(vL-vH)-Myc-z-P2A-

K13-Flag-T2A-PAC

CD276

1013
2758
CD8SP-CD276-17-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD324

1014
2759
CD8SP-CD32410-6-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD324

1015
2760
CD8SP-CD324-hSC10-17-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CDH6
051716-I05
1016
2761
CD8SP-CDH6-NOV710-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

CDH6
051716-J05
1017
2762
CD8SP-CDH6-NOV712-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

CDH17
051716-
1018
2763
CD8SP-CDH17-PTA001A4-(vL-vH)-

M06

Myc-z-P2A-K13-Flag-T2A-PAC

CDH19
051716-V04
1019
2764
CD8SP-CDH19-16A4-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

EGFR

1020
2765
CD8SP-Cetuximab-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CLEC5A
050516-E03
1021
2766
CD8SP-CLEC5A-8H8F5-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CLEC5A
051016-F06
1022
2767
CD8SP-CLEC5A-3E12A2-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

GR/LHR

1023
2768
SP-CGHb-Gly-Ser-Linker-CGHa-Myc-

(Gonadotropin

z-P2A-K13-Flag-T2A-PAC

Receptor)

CLL1

1024
2769
CD8SP-CLL1-M26-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CLL1

1025
2770
CD8SP-CLL1-M32-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CLL1

1026
2771
CD8SP-CLL1-21C9-L2H3-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CLL1

1027
2772
CD8SP-CLL1-6E7L4H1e-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CLL1

1028
2773
CD8SP-CLL1-hu1075-v1-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CLL1

1029
2774
CD8SP-CLL1-hu1075-v2-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CMVpp65/MHC

1030
2775
CD8SP-CMVpp65-F5-(vL-vH)-Myc-z-

class I complex

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1031
2776
CD8SP-CS1-huLuc63-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1032
2777
CD8SP-CS1-HuLuc64-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1033
2778
CD8SP-CS1-huLuc90-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1034
2779
CD8SP-CS1-PDL241-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1035
2780
CD8SP-CS1-Hu27A-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1036
2781
CD8SP-CS1Hu34C3-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1037
2782
CD8SP-CS1-Hu31-D2-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CS1(SLAMF7)

1038
2783
CD8SP-CS1-Luc34-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1039
2784
CD8SP-CS1-LucX2-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CSF2RA
051616-H05
1040
2785
CD8SP-CSF2RA-Ab6-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CSF2RA
051616-G01
1041
2786
CD8SP-CSF2RA-Ab1-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

CXCR4 and CD123

1042
2787
CD8SP-CXCR4-1-vHH-Gly-Ser-

Linker-CD123-1-vHH-Myc-z-P2A-

K13-Flag-T2A-PAC

CXCR4 and CD123

1043
2788
CD8SP-CXCR4-2-VHH-Gly-Ser-

Linker-CD123-2-VHH-Myc-z-P2A-

K13-Flag-T2A-PAC

DLL3 (Delta Like

1044
2789
CD8SP-DLL3-hSC16-13-(vL-vH)-

Ligand 3)

Myc-z-P2A-K13-Flag-T2A-PAC

DLL3 (Delta Like

1045
2790
CD8SP-DLL3-hSC16-56-(vL-vH)-

Ligand 3)

Myc-z-P2A-K13-Flag-T2A-PAC

EBNA3c/MHC

1046
2791
CD8SP-EBNA3c-315-(vL-vH)-Myc-z-

class I complex

P2A-K13-Flag-T2A-PAC

EBV-gp350

1047
2792
CD8SP-EBV-gp350-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

EGFR

1048
2793
CD8SP-EGFR1-vHH-Myc-z-P2A-

K13-Flag-T2A-PAC

EGFR & CEA
040716-O08
1049
2794
CD8SP-EGFR1-vHH-Gly-Ser-Linker-

CEA1-vHH-Myc-z-P2A-K13-Flag-

T2A-PAC

EGFR & CEA
040716-P01
1050
2795
CD8SP-EGFR33-vHH-Gly-Ser-Linker-

CEA5-vHH-Myc-z-P2A-K13-Flag-

T2A-PAC

EGFRvIII

1051
2796
CD8SP-EGFRvIII-139-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

EGFRvIII

1052
2797
CD8SP-EGFRvIII-2173-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

EpCam1

1053
2798
CD8SP-Epcam1-MM1-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

EpCam1

1054
2799
CD8SP-Epcam1-D5K5-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

FLT3

1055
2800
CD8SP-FLT3-NC7-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

FITC
051016-E04
1056
2801
CD8SP-FITC-(vL-vH)-Myc-z-P2A-

K13-Flag-T2A-PAC

FITC

1057
2802
CD8SP-FITC-4M-53-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

FITC

1058
2803
CD8SP-FITC-E2-HL-(vH-vL)-Myc-z-

P2A-K13-Flag-T2A-PAC

Influenza A HA

1059
2804
CD8SP-FLU-MEDI-8852-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

FR1 (Folate

1060
2805
CD8SP-FR1-huMov19-(vL-vH)-Myc-

Receptor alpha)

z-P2A-K13-Flag-T2A-PAC

FSHR (Follicle

1061
2806
CD8SP-FSHb-Gly-Ser-Linker-CGHa-

Stimulating

Myc-z-P2A-K13-Flag-T2A-PAC

Hormone Receptor)

GAD (Glutamic

1062
2807
CD8SP-GAD-G3H8-(vL-vH)-Myc-z-

Acid

P2A-K13-Flag-T2A-PAC

Decarboxylase)/

MHC class I

complex

GD2

1063
2808
CD8SP-GD2-hu14-18-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

GD2

1064
2809
CD8SP-GD2-hu3F8-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

GD3
051016-D04
1065
2810
CD8SP-GD3-KM-641-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

GFRa4 (GDNF
051716-K05
1066
2811
CD8SP-GFRAlpha4-P4-6-(vL-vH)-

Family Receptor

Myc-z-P2A-K13-Flag-T2A-PAC

Alpha 4)

GFRa4 (GDNF
051316-L02
1067
2812
CD8SP-GFRa4-P4-10-(vL-vH)-Myc-z-

Family Receptor

P2A-K13-Flag-T2A-PAC

Alpha 4)

GM1

1068
2813
CD8SP-GM1-5B2-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

GM1

1069
2814
CD8SP-GM1-7E5-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

GPRC5D (G-

1070
2815
CD8SP-GPRC5D-ET150-5-(vL-vH)-

protein coupled

Myc-z-P2A-K13-Flag-T2A-PAC

receptor family C

group 5 member D)

GPRC5D

1071
2816
CD8SP-GPRC5D-ET150-18-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

GPRC5D

1072
2817
CD8SP-GPRC5D-ET150-1-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

GPRC5D

1073
2818
CD8SP-GPRC5D-ET150-2-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

gp100/MHC class I

1074
2819
CD8SP-gp100-(vL-vH)-Myc-z-P2A-

complex

K13-Flag-T2A-PAC

gp100/MHC class I

1075
2820
CD8SP-gp100-G2D12-(vL-vH)-Myc-z-

complex

P2A-K13-Flag-T2A-PAC

GPC3 (Glypican 3)

1076
2821
CD8SP-GPC3-4E5-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

gpNMB
060616-I05
1077
2822
CD8SP-gpNMB-115-(vL-vH)-Myc-z-

(Glycoprotein

P2A-K13-Flag-T2A-PAC

Nmb)

GRP78

1078
2823
CD8SP-GRP78-GC18-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

Her2

1079
2824
CD8SP-Her2-5F7-vHH-Myc-z-P2A-

K13-Flag-T2A-PAC

Her2

1080
2825
IgHSP-Her2-Affi-Myc-z-P2A-K13-

Flag-T2A-PAC

Her2

1081
2826
CD8SP-Her2-1-Darpin-Myc-z-P2A-

K13-Flag-T2A-PAC

Her2

1082
2827
IgHSP-Her2-2-Darpin-Myc-z-P2A-

K13-Flag-T2A-PAC

Her2

1083
2828
CD8SP-Her2-5F7-vHH-Gly-Ser-

Linker-Her2-47D5-vHH-Myc-z-P2A-

K13-Flag-T2A-PAC

Her2
050516-I03
1084
2829
CD8SP-Her2-Hu4D5-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

Her3

1085
2830
CD8SP-Her3-17B05So-vHH-Myc-z-

P2A-K13-Flag-T2A-PAC

Her3

1086
2831
CD8SP-Her3-Affi-Myc-z-P2A-K13-

Flag-T2A-PAC

Her2 and Her3

1087
2832
CD8SP-Her3-17B05So-vHH-Gly-Ser-

Linker-Her2-2D3-vHH-Myc-z-P2A-

K13-Flag-T2A-PAC

HIV1-gag/MHC

1088
2833
CD8SP-HIV1-E5-(vL-vH)-Myc-z-P2A-

class I complex

K13-Flag-T2A-PAC

HIV1-envelop

1089
2834
CD8SP-HIV1-3BNC117-(vL-vH)-Myc-

glycoprotein

z-P2A-K13-Flag-T2A-PAC

HIV1-envelop

1090
2835
CD8SP-HIV1-PGT-128-(vL-vH)-Myc-

glycoprotein

z-P2A-K13-Flag-T2A-PAC

HIV1-envelop

1091
2836
CD8SP-HIV1-VR-C01-(vL-vH)-Myc-

glycoprotein

z-P2A-K13-Flag-T2A-PAC

HIV1-envelop

1092
2837
CD8SP-HIV1-X5-(vL-vH)-Myc-z-

glycoprotein

P2A-K13-Flag-T2A-PAC

HLA-A2

1093
2838
CD8SP-HLA-A2-3PB2-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

HMW-MAA
060116-C03
1094
2839
CD8SP-HMW-MAA-hIND-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

HPV16-E7/MHC

1095
2840
CD8SP-HPV16-7-8-(vL-vH)-Myc-z-

class I complex

P2A-K13-Flag-T2A-PAC

HPV16-E7/MHC

1096
2841
CD8SP-HPV16-2-(vL-vH)-Myc-z-

class I complex

P2A-K13-Flag-T2A-PAC

HTLV1-TAX/MHC

1097
2842
CD8SP-HTLV-TAX-T3F2-(vL-vH)-

class I complex

Myc-z-P2A-K13-Flag-T2A-PAC

HTLV1-TAX/MHC

1098
2843
CD8SP-HTLV-TAX-T3E3-(vL-vH)-

class I complex

Myc-z-P2A-K13-Flag-T2A-PAC

IL11Ra
050516-D01
1099
2844
CD8SP-IL11Ra-8E2-Ts107-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

IL6Ra

1100
2845
IgHSP-IL6R-304-vHH-Myc-z-P2A-

K13-Flag-T2A-PAC

IL13Ra2

1101
2846
CD8SP-IL13Ra2-hu107-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

IL13Ra2
050516-F04
1102
2847
CD8SP-IL13Ra2-Hu108-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

KSHV-K8.1
070315-G04
1103
2848
CD8SP-KSHV-4C3-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

LAMP1
051716-T05
1104
2849
CD8SP-LAMP1-humab1-2-(vL-vH)-

(Lysosomal-

Myc-z-P2A-K13-Flag-T2A-PAC

associated

membrane protein 1)

LAMP1
051916-B07
1105
2850
CD8SP-LAMP1-Mb4-(vL-vH)-Myc-z-

(Lysosomal-

P2A-K13-Flag-T2A-PAC

associated

membrane protein 1)

LewisY

1106
2851
CD8SP-LewisY-huS193-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

L1CAM

1107
2852
CD8SP-L1CAM-9-3-HU3-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

LHR

1108
2853
SP-LHb-Gly-Ser-Linker-CGHa-Myc-z-

P2A-K13-Flag-T2A-PAC

Lym1

1109
2854
CD8SP-Lym1-(vL-vH)-Myc-z-P2A-

K13-Flag-T2A-PAC

Lym2

1110
2855
CD8SP-Lym2-(vL-vH)-Myc-z-P2A-

K13-Flag-T2A-PAC

CD79b

1111
2856
CD8SP-huMA79bv28-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

MART1/MHC class

1112
2857
CD8SP-MART1-CAG10-(vL-vH)-

I complex

Myc-z-P2A-K13-Flag-T2A-PAC

MART1/MHC class

1113
2858
CD8SP-MART1-CLA12-(vL-vH)-

I complex

Myc-z-P2A-K13-Flag-T2A-PAC

Mesothelin

1114
2859
CD8SP-Mesothelin-m912-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

cMet

1115
2860
CD8SP-cMet-171-vHH-Myc-z-P2A-

K13-Flag-T2A-PAC

cMet and Her3
041116-B05
1116
2861
CD8SP-cMET-171-vHH-Gly-Ser-

Linker-Her3-21F06-vHH-Myc-z-P2A-

K13-Flag-T2A-PAC

MPL

1117
2862
CD8SP-MPL-175-(vL-vH)-Myc-z-

(Thrombopoietin

P2A-K13-Flag-T2A-PAC

receptor)

MPL
111516-N05
1118
2863
CD8SP-MPL-161-(vL-vH)-Myc-z-

(Thrombopoietin

P2A-K13-Flag-T2A-PAC

receptor)

MPL

1119
2864
CD8SP-MPL-161-HL-(vH-vL)-Myc-z-

P2A-K13-Flag-T2A-PAC

MPL
040716-
1120
2865
CD8SP-2-MPL-111-(vL-vH)-Myc-z-

M02

P2A-K13-Flag-T2A-PAC

MPL

1121
2866
CD8SP-MPL-178-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

MPL

1122
2867
CD8SP-MPL-AB317-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

MPL

1123
2868
CD8SP-MPL-12E10-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

MPL

1124
2869
CD8SP-MPL-huVB22Bw5-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

Muc1/MHC class I

1125
2870
CD8SP-Muc1-D6-M3B8-(vL-vH)-

complex

Myc-z-P2A-K13-Flag-T2A-PAC

Muc1/MHC class I

1126
2871
CD8SP-MUC1-D6-M3A1-(vL-vH)-

complex

Myc-z-P2A-K13-Flag-T2A-PAC

Muc16

1127
2872
CD8SP-Muc16-4H11-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

EGFR

1128
2873
CD8SP-Nimotuzumab-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

NKG2D Ligand
050516-J04
1129
2874
CD8SP-NKG2D-(GGGGS-GGGGD)-

Myc-z-P2A-K13-Flag-T2A-PAC

NKG2D

1130
2875
CD8SP-NKG2D-MS-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

NY-BR1
051716-Q05
1131
2876
CD8SP-NYBR1-(vL-vH)-Myc-z-P2A-

K13-Flag-T2A-PAC

NY-ESO/MHC

1132
2877
CD8SP-NYESO-T1-(vL-vH)-Myc-z-

class I complex

P2A-K13-Flag-T2A-PAC

NY-ESO/MHC

1133
2878
CD8SP-NYESO-T2-(vL-vH)-Myc-z-

class I complex

P2A-K13-Flag-T2A-PAC

PD1 ligand (e.g.,

1134
2879
CD8SP-PD1-ECD-Myc-z-P2A-K13-

PDL1)

Flag-T2A-PAC

PDL1

1135
2880
CD8SP-PDL1-Atezoli-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

PDL1

1136
2881
CD8SP-PDL1-SP142-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

PDL1

1137
2882
CD8SP-PDL1-10A5-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

PSCA (Prostate

1138
2883
CD8SP-PSCA-Ha14-121-(vL-vH)-

stem cell antigen)

Myc-z-P2A-K13-Flag-T2A-PAC

PSCA (Prostate

1139
2884
CD8SP-PSCA-Ha14-117-(vL-vH)-

stem cell antigen)

Myc-z-P2A-K13-Flag-T2A-PAC

PR1/MHC class I

1140
2885
CD8SP-PR1-(vL-vH)-Myc-z-P2A-K13-

complex

Flag-T2A-PAC

PSMA (Prostate

1141
2886
CD8SP-PSMA-006-(vL-vH)-Myc-z-

Specific Membrane

P2A-K13-Flag-T2A-PAC

Antigen)

PSMA (Prostate

1142
2887
CD8SP-PSMA-J591-(vL-vH)-Myc-z-

Specific Membrane

P2A-K13-Flag-T2A-PAC

Antigen)

PTK7 (Tyrosine-

1143
2888
CD8SP-PTK7-hSC6-23-(vL-vH)-Myc-

protein kinase-like 7)

z-P2A-K13-Flag-T2A-PAC

PTK7 (Tyrosine-

1144
2889
CD8SP-PTK76-10-2-(vL-vH)-Myc-z-

protein kinase-like 7)

P2A-K13-Flag-T2A-PAC

ROR1

1145
2890
CD8SP-ROR1-4A5-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

ROR1

1146
2891
CD8SP-ROR1-4C10-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

Mesothelin

1147
2892
CD8SP-SD1-vHH-Gly-Ser-Linker-

5D2-vHH-Myc-z-P2A-K13-Flag-

T2A-PAC

SLea

1148
2893
CD8SP-SLea-7E3-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

SLea
051716-X05
1149
2894
CD8SP-SLea-5B1-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

SSEA4 (stage-

1150
2895
CD8SP-SSEA4-(vL-vH)-Myc-z-P2A-

specific embryonic

K13-Flag-T2A-PAC

antigen 4)

TCRB1 (TCR beta

1151
2896
CD8SP-TCRB1-CP01-E09-(vL-vH)-

1 constant chain)

Myc-z-P2A-K13-Flag-T2A-PAC

TCRB1 (TCR beta

1152
2897
CD8SP-TCRB1-Jovi1-(vL-vH)-Myc-z-

1 constant chain)

P2A-K13-Flag-T2A-PAC

TCRB2 (TCR beta

1153
2898
CD8SP-TCRB2-CP01-D05-(vL-vH)-

2 constant chain)

Myc-z-P2A-K13-Flag-T2A-PAC

TCRB2 (TCR beta

1154
2899
CD8SP-TCRB2-CP01-E05-(vL-vH)-

2 constant chain)

Myc-z-P2A-K13-Flag-T2A-PAC

TCRgd (TCR
051716-H05
1155
2900
CD8SP-TCRgd-G5-4-(vL-vH)-Myc-z-

gamma/delta)

P2A-K13-Flag-T2A-PAC

hTERT/MHC class

1156
2901
CD8SP-TERT-4A9-T540-(vL-vH)-

I complex

Myc-z-P2A-K13-Flag-T2A-PAC

hTERT/MHC class

1157
2902
CD8SP-TERT-3G3-T865-(vL-vH)-

I complex

Myc-z-P2A-K13-Flag-T2A-PAC

Tissue Factor-1
051716-O05
1158
2903
CD8SP-TGFBR2-Ab1-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

TGFBR2

1159
2904
CD8SP-TF1-98-(vL-vH)-Myc-z-P2A

K13-Flag-T2A-PAC

TIM1/HAVCR
051716-S05
1160
2905
CD8SP-TIM1-HVCR1-270-2-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

TIM1/HAVCR
051716-P05
1161
2906
CD8SP-TIM1-HVCR1-ARD5-(vL-

vH)-Myc-z-P2A-K13-Flag-T2A-PAC

TnAg
051716-H05
1162
2907
CD8SP-TnAg-(vL-vH)-Myc-z-P2A-

K13-Flag-T2A-PAC

Tn-Muc1

1163
2908
CD8SP-TnMuc1-hu5E5-RHA8-RKA-

2-(vL-vH)-Myc-z-P2A-K13-Flag-

T2A-PAC

MPL

1164
2909
CD8SP-hTPO-Myc-z-P2A-K13-Flag-

(Thrombopoietin

T2A-PAC

receptor)

TROP2
051716-G05
1165
2910
CD8SP-TROP2-ARA47-HV3KV3-(vL-

(Trophoblast cell-

vH)-Myc-z-P2A-K13-Flag-T2A-PAC

surface antigen-2)

TROP2
052616-D04
1166
2911
CD8SP-TROP2-h7E6-SVG-(vL-vH)-

(Trophoblast cell-

Myc-z-P2A-K13-Flag-T2A-PAC

surface antigen-2)

TSHR (Thyrotropin

1167
2912
SP-TSHb-Gly-Ser-Linker-CGHa-Myc-

receptor)

z-P2A-K13-Flag-T2A-PAC

TSHR (Thyrotropin

1168
2913
CD8SP-TSHR-K1-70-(vL-vH)-Myc-z-

receptor)

P2A-K13-Flag-T2A-PAC

TSHR (Thyrotropin
051616-D04
1169
2914
CD8SP-TSHR-KB1-(vL-vH)-Myc-z-

receptor)

P2A-K13-Flag-T2A-PAC

TSHR (Thyrotropin

1170
2915
CD8SP-TSHR-5C9-(vL-vH)-Myc-z-

receptor)

P2A-K13-Flag-T2A-PAC

TSLPR (Thymic

1171
2916
CD8SP-TSLPR-(vL-vH)-Myc-z-P2A-

stromal

K13-Flag-T2A-PAC

lymphopoietin

receptor)

Tyrosinase/MHC

1172
2917
CD8SP-Tyros-B2-(vL-vH)-Myc-z-

class I complex

P2A-K13-Flag-T2A-PAC

Tyrosinase/MHC

1173
2918
CD8SP-Tyros-MC1-(vL-vH)-Myc-z-

class I complex

P2A-K13-Flag-T2A-PAC

Tyrosinase/MHC

1174
2919
CD8SP-Tyros-TA2-(vL-vH)-Myc-z-

class I complex

P2A-K13-Flag-T2A-PAC

VEGFR3
060616-P04
1175
2920
CD8SP-VEGFR3-Ab1-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

WT1/MHC class I

1176
2921
CD8SP-WT1-Ab1-(vL-vH)-Myc-z-

complex

P2A-K13-Flag-T2A-PAC

WT1/MHC class I

1177
2922
CD8SP-WT1-Ab5-(vL-vH)-Myc-z-

complex

P2A-K13-Flag-T2A-PAC

WT1/MHC class I

1178
2923
CD8SP-MYC3-WT1-Ab13-(vL-vH)-

complex

Myc-z-P2A-K13-Flag-T2A-PAC

WT1/MHC class I

1179
2924
CD8SP-MYC3-WT1-Ab15-(vL-vH)-

complex

Myc-z-P2A-K13-Flag-T2A-PAC

CDH19
051716-U05
1180
2925
CD8SP-CDH19-4B10-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

Folate Receptor

1181
2926
CD8SP-FRbeta-m923-(vL-vH)-Myc-z-

beta

P2A-K13-Flag-T2A-PAC

LHR (Luteinizing

1182
2927
CD8SP-LHR-8B7-(vL-vH)-Myc-z-

hormone Receptor)

P2A-K13-Flag-T2A-PAC

LHR (Luteinizing

1183
2928
CD8SP-LHR-5F4-21-(vL-vH)-Myc-z-

hormone Receptor)

P2A-K13-Flag-T2A-PAC

B7H4

1184
2929
CD8SP-B7H4-hu22Cl0-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

B7H4

1185
2930
CD8SP-B7H4-hu1D11-(vL-vH)-Myc-

z-P2A-K13-Flag-T2A-PAC

IgE

1186
2931
CD8SP-IgE-omalizumab-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD23

1187
2932
CD8SP-CD23-p5E8-(vL-vH)-Myc-z-

P2A-K13-Flag-T2A-PAC

GCC (Guanylyl

1188
2933
CD8SP-GCC-5F9-(vL-vH)-Myc-z-

cyclase C)

P2A-K13-Flag-T2A-PAC

GCC (Guanylyl

1189
2934
CD8SP-GCC-Ab229-(vL-vH)-Myc-z-

cyclase C)

P2A-K13-Flag-T2A-PAC

CD200R

1190
2935
CD8SP-CD200R-huDx182-(vL-vH)-

Myc-z-P2A-K13-Flag-T2A-PAC

Tn-Muc1

1191
2936
CD8SP-Tn-Muc1-5E5-HL-(vH-vL)-

Myc-z-P2A-K13-Flag-T2A-PAC

CD22

1192
2937
CD8SP-CD22-5-HL-(vH-vL)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD22

1193
2938
CD8SP-CD22-10-HL-(vH-vL)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD22

1194
2939
CD8SP-CD22-31-HL-(vH-vL)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD22

1195
2940
CD8SP-CD22-53-HL-(vH-vL)-Myc-z-

P2A-K13-Flag-T2A-PAC

CD22

1196
2941
CD8SP-CD22-65-HL-(vH-vL)-Myc-z-

P2A-K13-Flag-T2A-PAC

TABLE 20

Exemplary CAR constructs containing 41BB costimulatory domain, CD3z activation domain and coexpressing K13

Clone
SEQ ID
SEQ ID

Target
ID
(DNA)
(PRT)
CONSTRUCT NAME

CD19
111014-
1197
2942
CD8SP-FMC63-(vL-vH)-Myc-BBz-P2A-

Y11

K13-Flag-T2A-PAC

CD19

1198
2943
CD8SP-huFMC63-11-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD19

1199
2944
CD8SP-huFMC63-11-N203Q-(vL-vH)-

Myc-BBz-P2A-K13-Flag-T2A-PAC

CD19

1200
2945
CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD19

1201
2946
CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD19

1202
2947
CD8SP-CD19-4G7-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD19

1203
2948
CD8SP-CD19-MEDI-3649-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD19

1204
2949
CD8SP-CD19-Medrex-24D1-(vL-vH)-

Myc-BBz-P2A-K13-Flag-T2A-PAC

CD19

1205
2950
CD8SP-Ritx-CD19-MOR0028-(vL-vH)-

Myc-BBz-P2A-K13-Flag-T2A-PAC

CD19

1206
2951
CD8SP-CD19-HD37-H2L1-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD19

1207
2952
CD8SP-CD19-huBly3-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD19

1208
2953
CD8SP-CD19-huSJ25C1-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD19

1209
2954
CD8SP-Ritx-CD19-hB4-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD19

1210
2955
CD8SP-CD19-hu-mROO5-1-(vL-vH)-

Myc-BBz-P2A-K13-Flag-T2A-PAC

CD19

1211
2956
CD8SP-CD19-hA19-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

AFP/MHC class I

1212
2957
CD8SP-AFP-61-(vL-vH)-Myc-BBz-P2A-

complex

K13-Flag-T2A-PAC

AFP/MHC class I

1213
2958
CD8SP-AFP-76-(vL-vH)-Myc-BBz-P2A-

complex

K13-Flag-T2A-PAC

AFP/MHC class I

1214
2959
CD8SP-AFP-79-(vL-vH)-Myc-BBz-P2A-

complex

K13-Flag-T2A-PAC

HIV1-envelop

1215
2960
CD8SP-HIV1-N6-(vL-vH)-Myc-BBz-

glycoprotein

P2A-K13-Flag-T2A-PAC

ALK (Anaplastic

1216
2961
CD8SP-Alk-48-(vL-vH)-Myc-BBz-P2A-

Lymphoma Kinase)

K13-Flag-T2A-PAC

ALK (Anaplastic

1217
2962
CD8SP-Alk-58-(vL-vH)-Myc-BBz-P2A-

Lymphoma Kinase)

K13-Flag-T2A-PAC

Amyloid

1218
2963
SP-Amyloid-158-(vL-vH)-Myc-BBz-P2A-

K13-Flag-T2A-PAC

Biotin

1219
2964
CD8SP-dc-Avidin-Myc-BBz-P2A-K13-

Flag-T2A-PAC

CD45

1220
2965
CD8SP-BC8-CD45-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

BCMA

1221
2966
CD8SP-BCMA-J6M0-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

BCMA

1222
2967
CD8SP-BCMA-huC12A3-L3H3-(vL-vH)-

Myc-BBz-P2A-K13-Flag-T2A-PAC

BCMA

1223
2968
CD8SP-BCMA-ET-40-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

BCMA

1224
2969
CD8SP-BCMA-ET-54-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

BCMA

1225
2970
CD8SP-BCMA-ET-03-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

BCMA

1226
2971
CD8SP-BCMA-huC11.D5.3L1H3-(vL-

vH)-Myc-BBz-P2A-K13-Flag-T2A-PAC

BCMA

1227
2972
CD8SP-BCMA-huC13-F12-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CCR4

1228
2973
CD8SP-CCR4-humAb1567-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

HIV1-envelop

1229
2974
CD8SP-CD4-ECD-Gly-Ser-Linker-DC-

glycoprotein

SIGN-Myc-BBz-P2A-K13-Flag-T2A-PAC

CD5

1230
2975
CD8SP-CD5-9-(vL-vH)-Myc-BBz-P2A-

K13-Flag-T2A-PAC

CD5

1231
2976
CD8SP-CD5-18-(vL-vH)-Myc-BBz-P2A-

K13-Flag-T2A-PAC

Ig Fc

1232
2977
CD8SP-CD16A-V158-ECD-v2-Myc-BBz-

P2A-K13-Flag-T2A-PAC

Ig Fc

1233
2978
CD8SP-CD16A-V158-ECD-v1-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD20

1234
2979
CD8SP-CD20-2F2-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD20

1235
2980
CD8SP-CD20-GA101-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD20

1236
2981
CD8SP-CD20-Leu16-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD20

1237
2982
CD8SP-CD20-11B8-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD20

1238
2983
CD8SP-CD20-2C6-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD20

1239
2984
CD8SP-CD20-2H7-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD20

1240
2985
CD8SP-CD20-hA20-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD20

1241
2986
CD8SP-CD20-BM-CA-1925-v4-(vL-vH)-

Myc-BBz-P2A-K13-Flag-T2A-PAC

CD20

1242
2987
CD8SP-CD20-Ubli-v4-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD20

1243
2988
CD8SP-CD20-2H7-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD20

1244
2989
CD8SP-CD20-h1F5-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD20

1245
2990
CD8SP-CD20-7D8-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD20

1246
2991
CD8SP-CD20-AME-33-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD22

1247
2992
CD8SP-CD22-h10F4v2-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD22

1248
2993
CD8SP-CD22-H22Rhov2ACDRKA-(vL-

vH)-Myc-BBz-P2A-K13-Flag-T2A-PAC

CD22

1249
2994
CD8SP-CD22-m971-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD22

1250
2995
CD8SP-CD22-m971-HL-(vH-vL)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD30

1251
2996
CD8SP-CD30-5F11-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD30

1252
2997
CD8SP-CD30-Ac10-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD32

1253
2998
CD8SP-CD32-Med9-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD33

1254
2999
CD8SP-CD33-AF5-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD33

1255
3000
CD8SP-CD33-huMyc9-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD33

1256
3001
CD8SP-CD33-Boehr2800308-(vL-vH)-

Myc-BBz-P2A-K13-Flag-T2A-PAC

CD33

1257
3002
CD8SP-CD33-Him3-4-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD33

1258
3003
CD8SP-CD33-SGNh2H12-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD33

1259
3004
CD8SP-CD33-15G15-33-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD33

1260
3005
CD8SP-CD33-33H4-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD33

1261
3006
CD8SP-CD33-9C3-2-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD34

1262
3007
CD8SP-CD34-hu4C7-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD44v6

1263
3008
CD8SP-CD44v6-Biwa8-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD70

1264
3009
CD8SP-CD70-h1F6-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD79b

1265
3010
CD8SP-CD79b-2F2-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD79b

1266
3011
CD8SP-huMA79bv28-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD99

1267
3012
CD8SP-CD99-hu12E7-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD123

1268
3013
CD8SP-CD123-CSL362-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD123

1269
3014
CD8SP-CD123-1172-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD123

1270
3015
CD8SP-CD123-DART-1-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD123

1271
3016
CD8SP-CD123-DART-2-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD123

1272
3017
CD8SP-CD123-I3RB18-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD123

1273
3018
CD8SP-CD123-hu3E3-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD123

1274
3019
CD8SP-CD123-9F6-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD123

1275
3020
CD8SP-CD123-I3RB2-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD123

1276
3021
CD8SP-CD123-1176-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD123

1277
3022
CD8SP-Ritx2-CD123-8B11-(vL-vH)-

Myc-BBz-P2A-K13-Flag-T2A-PAC

CD123

1278
3023
CD8SP-CD123-2B8-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD123

1279
3024
CD8SP-CD123-9D7-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD123

1280
3025
CD8SP-CD123-3B10-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD138

1281
3026
CD8SP-CD138-(vL-vH)-Myc-BBz-P2A-

K13-Flag-T2A-PAC

CD179b

1282
3027
CD8SP-CD179b-(vL-vH)-Myc-BBz-P2A-

K13-Flag-T2A-PAC

CD276

1283
3028
CD8SP-CD276-17-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD324

1284
3029
CD8SP-CD324-SC10-6-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD324

1285
3030
CD8SP-CD324-hSC10-17-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CDH6

1286
3031
CD8SP-CDH6-NOV710-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CDH6

1287
3032
CD8SP-CDH6-NOV712-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CDH17

1288
3033
CD8SP-CDH17-PTA001A4-(vL-vH)-

Myc-BBz-P2A-K13-Flag-T2A-PAC

CDH19

1289
3034
CD8SP-CDH19-16A4-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

EGFR

1290
3035
CD8SP-Cetuximab-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CLEC5A

1291
3036
CD8SP-CLEC5A-8H8F5-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CLEC5A

1292
3037
CD8SP-CLEC5A-3E12A2-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

GR/LHR

1293
3038
SP-CGHb-Gly-Ser-Linker-CGHa-Myc-

(Gonadotropin

BBz-P2A-K13-Flag-T2A-PAC

Receptor)

CLL1

1294
3039
CD8SP-CLL1-M26-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CLL1

1295
3040
CD8SP-CLL1-M32-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CLL1

1296
3041
CD8SP-CLL1-21C9-L2H3-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CLL1

1297
3042
CD8SP-CLL1-6E7L4H1e-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CLL1

1298
3043
CD8SP-CLL1-hu1075-v1-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CLL1

1299
3044
CD8SP-CLL1-hu1075-v2-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CMVpp65/MHC

1300
3045
CD8SP-CMVpp65-F5-(vL-vH)-Myc-BBz-

class I complex

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1301
3046
CD8SP-CS1-huLuc63-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1302
3047
CD8SP-CS1-HuLuc64-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1303
3048
CD8SP-CS1-huLuc90-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1304
3049
CD8SP-CS1-PDL241-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1305
3050
CD8SP-CS1-Hu27A-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1306
3051
CD8SP-CS1-ScHu34C3-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1307
3052
CD8SP-CS1-Hu31-D2-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CS1(SLAMF7)

1308
3053
CD8SP-CS1-Luc34-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CS1 (SLAMF7)

1309
3054
CD8SP-CS1-LucX2-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CSF2RA

1310
3055
CD8SP-CSF2RA-Ab6-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CSF2RA

1311
3056
CD8SP-CSF2RA-Ab1-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CXCR4 and CD123

1312
3057
CD8SP-CXCR4-1-vHH-Gly-Ser-Linker-

CD123-1-vHH-Myc-BBz-P2A-K13-Flag-

T2A-PAC

CXCR4 and CD123

1313
3058
CD8SP-CXCR4-2-VHH-Gly-Ser-Linker-

CD123-2-VHH-Myc-BBz-P2A-K13-Flag-

T2A-PAC

DLL3 (Delta Like

1314
3059
CD8SP-DLL3-hSC16-13-(vL-vH)-Myc-

Ligand 3)

BBz-P2A-K13-Flag-T2A-PAC

DLL3 (Delta Like

1315
3060
CD8SP-DLL3-hSC16-56-(vL-vH)-Myc-

Ligand 3)

BBz-P2A-K13-Flag-T2A-PAC

EBNA3c/MHC class

1316
3061
CD8SP-EBNA3c-315-(vL-vH)-Myc-BBz-

I complex

P2A-K13-Flag-T2A-PAC

EBV-gp350

1317
3062
CD8SP-EBV-gp350-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

EGFR

1318
3063
CD8SP-EGFR1-vHH-Myc-BBz-P2A-

K13-Flag-T2A-PAC

EGFR & CEA

1319
3064
CD8SP-EGFR1-vHH-Gly-Ser-Linker-

CEA1-vHH-Myc-BBz-P2A-K13-Flag-

T2A-PAC

EGFR & CEA

1320
3065
CD8SP-EGFR33-vHH-Gly-Ser-Linker-

CEA5-vHH-Myc-BBz-P2A-K13-Flag-

T2A-PAC

EGFRvIII

1321
3066
CD8SP-EGFRvIII-139-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

EGFRvIII

1322
3067
CD8SP-EGFRvIII-2173-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

EpCam1

1323
3068
CD8SP-Epcam1-MM1-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

EpCam1

1324
3069
CD8SP-Epcam1-D5K5-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

FLT3

1325
3070
CD8SP-FLT3-NC7-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

FITC

1326
3071
CD8SP-FITC-(vL-vH)-Myc-BBz-P2A-

K13-Flag-T2A-PAC

FITC

1327
3072
CD8SP-FITC-4M-53-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

FITC

1328
3073
CD8SP-FITC-E2-HL-(vH-vL)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

Influenza A HA

1329
3074
CD8SP-FLU-MEDI-8852-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

FR1 (Folate

1330
3075
CD8SP-FR1-huMov19-(vL-vH)-Myc-

Receptor alpha)

BBz-P2A-K13-Flag-T2A-PAC

FSHR (Follicle

1331
3076
CD8SP-FSHb-Gly-Ser-Linker-CGHa-

Stimulating

Myc-BBz-P2A-K13-Flag-T2A-PAC

Hormone Receptor)

GAD (Glutamic

1332
3077
CD8SP-GAD-G3H8-(vL-vH)-Myc-BBz-

Acid

P2A-K13-Flag-T2A-PAC

Decarboxylase)/MHC

class I complex

GD2

1333
3078
CD8SP-GD2-hu14-18-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

GD2

1334
3079
CD8SP-GD2-hu3F8-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

GD3

1335
3080
CD8SP-GD3-KM-641-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

GFRa4 (GDNF

1336
3081
CD8SP-GFRAlpha4-P4-6-(vL-vH)-Myc-

Family Receptor

BBz-P2A-K13-Flag-T2A-PAC

Alpha 4)

GFRa4 (GDNF

1337
3082
CD8SP-GFRa4-P4-10-(vL-vH)-Myc-BBz-

Family Receptor

P2A-K13-Flag-T2A-PAC

Alpha 4)

GM1

1338
3083
CD8SP-GM1-5B2-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

GM1

1339
3084
CD8SP-GM1-7E5-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

GPRC5D (G-protein

1340
3085
CD8SP-GPRC5D-ET150-5-(vL-vH)-Myc-

coupled receptor

BBz-P2A-K13-Flag-T2A-PAC

family C group 5

member D)

GPRC5D

1341
3086
CD8SP-GPRC5D-ET150-18-(vL-vH)-

Myc-BBz-P2A-K13-Flag-T2A-PAC

GPRC5D

1342
3087
CD8SP-GPRC5D-ET150-1-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

GPRC5D

1343
3088
CD8SP-GPRC5D-ET150-2-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

gp100/MHC class I

1344
3089
CD8SP-gp100-(vL-vH)-Myc-BBz-P2A-

complex

K13-Flag-T2A-PAC

gp100/MHC class I

1345
3090
CD8SP-gp100-G2D12-(vL-vH)-Myc-BBz-

complex

P2A-K13-Flag-T2A-PAC

GPC3 (Glypican 3)

1346
3091
CD8SP-GPC3-4E5-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

gpNMB

1347
3092
CD8SP-gpNMB-115-(vL-vH)-Myc-BBz-

(Glycoprotein Nmb)

P2A-K13-Flag-T2A-PAC

GRP78

1348
3093
CD8SP-GRP78-GC18-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

Her2

1349
3094
CD8SP-Her2-5F7-vHH-Myc-BBz-P2A-

K13-Flag-T2A-PAC

Her2

1350
3095
IgHSP-Her2-Affi-Myc-BBz-P2A-K13-

Flag-T2A-PAC

Her2

1351
3096
CD8SP-Her2-1-Darpin-Myc-BBz-P2A-

K13-Flag-T2A-PAC

Her2

1352
3097
IgHSP-Her2-2-Darpin-Myc-BBz-P2A-

K13-Flag-T2A-PAC

Her2

1353
3098
CD8SP-Her2-5F7-vHH-Gly-Ser-Linker-

Her2-47D5-vHH-Myc-BBz-P2A-K13-

Flag-T2A-PAC

Her2

1354
3099
CD8SP-Her2-Hu4D5-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

Her3

1355
3100
CD8SP-Her3-17B05So-vHH-Myc-BBz-

P2A-K13-Flag-T2A-PAC

Her3

1356
3101
CD8SP-Her3-Affi-Myc-BBz-P2A-K13-

Flag-T2A-PAC

Her2 and Her3

1357
3102
CD8SP-Her3-17B05So-vHH-Gly-Ser-

Linker-Her2-2D3-vHH-Myc-BBz-P2A-

K13-Flag-T2A-PAC

HIV1-gag/MHC

1358
3103
CD8SP-HIV1-E5-(vL-vH)-Myc-BBz-

class I complex

P2A-K13-Flag-T2A-PAC

HIV1-envelop

1359
3104
CD8SP-HIV1-3BNC117-(vL-vH)-Myc-

glycoprotein

BBz-P2A-K13-Flag-T2A-PAC

HIV1-envelop

1360
3105
CD8SP-HIV1-PGT-128-(vL-vH)-Myc-

glycoprotein

BBz-P2A-K13-Flag-T2A-PAC

HIV1-envelop

1361
3106
CD8SP-HIV1-VR-C01-(vL-vH)-Myc-

glycoprotein

BBz-P2A-K13-Flag-T2A-PAC

HIV1-envelop

1362
3107
CD8SP-HIV1-X5-(vL-vH)-Myc-BBz-

glycoprotein

P2A-K13-Flag-T2A-PAC

HLA-A2

1363
3108
CD8SP-HLA-A2-3PB2-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

HMW-MAA

1364
3109
CD8SP-HMW-MAA-hIND-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

HPV16-E7/MHC

1365
3110
CD8SP-HPV16-7-8-(vL-vH)-Myc-BBz-

class I complex

P2A-K13-Flag-T2A-PAC

HPV16-E7/MHC

1366
3111
CD8SP-HPV16-2-(vL-vH)-Myc-BBz-

class I complex

P2A-K13-Flag-T2A-PAC

HTLV1-TAX/MHC

1367
3112
CD8SP-HTLV-TAX-T3F2-(vL-vH)-Myc-

class I complex

BBz-P2A-K13-Flag-T2A-PAC

HTLV1-TAX/MHC

1368
3113
CD8SP-HTLV-TAX-T3E3-(vL-vH)-Myc-

class I complex

BBz-P2A-K13-Flag-T2A-PAC

IL11Ra

1369
3114
CD8SP-IL11Ra-8E2-Ts107-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

IL6Ra

1370
3115
IgHSP-IL6R-304-vHH-Myc-BBz-P2A-

K13-Flag-T2A-PAC

IL13Ra2

1371
3116
CD8SP-IL13Ra2-hu107-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

IL13Ra2

1372
3117
CD8SP-IL13Ra2-Hu108-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

KSHV-K8.1

1373
3118
CD8SP-KSHV-4C3-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

LAMP1

1374
3119
CD8SP-LAMP1-humab1-2-(vL-vH)-Myc-

(Lysosomal-

BBz-P2A-K13-Flag-T2A-PAC

associated

membrane protein 1)

LAMP1

1375
3120
CD8SP-LAMP1-Mb4-(vL-vH)-Myc-BBz-

(Lysosomal-

P2A-K13-Flag-T2A-PAC

associated

membrane protein 1)

LewisY

1376
3121
CD8SP-LewisY-huS193-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

L1CAM

1377
3122
CD8SP-L1CAM-9-3-HU3-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

LHR

1378
3123
SP-LHb-Gly-Ser-Linker-CGHa-Myc-BBz-

P2A-K13-Flag-T2A-PAC

Lym1

1379
3124
CD8SP-Lym1-(vL-vH)-Myc-BBz-P2A-

K13-Flag-T2A-PAC

Lym2

1380
3125
CD8SP-Lym2-(vL-vH)-Myc-BBz-P2A-

K13-Flag-T2A-PAC

CD79b

1381
3126
CD8SP-huMA79bv28-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

MART1/MHC class

1382
3127
CD8SP-MART1-CAG10-(vL-vH)-Myc-

I complex

BBz-P2A-K13-Flag-T2A-PAC

MART1/MHC class

1383
3128
CD8SP-MART1-CLA12-(vL-vH)-Myc-

I complex

BBz-P2A-K13-Flag-T2A-PAC

Mesothelin

1384
3129
CD8SP-Mesothelin-m912-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

cMet

1385
3130
CD8SP-cMet-171-vHH-Myc-BBz-P2A-

K13-Flag-T2A-PAC

cMet and Her3

1386
3131
CD8SP-cMET-171-vHH-Gly-Ser-Linker-

Her3-21F06-vHH-Myc-BBz-P2A-K13-

Flag-T2A-PAC

MPL

1387
3132
CD8SP-MPL-175-(vL-vH)-Myc-BBz-

(Thrombopoietin

P2A-K13-Flag-T2A-PAC

receptor)

MPL

1388
3133
CD8SP-MPL-161-(vL-vH)-Myc-BBz-

(Thrombopoietin

P2A-K13-Flag-T2A-PAC

receptor)

MPL

1389
3134
CD8SP-MPL-161-HL-(vH-vL)-Myc-BBz-

(Thrombopoietin

P2A-K13-Flag-T2A-PAC

receptor)

MPL

1390
3135
CD8SP-2-MPL-111-(vL-vH)-Myc-BBz-

(Thrombopoietin

P2A-K13-Flag-T2A-PAC

receptor)

MPL

1391
3136
CD8SP-MPL-178-(vL-vH)-Myc-BBz-

(Thrombopoietin

P2A-K13-Flag-T2A-PAC

receptor)

MPL

1392
3137
CD8SP-MPL-AB317-(vL-vH)-Myc-BBz-

(Thrombopoietin

P2A-K13-Flag-T2A-PAC

receptor)

MPL

1393
3138
CD8SP-MPL-12E10-(vL-vH)-Myc-BBz-

(Thrombopoietin

P2A-K13-Flag-T2A-PAC

receptor)

MPL

1394
3139
CD8SP-MPL-huVB22Bw5-(vL-vH)-Myc-

(Thrombopoietin

BBz-P2A-K13-Flag-T2A-PAC

receptor)

Muc1/MHC class I

1395
3140
CD8SP-Muc1-D6-M3B8-(vL-vH)-Myc-

complex

BBz-P2A-K13-Flag-T2A-PAC

Muc1/MHC class I

1396
3141
CD8SP-MUC1-D6-M3A1-(vL-vH)-Myc-

complex

BBz-P2A-K13-Flag-T2A-PAC

Muc16

1397
3142
CD8SP-Muc16-4H11-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

EGFR

1398
3143
CD8SP-Nimotuzumab-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

NKG2D Ligand

1399
3144
CD8SP-NKG2D-(GGGGS-GGGGD)-

Myc-BBz-P2A-K13-Flag-T2A-PAC

NKG2D

1400
3145
CD8SP-NKG2D-MS-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

NY-BR1

1401
3146
CD8SP-NYBR1-(vL-vH)-Myc-BBz-P2A-

K13-Flag-T2A-PAC

NY-ESO/MHC class

1402
3147
CD8SP-NYESO-T1-(vL-vH)-Myc-BBz-

I complex

P2A-K13-Flag-T2A-PAC

NY-ESO/MHC class

1403
3148
CD8SP-NYESO-T2-(vL-vH)-Myc-BBz-

I complex

P2A-K13-Flag-T2A-PAC

PD1 ligand (e.g.,

1404
3149
CD8SP-PD1-ECD-Myc-BBz-P2A-K13-

PDL1)

Flag-T2A-PAC

PDL1

1405
3150
CD8SP-PDL1-Atezoli-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

PDL1

1406
3151
CD8SP-PDL1-SP142-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

PDL1

1407
3152
CD8SP-PDL1-10A5-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

PSCA (Prostate stem

1408
3153
CD8SP-PSCA-Ha14-121-(vL-vH)-Myc-

cell antigen)

BBz-P2A-K13-Flag-T2A-PAC

PSCA (Prostate stem

1409
3154
CD8SP-PSCA-Ha14-117-(vL-vH)-Myc-

cell antigen)

BBz-P2A-K13-Flag-T2A-PAC

PR1/MHC class I

1410
3155
CD8SP-PR1-(vL-vH)-Myc-BBz-P2A-

complex

K13-Flag-T2A-PAC

PSMA (Prostate

1411
3156
CD8SP-PSMA-006-(vL-vH)-Myc-BBz-

Specific Membrane

P2A-K13-Flag-T2A-PAC

Antigen)

PSMA (Prostate

1412
3157
CD8SP-PSMA-J591-(vL-vH)-Myc-BBz-

Specific Membrane

P2A-K13-Flag-T2A-PAC

Antigen)

PTK7 (Tyrosine-

1413
3158
CD8SP-PTK7-hSC6-23-(vL-vH)-Myc-

protein kinase-like 7)

BBz-P2A-K13-Flag-T2A-PAC

PTK7 (Tyrosine-

1414
3159
CD8SP-PTK7-SC6-10-2-(vL-vH)-Myc-

protein kinase-like 7)

BBz-P2A-K13-Flag-T2A-PAC

ROR1

1415
3160
CD8SP-ROR1-4A5-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

ROR1

1416
3161
CD8SP-ROR1-4C10-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

Mesothelin

1417
3162
CD8SP-SD1-vHH-Gly-Ser-Linker-SD2-

vHH-Myc-BBz-P2A-K13-Flag-T2A-PAC

SLea

1418
3163
CD8SP-SLea-7E3-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

SLea

1419
3164
CD8SP-SLea-5B1-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

SSEA4 (stage-

1420
3165
CD8SP-SSEA4-(vL-vH)-Myc-BBz-P2A-

specific embryonic

K13-Flag-T2A-PAC

antigen 4)

TCRB1 (TCR beta 1

1421
3166
CD8SP-TCRB1-CP01-E09-(vL-vH)-Myc-

constant chain)

BBz-P2A-K13-Flag-T2A-PAC

TCRB1 (TCR beta 1

1422
3167
CD8SP-TCRB1-Jovi1-(vL-vH)-Myc-BBz-

constant chain)

P2A-K13-Flag-T2A-PAC

TCRB2 (TCR beta 2

1423
3168
CD8SP-TCRB2-CP01-D05-(vL-vH)-Myc-

constant chain)

BBz-P2A-K13-Flag-T2A-PAC

TCRB2 (TCR beta 2

1424
3169
CD8SP-TCRB2-CP01-E05-(vL-vH)-Myc-

constant chain)

BBz-P2A-K13-Flag-T2A-PAC

TCRgd (TCR

1425
3170
CD8SP-TCRgd-G5-4-(vL-vH)-Myc-BBz-

gamma/delta)

P2A-K13-Flag-T2A-PAC

hTERT/MHC class I

1426
3171
CD8SP-TERT-4A9-T540-(vL-vH)-Myc-

complex

BBz-P2A-K13-Flag-T2A-PAC

hTERT/MHC class I

1427
3172
CD8SP-TERT-3G3-T865-(vL-vH)-Myc-

complex

BBz-P2A-K13-Flag-T2A-PAC

Tissue Factor-1

1428
3173
CD8SP-TGFBR2-Ab1-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

TGFBR2

1429
3174
CD8SP-TF1-98-(vL-vH)-Myc-BBz-P2A-

K13-Flag-T2A-PAC

TIM1/HAVCR

1430
3175
CD8SP-TIM1-HVCR1-270-2-(vL-vH)-

Myc-BBz-P2A-K13-Flag-T2A-PAC

TIM1/HAVCR

1431
3176
CD8SP-TIM1-HVCR1-ARD5-(vL-vH)-

Myc-BBz-P2A-K13-Flag-T2A-PAC

TnAg

1432
3177
CD8SP-TnAg-(vL-vH)-Myc-BBz-P2A-

K13-Flag-T2A-PAC

Tn-Muc1

1433
3178
CD8SP-TnMuc1-hu5E5-RHA8-RKA-2-

(vL-vH)-Myc-BBz-P2A-K13-Flag-T2A-

PAC

MPL

1434
3179
CD8SP-hTPO-Myc-BBz-P2A-K13-Flag-

(Thrombopoietin

T2A-PAC

receptor)

TROP2 (Trophoblast

1435
3180
CD8SP-TROP2-ARA47-HV3KV3-(vL-

cell-surface antigen-2)

vH)-Myc-BBz-P2A-K13-Flag-T2A-PAC

TROP2

1436
3181
CD8SP-TROP2-h7E6-SVG-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

TSHR (Thyrotropin

1437
3182
SP-TSHb-Gly-Ser-Linker-CGHa-Myc-

receptor)

BBz-P2A-K13-Flag-T2A-PAC

TSHR

1438
3183
CD8SP-TSHR-K1-70-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

TSHR

1439
3184
CD8SP-TSHR-KB1-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

TSHR

1440
3185
CD8SP-TSHR-5C9-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

TSLPR (Thymic

1441
3186
CD8SP-TSLPR-(vL-vH)-Myc-BBz-P2A-

stromal

K13-Flag-T2A-PAC

lymphopoietin

receptor)

Tyrosinase/MHC

1442
3187
CD8SP-Tyros-B2-(vL-vH)-Myc-BBz-

class I complex

P2A-K13-Flag-T2A-PAC

Tyrosinase/MHC

1443
3188
CD8SP-Tyros-MC1-(vL-vH)-Myc-BBz-

class I complex

P2A-K13-Flag-T2A-PAC

Tyrosinase/MHC

1444
3189
CD8SP-Tyros-TA2-(vL-vH)-Myc-BBz-

class I complex

P2A-K13-Flag-T2A-PAC

VEGFR3

1445
3190
CD8SP-VEGFR3-Ab1-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

WT1/MHC class I

1446
3191
CD8SP-WT1-Ab1-(vL-vH)-Myc-BBz-

complex

P2A-K13-Flag-T2A-PAC

WT1/MHC class I

1447
3192
CD8SP-WT1-Ab5-(vL-vH)-Myc-BBz-

complex

P2A-K13-Flag-T2A-PAC

WT1/MHC class I

1448
3193
CD8SP-MYC3-WT1-Ab13-(vL-vH)-Myc-

complex

BBz-P2A-K13-Flag-T2A-PAC

WT1/MHC class I

1449
3194
CD8SP-MYC3-WT1-Ab15-(vL-vH)-Myc-

complex

BBz-P2A-K13-Flag-T2A-PAC

CDH19

1450
3195
CD8SP-CDH19-4B10-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

Folate Receptor beta

1451
3196
CD8SP-FRbeta-m923-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

LHR (Luteinizing

1452
3197
CD8SP-LHR-8B7-(vL-vH)-Myc-BBz-

hormone Receptor)

P2A-K13-Flag-T2A-PAC

LHR (Luteinizing

1453
3198
CD8SP-LHR-5F4-21-(vL-vH)-Myc-BBz-

hormone Receptor)

P2A-K13-Flag-T2A-PAC

B7H4

1454
3199
CD8SP-B7H4-hu22Cl0-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

B7H4

1455
3200
CD8SP-B7H4-hu1D11-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

IgE

1456
3201
CD8SP-IgE-omalizumab-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD23

1457
3202
CD8SP-CD23-p5E8-(vL-vH)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

GCC (Guanylyl

1458
3203
CD8SP-GCC-5F9-(vL-vH)-Myc-BBz-

cyclase C)

P2A-K13-Flag-T2A-PAC

GCC (Guanylyl

1459
3204
CD8SP-GCC-Ab229-(vL-vH)-Myc-BBz-

cyclase C)

P2A-K13-Flag-T2A-PAC

CD200R

1460
3205
CD8SP-CD200R-huDx182-(vL-vH)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

Tn-Muc1

1461
3206
CD8SP-Tn-Muc1-5E5-HL-(vH-vL)-Myc-

BBz-P2A-K13-Flag-T2A-PAC

CD22

1462
3207
CD8SP-CD22-5-HL-(vH-vL)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD22

1463
3208
CD8SP-CD22-10-HL-(vH-vL)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD22

1464
3209
CD8SP-CD22-31-HL-(vH-vL)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD22

1465
3210
CD8SP-CD22-53-HL-(vH-vL)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

CD22

1466
3211
CD8SP-CD22-65-HL-(vH-vL)-Myc-BBz-

P2A-K13-Flag-T2A-PAC

TABLE 21

Exemplary CAR constructs containing 41BB costimulatory domain,

CD3z activation domain

SEQ ID
SEQ ID

Target
Clone ID
(DNA)
(PRT)
CONSTRUCT NAME

CD19
112014-
1467
3212
CD8SP-FMC63-(vL-vH)-Myc-

A13

BBz-T2A-PAC

CD19
052616-
1468
3213
CD8SP-huFMC63-11-(vL-vH)-

T03

Myc-BBz-T2A-PAC

CD19

1469
3214
CD8SP-huFMC63-11-N203Q-(vL-

vH)-Myc-BBz-T2A-PAC

CD19
082815-
1470
3215
CD8SP-CD19Bu12-(vL-vH)-Myc-

P08

BBz-T2A-PAC

CD19
062915-
1471
3216
CD8SP-2-CD19MM-(vL-vH)-Myc-

D03

BBz-T2A-PAC

CD19

1472
3217
CD8SP-CD19-4G7-(vL-vH)-Myc-

BBz-T2A-PAC

CD19

1473
3218
CD8SP-CD19-MEDI-3649-(vL-

vH)-Myc-BBz-T2A-PAC

CD19

1474
3219
CD8SP-CD19-Medrex-24D1-(vL-

vH)-Myc-BBz-T2A-PAC

CD19

1475
3220
CD8SP-Ritx-CD19-MOR0028-(vL-

vH)-Myc-BBz-T2A-PAC

CD19

1476
3221
CD8SP-CD19-HD37-H2L1-(vL-

vH)-Myc-BBz-T2A-PAC

CD19

1477
3222
CD8SP-CD19-huBly3-(vL-vH)-

Myc-BBz-T2A-PAC

CD19

1478
3223
CD8SP-CD19-huSJ25C1-(vL-vH)-

Myc-BBz-T2A-PAC

CD19

1479
3224
CD8SP-Ritx-CD19-hB4-(vL-vH)-

Myc-BBz-T2A-PAC

CD19

1480
3225
CD8SP-CD19-hu-mROO5-1-(vL-

vH)-Myc-BBz-T2A-PAC

CD19

1481
3226
CD8SP-CD19-hA19-(vL-vH)-Myc-

BBz-T2A-PAC

AFP/MHC class I

1482
3227
CD8SP-AFP-61-(vL-vH)-Myc-

complex

BBz-T2A-PAC

AFP/MHC class I

1483
3228
CD8SP-AFP-76-(vL-vH)-Myc-

complex

BBz-T2A-PAC

AFP/MHC class I

1484
3229
CD8SP-AFP-79-(vL-vH)-Myc-

complex

BBz-T2A-PAC

HIV1-envelop

1485
3230
CD8SP-HIV1-N6-(vL-vH)-Myc-

glycoprotein

BBz-T2A-PAC

ALK (Anaplastic
052616-
1486
3231
CD8SP-Alk-48-(vL-vH)-Myc-BBz-

Lymphoma Kinase)
C05

T2A-PAC

ALK (Anaplastic

1487
3232
CD8SP-Alk-58-(vL-vH)-Myc-BBz-

Lymphoma Kinase)

T2A-PAC

Amyloid

1488
3233
SP-Amyloid-158-(vL-vH)-Myc-

BBz-T2A-PAC

Biotin
052616-I05
1489
3234
CD8SP-dc-Avidin-Myc-BBz-T2A-

PAC

CD45

1490
3235
CD8SP-BC8-CD45-(vL-vH)-Myc-

BBz-T2A-PAC

BCMA

1491
3236
CD8SP-BCMA-J6M0-(vL-vH)-

Myc-BBz-T2A-PAC

BCMA
123015-J03
1492
3237
CD8SP-BCMA-huC12A3-L3H3-

(vL-vH)-Myc-BBz-T2A-PAC

BCMA

1493
3238
CD8SP-BCMA-ET-40-(vL-vH)-

Myc-BBz-T2A-PAC

BCMA

1494
3239
CD8SP-BCMA-ET-54-(vL-vH)-

Myc-BBz-T2A-PAC

BCMA

1495
3240
CD8SP-BCMA-ET-03-(vL-vH)-

Myc-BBz-T2A-PAC

BCMA

1496
3241
CD8SP-BCMA-huC11.D5.3L1H3-

(vL-vH)-Myc-BBz-T2A-PAC

BCMA

1497
3242
CD8SP-BCMA-huC13-F12-(vL-

vH)-Myc-BBz-T2A-PAC

CCR4

1498
3243
CD8SP-CCR4-humAb1567-(vL-

vH)-Myc-BBz-T2A-PAC

HIV1-envelop

1499
3244
CD8SP-CD4-ECD-Gly-Ser-Linker-

glycoprotein

DC-SIGN-Myc-BBz-T2A-PAC

CD5
031416-
1500
3245
CD8SP-CD5-9-(vL-vH)-Myc-BBz-

B03

T2A-PAC

CD5
031416-
1501
3246
CD8SP-CD5-18-(vL-vH)-Myc-

A04

BBz-T2A-PAC

Ig Fc

1502
3247
CD8SP-CD16A-V158-ECD-v2-

Myc-BBz-T2A-PAC

Ig Fc

1503
3248
CD8SP-CD16A-V158-ECD-v1-

Myc-BBz-T2A-PAC

CD20
081115-
1504
3249
CD8SP-CD20-2F2-(vL-vH)-Myc-

Y02 and

BBz-T2A-PAC

081115-

B01

CD20
111815-
1505
3250
CD8SP-CD20-GA101-(vL-vH)-

A03

Myc-BBz-T2A-PAC

CD20

1506
3251
CD8SP-CD20-Leu16-(vL-vH)-

Myc-BBz-T2A-PAC

CD20

1507
3252
CD8SP-CD20-11B8-(vL-vH)-Myc-

BBz-T2A-PAC

CD20

1508
3253
CD8SP-CD20-2C6-(vL-vH)-Myc-

BBz-T2A-PAC

CD20

1509
3254
CD8SP-CD20-2H7-(vL-vH)-Myc-

BBz-T2A-PAC

CD20

1510
3255
CD8SP-CD20-hA20-(vL-vH)-Myc-

BBz-T2A-PAC

CD20

1511
3256
CD8SP-CD20-BM-CA-1925-v4-

(vL-vH)-Myc-BBz-T2A-PAC

CD20

1512
3257
CD8SP-CD20-Ubli-v4-(vL-vH)-

Myc-BBz-T2A-PAC

CD20

1513
3258
CD8SP-CD20-2H7-(vL-vH)-Myc-

BBz-T2A-PAC

CD20

1514
3259
CD8SP-CD20-h1F5-(vL-vH)-Myc-

BBz-T2A-PAC

CD20

1515
3260
CD8SP-CD20-7D8-(vL-vH)-Myc-

BBz-T2A-PAC

CD20

1516
3261
CD8SP-CD20-AME-33-(vL-vH)-

Myc-BBz-T2A-PAC

CD22
052616-
1517
3262
CD8SP-CD22-h10F4v2-(vL-vH)-

H04 &

Myc-BBz-T2A-PAC

052516-I07

CD22
052316-
1518
3263
CD8SP-CD22-

H07

H22Rhov2ACDRKA-(vL-vH)-

Myc-BBz-T2A-PAC

CD22
091515-
1519
3264
CD8SP-CD22-m971-(vL-vH)-Myc-

A02

BBz-T2A-PAC

CD22

1520
3265
CD8SP-CD22-m971-HL-(vH-vL)-

Myc-BBz-T2A-PAC

CD30

1521
3266
CD8SP-CD30-5F11-(vL-vH)-Myc-

BBz-T2A-PAC

CD30
012216-
1522
3267
CD8SP-CD30-Ac10-(vL-vH)-Myc-

H04

BBz-T2A-PAC

CD32
060916-
1523
3268
CD8SP-CD32-Med9-(vL-vH)-Myc-

A02

BBz-T2A-PAC

CD33

1524
3269
CD8SP-CD33-AF5-(vL-vH)-Myc-

BBz-T2A-PAC

CD33
111815-
1525
3270
CD8SP-CD33-huMyc9-(vL-vH)-

C07

Myc-BBz-T2A-PAC

CD33

1526
3271
CD8SP-CD33-Boehr2800308-(vL-

vH)-Myc-BBz-T2A-PAC

CD33

1527
3272
CD8SP-CD33-Him3-4-(vL-vH)-

Myc-BBz-T2A-PAC

CD33

1528
3273
CD8SP-CD33-SGNh2H12-(vL-

vH)-Myc-BBz-T2A-PAC

CD33

1529
3274
CD8SP-CD33-15G15-33-(vL-vH)-

Myc-BBz-T2A-PAC

CD33

1530
3275
CD8SP-CD33-33H4-(vL-vH)-Myc-

BBz-T2A-PAC

CD33

1531
3276
CD8SP-CD33-9C3-2-(vL-vH)-

Myc-BBz-T2A-PAC

CD34
052316-I03
1532
3277
CD8SP-CD34-hu4C7-(vL-vH)-

& 052616-

Myc-BBz-T2A-PAC

H06

CD44v6

1533
3278
CD8SP-CD44v6-Biwa8-(vL-vH)-

Myc-BBz-T2A-PAC

CD70

1534
3279
CD8SP-CD70-h1F6-(vL-vH)-Myc-

BBz-T2A-PAC

CD79b
111815-
1535
3280
CD8SP-CD79b-2F2-(vL-vH)-Myc-

B04

BBz-T2A-PAC

CD79b

1536
3281
CD8SP-huMA79bv28-(vL-vH)-

Myc-BBz-T2A-PAC

CD99

1537
3282
CD8SP-CD99-hu12E7-(vL-vH)-

Myc-BBz-T2A-PAC

CD123
081115-
1538
3283
CD8SP-CD123-CSL362-(vL-vH)-

X01

Myc-BBz-T2A-PAC

CD123

1539
3284
CD8SP-CD123-1172-(vL-vH)-

Myc-BBz-T2A-PAC

CD123

1540
3285
CD8SP-CD123-DART-1-(vL-vH)-

Myc-BBz-T2A-PAC

CD123

1541
3286
CD8SP-CD123-DART-2-(vL-vH)-

Myc-BBz-T2A-PAC

CD123

1542
3287
CD8SP-CD123-I3RB18-(vL-vH)-

Myc-BBz-T2A-PAC

CD123

1543
3288
CD8SP-CD123-hu3E3-(vL-vH)-

Myc-BBz-T2A-PAC

CD123

1544
3289
CD8SP-CD123-9F6-(vL-vH)-Myc-

BBz-T2A-PAC

CD123

1545
3290
CD8SP-CD123-I3RB2-(vL-vH)-

Myc-BBz-T2A-PAC

CD123

1546
3291
CD8SP-CD123-1176-(vL-vH)-

Myc-BBz-T2A-PAC

CD123

1547
3292
CD8SP-Ritx2-CD123-8B11-(vL-

vH)-Myc-BBz-T2A-PAC

CD123

1548
3293
CD8SP-CD123-2B8-(vL-vH)-Myc-

BBz-T2A-PAC

CD123

1549
3294
CD8SP-CD123-9D7-(vL-vH)-Myc-

BBz-T2A-PAC

CD123

1550
3295
CD8SP-CD123-3B10-(vL-vH)-

Myc-BBz-T2A-PAC

CD138
041715-
1551
3296
CD8SP-CD138-(vL-vH)-Myc-BBz-

D08

T2A-PAC

CD179b

1552
3297
CD8SP-CD179b-(vL-vH)-Myc-

BBz-T2A-PAC

CD276
052316-
1553
3298
CD8SP-CD276-17-(vL-vH)-Myc-

C05

BBz-T2A-PAC

CD324
052516-
1554
3299
CD8SP-CD32410-6-(vL-vH)-Myc-

B02

BBz-T2A-PAC

CD324
052516-
1555
3300
CD8SP-CD324-hSC10-17-(vL-

A07

vH)-Myc-BBz-T2A-PAC

CDH6

1556
3301
CD8SP-CDH6-NOV710-(vL-vH)-

Myc-BBz-T2A-PAC

CDH6

1557
3302
CD8SP-CDH6-NOV712-(vL-vH)-

Myc-BBz-T2A-PAC

CDH17

1558
3303
CD8SP-CDH17-PTA001A4-(vL-

vH)-Myc-BBz-T2A-PAC

CDH19

1559
3304
CD8SP-CDH19-16A4-(vL-vH)-

Myc-BBz-T2A-PAC

EGFR

1560
3305
CD8SP-Cetuximab-(vL-vH)-Myc-

BBz-T2A-PAC

CLEC5A

1561
3306
CD8SP-CLEC5A-8H8F5-(vL-vH)-

Myc-BBz-T2A-PAC

CLEC5A
052316-
1562
3307
CD8SP-CLEC5A-3E12A2-(vL-

G04

vH)-Myc-BBz-T2A-PAC

GR/LHR (Gonadotropin

1563
3308
SP-CGHb-Gly-Ser-Linker-CGHa-

Receptor)

Myc-BBz-T2A-PAC

CLL1
110215-
1564
3309
CD8SP-CLL1-M26-(vL-vH)-Myc-

H06

BBz-T2A-PAC

CLL1
110215-I08
1565
3310
CD8SP-CLL1-M32-(vL-vH)-Myc-

BBz-T2A-PAC

CLL1

1566
3311
CD8SP-CLL1-21C9-L2H3-(vL-

vH)-Myc-BBz-T2A-PAC

CLL1

1567
3312
CD8SP-CLL1-6E7L4H1e-(vL-vH)-

Myc-BBz-T2A-PAC

CLL1

1568
3313
CD8SP-CLL1-hu1075-v1-(vL-vH)-

Myc-BBz-T2A-PAC

CLL1

1569
3314
CD8SP-CLL1-hu1075-v2-(vL-vH)-

Myc-BBz-T2A-PAC

CMVpp65/MHC class I

1570
3315
CD8SP-CMVpp65-F5-(vL-vH)-

complex

Myc-BBz-T2A-PAC

CS1 (SLAMF7)

1571
3316
CD8SP-CS1-huLuc63-(vL-vH)-

Myc-BBz-T2A-PAC

CS1 (SLAMF7)
052616-
1572
3317
CD8SP-CS1-HuLuc64-(vL-vH)-

U05

Myc-BBz-T2A-PAC

CS1 (SLAMF7)

1573
3318
CD8SP-CS1-Luc90-(vL-vH)-Myc-

BBz-T2A-PAC

CS1 (SLAMF7)

1574
3319
CD8SP-CS1-PDL241-(vL-vH)-

Myc-BBz-T2A-PAC

CS1 (SLAMF7)

1575
3320
CD8SP-CS1-Hu27A-(vL-vH)-Myc-

BBz-T2A-PAC

CS1 (SLAMF7)

1576
3321
CD8SP-CS1Hu34C3-(vL-vH)-

Myc-BBz-T2A-PAC

CS1 (SLAMF7)

1577
3322
CD8SP-CS1-Hu31-D2-(vL-vH)-

Myc-BBz-T2A-PAC

CS1(SLAMF7)

1578
3323
CD8SP-CS1-Luc34-(vL-vH)-Myc-

BBz-T2A-PAC

CS1 (SLAMF7)

1579
3324
CD8SP-CS1-LucX2-(vL-vH)-Myc-

BBz-T2A-PAC

CSF2RA
052616-
1580
3325
CD8SP-CSF2RA-Ab6-(vL-vH)-

G03

Myc-BBz-T2A-PAC

CSF2RA

1581
3326
CD8SP-CSF2RA-Ab1-(vL-vH)-

Myc-BBz-T2A-PAC

CXCR4 and CD123

1582
3327
CD8SP-CXCR4-1-vHH-Gly-Ser-

Linker-CD123-1-vHH-Myc-BBz-

T2A-PAC

CXCR4 and CD123

1583
3328
CD8SP-CXCR4-2-VHH-Gly-Ser-

Linker-CD123-2-VHH-Myc-BBz-

T2A-PAC

DLL3 (Delta Like
052516-
1584
3329
CD8SP-DLL3-hSC16-13-(vL-vH)-

Ligand 3)
D07

Myc-BBz-T2A-PAC

DLL3 (Delta Like
052516-
1585
3330
CD8SP-DLL3-hSC16-56-(vL-vH)-

Ligand 3)
C07

Myc-BBz-T2A-PAC

EBNA3c/MHC class I

1586
3331
CD8SP-EBNA3c-315-(vL-vH)-

complex

Myc-BBz-T2A-PAC

EBV-gp350

1587
3332
CD8SP-EBV-gp350-(vL-vH)-Myc-

BBz-T2A-PAC

EGFR

1588
3333
CD8SP-EGFR1-vHH-Myc-BBz-

T2A-PAC

EGFR & CEA

1589
3334
CD8SP-EGFR1-vHH-Gly-Ser-

Linker-CEA1-vHH-Myc-BBz-T2A-

PAC

EGFR & CEA

1590
3335
CD8SP-EGFR33-vHH-Gly-Ser-

Linker-CEA5-vHH-Myc-BBz-T2A-

PAC

EGFRvIII
081115-
1591
3336
CD8SP-EGFRvIII-139-(vL-vH)-

A02

Myc-BBz-T2A-PAC

EGFRvIII
081115-
1592
3337
CD8SP-EGFRvIII-2173-(vL-vH)-

E01

Myc-BBz-T2A-PAC

EpCam1

1593
3338
CD8SP-Epcam1-MM1-(vL-vH)-

Myc-BBz-T2A-PAC

EpCam1
111915-
1594
3339
CD8SP-Epcam1-D5K5-(vL-vH)-

E05 &

Myc-BBz-T2A-PAC

112015-

C04

FLT3

1595
3340
CD8SP-FLT3-NC7-(vL-vH)-Myc-

BBz-T2A-PAC

FITC
052316-
1596
3341
CD8SP-FITC-(vL-vH)-Myc-BBz-

B01

T2A-PAC

FITC

1597
3342
CD8SP-FITC-4M-53-(vL-vH)-

Myc-BBz-T2A-PAC

FITC

1598
3343
CD8SP-FITC-E2-HL-(vH-vL)-

Myc-BBz-T2A-PAC

Influenza A HA

1599
3344
CD8SP-FLU-MEDI-8852-(vL-vH)-

Myc-BBz-T2A-PAC

FR1 (Folate Receptor
101215-
1600
3345
CD8SP-FR1-huMov19-(vL-vH)-

alpha)
A01

Myc-BBz-T2A-PAC

FSHR (Follicle

1601
3346
CD8SP-FSHb-Gly-Ser-Linker-

Stimulating Hormone

CGHa-Myc-BBz-T2A-PAC

Receptor)

GAD (Glutamic Acid

1602
3347
CD8SP-GAD-G3H8-(vL-vH)-Myc-

Decarboxylase)/MHC

BBz-T2A-PAC

class I complex

GD2
100515
1603
3348
CD8SP-GD2-hu14-18-(vL-vH)-

F01

Myc-BBz-T2A-PAC

GD2
052516-
1604
3349
CD8SP-GD2-hu3F8-(vL-vH)-Myc-

O08

BBz-T2A-PAC

GD3
052316-
1605
3350
CD8SP-GD3-KM-641-(vL-vH)-

A06

Myc-BBz-T2A-PAC

GFRa4 (GDNF Family

1606
3351
CD8SP-GFRAlpha4-P4-6-(vL-vH)-

Receptor Alpha 4)

Myc-BBz-T2A-PAC

GFRa4 (GDNF Family

1607
3352
CD8SP-GFRa4-P4-10-(vL-vH)-

Receptor Alpha 4)

Myc-BBz-T2A-PAC

GM1

1608
3353
CD8SP-GM1-5B2-(vL-vH)-Myc-

BBz-T2A-PAC

GM1

1609
3354
CD8SP-GM1-7E5-(vL-vH)-Myc-

BBz-T2A-PAC

GPRC5D (G-protein

1610
3355
CD8SP-GPRC5D-ET150-5-(vL-

coupled receptor family

vH)-Myc-BBz-T2A-PAC

C group 5 member D)

GPRC5D

1611
3356
CD8SP-GPRC5D-ET150-18-(vL-

vH)-Myc-BBz-T2A-PAC

GPRC5D

1612
3357
CD8SP-GPRC5D-ET150-1-(vL-

vH)-Myc-BBz-T2A-PAC

GPRC5D

1613
3358
CD8SP-GPRC5D-ET150-2-(vL-

vH)-Myc-BBz-T2A-PAC

gp100/MHC class I

1614
3359
CD8SP-gp100-(vL-vH)-Myc-BBz-

complex

T2A-PAC

gp100/MHC class I

1615
3360
CD8SP-gp100-G2D12-(vL-vH)-

complex

Myc-BBz-T2A-PAC

GPC3 (Glypican 3)

1616
3361
CD8SP-GPC3-4E5-(vL-vH)-Myc-

BBz-T2A-PAC

gpNMB (Glycoprotein

1617
3362
CD8SP-gpNMB-115-(vL-vH)-

Nmb)

Myc-BBz-T2A-PAC

GRP78

1618
3363
CD8SP-GRP78-GC18-(vL-vH)-

Myc-BBz-T2A-PAC

Her2

1619
3364
CD8SP-Her2-5F7-vHH-Myc-BBz-

T2A-PAC

Her2

1620
3365
IgHSP-Her2-Affi-Myc-BBz-T2A-

PAC

Her2

1621
3366
CD8SP-Her2-1-Darpin-Myc-BBz-

T2A-PAC

Her2

1622
3367
IgHSP-Her2-2-Darpin-Myc-BBz-

T2A-PAC

Her2

1623
3368
CD8SP-Her2-5F7-vHH-Gly-Ser-

Linker-Her2-47D5-vHH-Myc-BBz-

T2A-PAC

Her2

1624
3369
CD8SP-Her2-Hu4D5-(vL-vH)-

Myc-BBz-T2A-PAC

Her3

1625
3370
CD8SP-Her3-17B05So-vHH-Myc-

BBz-T2A-PAC

Her3

1626
3371
CD8SP-Her3-Affi-Myc-BBz-T2A-

PAC

Her2 and Her3
041316-B06
1627
3372
CD8SP-Her3-17B05So-vHH-Gly-

Ser-Linker-Her2-2D3-vHH-Myc-

BBz-T2A-PAC

HIV1-gag/MHC class I

1628
3373
CD8SP-HIV1-E5-(vL-vH)-Myc-

complex

BBz-T2A-PAC

HIV1-envelop

1629
3374
CD8SP-HIV1-3BNC117-(vL-vH)-

glycoprotein

Myc-BBz-T2A-PAC

HIV1-envelop

1630
3375
CD8SP-HIV1-PGT-128-(vL-vH)-

glycoprotein

Myc-BBz-T2A-PAC

HIV1-envelop

1631
3376
CD8SP-HIV1-VR-C01-(vL-vH)-

glycoprotein

Myc-BBz-T2A-PAC

HIV1-envelop

1632
3377
CD8SP-HIV1-X5-(vL-vH)-Myc-

glycoprotein

BBz-T2A-PAC

HLA-A2

1633
3378
CD8SP-HLA-A2-3PB2-(vL-vH)-

Myc-BBz-T2A-PAC

HMW-MAA
060116-
1634
3379
CD8SP-HMW-MAA-hIND-(vL-

B02

vH)-Myc-BBz-T2A-PAC

HPV16-E7/MHC class I
1635
3380

CD8SP-HPV16-7-8-(vL-vH)-Myc-

complex

BBz-T2A-PAC

HPV16-E7/MHC class I

1636
3381
CD8SP-HPV16-2-(vL-vH)-Myc-

complex

BBz-T2A-PAC

HTLV1-TAX/MHC

1637
3382
CD8SP-HTLV-TAX-T3F2-(vL-

class I complex

vH)-Myc-BBz-T2A-PAC

HTLV1-TAX/MHC

1638
3383
CD8SP-HTLV-TAX-T3E3-(vL-

class I complex

vH)-Myc-BBz-T2A-PAC

IL11Ra
052316-
1639
3384
CD8SP-IL11Ra-8E2-Ts107-(vL-

D02

vH)-Myc-BBz-T2A-PAC

IL6Ra

1640
3385
IgHSP-IL6R-304-vHH-Myc-BBz-

T2A-PAC

IL13Ra2
052616-
1641
3386
CD8SP-IL13Ra2-hu107-(vL-vH)-

B03

Myc-BBz-T2A-PAC

IL13Ra2

1642
3387
CD8SP-IL13Ra2-Hu108-(vL-vH)-

Myc-BBz-T2A-PAC

KSHV-K8.1
042315-
1643
3388
CD8SP-KSHV-4C3-(vL-vH)-Myc-

N01

BBz-T2A-PAC

LAMP1 (Lysosomal-

1644
3389
CD8SP-LAMP1-humab1-2-(vL-

associated membrane

vH)-Myc-BBz-T2A-PAC

protein 1)

LAMP1 (Lysosomal-

1645
3390
CD8SP-LAMP1-Mb4-(vL-vH)-

associated membrane

Myc-BBz-T2A-PAC

protein 1)

LewisY

1646
3391
CD8SP-LewisY-huS193-(vL-vH)-

Myc-BBz-T2A-PAC

L1CAM
052516-
1647
3392
CD8SP-L1CAM-9-3-HU3-(vL-

Q07

vH)-Myc-BBz-T2A-PAC

LHR

1648
3393
SP-LHb-Gly-Ser-Linker-CGHa-

Myc-BBz-T2A-PAC

Lym1

1649
3394
CD8SP-Lym1-(vL-vH)-Myc-BBz-

T2A-PAC

Lym2

1650
3395
CD8SP-Lym2-(vL-vH)-Myc-BBz-

T2A-PAC

CD79b

1651
3396
CD8SP-huMA79bv28-(vL-vH)-

Myc-BBz-T2A-PAC

MART1/MHC class I

1652
3397
CD8SP-MART1-CAG10-(vL-vH)-

complex

Myc-BBz-T2A-PAC

MART1/MHC class I

1653
3398
CD8SP-MART1-CLA12-(vL-vH)-

complex

Myc-BBz-T2A-PAC

Mesothelin
052516-
1654
3399
CD8SP-Mesothelin-m912-(vL-vH)-

P07

Myc-BBz-T2A-PAC

cMet

1655
3400
CD8SP-cMet-171-vHH-Myc-BBz-

T2A-PAC

cMet and Her3
041316-
1656
3401
CD8SP-cMET-171-vHH-Gly-Ser-

F06

Linker-Her3-21F06-vHH-Myc-

BBz-T2A-PAC

MPL (Thrombopoietin
022415-
1657
3402
CD8SP-MPL-175-(vL-vH)-Myc-

receptor)
Q05

BBz-T2A-PAC

MPL (Thrombopoietin

1658
3403
CD8SP-MPL-161-(vL-vH)-Myc-

receptor)

BBz-T2A-PAC

MPL (Thrombopoietin

1659
3404
CD8SP-MPL-161-HL-(vH-vL)-

receptor)

Myc-BBz-T2A-PAC

MPL (Thrombopoietin
041316-
1660
3405
CD8SP-2-MPL-111-(vL-vH)-Myc-

receptor)
A03

BBz-T2A-PAC

MPL (Thrombopoietin

1661
3406
CD8SP-MPL-178-(vL-vH)-Myc-

receptor)

BBz-T2A-PAC

MPL (Thrombopoietin

1662
3407
CD8SP-MPL-AB317-(vL-vH)-

receptor)

Myc-BBz-T2A-PAC

MPL (Thrombopoietin

1663
3408
CD8SP-MPL-12E10-(vL-vH)-Myc-

receptor)

BBz-T2A-PAC

MPL (Thrombopoietin

1664
3409
CD8SP-MPL-huVB22Bw5-(vL-

receptor)

vH)-Myc-BBz-T2A-PAC

Muc1/MHC class I
052316
1665
3410
CD8SP-Muc1-D6-M3B8-(vL-vH)-

complex
A02

Myc-BBz-T2A-PAC

Muc1/MHC class I

1666
3411
CD8SP-MUC1-D6-M3A1-(vL-

complex

vH)-Myc-BBz-T2A-PAC

Muc16
111915-
1667
3412
CD8SP-Muc16-4H11-(vL-vH)-

F04

Myc-BBz-T2A-PAC

EGFR

1668
3413
CD8SP-Nimotuzumab-(vL-vH)-

Myc-BBz-T2A-PAC

NKG2D Ligand

1669
3414
CD8SP-NKG2D-(GGGGS-

GGGGD)-Myc-BBz-T2A-PAC

NKG2D

1670
3415
CD8SP-NKG2D-MS-(vL-vH)-

Myc-BBz-T2A-PAC

NY-BR1

1671
3416
CD8SP-NYBR1-(vL-vH)-Myc-

BBz-T2A-PAC

NY-ESO/MHC class I

1672
3417
CD8SP-NYESO-T1-(vL-vH)-Myc-

complex

BBz-T2A-PAC

NY-ESO/MHC class I

1673
3418
CD8SP-NYESO-T2-(vL-vH)-Myc-

complex

BBz-T2A-PAC

PD1 ligand (e.g., PDL1)

1674
3419
CD8SP-PD1-ECD-Myc-BBz-T2A-

PAC

PDL1
100516-J03
1675
3420
CD8SP-PDL1-Atezoli-(vL-vH)-

Myc-BBz-T2A-PAC

PDL1
100516-
1676
3421
CD8SP-PDL1-SP142-(vL-vH)-

K03

Myc-BBz-T2A-PAC

PDL1

1677
3422
CD8SP-PDL1-10A5-(vL-vH)-Myc-

BBz-T2A-PAC

PSCA (Prostate stem cell

1678
3423
CD8SP-PSCA-Ha14-121-(vL-vH)-

antigen)

Myc-BBz-T2A-PAC

PSCA (Prostate stem cell

1679
3424
CD8SP-PSCA-Ha14-117-(vL-vH)-

antigen)

Myc-BBz-T2A-PAC

PR1/MHC class I
052516-
1680
3425
CD8SP-PR1-(vL-vH)-Myc-BBz-

complex
K07

T2A-PAC

PSMA (Prostate Specific
052516-
1681
3426
CD8SP-PSMA-006-(vL-vH)-Myc-

Membrane Antigen)
N07

BBz-T2A-PAC

PSMA (Prostate Specific
111815-
1682
3427
CD8SP-PSMA-J591-(vL-vH)-Myc-

Membrane Antigen)
E06

BBz-T2A-PAC

PTK7 (Tyrosine-protein
052516-
1683
3428
CD8SP-PTK7-hSC6-23-(vL-vH)-

kinase-like 7)
F07

Myc-BBz-T2A-PAC

PTK7 (Tyrosine-protein
052516-
1684
3429
CD8SP-PTK76-10-2-(vL-vH)-Myc-

kinase-like 7)
E07

BBz-T2A-PAC

ROR1
082815-
1685
3430
CD8SP-ROR1-4A5-(vL-vH)-Myc-

M05

BBz-T2A-PAC

ROR1
082815-
1686
3431
CD8SP-ROR1-4C10-(vL-vH)-Myc-

N06

BBz-T2A-PAC

Mesothelin

1687
3432
CD8SP-SD1-vHH-Gly-Ser-Linker-

SD2-vHH-Myc-BBz-T2A-PAC

SLea

1688
3433
CD8SP-SLea-7E3-(vL-vH)-Myc-

BBz-T2A-PAC

SLea

1689
3434
CD8SP-SLea-5B1-(vL-vH)-Myc-

BBz-T2A-PAC

SSEA4 (stage-specific

1690
3435
CD8SP-SSEA4-(vL-vH)-Myc-BBz-

embryonic antigen 4)

T2A-PAC

TCRB1 (TCR beta 1

1691
3436
CD8SP-TCRB1-CP01-E09-(vL-

constant chain)

vH)-Myc-BBz-T2A-PAC

TCRB1 (TCR beta 1
050516-
1692
3437
CD8SP-TCRB1-Jovil-(vL-vH)-

constant chain)
A07

Myc-BBz-T2A-PAC

TCRB2 (TCR beta 2
050516-
1693
3438
CD8SP-TCRB2-CP01-D05-(vL-

constant chain)
C07

vH)-Myc-BBz-T2A-PAC

TCRB2 (TCR beta 2
050516-
1694
3439
CD8SP-TCRB2-CP01-E05-(vL-

constant chain)
B05

vH)-Myc-BBz-T2A-PAC

TCRgd (TCR

1695
3440
CD8SP-TCRgd-G5-4-(vL-vH)-

gamma/delta)

Myc-BBz-T2A-PAC

hTERT/MHC class I
051816-
1696
3441
CD8SP-TERT-4A9-T540-(vL-vH)-

complex
H02

Myc-BBz-T2A-PAC

hTERT/MHC class I

1697
3442
CD8SP-TERT-3G3-T865-(vL-vH)-

complex

Myc-BBz-T2A-PAC

Tissue Factor-1

1698
3443
CD8SP-TGFBR2-Ab1-(vL-vH)-

Myc-BBz-T2A-PAC

TGFBR2

1699
3444
CD8SP-TF1-98-(vL-vH)-Myc-

BBz-T2A-PAC

TIM1/HAVCR

1700
3445
CD8SP-TIM1-HVCR1-270-2-(vL-

vH)-Myc-BBz-T2A-PAC

TIM1/HAVCR

1701
3446
CD8SP-TIM1-HVCR1-ARD5-(vL-

vH)-Myc-BBz-T2A-PAC

TnAg
052616-
1702
3447
CD8SP-TnAg-(vL-vH)-Myc-BBz-

F06

T2A-PAC

Tn-Muc1

1703
3448
CD8SP-TnMuc1-hu5E5-RHA8-

RKA-2-(vL-vH)-Myc-BBz-T2A-

PAC

MPL (Thrombopoietin

1704
3449
CD8SP-hTPO-Myc-BBz-T2A-PAC

receptor)

TROP2 (Trophoblast

1705
3450
CD8SP-TROP2-ARA47-HV3KV3-

cell-surface antigen-2)

(vL-vH)-Myc-BBz-T2A-PAC

TROP2 (Trophoblast

1706
3451
CD8SP-TROP2-h7E6-SVG-(vL-

cell-surface antigen-2)

vH)-Myc-BBz-T2A-PAC

TSHR (Thyrotropin

1707
3452
SP-TSHb-Gly-Ser-Linker-CGHa-

receptor)

Myc-BBz-T2A-PAC

TSHR (Thyrotropin

1708
3453
CD8SP-TSHR-K1-70-(vL-vH)-

receptor)

Myc-BBz-T2A-PAC

TSHR (Thyrotropin
052616-
1709
3454
CD8SP-TSHR-KB1-(vL-vH)-Myc-

receptor)
E05

BBz-T2A-PAC

TSHR (Thyrotropin

1710
3455
CD8SP-TSHR-5C9-(vL-vH)-Myc-

receptor)

BBz-T2A-PAC

TSLPR (thymic stromal
052516-
1711
3456
CD8SP-TSLPR-(vL-vH)-Myc-

lymphopoietin receptor)
L07

BBz-T2A-PAC

Tyrosinase/MHC class I
052516-
1712
3457
CD8SP-Tyros-B2-(vL-vH)-Myc-

complex
D06

BBz-T2A-PAC

Tyrosinase/MHC class I

1713
3458
CD8SP-Tyros-MC1-(vL-vH)-Myc-

complex

BBz-T2A-PAC

Tyrosinase/MHC class I

1714
3459
CD8SP-Tyros-TA2-(vL-vH)-Myc-

complex

BBz-T2A-PAC

VEGFR3

1715
3460
CD8SP-VEGFR3-Ab1-(vL-vH)-

Myc-BBz-T2A-PAC

WT1/MHC class I
101415-
1716
3461
CD8SP-WT1-Abl-(vL-vH)-Myc-

complex
P01

BBz-T2A-PAC

WT1/MHC class I
052516-
1717
3462
CD8SP-WT1-Ab5-(vL-vH)-Myc-

complex
M07

BBz-T2A-PAC

WT1/MHC class I
052516-
1718
3463
CD8SP-MYC3-WT1-Ab13-(vL-

complex
R04

vH)-Myc-BBz-T2A-PAC

WT1/MHC class I
052616-
1719
3464
CD8SP-MYC3-WT1-Ab15-(vL-

complex
S02

vH)-Myc-BBz-T2A-PAC

CDH19

1720
3465
CD8SP-CDH19-4B10-(vL-vH)-

Myc-BBz-T2A-PAC

Folate Receptor beta

1721
3466
CD8SP-FRbeta-m923-(vL-vH)-

Myc-BBz-T2A-PAC

LHR (Luteinizing

1722
3467
CD8SP-LHR-8B7-(vL-vH)-Myc-

hormone Receptor)

BBz-T2A-PAC

LHR (Luteinizing

1723
3468
CD8SP-LHR-5F4-21-(vL-vH)-

hormone Receptor)

Myc-BBz-T2A-PAC

B7H4

1724
3469
CD8SP-B7H4-hu22C10-(vL-vH)-

Myc-BBz-T2A-PAC

B7H4

1725
3470
CD8SP-B7H4-hu1D11-(vL-vH)-

Myc-BBz-T2A-PAC

IgE

1726
3471
CD8SP-IgE-omalizumab-(vL-vH)-

Myc-BBz-T2A-PAC

CD23

1727
3472
CD8SP-CD23-p5E8-(vL-vH)-Myc-

BBz-T2A-PAC

GCC (Guanylyl cyclase

1728
3473
CD8SP-GCC-5F9-(vL-vH)-Myc-

C)

BBz-T2A-PAC

GCC (Guanylyl cyclase

1729
3474
CD8SP-GCC-Ab229-(vL-vH)-

C)

Myc-BBz-T2A-PAC

CD200R

1730
3475
CD8SP-CD200R-huDx182-(vL-

vH)-Myc-BBz-T2A-PAC

TABLE 22

Exemplary CAR constructs targeting different antigens

SEQ ID
SEQ ID

Target
CLONE ID
(DNA)
(PRT)
CONSTRUCT NAME

MPL
021715-Z07
1731
3476
CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC

MPL
090814-C03
1732
3477
CD8SP-161-(vL-vH)-Myc-CD8TM-BBz-T2A-EGFP

MPL
031615-Q04
1733
3478
CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC

MPL
031615-R04
1734
3479
CD8SP-178-(vL-vH)-Myc-CD28z-T2A-PAC

MPL
031615-T04
1735
3480
CD8SP-AB317-(vL-vH)-Myc-CD28z-T2A-PAC

MPL
031615-S03
1736
3481
CD8SP-12E10-(vL-vH)-Myc-CD28z-T2A-PAC

MPL
032415-M03
1737
3482
CD8SP-huVB22Bw5-(vL-vH)-Myc-CD28z-T2A-PAC

MPL
031915-U04
1738
3483
hTPO-(1-187)-Myc-CD28z-T2A-PAC

MPL
031915-V03
1739
3484
mTPO-(1-187)-Myc-CD28z-T2A-PAC

MPL
021216-D01
1740
3485
CD8SP-161-(vL-vH)-BBz-P2A-IgHSP-IL6R-304-

vHH-Alb8-vHH-Flag-T2A-PAC

MPL
112916-U06
1741
3486
CD8SP-161-(vL-vH)-Myc-z-P2A-FKBP-K13-FLAG-

T2A-PAC

MPL
112916-V01
1742
3487
CD8SP-161-(vL-vH)-Myc-z-P2A-FLAG-HTLV2-

TAX-RS-T2A-PAC

MPL
112916-W06
1743
3488
CD8SP-161-(vL-vH)-Myc-z-P2A-HTLV2-TAX-RS-

T2A-PAC

MPL
112614-E05
1744
3489
CD8SP-161-(vL-vH)-Myc-BBz-P2A-FKBP-K13-Flag-

T2A-EGFP

MPL
011315-F02
1745
3490
CD8SP-161(vL-vH)-BBz-P2A-IgHSP-IL6-19A(vL-

vH)-Flag-T2A-EGFP

MPL
012015-I29
1746
3491
CD8SP-161(vL-vH)-BBz-P2A-IgHSP-IL6R-M83(vL-

vH)-Flag-T2A-EGFP

MPL
022415-T02
1747
3492
CD8SP-161-(vL-vH)-Myc-CD28z-P2A-K13-Flag-

T2A-EGFP

MPL
012115-L04
1748
3493
CD8SP-161-(vL-vH)-BBz-P2A-IgHSP-Fx06-Flag-

T2A-EGFP

MPL
070315-H03
1749
3494
CD8SP-161-(vL-vH)-Myc-BBZ-P2A-MC159-Flag-

T2A-Pac

CD19
112614-C06
1750
3495
CD8SP-FMC63(vL-vH)-Myc-z-P2A-MC159-Flag-

T2A-PAC

CD19
111014-Z13
1751
3496
CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-MC159-Flag-

T2A-PAC

CD19
010100-N01
1752
3497
CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-Flag-HTLV2-

TAX-RS-T2A-PAC

CD19
100215-B07
1753
3498
CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-cFLIP-p22-

Flag-T2A-PAC

CD19
092215-A06
1754
3499
CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-cFLIP-L-

Flag-T2A-PAC

CD19
112614-B06
1755
3500
CD8SP-FMC63(vL-vH)-Myc-z-P2A-FKBP-K13-

FLAG-T2A-EGFP

CD19
120314-J03
1756
3501
CD8SP-FMC63(vL-vH)-Myc-z-P2A-FKBPx2-K13-

FLAG-T2A-EGFP

CD19
120314-N07
1757
3502
CD8SP-FMC63(vL-vH)-Myc-z-P2A-Myr-FKBPx2-

K13-FLAG-T2A-EGFP

CD19
012315-O01
1758
3503
CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-FKBPx2-

HTLV2-Tax-RS-T2A-EGFP

CD19
033115-P06
1759
3504
CD8SP-FMC63-(vL-vH)-Myc-CD28z-P2A-K13-Flag-

T2A-PAC

CD19
032415-Q03
1760
3505
CD8SP-FMC63-(vL-vH)-Myc-CD28z-P2A-MC159-

Flag-T2A-PAC

CD19
022415-S03
1761
3506
CD8SP-FMC63-(vL-vH)-Myc-CD28z-P2A-K13-Flag-

T2A-EGFP

CD19
011315-H06
1762
3507
CD8SP-FMC63(vL-vH)-BBz-P2A-IgHSP-IL6-

19A(vL-vH)-Flag-T2A-PAC

CD19
011315-K04
1763
3508
CD8SP-FMC63(vL-vH)-BBz-P2A-IgHSP-IL6R-

M83(vL-vH)-Flag-T2A-PAC

CD19
012115-N04
1764
3509
CD8SP-FMC63-(vL-vH)-BBz-P2A-IgHSP-Fx06-Flag-

T2A-PAC

CD19
091715-C01
1765
3510
CD8SP-FMC63-(vL-vH)-Myc-z-P2A-HTLV2-TAX2-

FLAG-T2A-Pac

CD19
091715-D05
1766
3511
CD8SP-FMC63-(vL-vH)-Myc-z-P2A-HTLV2-TAX-

RS-T2A-Pac

CD19
091715-L04
1767
3512
CD8SP-FMC63-(vL-vH)-Myc-z-P2A-FLAG-HTLV2-

TAX-RS-T2A-Pac

CD19
091715-O04
1768
3513
CD8SP-FMC63-(vL-vH)-MYC-z-P2A-HTLV2-TAX-

T2A-Pac

CD19
033115-T01
1769
3514
CD8SP-FMC63-(vL-vH)-Myc-CD28z-T2A-PAC

CD19
112316-S06
1770
3515
CD8SP-FMC63(vL-vH)-Myc-z-P2A-Myr-FKBPx2-

K13-FLAG-T2A-PAC

GRP78
031615-O05
1771
3516
CD8SP-GRP78-GD4-(vL-vH)-MYC-CD28z-T2A-Pac

CD19
093015-D10
1772
3517
CD8SP-hCD19-Bu12-(vL-vH)-MYC-CD28z-T2A-Pac

Lym1
031615-M03
1773
3518
CD8SP-Lym1-(vL-vH)-Myc-CD28z-T2A-Pac

Lym2
031615-N03
1774
3519
CD8SP-Lym2(vL-vH)-Myc-CD28z-T2A-Pac

GRP78
031615-P03
1775
3520
CD8SP-GRP78-GC18-(vL-vH)-Myc-CD28z-T2A-Pac

FLT3
032415-L05
1776
3521
CD8SP-FLT3-NC7-(vL-vH)-Myc-CD28z-T2A-Pac

CD79b
031915-D05
1777
3522
CD8SP-huMA79bv28-(vL-vH)-Myc-CD28z-T2A-Pac

CS1
031915-F03
1778
3523
CD8SP-Luc90-(vL-vH)-MYC-CD28z-T2A-PAC

CD4
101415-O04
1779
3524
SP-CD4-8-03F1-(vHH)-MYC-BBZ-T2A-Pac

CXCR4
101415-U01
1780
3525
CD8SP-CXCR4-1-(vHH)-MYC-BBZ-T2A-Pac

KSHV-
031615-W05
3534
3540
CD8SP-4C3-(vL-vH)-Myc-CD28z-T2A-Pac

K8.1

CD19
070814-D06
3535
3541
CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-EGFP

MPL
031615-B06
3536
3542
CD8SP-MPL-VB22Bw4-(vL-vH)-Myc-CD28z-T2A-

PAC

KSHV-
100814-K06
3537
3543
CD8SP-4C3-(vL-vH)-Myc-BBz-T2A-EGFP

K8.1

CD19
111214-D05
3538
3544
CD8SP-FMC63-(vL-vH)-Myc-z-T2A-PAC

CD19
012315-M03
3539
3545
CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-FKBPx2-

FLAG-TAX2U2RS-T2A-eGFP

TABLE 23

HLA-A2 restricted peptides used for generaton of CAR

Protein
Fragment Name
Amino Acid Seq

gp100
G9-209
(IMDQVPFSV)

gp100
G9-280
(YLEPGPVTV)

gp100
G9-154
(KTWGQYWQV)

MUC1-A7 (130-138)
A7
(NLTISDVSV)

MUC1-D6 (13-21)
D6
(LLLTVLTVV)

TAX (11-19)

(LLFGYPVYV)

hTERT(540-548)
T540
(ILAKFLHWL)

hTERT (865-873)
T865
(RLVDDFLLV)

HIV1 gag (77-85)
SL9
(SLYNTVATL)

CMV-pp65(495-503)

(NLVPMVATV)

MART (26-35)

(EAAGIGILTV)

EBNA-3A (596-604)

(SVRDRLARL)

EBNA-3c

(LLDFVRFMGV)

WT1

(RMFPNAPYL)

PR1

(VLQELNVTV)

AFP
AFP-158
(FMNKFIYEI)

HPV16-E7
E7 (11-19)
(YMLDLQPET)

Tyrosinase
Tyr (369-377)
(YMDGTMSQV)

EXAMPLES

The following examples are not intended to limit the scope of the claims to the invention, but are rather intended to be exemplary of certain embodiments. Any variations in the exemplified methods which occur to the skilled artisan are intended to fall within the scope of the present invention.

MPL (TPO Receptor) as Target for CAR-T Cell Therapy

Thrombopoietin and its cognate receptor, c-Mpl, are the primary molecular regulators of megakaryocytopoiesis(Zhan et al., Monoclonal antibodies in immunodiagnosis and immunotherapy 32:149-61, 2013). Binding of TPO to cell surface c-Mpl activates a cascade of signaling events that result in the proliferation and differentiation of megakaryocytic progenitor cells and ultimately platelet production. TPO and c-Mpl also regulate hematopoietic stem cell self-renewal. Consistent with these biological functions of TPO in the megakaryocytic lineage, c-Mpl expression is mostly restricted to non-lymphoid hematopoietic tissues. c-Mpl mRNA and cell surface protein have been identified in human CD34+ cells, megakaryocytes, platelets, primary leukemia samples of myeloid origin, and megakaryocytic and erythroid leukemia cell lines. c-Mpl mRNA has not been detected in most normal non-hematopoietic tissues or in lymphoid cell lines.

We examined the public gene expression databases for MPL expression. As shown in FIG. 2A-FIG. 2D, we confirmed extremely restrictive expression of MPL in normal tissues, with only one organ showing low level expression. In contrast, MPL was significantly expressed in most patient samples of Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myeloid leukemia (CML). These results suggest that MPL is an excellent therapeutic target for patients with myeloid malignancies, such as AML, MDS and CML, using chimeric antigen receptor modified T cells.

Cell Lines and Cells

The cell lines used in this invention and their growth media are shown in the Table 24. Cells were cultured at 37° C., in a 5% CO2 humidified incubator. The cell lines were obtained from ATCC, NIH AIDS reagent program or were available in our laboratory or obtained from other laboratories.

TABLE 24

Cell lines and growth media

Cell lines
Media
Cell lines
Media

BC-1
RPMI, 20% FCS
THP-1
RPMI, 10% FCS

BC-3
RPMI, 20% FCS
U87MG
DMEM, 10% FCS

BCBL-1
RPMI, 20% FCS
NCI-H540
DMEM, 10% FCS

JSC-1
RPMI, 20% FCS
LoVo
DMEM, 10% FCS

UMPEL-1
RPMI, 20% FCS
SKOV-3
DMEM, 10% FCS

MM1S
RPMI, 10% FCS
NCI-H1993
DMEM, 10% FCS

U266
RPMI, 10% FCS
Kasumi-1
RPMI, 20% FCS

L363
RPMI, 10% FCS
Jeko-1
RPMI, 20% FCS

K562
RPMI, 10% FCS
PC-3
DMEM, 10% FCS

BV173
RPMI, 10% FCS
HeLa
DMEM, 10% FCS

Nalm6
RPMI, 10% FCS
NCI-H2452
DMEM, 10% FCS

HL60
RPMI, 10% FCS
LnCap
DMEM, 10% FCS

U937
RPMI, 10% FCS
SNU-5
RPMI, 20% FCS

RS: 411
RPMI, 20% FCS
OVCAR-3
DMEM, 10% FCS

MV: 411
RPMI, 10% FCS
MEL-624
DMEM, 10% FCS

Raji
RPMI, 10% FCS
LS174-T
DMEM, 10% FCS

HEL-92.1.7
RPMI, 10% FCS
MEL-526
DMEM, 10% FCS

Meg-01
RPMI, 10% FCS
MDA-
DMEM, 10% FCS

Jurkat
RPMI, 10% FCS
MB231

MM1
DMEM, 10% FCS
L1236
RPMI, 20% FCS

Daudi
RPMI, 10% FCS
L428
RPMI, 20% FCS

REC-1
RPMI, 10% FCS
Molt-16
RPMI, 20% FCS

U2932
RPMI, 10% FCS
RPMI8402
RPMI, 20% FCS

H929
RPMI, 10% FCS
KN5-5F2
RPMI, 20% FCS

beta
CCRF-CEM
RPMI, 10% FCS

Mercaptoethanol
(ATCC)

(BME)
MG-63
DMEM, 10% FCS

KMS28
RPMI, 10% FCS
Karpass-299
RPMI, 20% FCS

EJM
RPMI, 10% FCS
MCF7
DMEM, 10% FCS

MRC-5
DMEM, 10% FCS
SUDHL-1
RPMI, 10% FCS

CMK
RPMI, 20% FCS
AA-2
RPMI, 10% FCS

TF-1
RPMI, 10%
HL2/3
DMEM, 10% FCS

FCS + GMCSF
TF228.1.16
DMEM, 10% FCS

ML-2
RPMI, 20% FCS
MT-4
RPMI, 10% FCS

A20
RPMI, 10%
Sup-T1
RPMI, 10% FCS

FCS + BME
HuT-78
RPMI, 10% FCS

KMS28BM
RPMI, 10% FCS
TT
DMEM, 10% FCS

KG-1
RPMI, 20% FCS
DMS79
RPMI, 10% FCS

CEM
RPMI, 10% FCS
LAN-5
DMEM, 10% FCS

U937
RPMI, 10% FCS
PEER1
RPMI, 10% FCS

LAMA5
RPMI, 10% FCS
SK-MEL-37
DMEM, 10% FCS

A549
DMEM, 10% FCS
Jurkat-
RPMI, 10% FCS

HT29
DMEM, 10% FCS
NFAT-GFP

Molm-13
RPMI, 20% FCS
F9
DMEM, 10% FCS

A431
DMEM, 10% FCS

P19
DMEM, 10% FCS

Jurkat cell line (clone E6-1) engineered with a NFAT-dependent EGFP (or GFP) reporter gene was a gift from Dr. Arthur Weiss at University of California San Francisco and have been described to study CAR-signaling ((Wu, C Y et al., Science 350:293-302,2015). Jurkat cells were maintained in RPMI-1640 medium supplemented with 10% FBS, penicillin and streptomycin.

Generation of Lentiviral Vectors Encoding Chimeric Antigen Receptors Against MPL

The pLENTI-Blast vector was derived from pLenti6v5gw_lacz vector (Invitrogen; ThermoFisher Scientific) by removal of the LacZ gene. pLenti-MP2 was a gift from Pantelis Tsoulfas (Addgene plasmid #36097) and was used to generate pLenti-EF1α or pLenti-EF1α [SEQ ID NO:905] lentiviral vector by replacement of the CMV promoter with human EF1α promoter using standard molecular biology techniques. pLenti-EF1a-DWPRE [SEQ ID NO:906] was derived from the pLENTI-EF1α vector by deletion of WPRE sequence. The psPAX2 vector was a gift from Didier Trono (Addgene plasmid #12260). The pLP/VSVG envelope plasmid and 293FT cells were obtained from Invitrogen (ThermoFisher Scientific). The retroviral transfer vector MSCVneo, MSCVhygro, and MSCVpac and the packaging vector pKAT were obtained from Dr. Robert Illaria's laboratory. phRGTK Renilla Luciferase plasmid was from Promega.

Several monoclonal antibodies targeting human MPL have been described (US20120269814A1, U.S. Pat. No. 6,342,220 B1, EP1616881A1 and WO 02568109). The nucleotide sequences of the 1.6.1 monoclonal antibody described in US20120269814A1 was used for the synthesis of its corresponding scFV fragment consisting from 5′ to 3′ ends of a nucleotide sequences encoding a signal peptide derived from human CD8 molecule [SEQ ID NO: 1-4], the vL fragment, a (Gly4Ser)x3 linker and the vH fragment. The sequence of the scFV fragment was codon optimized using GeneArt™ software (Thermo Fisher Scientific) and gene-fragments encoding the optimized sequences synthesized by GeneArt™ or Integrated DNA Technologies (IDT). The gene fragment was used as templates in PCR reaction using custom primers containing NheI and MluI restriction enzyme sites and then cloned in a modified pLenti-EF1α vector containing the hinge, transmembrane and cytosolic domains of the CAR cassette by standard molecular biology techniques. The final CAR construct named CD8SP-161-(vL-vH)-Myc-CD8TM-BBz-T2A-EGFP(090814-C03)[SEQ ID NO:1732] consisted of human CD8 signal peptide (hCD8SP), fused in frame to the scFv (vL-vH) fragment derived from the monoclonal antibody 1.6.1 against human MPL [SEQ ID NO:730], a Myc epitope tag [SEQ ID NO:553], the hinge and transmembrane domain of human CD8 [SEQ ID NO:842], the cytosolic domain of human 41BB (CD137) receptor [SEQ ID NO:845], the cytosolic domain of human CD3z, [SEQ ID NO:846], a T2A ribosomal skip sequence [SEQ ID NO:832] and a cDNA encoding enhanced Green Fluorescent Protein (EGFP). The CAR construct CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658] is nearly identical to the above except EGFP cDNA is replaced by cDNA encoding a variant of puromycin resistance gene (SEQ ID NO: 850). In the CAR construct CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731], the hinge and transmembrane domain of human CD8 and the cytosolic domain of human 41BB (CD137) receptor are replaced by the human CD28-hinge, -transmembrane and-cytosolic domains (SEQ ID NO: 848). Essentially a similar approach was used to generate several additional CARs against multiple antigens in which the 161 scFv fragment was replaced by the scFv fragments of antibodies targeting different antigens. The SEQ ID NOs of the nucleotide and protein sequences of the different scFv fragments and the name of their target antigens are provided in Table 11. Additionally, two constructs targeting MPL were made in which the scFv region was replaced by the extracellular domains of human and mouse thrombopoietin (TPO) (SEQ ID NOs: 553 and 554). These constructs, hTPO-(1-187)-Myc-CD28z-T2A-PAC(031915-U04)[SEQ ID NO:1738] and mTPO-(1-187)-Myc-CD28z-T2A-PAC(031915-V03)[SEQ ID NO:1739], consisted of the extracellular receptor binding domains of human and mouse thrombopoietin (TPO) fused to the CD28-hinge, -transmembrane and-cytosolic domains and CD3z cytosolic domains. The SEQ ID NOs of the nucleotide and protein sequences of the different camelid vHH fragments, non-immunoglobulin binding scaffolds and ligands that can be used to generate CAR and the name of their target antigens are provided in Tables 7, 8 and 10.

In the CAR construct CD8SP-161-(vL-vH)-Myc-CD28z-P2A-K13-Flag-T2A-EGFP(022415-T02)[SEQ ID NO:1747], the cDNA encoding K13-vFLIP from the Kaposi's sarcoma associated herpesvirus containing a carboxy-terminal Flag epitope tag is inserted downstream of the nucleotide sequence encoding the CD8SP-161-(vL-vH)-Myc-CD28z CAR and is separated from it by nucleotide sequence encoding P2A cleavable linker. The CAR construct CD8SP-MPL-161-(vL-vH)-Myc-BBz-P2A-K13-Flag-T2A-PAC[SEQ ID NO:1388] is similar in design to SEQ ID NO: 1747 except that it contains the CD8 hinge and transmembrane domains and the 41BB costimulatory domain. Essentially, a similar approach was used to clone other accessory modules, such as MC159-vFLIP, cFLIP-L, HTLV1-Tax and HTLV2-Tax, in the CAR-encoding lentiviral vectors. The construct CD8SP-MPL-161-(vL-vH)-Myc-BBz-P2A-K13-Flag-T2A-PAC[SEQ ID NO:1388] comprises a CAR containing a 41BB costimulatory domain (BB) and a CD3z activation domain (z). This construct also co-expresses a Flag-epitope tagged K13-vFLIP downstream of the CAR-encoding sequence and separated from it by a P2A cleavable linker. The construct CD8SP-MPL-161-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC(111516-N05)[SEQ ID NO:1118] is similar in design to SEQ ID NO: 1388 except that it lacks the 41BB costimulatory domain. The SEQ ID NOs of the nucleotide and protein sequences of the different CAR constructs and the name of their target antigens are provided in Tables 19-22. All the CAR constructs were generated using standard molecular biology techniques and their sequences confirmed using automated sequencing.

Lentivirus and Retrovirus Vectors

Lentiviruses were generated by calcium phosphate based transfection in 293FT cells essentially as described previously (Matta H et al, Cancer biology and therapy. 2(2):206-10. 2003). 293FT cells were grown in DMEM with 10% FCS 4 mM L-Glutamine, 0.1 mM MEM Non-Essential Amino Acids, and 1 mM MEM Sodium Pyruvate (hereby referred to as DMEM-10). For generation of lentivirus, 293FT cells were plated in 10 ml of DMEM-10 medium without antibiotics in a 10 cm tissue culture plate so that they will be approximately 80 confluent on the day of transfection. The following day, the cells were transfected by calcium phosphate transfection method using 10 μg of lentiviral expression plasmid encoding different genes, 7.5 μg of PSPAX2 plasmid and 2 μg of PLP/VSVG plasmid. Approximately 15-16 hours post-transfection, 9 ml of media was removed and replaced with 5 ml of fresh media. Approximately, 48 hours post-transfection, 5 ml of supernatant was collected (first collection) and replaced with fresh 5 ml media. Approximately 72 hrs post-transfection, all media was collected (second collection, usually around 6 ml). The collected supernatants were pooled and centrifuged at 1000 rpm for 1 minute to remove any cell debris and non-adherent cells. The cell-free supernatant was filtered through 0.45 m syringe filter. In some cases, the supernatant was further concentrated by ultra-centrifugation at 18500 rpm for 2 hours at 4° C. The viral pellet was re-suspended in 1/10 of the initial volume in XVIVO medium. The virus was either used fresh to infect the target cells or stored frozen in aliquots at −80° C.

Infection of T cells and PBMC

Buffy coat cells were obtained from healthy de-identified adult donors from the Blood Bank at Children Hospital of Los Angeles and used to isolate peripheral blood mononuclear cells (PBMC) by Ficoll-Hypaque gradient centrifugation. PBMC were either used as such or used to isolate T cells using CD3 magnetic microbeads (Miltenyi Biotech) and following the manufacturer's instructions. PBMC or isolated T cells were re-suspended in XVIVO medium (Lonza) supplanted with 10 ng/ml CD3 antibody, 10 ng/ml CD28 antibody and 100 IU recombinant human-IL2. Cells were cultured at 37° C., in a 5% CO2 humidified incubator. Cells were activated in the above medium for 1 day prior to infection with lentiviral vectors. In general, primary cells (e.g. T cells) were infected in the morning using spin-infection (1800 rpm for 90 minutes at 37° C. with 300 μl of concentrated virus that had been re-suspended in XVIVO medium in the presence of 8 μg/ml of Polybrene® (Sigma, Catalog no. H9268). The media was changed in the evening and the infection was repeated for two more days for a total of 3 infections. After the 3rd infection, the cells were pelleted and resuspended in fresh XVIVO media containing 10 ng/ml CD3 antibody, 10 ng/ml CD28 antibody and 100 IU recombinant human-IL2 and supplemented with respective antibiotics (if indicated) and place in the cell culture flask for selection, unless indicated otherwise. Cells were cultured in the above medium for 10⁻¹⁵days in case no drug selection was used and for 20-30 days in case drug-selection was used. In cases, where cells were infected with a lentivirus expressing EGFP, they were expanded without drug-selection or flow-sorted to enrich for EGFP-expressing cells. For infection of cancer cell lines, approximately 500,000 cells were infected with 2 ml of the un-concentrated viral supernatant in a total volume of 3 ml with Polybrene® (Sigma, Catalog no. H9268). Then next morning, the cells were pelleted and resuspended in the media with respective antibiotics and place in the cell culture flask for selection.

Essentially a similar procedure as described above for lentivirus vector production was used for generation of retroviral vectors with the exception that 293FT cells were generally transfected in 10 cm tissue culture plates in 10 ml of DMEM-10 medium using g of retroviral construct, 4 g of pKAT and 2 g of VSVG plasmid. The virus collection and infection of target cells was carried out essentially as described above for lentiviral vectors.

Antibodies and Drugs

Blinatumomab was obtained from Amgen. Digitonin was purchased from Sigma (Cat. no D141) and a stock solution of 100 mg/ml was made in DMSO. A diluted stock of 1 mg/ml was made in PBS. Final concentration of digitonin used for cell lysis was 30 g/ml unless indicated otherwise.

ELISA

Human IL2, IFNγ, IL6 and TNFα were measured in the cell culture supernatant of CAR-expressing Jurkat-NFAT-GFP effector cells or T cells that had been co-cultured with the specific target cell lines for 24 to 96 hours using commercially available ELISA kits from R&D systems (Minneapolis, MN) and BD Biosciences and following the recommendations of the manufacturer.

FACS Analysis for Detecting Expression of CAR

Mouse Anti-Human c-Myc APC-conjugated Monoclonal Antibody (Catalog #IC3696A) was from R&D Systems (Minneapolis, MN). Biotinylated protein L was purchased from GeneScript (Piscataway, NJ), reconstituted in phosphate buffered saline (PBS) at 1 mg/ml and stored at 4° C. Streptavidin-APC (SA1005) was purchased from ThermoFisher Scientific.

For detection of CARs using Myc staining, 1×10⁶cells were harvested and washed three times with 3 ml of ice-cold 1× PBS containing 4% bovine serum albumin (BSA) wash buffer. After wash, cells were resuspended in 0.1 ml of the ice-cold wash buffer containing 10 μl of APC-conjugated Myc antibody and incubated in dark for 1 hour followed by two washings with ice cold wash buffer.

For detection of CARs using Protein L staining, 1×10⁶cells were harvested and washed three times with 3 ml of ice-cold 1× PBS containing 4% bovine serum albumin (BSA) wash buffer. After wash, cells were resuspended in 0.1 ml of the ice-cold wash buffer containing 1 μg of protein L at 4° C. for 1 hour. Cells were washed three times with ice-cold wash buffer, and then incubated (in the dark) with 10 μl of APC-conjugated streptavidin in 0.1 ml of the wash buffer for 30 minutes followed by two washings with ice cold wash buffer. FACS was done using FACSVerse analyzer from BD Biosciences.

Cell Death Assay

To measure cell death, a novel assay based on ectopic cytosolic expression of Gluc, NLuc and other luciferases was utilized as described in U.S. provisional patent application 62/396,650 “A Non-Radioactive Cytotoxicity Assay”. The method involves expression of a reporter in a target cells in a manner so that it is preferentially retained within the healthy cells but is either released from dead and dying cells or whose activity can be preferentially measured in dead and dying cells. The preferred reporter for this assay are 1) non-secreted forms of luciferases from the copepods, such as Gaussia princeps, Pleuromamma abdominalis, Metridia pacifica, Metridia curticauda, Metridia asymmetrica, Metridia okhotensis, Metridia longa, Lucicutia ovaliformis, Heterorhabdus tanneri, and Pleuromamma scutullata 2) engineered luciferase reporters from deep sea shrimp, such as NanoLuc. The sequence of several such exemplary reporter vectors is provided in SEQ ID NO: 912 to SEQ ID NO: 918. The above vectors were used to generate retrovirus and lentiviruses which in turn were used to generate polyclonal population of several target cell lines stably expressing GLuc, NLuc, or TurboLuc following selection with appropriate antibiotics. Unless indicated otherwise, the target cells stably expressing the different luciferases were plated in triplicate in a 384 well plate in the media used for growing the target cells. Target cells which grow in suspension were generally plated at a concentration of 2-3×10⁴per well, while target cells which grow as adherent monolayers were plated at a concentration of 1-2×10⁴per well. Unless indicated otherwise, the target cells were cocultured with the genetically modified T cells (i.e. those expressing CAR) at an Effector: Target (E:T) ratio varying from 1:1 to 10:1 for 4 hours to 96 hours. In the case target cells grow as adherent cells (e.g., HeLa cells), they were allowed to attach to the bottom of the wells overnight before the T cells were added. T cells mediated induction of lysis of target cells was assayed by increase of luciferase activity as measured by BioTek synergy plate reader by directly injecting 0.5× CTZ assay buffer containing native coeloentrazine (Nanaolight) as described below.

CTZ Assay

A 100× stock solution of native coelenterazine (CTZ; Nanolight, cat #303) was made by dissolving 1 mg of lyophilized CTZ powder in 1.1 ml of 100% Methanol supplemented with 30 μl of 6N HCl to avoid oxidation of CTZ with time. To make CTZ assay buffer, the 100× stock solution of CTZ was diluted to 0.5× concentration in PBS. Unless indicated otherwise, a total volume of 15 μl of the CTZ assay buffer (as prepared above) was added to each well of a 384-well white plate (Greiner, 384 well white plate cat #781075) containing cells expressing the non-secretory form of the luciferase in approximately 50-60 μl volume of medium and plates were read for luminescence in endpoint mode using BioTek synergyH4 plate reader. For 96 well plates, cells were plated in 200 μl of media and approximately 50 μl of 0.5× CTZ assay buffer was added. Unless indicated otherwise, the 0.5× CTZ assay buffer was used for assaying the activity of GLuc, TurboLuc16, and MLuc7. The CTZ assay buffer (diluted to 0.125× concentration) was also used for measurement of NLuc activity in some experiments (see below). In general, unless indicated otherwise, the volume of 0.5× CTZ assay buffer added was approximately ¼th of the volume of the liquid in the well containing the cells, although the assay also worked when the 0.5× CTZ assay was added to the media containing the cells in 1:1 volume. Gluc activity in wells containing media alone (Med) and in wells in which target cells were incubated with T cells that were not infected with any SIR construct (T-UI) were used as controls, where indicated.

NLuc Assay:

Nano-Glo® Luciferase Assay System (Promega) was used for measurement of NLuc activity by following the manufacturer's instructions. Briefly, Nano-Glo Reagent was prepared by adding 5 μl of Nano-Glo substrate in 1 ml of Nano-Glo assay buffer (Promega). Unless indicated otherwise, 15 μl of Nano-Glo Reagent prepared above was manually added directly to each well of a 384-well white plate containing cells in 60 μl of media and plates. For 96 well plates, cells were plated in 200 μl of media and approximately 501 of assay buffer was added.

Plates were read for luminescence in endpoint mode using BioTek synergyH4 plate reader without prior cell lysis. In some experiments, NLuc activity was measured using CTZ assay buffer but here the buffer was diluted to final concentration of 0.125×. When CTZ assay buffer was used for measurement of NLuc activity, a total volume of approximately 15 (unless indicated otherwise) of the 0.125× CTZ assay buffer was added by injector to each well of a 384-well white plate (Greiner, 384 well white plate cat #781075) containing cells in approximately 50-60 μl volume of medium and plates were read for luminescence in endpoint mode using BioTek synergyH4 plate reader. For 96 well plates, cells were generally plated in 200 μl of media and approximately 50 μl of 0.125× CTZ assay buffer was added.

Assay to Detect the Expression of Antigens on Target Cells

Both CD19 and MPL (also known as Thrombopoietin receptor or TPO-R) are expressed on hematopoietic cells but show differential expression in cells of different lineages. FMC63 is a well characterized mouse monoclonal antibody that specifically recognizes human CD19. Similarly, 161 (also designated as 1.6.1) is a monoclonal antibody that recognizes human MPL and is described in U.S. patent application US 2012/0269814 A1. We generated a FMC63 single chain Fv (scFv) fragment based on the known sequence of FMC63 vL and vH fragments. The cDNA encoding FMC63 scFv fragment consisted from 5′ to 3′ ends a nucleotide sequences encoding a signal peptide derived from human CD8 molecule, FMC63 vL fragment, a (Gly4Ser)x3 linker and FMC63-vH fragment. The cDNA encoding the FMC63 scFv fragment was then fused in-frame at its 3′ end to cDNA encoding AcV5-tagged NLuc through a Gly-Gly-Ser-Gly (SEQ ID NO:3571) linker to generate FMC63-GGSG-NLuc. The resulting fragment was then cloned down-stream of the human EF1α promoter into the lentiviral vector pLenti-EF1α (SEQ ID NO: 905) to make the construct Plenti-EF1a-FMC63(vL-vH)-GGSG-NLuc-AcV5-U09. The DNA and PRT sequences of the insert fragment are provided in SEQ ID NO: 923 and SEQ ID NO: 2668, respectively. A construct encoding 161-GGSG-NLuc was similarly generated using the vL and vH fragment of 1.6.1 monoclonal antibody against MPL. The DNA and PRT sequences of the insert fragment are provided in SEQ ID NO: 924 and SEQ ID NO: 2669, respectively. The pLenti-EF1a-FMC63(vL-vH)-GGSG-NLuc-AcV5 and pLenti-EF1a-161(vL-vH)-GGSG-NLuc-AcV5 plasmids were transfected into 293FT cells by calcium phosphate co-precipitation method. Approximately 20h post-transfection, the cell culture media was replaced with XVIVO medium. The conditioned media containing the secreted FMC63(vL-vH)-GGSG-NLuc-AcV5 (also referred to as FMC63-GGSG-NLuc-AcV5) and 161(vL-vH)-GGSG-NLuc-AcV5 (also referred to as 161-GGSG-NLuc-AcV5) proteins was collected 48-72h later.

The supernatant containing FMC63-GGSG-NLuc-AcV5 and 161-GGSG-NLuc-AcV5 proteins were used to detect the expression of CD19 and MPL on the surface of Jurkat, K562, RAJI, RS-4-11 (RS411) and HEL.92.1.7 (HEL) cells that had been engineered to express a c-MPL cDNA by transducing these cells with a lentiviral vector expressing human c-MPL cDNA or an empty vector. The cells also expressed a humanized Gluc cDNA lacking its signal peptide. The vector- and MPL-expressing Jurkat-Gluc, K562-Gluc, HEL.92.1.7-Gluc, RAJI-Gluc and RS411-Gluc cells were incubated with the FMC63-GGSG-NLuc-AcV5 and 161-GGSG-NLuc-AcV5 supernatants at 4° C. for 1h followed by extensive washings with cold PBS supplemented with 0.1% BSA. The cells were re-suspended in cold PBS and 30 μl of cell suspension was plated per well in a flat-bottom 384 well plate (Greiner, 384 well white plate cat. #781075) in triplicate. NLuc assay buffer containing native coelenterazine (CTZ) as NLuc substrate (30 μl/well of native coelenterazine diluted in PBS) was added to each well by an automatic dispenser in a well mode using a BioTek synergy H4 plate reader and light emission as a measure of NLuc activity was measured. FIG. 3A shows that strong binding with 161-GGSG-NLuc-AcV5 was observed on HEL.92.1.7-Gluc-vector cells suggesting significant expression of MPL endogenously. Ectopic expression of MPL in HEL.92.1.7-Gluc-MPL cells led to a modest increase in 161-GGSG-NLuc-AcV5 binding. In contrast, very weak binding with 161-GGSG-NLuc-AcV5 was observed on vector-expressing Jurkat, RAJI and RS411 cells and was only modestly increased upon ectopic expression of MPL. Finally, weak but stronger binding of 161-GGSG-NLuc-AcV5 was observed on K562-vector cells, and was significantly increased on K562-MPL cells. In contrast to161-GGSG-NLuc-AcV5, the FMC63-GGSG-NLuc-AcV5 supernatant showed strongest binding on vector- and MPL-expressing RAJI cells, modestly strong binding on RS411 cells and very weak to negligible binding on the other cells.

Assay to Detect the Expression of Chimeric Antigen Receptors Targeting CD19 and MPL (Thrombopoietin Receptor)

A frequent problem in the field of chimeric antigen receptors is lack of a sensitive and specific assay that can detect cells that express chimeric antigen receptors. To detect the expression of CAR targeting CD19 and MPL, we fused the extracellular domains (ECD) of human CD19 and human MPL, including their signal peptides, in frame with nucleotide sequence encoding a Gly-Gly-Ser-Gly linker, NLuc (without a secretory signal) and an AcV5 epitope tag. In the case of CD19 construct, a FLAG tag was inserted between the signal peptide and the beginning of the extracellular domain. The whole cassette was cloned downstream of the human EF1α promoter into the lentiviral vector pLenti-EF1 to make constructs pLenti-EF1-FLAG-CD19-ECD-GGSG-NLuc-AcV5 and pLenti-EF1-MPL-ECD-GGSG-NLuc-AcV5, respectively. The nucleic acid sequences of the insert fragments are provided in SEQ ID NO: 926 and SEQ ID NO: 925, respectively. The protein sequences of the insert fragments are provided in SEQ ID NO: 2671 and SEQ ID NO: 2670, respectively. The constructs were transfected into 293FT cells by calcium phosphate co-precipitation method. Approximately 20 h post-transfection, the cell culture media was replaced with fresh medium. The conditioned media containing the secreted FLAG-CD19-ECD-GGSG-NLuc-AcV5 (also referred to as CD19-GGSG-NLuc-AcV5) and MPL-ECD-GGSG-NLuc-AcV5 (also referred to as MPL-GGSG-NLuc-AcV5) proteins was collected 48-72 h later.

293FT-cells were transiently transfected (in a 24-well plate, 500 μl volume) with lentiviral constructs expressing chimeric antigen receptors CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467], CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658] or CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731] using calcium phosphate co-transfection method or left untransfected. Next day morning, approximately 18 hours post-transfection, cells were collected by pipetting up and down in 1.5 ml tubes. The tubes were spun down at 1500 RPM for 5 minutes. Then the cells were washed once with wash buffer (1% FBS in PBS), followed by incubation with 1001 of indicated secretory forms of GGS NLuc supernatants. The cells were incubated at 4° C. for 1 hour.

After the incubation, cells were washed 5 times with wash buffer (1 ml each wash). Finally the pellet was resuspended in 200 μl wash buffer. Resuspended cells were placed in a 384 well plate in triplicate (25 μl each). Luciferase activity was measured using a BioTek synergy H4 plate reader after addition of NLuc assay buffer (Promega) containing native coelenterazine (25 μl each well) directly to each well (one at a time).

As shown in the FIG. 4A, 293FT cells expressing the CAR CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467] that targets CD19 demonstrated strong binding to FLAG-CD19-ECD-GGSG-NLuc-AcV5[SEQ ID NO: 926] as measured by NLuc assay while very little binding was seen on uninfected T cells (UI) or those expressing the control CAR CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658]. Similarly, 293FT cells expressing the CAR CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731] showed strong binding with MPL-ECD-GGSG-NLuc-AcV5[SEQ ID NO: 925] supernatant as compared to un-transfected 293FT cells or those transfected with the CAR CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467] (FIG. 4B).

Assay to Detect the Expression of Chimeric Antigen Receptors Targeting MPL (Thrombopoietin Receptor) on 293FT Cells that had been Transfected with the Different CAR Constructs

The construct hTPO-(1-187)-Myc-CD28z-T2A-PAC(031915-U04)[SEQ ID NO:1738], mTPO-(1-187)-Myc-CD28z-T2A-PAC(031915-V03)[SEQ ID NO:1739], CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658] and a control CAR construct containing a scFv derived from an irrelevant antibody were transiently transfected into 293FT cells and incubated with MPL-ECD-GGSG-NLuc-AcV5[SEQ ID NO: 925] supernatant essentially as described in the preceding example. FIG. 5 shows modest binding of MPL-ECD-GGSG-NLuc-AcV5 to 293FT cells transfected with hTPO-(1-187)-Myc-CD28z-T2A-PAC(031915-U04)[SEQ ID NO:1738] and mTPO-(1-187)-Myc-CD28z-T2A-PAC(031915-V03)[SEQ ID NO:1739] constructs and strong binding to 293FT cells transfected with CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658]construct as compared to untransfected cells or cells that had been transfected with control CAR construct.

MPL-CARs are Expressed on the Surface of T Cells

Purified T cells were infected with lentiviruses encoding the different Myc-tagged CAR constructs targeting MPL. The constructs also co-expressed EGFP. The expression of CAR on T cells was examined by EGFP fluorescence and immunofluorescence staining with an APC-conjugated Myc-antibody followed by FACS analysis on a BD verse flow cytometer. FIG. 6 shows expression of MPL CARs on the surface of T cells as determined by increased EGFP fluorescence and increased staining with APC-Myc as compared to the uninfected T cells (UI).

T Cells Expressing MPL CARs are Capable of Binding MPL-GGSG-NLuc Fusion Protein

T cells expressing the different MPL CAR constructs were incubated with MPL-GGSG-NLuc-AcV5 and CD19-GGSG-NLuc-AcV5 supernatants and after extensive washes assayed for NLuc activity essentially as described in the preceding example. FIG. 7 shows strong binding of T cells expressing CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658], CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-Q04)[SEQ ID NO:1733], CD8SP-MPL-VB22Bw4-(vL-vH)-Myc-CD28z-T2A-PAC(031615-B06)[SEQ ID NO:3536] CARs and modest binding of T cells expressing CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731], CD8SP-AB317-(vL-vH)-Myc-CD28z-T2A-PAC(031615-T04)[SEQ ID NO:1735] and CD8SP-12E10-(vL-vH)-Myc-CD28z-T2A-PAC(031615-S03)[SEQ ID NO:1736] to MPL-GGSG-NLuc AcV5 supernatant, while no significant binding was observed on uninfected T cells or those expressing the control CAR CD8SP-4C3-(vL-vH)-Myc-CD28z-T2A-Pac(031615-WO5)[SEQ ID NO:3534]. Similarly, no specific binding was observed on any MPL CAR-T cells with CD19-GGSG-NLuc-AcV5 supernatant, thereby demonstrating the specificity of the assay.

MPL CARs Activate T Cell Signaling in Jurkat Cells Upon Antigen Stimulation.

Jurkat cells stably expressing an NFAT-EGFP reporter construct were stably transduced with lentiviral vectors expressing the different CAR constructs targeting MPL followed by selection with puromycin. Cells were subsequently co-cultured with MPL-expressing HEL.92.1.7 (HEL) cells. Co-culturing of MPL-CAR expressing Jurkat-NFAT-EGFP cells with HEL cells resulted in increase in EGFP expression as determined by FACS analysis, which was evident as early as 4 h after co-culture. The increase in EGFP expression was strongest in Jurkat-NFAT-EGFP cells expressing the CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658], CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731] and CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-Q04)[SEQ ID NO:1733] constructs. In an independent experiment, significant EGFP induction was also observed upon culturing of Jurkat-NFAT-EGFP cells expressing the CD8SP-2-MPL-111-(vL-vH)-Myc-BBz-T2A-PAC(041316-A03)[SEQ ID NO:1660] CAR construct with HEL cells. The experiment was repeated by co-culturing the Jurkat-NFAT-EGFP cells with either RAJI cells, which have weak MPL expression, or with RAJI-MPL cells that were engineered to ectopically express human MPL receptor. Jurkat-NFAT-EGFP cells expressing CAR directed against MPL showed more increase in EGFP expression when incubated with RAJI-MPL cells as compared with RAJI-vector cells. The increase in EGFP expression was again strongest in Jurkat-NFAT-EGFP cells expressing the CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658], CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731] and CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-Q04)[SEQ ID NO:1733] constructs.

TABLE 25

EGFP induction in Jurkat-NFAT-eGFP cells expressing

different CARs

GFP induction (%)

TARGET CELL LINE

RAJI-
RAJI-

S. No.
Jurkat-NFAT-EGFP
NONE
HEL
vector
Mpl

1
Jurkat-NFAT-EGFP (Parental cells)
3
1
3
3

2
CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-
4
27
4
23

PAC(021015-R07)[SEQ ID NO: 1658]

3
CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-
4
14
5
11

Z07)[SEQ ID NO: 1731]

4
CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-
6
33
11
18

Q04)[SEQ ID NO: 1733]

5
CD8SP-178-(vL-vH)-Myc-CD28z-T2A-PAC(031615-
4
2
4
3

R04)[SEQ ID NO: 1734]

6
CD8SP-12E10-(vL-vH)-Myc-CD28z-T2A-
2
5
4
6

PAC(031615-S03)[SEQ ID NO: 1736]

7
CD8SP-AB317-(vL-vH)-Myc-CD28z-T2A-
1
1
3
6

PAC(031615-T04)[SEQ ID NO: 1735]

T Cells Expressing MPL CAR Induce Cytotoxicity in MPL-Expressing Target Leukemia Cells

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the CAR construct CD8SP-161-(vL-vH)-Myc-CD8TM-BBz-T2A-EGFP(090814-C03)[SEQ ID NO:1732] targeting MPL or left uninfected (UI). The indicated number of HEL cells stably expressing GLuc were cocultured with T cells expressing the CD8SP-161-(vL-vH)-Myc-CD8TM-BBz-T2A-EGFP(090814-C03)[SEQ ID NO:1732] in a 384 well plate at an Effector: Target (E:T) ratio of 1:1 for 4 hours. CAR-T cells mediated induction of lysis of target cells was assayed by increase of GLuc activity as measured by BioTek synergy plate reader by directly injecting 0.5× CTZ assay buffer containing native coeloentrazine (Nanaolight). FIG. 8 shows increase in GLuc activity following co-culture with T cells expressing MPL-specific CD8SP-161-(vL-vH)-Myc-CD8TM-BBz-T2A-EGFP(090814-C03)[SEQ ID NO:1732] CAR as compared to the uninfected T cells indicating lysis of target cells by the different MPL-CAR-T cells.

PBMC Expressing MPL CAR Induce Lysis of Target Leukemia Cells Expressing MPL

The blood samples to isolate Peripheral blood mononuclear cells (PBMCs) were obtained from healthy de-identified adult donors. PBMC were isolated from buffy coats by Ficoll-Hypaque gradient centrifugation and re-suspended in XVIVO medium (Lonza) supplanted with 10 ng/ml soluble anti-CD3, 10 ng/ml soluble anti-CD28 and 100 IU recombinant human-IL2. PBMCs were engineered to express CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658]CAR targeting MPL and CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467] targeting CD19 by infection with the respective lentiviral vectors followed by selection with puromycin. The PBMC expressing the indicated CARs and uninfected PBMC were co-cultured with HEL-GLuc target cells for 4 h and lysis of target cells measured by the single-step homogenous GLuc assay by injecting 0.5× CTZ assay buffer as described above. FIG. 9 shows increased killing of HEL-GLuc cells by CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658] CAR-expressing PBMC as compared to the FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467]CAR-expressing PBMC or uninfected PBMC.

PBMC Expressing MPL CAR Induce Lysis of Target Leukemia Cells Expressing MPL

The blood samples to isolate Peripheral blood mononuclear cells (PBMCs) were obtained from healthy de-identified adult donors. PBMC were isolated from buffy coats by Ficoll-Hypaque gradient centrifugation and re-suspended in XVIVO medium (Lonza) supplanted with 10 ng/ml soluble anti-CD3, 10 ng/ml soluble anti-CD28 and 100 IU recombinant human-IL2. PBMCs were engineered to express CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-Q04)[SEQ ID NO:1733]CAR targeting MPL by infection with the lentiviral vector followed by selection with puromycin. The PBMCs expressing the indicated CAR and uninfected PBMCs were co-cultured with HEL-GLuc target cells for 4 h and lysis of target cells measured by the single-step homogenous GLuc assay by injecting 0.5× CTZ assay buffer as described above. FIG. 10 shows increased killing of HEL-GLuc cells by the CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-Q04)[SEQ ID NO:1733] CAR expressing PBMC as compared to uninfected PBMC.

T Cells Expressing MPL CARs Expressing CD28 Costimulatory Domain Induce Cytotoxicity in MPL-Expressing Target Leukemia Cells

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the CAR constructs CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731], CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-Q04)[SEQ ID NO:1733], CD8SP-178-(vL-vH)-Myc-CD28z-T2A-PAC(031615-R04)[SEQ ID NO:1734], and CD8SP-AB317-(vL-vH)-Myc-CD28z-T2A-PAC(031615-T04)[SEQ ID NO:1735] targeting MPL. Cells were selected with puromycin and expanded. HEL cells stably expressing GLuc were cocultured with T cells expressing the CARs at an Effector: Target (E:T) ratio of 10:1 for 4 hours. CAR-T cells mediated induction of lysis of target cells was assayed by increase of GLuc activity. FIG. 11 shows increase in GLuc activity, indicating lysis of target cells, following co-culture with T cells expressing MPL-specific CARs, which was stronger with the CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731], CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-Q04)[SEQ ID NO:1733], and CD8SP-AB317-(vL-vH)-Myc-CD28z-T2A-PAC(031615-T04)[SEQ ID NO:1735] constructs and modest with the CD8SP-178-(vL-vH)-Myc-CD28z-T2A-PAC(031615-R04)[SEQ ID NO:1734] construct as compared to the uninfected T cells.

T Cells Expressing MPL CARs Expressing CD28 Costimulatory Domain Induce Cytotoxicity in MPL-Expressing Target Leukemia Cells

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the CAR constructs CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731], CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-Q04)[SEQ ID NO:1733], CD8SP-178-(vL-vH)-Myc-CD28z-T2A-PAC(031615-R04)[SEQ ID NO:1734], CD8SP-AB317-(vL-vH)-Myc-CD28z-T2A-PAC(031615-T04)[SEQ ID NO:1735], CD8SP-12E10-(vL-vH)-Myc-CD28z-T2A-PAC(031615-S03)[SEQ ID NO:1736] and CD8SP-VB22Bw4-(vL-vH)-Myc-CD28z-T2A-PAC(031615-B06)[SEQ ID NO:3536] targeting MPL. Cells were selected with puromycin and expanded. Jurkat cells stably expressing MPL and GLuc were cocultured with T cells expressing the CARs at an Effector: Target (E:T) ratio of 10:1 for 4 hours. CAR-T cells mediated induction of lysis of target cells was assayed by increase of GLuc activity as measured by BioTek synergy plate reader by directly injecting 0.5× CTZ assay buffer containing native coeloentrazine (Nanaolight). FIG. 12 shows increase in GLuc activity, indicating lysis of target cells, following co-culture with T cells expressing MPL-specific CARs, which was stronger with the CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731], CD8SP-175-(vL-vH)-Myc-CD28z-T2A-PAC(031615-Q04)[SEQ ID NO:1733], CD8SP-AB317-(vL-vH)-Myc-CD28z-T2A-PAC(031615-T04)[SEQ ID NO:1735], and CD8SP-12E10-(vL-vH)-Myc-CD28z-T2A-PAC(031615-503)[SEQ ID NO:1736] constructs and modest with the CD8SP-178-(vL-vH)-Myc-CD28z-T2A-PAC(031615-R04)[SEQ ID NO:1734] and CD8SP-VB22Bw4-(vL-vH)-Myc-CD28z-T2A-PAC(031615-B06)[SEQ ID NO:3536] constructs as compared to the uninfected T cells.

NK92MI Cells Expressing MPL-Specific 161-CAR Induce Cytotoxicity in K562 and HEL.92.1.7 Cells

Natural Killer cell derived NK92MI (ATCC) cells were stably transduced with lentiviral vectors expressing the indicated CAR constructs targeting CD8SP-161-(vL-vH)-Myc-CD8TM-BBz-T2A-EGFP(090814-C03)[SEQ ID NO:1732] and CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-EGFP(070814-D06)[SEQ ID NO:3535]. Cells were subsequently co-cultured overnight with HEL.92.1.7 cells that had been engineered to express GLuc. CAR-expressing NK92MI cells-mediated induction of lysis of target cells was assayed by increase of GLuc activity as measured by directly injecting 0.5× CTZ assay buffer containing native coeloentrazine (Nanaolight). FIG. 13 shows increase in GLuc activity, indicating lysis of target cells, following co-culture with NK92MI cells expressing MPL-specific CD8SP-161-(vL-vH)-Myc-CD8TM-BBz-T2A-EGFP(090814-C03)[SEQ ID NO:1732]CAR.

NK92MI Cells Expressing MPL-Specific CARs Induce Cytotoxicity in K562-MPL Cells

Natural Killer cell derived NK92MI (ATCC) cells were stably transduced with lentiviral vectors expressing the indicated CAR constructs targeting MPL followed by selection with puromycin. Cells were subsequently co-cultured overnight with K562 cells that had been engineered to express MPL and GLuc. The effector to target (E:T) ratio was 5:1. MPL-CAR-expressing NK92MI cells-mediated induction of lysis of target cells was assayed by increase of GLuc activity as measured by directly injecting 0.5× CTZ assay buffer containing native coeloentrazine (Nanaolight). FIG. 14 shows increase in GLuc activity, indicating lysis of target cells, following co-culture with NK92MI cells expressing MPL-specific CARs.

Cytokine Production by T Cells Expressing MPL-Specific CAR Constructs on Exposure to Target Cells Expressing MPL

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-PAC(021015-R07)[SEQ ID NO:1658] and CD8SP-161-(vL-vH)-Myc-CD28z-T2A-PAC(021715-Z07)[SEQ ID NO:1731] CAR constructs targeting MPL. Cells were selected with puromycin and expanded. HEL cells were co-cultured with T cells expressing the CARs for approximately 96 hours and secretion of TNFα in the supernatant measured by ELISA. FIG. 15 shows increased secretion of TNFα upon co-culture of T cells expressing CAR targeting MPL with HEL cells as compared to uninfected T cells used as controls.

In Vivo Efficacy of MPL CAR-Expressing Immune Effector Cells Against Leukemia

The in vivo efficacy of MPL CAR-expressing NK92MI cells against HEL leukemia cell line model was tested in NOD/SCID/γ^−/− (NSG) mouse model. On day 0, the NSG mice (Jackson Lab) were sub-lethally irradiated at a dose of 275 cGy. 24 hours post irradiation (day 1), mice were injected with 1×10⁶HEL cells intravenously. On day 9 and day 19, the mice were treated with 2 million NK92MI cells expressing the indicated CAR constructs intravenously and followed for survival. FIG. 16 shows that the median survival of mice given CD8SP-161-(vL-vH)-Myc-CD8TM-BBz-T2A-EGFP(090814-C03)[SEQ ID NO:1732]-expressing NK92MI cells was 31.5 days, which was significantly higher than mice given unmodified NK92MI cells (28.5 days; p=0.03) or those given NK92MI cells expressing a control CAR CD8SP-4C3-(vL-vH)-Myc-BBz-T2A-EGFP(100814-K06)[SEQ ID NO:3537]; 28 days; p=0.04).

Chimeric Antigen Receptors Targeting CD19 with scFV Fragments Derived from a Humanized CD19 Antibody

The CD19 CARs in current clinical trials contain scFV fragments derived from murine monoclonal antibodies. The development of antibodies against the murine antibody fragments not only contributes to lack of persistence of T cells expressing such CARs but could also lead to allergic reactions, including anaphylaxis. To overcome this limitation, a CD19 CARs was generated containing an scFv fragment (SEQ ID NO: 566) derived from a humanized CD19 monoclonal antibody huCD19-Bu12 (or Bu12) described in PCT/US2008/080373. Another CAR was constructed containing an scFv (SEQ ID NO: 567) fragment derived from a murine antibody described in U.S. Pat. No. 7,112,324 and was designated CD19MM.

The scFV fragments based on CD19-Bu12 and CD19MM were designed consisting from 5′ to 3′ ends of a nucleotide sequences encoding a signal peptide derived from human CD8 molecule, the vL fragment, a (Gly4Ser)x3 linker and the vH fragment. The sequence of the scFV fragments were codon-optimized using GeneArt™ software (Thermo Fisher Scientific) and gene-fragments encoding the optimized sequences synthesized using a commercial vendor. The gene fragments were used as templates in PCR reaction using custom primers and then cloned in a modified pLENTI-EF1α vector containing the hinge, transmembrane and cytosolic domains of the CAR cassette by standard molecular biology techniques. The final CAR construct CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471] consisted of human CD8 signal peptide, fused in frame to the CD19MM scFv fragment (SEQ ID NO: 567), a Myc epitope tag, the hinge and transmembrane domain of human CD8 (SEQ ID NO: 842), the cytosolic domain of human 41BB (CD137) receptor (SEQ ID NO: 845), the cytosolic domain of human CD3z (SEQ ID NO: 846), a T2A ribosomal skip sequence (SEQ ID NO: 832) and a cDNA encoding a variant of puromycin resistance gene (SEQ ID NO: 850). A CAR construct CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470] based on CD19Bu12 scFv fragment (SEQ ID NO: 566) was designed similarly. The CAR construct CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467] was designed based on the previously described CD19 CAR containing the scFV fragment (SEQ ID NO: 564) derived from mouse monoclonal antibody FMC63. Finally, the CAR construct CD8SP-KSHV-4C3-(vL-vH)-Myc-BBz-T2A-PAC(042315-N01)[SEQ ID NO:1643] contains an scFV fragment (SEQ ID NO: 718) derived from an antibody against a KSHV encoded K8.1 protein and was used as a negative control. Lentiviruses encoding the above CARs were generated using 293FT and used to infect T cells as described previously for MPL CARs.

CD19-CARs are Expressed on the Surface of T Cells

Purified T cells were infected with lentiviruses encoding the different Myc-tagged CAR constructs targeting MPL (CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467], CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470], CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471] and CD8SP-KSHV-4C3-(vL-vH)-Myc-BBz-T2A-PAC(042315-N01)[SEQ ID NO:1643]) and selected with puromycin. The expression of CAR on T cells (both puromycin selected and unselected) was examined by immunofluorescence staining with an APC-conjugated Myc-antibody followed by FACS analysis as described previously. FIG. 17 shows increased expression of the different CD19 CARs (shown with grey lines) on the surface of T cells as determined by staining with APC-Myc as compared to the uninfected T cells (UI; shown with dotted lines). The expression of the different CAR constructs was further increased following puromycin selection.

Jurkat Cells Expressing CD19 CARs are Capable of Binding CD19-GGSG-NLuc Fusion Protein

Jurkat-NFAT-Luc cells were stably transduced with the different CD19 targeted CAR constructs and selected in puromycin. Cells were incubated with FLAG-CD19-ECD-GGSG-NLuc-AcV5 [SEQ ID NO:2671] supernatant and after extensive washes assayed for NLuc activity essentially as described previously. FIG. 18 shows strong binding of Jurkats expressing CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470], CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471] and CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467], and CD19Bu12(vL-vH)-Myc-BBz-PAC-P08 CAR constructs to FLAG-CD19-ECD-GGSG-NLuc-AcV5 [SEQ ID NO:2671] supernatant, while no significant binding was observed on parental cells or those expressing CD8SP-KSHV-4C3-(vL-vH)-Myc-BBz-T2A-PAC(042315-N01)[SEQ ID NO:1643] control CAR.

T Cells Expressing CD19 CARs are Capable of Binding CD19-GGSG-NLuc Fusion Protein

Purified T cells were stably transduced with the different CD19-targeted CAR constructs and selected in puromycin. Cells were incubated with FLAG-CD19-ECD-GGSG-NLuc-AcV5 [SEQ ID NO:2671] supernatant and after extensive washes assayed for NLuc activity essentially as described previously. FIG. 19 shows strong binding of T cells expressing CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470], CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471] and CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467], and CD19Bu12(vL-vH)-Myc-BBz-PAC-P08 CAR constructs to FLAG-CD19-ECD-GGSG-NLuc-AcV5 [SEQ ID NO:2671] supernatant, while no significant binding was observed on uninfected T cells (UI) or those expressing CD8SP-KSHV-4C3-(vL-vH)-Myc-BBz-T2A-PAC(042315-N01)[SEQ ID NO:1643] control CAR.

T Cells Expressing CD19 CARs Induce Cytotoxicity in CD19-Expressing RAJI Lymphoma Cells

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the indicated CAR constructs targeting CD19. Cells were left unselected or selected with puromycin and expanded. RAJI cells stably expressing GLuc were cocultured with T cells expressing the CARs at an Effector: Target (E:T) ratio of 10:1 for 96 hours. CAR-T cells mediated induction of lysis of target cells was assayed by increase of GLuc activity. FIG. 20 shows increase in GLuc activity, indicating lysis of target cells, following co-culture with T cells expressing CD19-specific CARs as compared to uninfected T cells (T-UI) or those expressing the control CAR 4C3. The increased cell death was seen in CD19 CAR-expressing T cells that had been selected with puromycin as well as those that had not been selected.

T Cells Expressing CD19 CARs Induce Cytotoxicity in CD19-Expressing RAJI Lymphoma Cells

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the indicated CAR constructs targeting CD19. Cells were left unselected or selected with puromycin and expanded. RAJI cells stably expressing GLuc were cocultured with T cells expressing the CARs at the indicated Effector: Target (E:T) ratios for 4 hours. CAR-T cells mediated induction of lysis of target cells was assayed by increase of GLuc activity. FIG. 21 shows increase in GLuc activity, indicating lysis of target cells, following co-culture with T cells expressing CD19-specific CARs as compared to uninfected T cells (T-UI) or those expressing the control 4C3 CAR. In contrast to the results in the preceding section, the increased cell death was seen primarily in CD19 CAR-expressing T cells that had been selected with puromycin. This could be attributable to the fact that cell death was measured after 96 h of co-culture in the preceding example while it was measured after only 4 h in the current example.

In Vivo Efficacy of CD19MM-BBz and CD19Bu12-BBz CAR T Cells

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the indicated CAR constructs targeting CD19 or the control CAR (4C3) and expanded in vitro with (with puro) or without (No puro) puromycin selection. NSG mice (Jackson Lab) were sub-lethally irradiated at a dose of 175 cGy. 24 hours post irradiation (day2), mice were injected with 2.5×10⁴RAJI cells via tail-vein. On day3, the mice (n=5 for each group) were treated with 1 million T cells that had been infected with the CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470], CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471] encoding lentiviruses and either selected with puromycin (with puro) or left unselected (No puro). Control mice (n=5) were injected with 1 million T cells expressing the CD8SP-KSHV-4C3-(vL-vH)-Myc-BBz-T2A-PAC(042315-N01)[SEQ ID NO:1643] CAR or given no T cells. FIG. 22 shows the survival of mice in each group. The median survival of mice given RAJI cells alone and CD8SP-KSHV-4C3-(vL-vH)-Myc-BBz-T2A-PAC(042315-N01)[SEQ ID NO:1643]CAR-T cells were 17 days and 21 days respectively. In contrast, the median survival of mice which received CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471] CAR-T cells with and without puromycin selection were 26 and 30 days, respectively. Similarly, the median survival of mice which received CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470] CAR-T cells with and without puromycin selection were 30 and 31 days, respectively. Thus, infusion of T cells expressing CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470], CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471] CARs lead to statistically significant improvement in survival of mice in this RAJI xenograft model of lymphoma as compared to mice given no T cells or those given T cells expressing the CD8SP-KSHV-4C3-(vL-vH)-Myc-BBz-T2A-PAC(042315-N01)[SEQ ID NO:1643] control CAR.

Applications of Anti-CD19 Humanized CAR Constructs when Used Alone or in Combination with Other Strategies

The humanized CARs of this invention can be expressed in the following way to enhance their safety and efficacy:

Although we have used lentiviral methods for expression of the humanized CARs, alternate methods such as use of mRNA/DNA transfection by electroporation or by transient perturbation in cell membrane can be used to express them in the target cells. The mRNA transfection may involve natural or stabilizing nucleotides to enhance the longevity of expression. Alternate methods for gene delivery, such as use of retroviral, adenoviral and adeno-associated viral vectors have been well described in the literature and are known to those skilled in the art. Alternate promoters for expression of the humanized CAR including CMV, MSCV etc. have been described in the literature.

The CARs of the present invention could be also expressed with suitable selection markers, such as extracellular domain sequences of EGFR, tEGFR, CD19, BCMA (SEQ ID NOs: 853-856), to positively select CAR-expressing cells and to reduce the clonal diversity of the final T cell product before it is used for infusion into the patient. Reduction in clonal-diversity of the CAR-T cell product will lead to reduction in the incidence and severity of Graft versus Host Disease (GVHD) as it will reduce the probability and number of host-reactive T cell clones in the product. Alternate resistance gene, such as CNB30 (SEQ ID NO: 852), which confers resistance to calcineurin inhibitors, can be included to positively select CAR-expressing cells and to reduce the clonal diversity of the final T cell product before it is used for infusion into the patient to reduce the incidence of GVHD.

One of the limitations of CD19 CAR-T cell therapy is long-term depletion of normal B cells, which also express CD19 antigen. To circumvent this problem, CD19 CAR-T cell therapy can be combined with knock-out or mutation of endogenous CD19 in normal hematopoietic stem cells using CRIPS/Cas9, TALONS or other suitable gene editing methods which are known in the art. The epitope of CD19 bound by the CD19 CAR-T cells in current clinical use has been mapped to exons 2-4. Thus, missense or nonsense mutations can be generated in exon 2 (or other suitable exons/regions that are recognized by CD19Bu12 and CD19MM CAR T-cells) of autologous or allogeneic hematopoietic stem cells using CRISP/Cas9, Zn finger nucleases, Talons or other methods known in the art. The patient can be given CD19 CAR-T cells infusion to control his/her disease and an autologous or allogeneic transplant using CD19 deleted/mutated hematopoietic stem cells. As the B cells that will originate from the modified stem cells will not be targeted by CD19-CAR-T cells, the patient will escape B cell aplasia which is a common side effect of CD19 CAR-T cells.

The CD19 targeted humanized CARs of the present invention can be also combined with CAR targeting other antigens, such as CD22 and CD20, to overcome resistance due to loss of CD19 antigens. Such bispecific CARs have been described in the literature and are known to one skilled in the art.

The humanized CAR constructs of the present invention can be expressed not only in T cells but in defined subsets of T cells such as CD4 and CD8 T cells, central memory T cells, naïve T cells and regulatory T cells. They can be also expressed in NK cells, NK92 cell line, hematopoietic stem cells, and iPSC derived stem cells.

To control their activity, the humanized CAR of the current invention can be expressed in an inducible fashion as is known in the art (Roybal et al., Cell 164:770-9, 2016; Wu et al., Curr Opin Immunol 35:123-30, 2015; Wu et al., Science 350:aab4077, 2015)). Alternatively, suicide genes (such as icaspase 9), can be used to control the activity of CAR-T cells in vivo.

The activity of the CAR-T cells of this invention can be further modulated by use of inhibitors of various signaling pathways, such as mTOR and PI3-AKT pathways. Furthermore, various cytokines, chemokines and their receptors, and costimulatory ligands (e.g. 41BB) and their receptor (e.g. 41BB-receptor or CD137) can be coexpressed with the humanized CAR of the current invention.

Novel Chimeric Antigen Receptors Expressing Viral and Cellular Signaling Proteins

As discussed previously, the CAR constructs in clinical trials include one or more costimulatory domains derived from 41BB, CD28 or both. These costimulatory domains are generally derived from the cytosolic signaling domains of TNF (Tumor Necrosis Factor) family receptors and are believed to activate signaling pathways, such as NF-κB and AKT, which are believed to contribute to increased proliferation and survival of CAR-T cells, resulting in their expansion and persistence in vivo. However, tonic signaling through these costimulatory domains when expressed as part of an artificial receptor, such as a CAR, is not physiological and is not under the control of feedback regulatory mechanisms that are normally present to control signaling via the TNF family receptors from which they are derived. Therefore, it is conceivable that robust and persistent activation of signaling pathways by the costimulatory domains present in the current CAR constructs contributes to the cytokine release syndrome and neurological toxicity, which re a major side effect of current CAR-T cells based therapies. It is important to note in this context that cytokine release syndrome was a major side effect in human clinical trials of a CD28 super-agonist antibody.

The present invention circumvents the above limitation of the current CAR vectors by deleting the costimulatory domains. The costimulatory function instead is provided by viral and cellular proteins that are known to constitutively activate various pro-survival signaling pathways and/or block cell death. The viral proteins suitable for this purpose include viral FLICE Inhibitory Protein (vFLIP) K13 encoded by the Kaposi's sarcoma associated herpesvirus (also known as human herpesvirus 8), vFLIP MC159 and MC160 from the molluscum contagiosum virus (MCV), E8 from the equine herpesvirus 2 (EHV2), vFLIP encoded by the bovine herpesvirus 4, vFLIP encoded by herpesvirus mecaca, vFLIP encoded by herpesvirus saimiri, cFLIP-L isoform or MRIT-α, cFLIP-p22 deletion mutant or MRIT-p22, HTLV1-Tax, HTLV2-Tax and HTLV2-Tax-RS mutant (Jeang, Cytokine Growth Factor Rev 12:207-17, 2001; Sieburg et al., J Virol 78:10399-409, 2004). In contrast to artificial and non-physiological nature of the pro-survival signal provided by the costimulatory domains that are components of the CAR constructs in common use today, these signaling proteins have evolved to provide constitutive pro-survival signals to the cells in which they are expressed.

KSHV-Encoded Viral FLICE Inhibitory Protein K13 Immortalizes T Cells

vFLIP K13 was originally believed to protect KSHV-infected cells from death receptor-induced apoptosis (Bertin et al., Proc Natl Acad Sci USA 94:1172-6, 1997; Hu et al., J Biol Chem 272:9621-4, 1997; Thome et al., Nature 386:517-21, 1997)). However, it was subsequently reported that K13 selectively activates the NF-κB pathway (Chaudhary et al., Oncogene 18:5738-46, 1999; Chugh et al., Proc Natl Acad Sci USA 102:12885-90, 2005) by interacting with a −700 kDa IκB kinases (IKK) complex which consists of IKK1/IKKα, IKK2/IKKβ and NEMO/IKKγ (Chaudhary et al., Oncogene 18:5738-46, 1999; Liu et al., J Biol Chem 277:13745-51, 2002). HTLV1-encoded Tax protein is also known to activate the NF-κB pathway by binding to NEMO/IKKγ. Tax has been also shown to immortalize T cells (Ren et al., J Biol Chem 287:34683-93, 2012; Robek and Ratner, J Virol 73:4856-65, 1999).

Human peripheral blood mononuclear cells (PBMC), CD3+ve T cells and CD3-ve cells (designated B cells) were cultured in XVIVO medium (Lonza) supplanted with 10 ng/ml soluble anti-CD3, 10 ng/ml soluble anti-CD28 and 100 IU recombinant human-IL2. Cells were cultured at 37° C., in a 5% CO2 humidified incubator, and after 1 day infected with an empty lentiviral vector (pLENTI) carrying blasticidin resistance gene and lentiviral vectors expressing C-terminal Flag-Tagged K13 (pLENTI-K13-FLAG), a deletion mutant of K13 (pLENTI-K13A45-48-FLAG) that is known to lack NF-κB activity (Matta et al., Oncogene 27:5243-53, 2008), and HTLV1-Tax protein (pLENTI-Tax). The nucleotide and protein sequences of K13 are provided in SEQ ID NOs: 866 and 2629, respectively. Approximately 1 day post-infection, cells were selected with blasticidin. After selection, the cells were grown in XVIVO medium and IL2 withdrawn. Table 26 shows that both PBMC and T cells infected with K13-Flag and HTLV1-Tax encoding vectors continued to proliferate in culture long after IL2 withdrawal, while no long term proliferating cells were obtained with cultures infected with empty lentiviral vector or those infected with K13A45-48-FLAG encoding vector. These results demonstrate that similar to HTLV1-Tax, K13 can promote long term proliferation and immortalization of primary T cells and PBMC and its NF-κB activity is essential for this process.

TABLE 26

Table: K13-induced immortalization

of primary lymphocytes.

PBMCs
T-cells
B-cells

Vector
−
−
−

K13
+
+
−

K13-Δ45-48
−
−
−

HTLV-Tax
+
+
−

Expression of K13-FLAG in the surviving culture of T cells was examined by immunofluorescence staining with FITC-conjugated FLAG antibody followed by FACS analysis. FIG. 23 shows increased staining with FITC-FLAG antibody in K13-expressing T cells as compared to uninfected T cells. The immunophenotype of K13 immortalized T cells was examined by staining with CD4 and CD8 antibodies. FIG. 23 shows that K13 immortalized T cells are CD8+/CD4−(49%), CD8−/CD4+(21%) and CD8+/CD4+(29%). In contrast, a majority of uninfected T cells persisting in culture were CD8+/CD4−(94%). There was no significant difference in the expression of CD69 between uninfected and K13-immortalized T cells.

FMC63 CAR Expressing K13 Retain the Capacity to Induce Lysis of RS4;11 Target Cells

T cells were infected with lentiviral vectors encoding GFP, CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-EGFP(070814-D06)[SEQ ID NO:3535], CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467], and CD8SP-FMC63-(vL-vH)-Myc-BBz-P2A-K13-Flag-T2A-PAC(111014-Y11)[SEQ ID NO:1197]. The cells infected with PAC containing vectors were selected with puromycin or left unselected. FIG. 24 shows that CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467], and CD8SP-FMC63-(vL-vH)-Myc-BBz-P2A-K13-Flag-T2A-PAC(111014-Y11)[SEQ ID NO:1197]-expressing T cells that have been selected with puromycin induce specific lysis of RS411 cells as measured by Gluc assay.

T Cells Expressing CAR Containing K13, MC159 or Tax2 Induce Specific Lysis of RAJI-Gluc Cells

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the following constructs targeting CD19. The features of the constructs are as follows:

CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467]: A standard FMC63 based conventional CAR II containing a 41BB costimulatory domain and a CD3z domain separated by a T2A sequence from a Puromycin resistance gene.

CD8SP-FMC63-(vL-vH)-Myc-z-T2A-PAC(111214-D05)[SEQ ID NO:3538]: A FMC63-based conventional CAR I that lacks a 41BB co-stimulatory domain and contains a CD3z activation domain.

CD8SP-FMC63-(vL-vH)-Myc-BBz-P2A-K13-Flag-T2A-PAC(111014-Y11)[SEQ ID NO:1197]: A standard FMC63 based conventional CAR II containing a 41BB costimulatory domain and a CD3z domain, a P2A cleavable linker, a K13-Flag sequence, a T2A cleavable linker, and a Puromycin resistance gene.

CD8SP-FMC63-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC(111614-B05)[SEQ ID NO:927]: A standard FMC63 based conventional CAR I containing a CD3z domain, a P2A cleavable linker, a K13-Flag sequence, a T2A cleavable linker, and a Puromycin resistance gene.

CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-MC159-Flag-T2A-PAC(111014-Z13)[SEQ ID NO:1751]: A standard FMC63 based conventional CAR II containing a 41BB costimulatory domain and a CD3z domain, a P2A cleavable linker, a MC159-Flag sequence, a T2A cleavable linker, and a Puromycin resistance gene.

CD8SP-FMC63(vL-vH)-Myc-z-P2A-MC159-Flag-T2A-PAC(112614-C06)[SEQ ID NO:1750] A standard FMC63 based conventional CAR I containing a CD3z domain, a P2A cleavable linker, a MC159-Flag sequence, a T2A cleavable linker, and a Puromycin resistance gene.

CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-Flag-HTLV2-TAX-RS-T2A-PAC(010100-N01)[SEQ ID NO:1752]: A standard FMC63 based conventional CAR II containing a 41BB costimulatory domain and a CD3z domain, a P2A cleavable linker, an RS mutant of HTLV2-encoded TAX, a T2A cleavable linker, and a Puromycin resistance gene.

Cells were left unselected or selected with puromycin and expanded. RAJI cells stably expressing Glue were cocultured with T cells expressing the CARs at the Effector: Target (E:T) ratio of 10:1 for 4 hours. CAR-T cells mediated induction of lysis of target cells was assayed by increase of GLuc activity. FIG. 25 shows increase in GLuc activity, indicating lysis of target cells, following co-culture with T cells expressing CD19-specific CARs as compared to uninfected T cells (T-UI) or those expressing the control CAR targeting 4C3 (SEQ ID NO: 1643). These results demonstrate that incorporation of K13, MC159 or HTLV2-Tax (Tax2) does not negatively impact the killing ability of CARs with or without the presence of 41BB domain.

The above experiment was repeated at E:T ratio of 1:1 and cell death was assayed after 48h. FIG. 26 confirms that incorporation of K13, MC159 or HTLV2-Tax (Tax2) does not negatively impact the killing ability of CARs with or without the presence of 41BB domain.

The experiment was repeated with cells that had been selected with puromycin and were in culture for approximately 2 months. FIG. 27 shows that the T cells expressing CAR containing MC159 and HTLV2-Tax continue to exert cytotoxicity after 2 months in culture while the T cells expressing the other CARs lost this ability.

In Vivo Efficacy of CAR T Cells Containing vFLIPs and Tax

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the indicated CAR constructs targeting CD19. NSG mice (Jackson Lab) were sub-lethally irradiated at a dose of 175 cGy. 24 hours post irradiation (day2), mice were injected with 2.5×10⁴RAJI cells via tail-vein. On day3, the mice (n=3 for each group) were treated with 1 million T cells that had been infected with the CAR encoding lentiviruses. Table 27 shows the survival of mice in each group. These results demonstrate that highest survival (38 days) is observed in mice injected with T cells expressing FMC63 based CAR CD8SP-FMC63-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC(111614-B05)[SEQ ID NO:927] that lacks 41BB costimulatory domain but expresses K13.

TABLE 27

Median

CAR
Survival

CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)
32

[SEQ ID NO: 1467]

CD8SP-FMC63-(vL-vH)-Myc-z-T2A-PAC(111214-D05)
32

[SEQ ID NO: 3538]

CD8SP-FMC63-(vL-vH)-Myc-BBz-P2A-K13-Flag-T2A-
32

PAC(111014-Y11)[SEQ ID NO: 1197]

CD8SP-FMC63-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC
38

(111614-B05)[SEQ ID NO: 927]

CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-MC159-Flag-T2A-
24

PAC(111014-Z13)[SEQ ID NO: 1751]

CD8SP-FMC63(vL-vH)-Myc-z-P2A-MC159-Flag-T2A-
20

PAC(112614-C06)[SEQ ID NO: 1750]

CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-Flag-HTLV2-TAX-
25

RS-T2A-PAC(010100-N01)[SEQ ID NO: 1752]

Control
20

Inducible Expression of K13 by Fusion with FKBP

To control the expression of K13, different vectors were generated expressing K13 in fusion with one or two copies of N-terminal FKBP-based switch or dimerization domains. In addition, a construct was constructed in which 2 copies of FKBP domain were fused at the N-terminal with a myrisotylation signal and at C-terminus with K13. The above constructs of K13 were either expressed alone or in constructs expressing different CAR constructs.

NF-κB reporter assay was carried out essentially as described (Chaudhary et al., Oncogene 18:5738-46, 1999). The indicated constructs were transiently transfected in 293FT cells along with a luciferase reporter construct driven by 4 copies of NF-κB binding site and a RSV-LacZ reporter construct. Cells were left untreated or treated with AP20187, which dimerizes the FKBP domains, resulting in activation of K13 signaling. Approximately 24 hr later, cells were lysed and NF-κB-Luc and LacZ activities measured in cell lysates. NF-κB-Luc activity was normalized relative to LacZ activity to control for difference in transfection efficiency. As shown in FIG. 28A, treatment with AP20187 (100 nM) led to increase in K13-induced NF-κB-Luc activity in all constructs in which K13 was expressed in fusion with FKBP. Essentially similar results were obtained when RS mutant of HTLV2 encoded Tax was expressed in fusion with FKBP (FIG. 28B). Thus, activity of K13 and Tax can be controlled by fusion with FKBP and subsequent administration of AP20187 when they are expressed alone or as part of CAR constructs.

Activation of K13 Activity by AP20187 does not Impair the Ability of CARs to Induce Cell Death

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the constructs CD8SP-FMC63(vL-vH)-Myc-z-P2A-FKBP-K13-FLAG-T2A-PAC(112316-S06) [SEQ ID NO:1770] and CD8SP-161-(vL-vH)-Myc-z-P2A-FKBP-K13-FLAG-T2A-PAC(112916-U06) [SEQ ID NO: 1741] and selected with puromycin as described previously. RAJI and HEL cells stably expressing Glue were cocultured with uninfected T cells (UI) or T cells expressing the indicated constructs [SEQ ID NO:1770] and [SEQ ID NO: 1741], respectively, at the Effector: Target (E:T) ratio of 10:1 for 4 hours in the absence and presence of 100 nM AP20187 (AP) compound. CAR-T cells mediated induction of lysis of target cells was assayed by increase of GLuc activity. FIGS. 29A and 29B show that activation of K13-mediated NF-κB activity by addition of AP20187 does not adversely affect cell killing induced by the two CAR constructs that coexpress FKBP-K13.

Cytotoxic Activity of CARs I and II Coexpressing K13, MC159, HTLV2-Tax and HTLV2-Tax RS Mutant

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the indicated constructs expressing CAR I and II targeting MPL and coexpressing different accessory modules (FIG. 30A). Cells were selected with puromycin as described previously. HEL cells stably expressing Glue were cocultured with uninfected T cells (UI) or T cells expressing the indicated constructs at the Effector: Target (E:T) ratio of 10:1 for 4 hours. CAR-T cells mediated induction of lysis of target cells was assayed by increase of GLuc. FIG. 30A shows induction of target cell death by different MPL-directed CAR constructs that coexpress K13, MC159, HTLV2-Tax and HTLV2-Tax RS mutant.

Essentially a similar experiment was conducted with a construct (SEQ ID NO: 983) expressing CAR I targeting CD32 and coexpressing K13. FIG. 30B shows effective induction of HEL cell death by T cells expressing this construct as measured by Gluc assay.

Cytotoxic Activity of Backbone 1 Constructs Comprising a Conventional CARs I Targeting TROP2 and Coexpressing K13

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the construct CD8SP-TROP2-h7E6-SVG-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC(052616-D04)[SEQ ID NO:1166] targeting TROP2 and selected with puromycin and tested for the ability to kill PC3 (prostate cancer) cells expressing GLuc using the assay described previously. FIG. 31 shows effective killing of PC3 cells by T cells expressing the CD8SP-TROP2-h7E6-SVG-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC(052616-D04)[SEQ ID NO:1166] construct.

Cytotoxic Activity of Backbone 1 Constructs Comprising a Conventional CARs I Targeting LAMP1 and Coexpressing K13

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the indicated constructs targeting LAMP1 and selected with puromycin. Cells were tested for the ability to kill L363 and U266 cells expressing GLuc using the assay described previously. FIGS. 32A and 32B shows effective killing of L363 and U266 cells by T cells expressing the CD8SP-LAMP1-humab1-2-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC(051716-T05)[SEQ ID NO:1104] and CD8SP-LAMP1-Mb4-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC(051916-B07)[SEQ ID NO:1105] constructs.

Activation of K13 Signaling by Addition of AP20187 in Jurkat Cells Expressing a CD19-Directed CAR and Coexpressing FKBP-K13 Fusion Protein

The effect of induction of K13 induced NF-κB activity on CAR-induced NFAT signaling was studied by stably expressing the construct CD8SP-FMC63(vL-vH)-Myc-z-P2A-FKBP-K13-FLAG-T2A-PAC(112316-506)[SEQ ID NO:1770], which encodes a conventional CAR I targeting CD19 and expresses an FKBP-K13-FLAG fusion protein, in Jurkat-NFAT-GFP cells (JP). The parental Jurkat-NFAT-GFP cells (JP) cells and those expressing the construct CD8SP-FMC63(vL-vH)-Myc-z-P2A-FKBP-K13-FLAG-T2A-PAC(112316-S06)[SEQ ID NO:1770] were cocultured with RAJI cells in the absence and presence of 100 nM AP20187 for approximately 18 hours and induction of NFAT-driven GFP expression examined by FACS analysis as described previously. FIG. 33 shows effective induction of GFP expression in Jurkat cells expressing the CD8SP-FMC63(vL-vH)-Myc-z-P2A-FKBP-K13-FLAG-T2A-PAC(112316-S06)[SEQ ID NO:1770] construct upon coculture with RAJI cells in the absence (38.7% GFP-expressing cells) and presence (45.85% GFP expressing cells) of AP20187 compound. In contrast, no significant GFP induction was observed upon co-culture of parental Jurkat-NFAT-GFP cells (JP) cells with RAJI cells either in the absence or presence of the AP20187 compound. These results demonstrate that activation of K13 signaling in T cells expressing the FKBP-K13 fusion protein by addition of AP20187 compound does not adversely affect activation of CAR-induced NFAT signaling.

Generation of K13 Mutants with Varying Level of NF-κB Activity

It would be useful to have novel mutants of K13 with varying levels of NF-κB activity for the purpose of adoptive cellular therapy and other applications. Site-directed mutagenesis was conducted using Quickchange site-directed kit (Stratagene) to generate several point mutants of K13 in which the different amino acids of K13 (SEQ ID NO:2629) were mutated. For example, in the mutant K19A the amino acid Lysine at position 19 is mutated to alanine. The wild type and the various mutant constructs were transfected in 293FT cells along with a luciferase reporter construct driven by 4 copies of NF-κB binding site and a RSV-LacZ reporter construct essentially as described (Chaudhary et al., Oncogene 18:5738-46, 1999). Approximately 24 hr later, cells were lysed and NF-κB-Luc and LacZ activities measured in cell lysates. NF-κB-Luc activity was normalized relative to LacZ activity to control for difference in transfection efficiency (Chaudhary et al., Oncogene 18:5738-46, 1999). FIG. 34 shows that many mutants have either increase (e.g. E48A mutant) or decrease (e.g., E47A mutant) in NF-κB activity as compared to the wild-type K13. These mutants will have application in adoptive cellular therapy and other applications where varying level of NF-κB activities are required. Thus, mutant E48A can be coexpressed in CAR constructs where strong NF-κB activity is desirable while mutant R50A can be coexpressed in CAR constructs where only modest NF-κB activity is desirable. The activity of these mutants can be also controlled by fusing them with FKBP domains (SEQ ID NOs: 2621 and 2622) as described above for wild-type K13.

A Method of Controlling the Activity of CAR-T Cells, Bispecific T Cell Engagers (BiTEs) and DARTs (Dual Affinity Re-Targeting Proteins) with Src Inhibitors Dasatinib, Ponatinib and A-770041 CAR

CARs are synthetic receptors which combine antibody binding specificity with T cell functionality. CARs are generated by fusing a single chain antibody (scFv) that dictates the specific recognition of desired tumor antigen with the intracellular signaling components of CD3z chain of T cell receptor to enable activation of T cell effector function. The HLA-independent recognition of TAA by CAR not only minimize tolerance induction mechanisms, but also allow the versatile design of CARs recognizing virtually any antigen including non-protein moieties on cell surface. Although CARs activate T cells via the CD3z chain, signaling via CARs is different from signaling via the normal T cell receptor (TCR) as they do not engage all the components of the TCR complex. For example, signaling via a normal TCR results in engagement of several molecules, such as TCRα, TCRβ, CD3γ, CD3δ, CD3ϵ, CD3ξ, and CD4 or CD8 as well as their associated downstream signaling proteins, such as Lck, LAT, ZAP70 and SLP-76 (Chakraborty, A K and Weiss, A Nat Immunol 15:798-807,2014). It is unclear if any of these receptors and signaling intermediates are involved in signaling via a chimeric antigen receptor (CAR). The notion that signaling via CAR is distinct from signaling via a normal TCR is evident from the side effects observed following the infusion of CAR versus those observed after infusion of TCR in patients. While cytokine release syndrome (CSR) and neurological complications are frequently observed following the infusion of CAR-T cells, they are not seen following the infusion of tumor infiltrating lymphocytes or after infusion of T cells that had been engineered to express a TCR against a particular antigen, such as NY-ESO (Brentjens, Blood 118:4817-28,2011; Rapoport et al., Nat Med 21:914-21, 2015; Robbins et al., Clin Cancer Res 21:1019-27, 2015; Sadelain et al., Curr. Opin. Immunol. 21:215-23, 2009; Turtle et al., Curr. Opin. Immunol. 24:633-39, 2012).

Bispecific T Cell Engager (BiTE)

Bispecific T cell engager (BiTE®) antibody constructs are a type of immunotherapy being investigated for fighting cancer by helping the body's immune system to detect and target malignant cells. The modified antibodies are designed to engage two different targets simultaneously, thereby juxtaposing T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. BiTE® antibody constructs help place the T cells within reach of the targeted cell, with the intent of allowing T cells to inject toxins and trigger the cancer cell to die (apoptosis). BiTE® antibody constructs are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO (Blinatumomab) is a bispecific CD19-directed CD3 T cell engager (BiTE®) antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells. Although BiTEs, such as Blinatumomab, activate T cells, they bind to the CD3 chain of TCR rather than TCRα and TCRβ chains, and therefore signaling through BiTEs is not physiological and is not identical to signaling via the normal T cells.

Limitation of CAR T Cells and Bispecific Antibodies

In majority of patients who respond to engineered CAR T cells and Blinatumomab, excessive release of proinflammatory cytokines causes symptoms that include fevers, hypotension, hypoxemia, cardiac dysfunction, kidney failure and electrolyte abnormalities, collectively termed as “Cytokine release syndrome’ (CRS). A number of these patients require admission to intensive care units for pressure support and artificial ventilation. In significant number of cases (up to 50%), CAR T cells and Blinatumomab therapy can lead to neurologic symptoms including tremor, seizures and can be fatal. For example, approximately 50% of patients receiving Blinatumomab in clinical trials experienced neurological toxicities. Severe, life-threatening, or fatal neurological toxicities occurred in approximately 15% of patients, including encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders. Strategies to counteract CRS include treatment with immunosuppressive agents and antibodies to cytokines to block cytokine release and/or activity. Nevertheless, treatment-related deaths have occurred at many institutions. Therefore, there is an unmet and urgent need for new drugs/agents to control the activity of CAR T cells and Blinatumomab.

Dasatinib as an Inhibitor of Physiological T Cell and NK Function

The dual BCR-ABL/Src kinase inhibitor dasatinib is FDA approved for the treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. Src kinases are known to play an important role in physiological T-cell activation. Consistent with this, dasatinib has been shown to profoundly inhibit antigen specific physiological T-cell activation, proliferation, cytokine production, and degranulation in a dose-dependent manner (Schade et al., Blood 111:1366-77, 2008; Weichsel et al., Clin Cancer Res 14:2484-91, 2008). Dasatinib has been also shown to inhibit the activation of NK cells. However, since the CAR modified T cells and BiTE do not engage the physiological T cell receptor (see above), it is not clear whether dasatinib can be used to modulate the activity of CAR-T cells and T cells activated via BiTE.

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the indicated CAR construct targeting CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471] and selected with puromycin. CAR-T cells were pre-incubated with the indicated concentrations of Dasatinib and Imatinib for approximately 30 min at 37° C. The drug-treated and untreated T cells were plated in a white 384-cell plate. RAJI cells stably expressing GLuc were added to the wells containing the T cells at a concentration of 30K cells/30 μl/well to give an E:T ratio was 5:1. Dasatinib (Das) and Imatinib (Imat) were added to the wells to maintain the final concentrations as indicated. After 4 h of co-culture, CAR-T cells mediated induction of lysis of target cells was assayed by increase of GLuc activity by directly injecting 0.5× CTZ assay buffer containing native coeloentrazine. FIG. 35 shows inhibition of CAR CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471]-induced cell death by 50 nM and 100 nM Dasatinib, while Imatinib has no effect.

Effect of Different Tyrosine Kinase Inhibitors on Cell Death Induced by CAR Modified T Cells

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentiviruses expressing the indicated CAR constructs targeting human and CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467] and CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471]). RAJI cells stably expressing GLuc were co-cultured for approximately 4 h with T cells expressing the CARs in the presence and absence of indicated concentrations of the tyrosine kinase inhibitors (TKI) Dasatinib, Imatinib, Nilotinib, Ponatinib and Axitinib essentially as described above. Among these inhibitors, Dasatinib and Ponatinib have been reported to have activity against Src kinase, while the others lack this activity. CAR-T cells mediated induction of lysis of target cells was assayed by increase of GLuc activity as measured by BioTek synergy plate reader by directly injecting 0.5× CTZ assay buffer containing native coeloentrazine (Nanolight). For measurement of maximum cell death, cells were treated with 301 of digitonin (final concentration 30 μg/ml) for approximately 90 min prior to measurement of Glue activity. The % specific lysis was calculated by taking digitonin-induced cell death as 100% and untreated cells as 0%. The formula for % specific lysis calculation is: % Specific lysis=100× [(experimental data)−(spontaneous cell death))]/[(maximum cell death)-spontaneous cell death)]. FIG. 36 shows increase in GLuc activity following co-culture with T cells expressing CD19-specific CARs CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-A13)[SEQ ID NO:1467] and CD8SP-2-CD19MM-(vL-vH)-Myc-BBz-T2A-PAC(062915-D03)[SEQ ID NO:1471] as compared to the uninfected T cells (T-UI) indicating lysis of target cells by the different CD19-CAR-T cells. However, CD19-CAR-T cells induced cell death was partially blocked by treatment with 50 nM Dasatinib and completely blocked by treatment with 100 nM Dasatinib. Similarly, CD19-CAR-T cells-induced cell death was partially blocked by treatment with 100 nM Ponatinib. However, treatment with the indicated doses of Imatinib (50 nM and 500 nM), Nilotinib (10 nM and 100 nM), and Axitinib (1 M and 10 M) had no effect on CAR-T cell induced cell death. These results demonstrate that TKI with activity against Src can effectively block CAR-T cell induced cell death. It is also possible that treatment with higher doses of Imatinib and Nilotinib than those used in the above study could block CAR-T cell-induced cell death.

Dasatinib Blocks Cell Death Induced by CAR Targeting CD22

Human peripheral blood T cells isolated using CD3 magnetic beads were infected with lentivirus expressing the a CAR construct targeting human CD22 (CD8SP-CD22-m971-(vL-vH)-Myc-BBz-T2A-PAC(091515-A02)[SEQ ID NO:1519]) and selected with puromycin. The effect of dasatinib on puromycin selected CD22 CAR-T cells induced death of RAJI-GLuc cells was examined after 96 h of co-culture of effector and target cells. FIG. 37 shows that Dasatinib effectively blocks killing of RAJI-GLuc cells by T cells expressing the CD8SP-CD22-m971-(vL-vH)-Myc-BBz-T2A-PAC(091515-A02)[SEQ ID NO:1519] CAR as determined by GLuc assay.

Dasatinib Blocks Cytotoxicity Induced by Parental NK92MI Cells and Those Modified to Express a CAR

NK92 cells are under clinical development for the treatment of a number of cancers. To test if Dasatinib can block the activity of NK92 cells, NK92MI cells (a derivative of NK92 cells expressing IL2) were co-cultured with K562-Gluc cells in the absence and presence of indicated concentrations of Dasatinib. The target cells were plated a concentration of 100K cells/100 μl/well in a black 96-cell plate and either left untreated or treated with two different doses of Dasatinib (50 nM and 100 nM) for 30 min followed by co-culture of target cells with NK92MIMI effector cells at an E:T ratio of 0.5:1 for 4 h. FIG. 38A shows that Dasatinib blocks NK92 cells mediated death of K562 cells as determined by Gluc assay.

To test if Dasatinib would also block cell death induced by NK92 cells which have been engineered to express a CAR, NK92MI cells were engineered to express CAR CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-EGFP(070814-D06)[SEQ ID NO:3535] targeting CD19. NK92MI cells expressing the CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-EGFP(070814-D06)[SEQ ID NO:3535] CAR were co-cultured with CD19 positive RAJI-GLuc target cells in the absence and presence of Dasatinib for 4 h and cell death measured by GLuc assay. FIG. 38B shows that Dasatinib blocks death of RAJI-GLuc cells by CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-EGFP(070814-D06)[SEQ ID NO:3535] CAR-expressing NK92MI cells as determined by Gluc assay.

Dasatinib Blocks Blinatumomab (Blincyto) Induced Cell Death and Cytokine Production

Effector T-cells (isolated by CD3 microbeads from Miltenyi Biotech) were left untreated or preincubated with 50 nM or 100 nM Dasatinib for 1 hour at 37° C. followed by plating cells in a U-bottom 96-well plates. RAJI-MSCVhygro-Gluc target cells were incubated with a bispecific antibody (Blinatumomab or BLINCYTO; AMGEN) at 100 ng/10⁶cells for 30 min at 37° C. in PBS/2% FBS. Next, Blinatumomab-treated RAJI-Gluc or untreated (control) RAJI-Gluc cells were washed three times in PBS, re-suspended in XVIVO medium and 100 μl (100K) cells were plated per well of a 96-well U-bottom plate (Effector:Target ratio of 1:1) in the absence and presence of indicated concentrations of Dasatinib. Total volume in each well was adjusted to 200 μl with medium. Plates were quickly centrifuged to settle cells, and incubated at 37° C. in a 5% CO₂incubator for 96 hours. For maximum cell death, one hour prior to doing GLuc cell death assay, a total volume of 6 μl of Digitonin (stock 1 mg/ml, Sigma) was added to wells containing target cells alone to achieve a final concentration of 30 g/ml of Digitonin. The plates were centrifuge at 1,000 rpm for 5 min and 50 μl of supernatants were transferred to a Greiner 384-well flat bottom white opaque plate. The luciferase activity was measured by BioTek synergy plate reader by directly injecting 0.5× CTZ assay buffer containing native coeloentrazine (Nanaolight) into the 384 well plates in a well mode. FIG. 39A shows that treatment with Blinatumomab in the presence of T cells result in strong induction of death of RAJI-GLuc cells which is effectively blocked by 100 nM Dasatinib. The supernatant from the above experiment was also assayed for measurement of IFNγ production by ELISA. FIG. 39B shows that co-culture of RAJI-GLuc cells with Blinatumomab in the presence of T cells result in strong induction of IFNγ production which is effectively blocked by 100 nM Dasatinib.

Effect of Ruxolitinib, Fosatamatinib and Alisertib on CAR T Cells and Blinatumomab Induced Cell Death

The effect of Ruxolitinib (JAK-1/2 inhibitor), Fosatamatinib (syk inhibitor) and Alisertib (Aurara Kinase inhibitor) on CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470]-expressing CAR T cells- and Blinatumomab-induced death of RAJI-pLenti-GLuc cells was studied using the assay as described above. FIG. 40A shows no significant toxic effect of the various drugs on RAJI-pLenti-Gluc cells that had not been co-cultured with CAR T cells. FIG. 40B shows significant induction of cell death, as measured by increase in Gluc activity, when RAJI-pLenti-Gluc cells are incubated with the CAR-T cells. FIG. 40B also shows mild to modest inhibition of -CAR-T cell-induced death of RAJI-pLenti-GLuc cells by Ruxolitinib, Fosatamatinib and Alisertib as compared to cells treated with media (Med) alone. Dasatinib was used as a positive control and led to significant inhibition of CAR-T cell-induced death of RAJI cells. FIG. 40C shows that the above compound have only a minimal effect on Blinatumomab induced cell death mediated by T cells at the indicated concentrations.

Effect of A-770041, Saracatinib, Avasimibe on CAR T Cells- and Blinatumomab-Induced Cell Death

A-770041 is a selective small molecule inhibitor of LCK, one of the 8 members of the src family, that is required for T cell activation and IL2 production (Burchat et al., Bioorg Med Chem Lett 16:118-22, 2006). A770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300 fold selective against Fyn, the other src family kinase involved in T cell signaling. Saracatinib (AZD0530) is a src family that can be administered orally. Avasimibe is an inhibitor of ACAT1, a key cholesterol esterification enzyme that has been shown to augment anti-tumor response of CD8 cells.

The effect of A-770041, Saracatinib and Avasimibe on CD19Bu12(vL-vH)-BBz-Pac-P08 expressing CAR T cells- and Blinatumomab-induced death of RAJI-pLenti-GLuc cells was studied next using the assay as described above. FIG. 41A shows the release of Gluc in cells treated with the indicated drugs in the presence of media alone without any CAR-T cells. FIG. 41B shows near complete inhibition of CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470] CAR-T cells induced death of RAJI-pLenti-GLuc cells by A-770041 at 100 nM and 200 nM while Saracatinib had no significant effect. Dasatinib was used as a positive control in the above experiment and as expected blocked CAR-T cells induced cell death. Avasimibe had no significant effect on CAR-T cells induced cell death at 100 nM but completely blocked it at 1 μM. FIG. 41C shows that treatment with 100 nM A770041 partially blocked cell death induced by combination of Blinatumomab with T cells while treatment with 200 nM A770041 led to complete inhibition. Similarly, treatment with 1 μM Avasimibe blocked Blinatumomab induced cell death mediated by T cells. Collectively, the above studies demonstrate that inhibitors of LCK kinase can block the effect of CAR-T cells and Blinatumomab and therefore can be used for the treatment of cytokine release syndrome and neurological complications associated with treatment with CAR-T cells and Blinatumomab.

Generation of CAR Constructs Coexpressing scFv Targeting IL6R and IL6R

One of the major limitations of CAR therapy is cytokine release syndrome (CRS). One approach currently being used in clinical practice to control CRS is administration of anti-IL-6R monoclonal antibody tocilizumab. To control CRS associated with CAR, we constructed exemplary CARs against CD19 (CD8SP-FMC63(vL-vH)-BBz-P2A-IgHSP-IL6R-M83(vL-vH)-Flag-T2A-PAC(011315-K04)[SEQ ID NO:1763])) and MPL (CD8SP-161(vL-vH)-BBz-P2A-IgHSP-IL6R-M83(vL-vH)-Flag-T2A-EGFP(012015-129)[SEQ ID NO:1746])) which expresses a scFv against IL6R, designated M83, along with a C-terminal Flag tag. To control CRS, we also constructed exemplary CARs against CD19 (CD8SP-FMC63(vL-vH)-BBz-P2A-IgHSP-IL6-19A(vL-vH)-Flag-T2A-PAC(011315-H06)[SEQ ID NO:1762]) and MPL (CD8SP-161(vL-vH)-BBz-P2A-IgHSP-IL6-19A(vL-vH)-Flag-T2A-EGFP(011315-F02)[SEQ ID NO:1745]) which co-expresses an scFv against IL6, designated IL6-19A. The scFv fragments in these constructs are separated from the CAR fragment by a P2A cleavable linker. Jurkat-NFAT-EGFP (J-N-G) cells were stably transduced with the lentivirus encoding the CAR constructs CD8SP-FMC63(vL-vH)-BBz-P2A-IgHSP-IL6-19A(vL-vH)-Flag-T2A-PAC(011315-H06)[SEQ ID NO:1762] and CD8SP-FMC63(vL-vH)-BBz-P2A-IgHSP-IL6R-M83(vL-vH)-Flag-T2A-PAC(011315-K04)[SEQ ID NO:1763]. The parental and CAR-expressing Jurkats were subsequently cocultured with RAJI cells and induction of EGFP expression monitored by FACS analysis after 4 h. FIG. 42A shows that coculturing of Jurkat cells expressing CD8SP-FMC63(vL-vH)-BBz-P2A-IgHSP-IL6-19A(vL-vH)-Flag-T2A-PAC(011315-H06)[SEQ ID NO:1762] with RAJI led to increase in EGFP expression as compared to cells that had not been exposed to RAJI cells. Essentially similar results were obtained with Jurkats expressing the CAR construct CD8SP-FMC63(vL-vH)-BBz-P2A-IgHSP-IL6R-M83(vL-vH)-Flag-T2A-PAC(011315-K04)[SEQ ID NO:1763]. No increase in EGFP expression was observed in parental Jurkats (J-N-G-P) without or with culturing with RAJI (FIG. 42B). Thus, a CAR can be coexpressed with a scFV against IL6 and IL6R from a single vector without loss of activity.

Due to their small size, one of the limitations of the scFv is their short half-life due to their rapid clearance by the kidneys. Therefore, we also constructed a CAR against MPL (161) that expresses a bispecific antibody consisting of a camel-derived IL6R single chain antibody (vHH) designated 304 which is fused via a (GGGGS)x3 linker to a single chain camel-derived antibody (vHH) against human serum albumin (Alb8). The IL6R-Alb8 cassette carries a human IgH signal peptide at the N-terminus and a Flag epitope tag at the C-terminus. The secreted bispecific IL6R-304-Alb8 antibody will bind to human serum albumin through its Alb8 region, which will prevent its excretion via the kidneys and thereby prolong its half-life.

CAR Expressing Fx06 Peptide to Block Increased Vascular Leakiness During CRS

Capillary leak syndrome is another major complication of CARs. A natural plasmin digest product of fibrin, peptide BB15-42 (also called FX06), has been shown to significantly reduce vascular leak (Groger et al., PLoS ONE 4:e5391, 2009). We generated vectors that coexpress CARs targeting CD19 or MPL with FX06 peptide. To facilitate extracellular secretion of FX06, a signal peptide derived from human IgH was fused to its N-terminus. The coexpression of FX06 peptide with CARs will help ameliorate the capillary leak syndrome seen as part of cytokine release syndrome following infusion of CAR modified T cells.

Jurkat-NFAT-EGFP cells were stably transduced with the lentivirus CD8SP-FMC63-(vL-vH)-BBz-P2A-IgHSP-Fx06-Flag-T2A-PAC(012115-N04)[SEQ ID NO:1764] that expresses FMC63 CAR against CD19 along with FX06. The parental and CAR expressing Jurkats were subsequently cocultured with RAJI cells and induction of EGFP expression monitored by flow cytometry. Coculturing of Jurkat-NFAT-EGFP cells expressing CD8SP-FMC63-(vL-vH)-BBz-P2A-IgHSP-Fx06-Flag-T2A-PAC(012115-N04)[SEQ ID NO:1764] with RAJI led to increase in EGFP expression as compared to cells that had not been exposed to RAJI cells. Essentially similar results were obtained upon culture with Bv173 and NALM6 cells. Thus, a CAR can be expressed along with FX06 from a single vector without loss of activity.

CARs Targeting Multiple Diverse Antigens

We next generated lentiviral constructs encoding for CARs targeting many diverse antigens that are overexpressed in cancer and other diseased causing or disease associated cells. The lentiviruses were generated and used to infect the Jurkat-NFAT-EGFP reporter cell line. The Jurkat-NFAT-GFP cells were engineered to express the different CARs and backbone targeting the different antigens and were tested for their ability to activate NFAT-dependent EGFP reporter upon coculture with the target cells expressing their respective target antigen. The Jurkat-NFAT-EGFP (parental) cells were used as control. The results with different CARs are summarized in the following summary Table 28. A CAR is considered positive in the assay in case the CAR-expressing Jurkat-NFAT-GFP cells show greater % GFP positive cells when cultured with the target cell line as compared to parental Jurkat-NFAT-GFP cells. Thus, the Jurkat-NFAT-GFP cells expressing the CAR CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-cFLIP-L-Flag-T2A-PAC(092215-A06)[SEQ ID NO:1754] showed greater induction of EGFP expression when co-cultured with RAJI cell as compared to EGFP expression induced in parental Jurkat-NFAT-EGFP cells upon co-culture with RAJI cells. These results also demonstrate that cFLIP-L, an agent known to block activation induced cell death, can be co-expressed with a CAR without adversely affecting its signaling activity. The results in Table 28 demonstrate the functional activity of several conventional CAR II constructs comprising 41BB costimulatory domain and CD3z activation domain and targeting novel antigens, such as PTK7, DLL3, cMET, TSHR, CD22, Muc1/MHC class I complex, tyrosinase/MHC class I complex. The data in Table 28 also demonstrate the functional activity of several backbone 1 constructs comprising a conventional CAR I and K13-vFLIP and targeting novel antigens, such as CD34, CD179b, CLEC5A, CSF2RA, CD200R, LAMP1, TROP2, TnAg, CDH6, CDH17, CDH19, GD3, GFRalpha4, Her2, IL11Ra, IL13Ra2, NYBR-1, Slea, and TGFBR2. Additionally, several bispecific constructs, such as those targeting EGFR and CEA and those targeting cMet and Her3 were positive in this assay. Essentially a similar experimental approach can be used to test the functional activity of other CARs and backbones described in Tables 19-22.

TABLE 28

Exemplary CARs positive on Jurkat-NFAT-GFP Assay

Positive Cell Line on

No.
Target
SEQUENCE NAME
co-culture assay

1
CD34
CD8SP-CD34-hu4C7-(vL-vH)-Myc-z-P2A-K13-Flag-
HL60

T2A-PAC(051616-I02)[SEQ ID NO: 992]

2
CD179b
CD8SP-CD179b-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-
HL60

PAC(051716-N05)[SEQ ID NO: 1012]

3
CD200R
CD8SP-CD200R-huDx182-(vL-vH)-Myc-z-P2A-K13-
HEL

Flag-T2A-PAC(051716-W05)[SEQ ID NO: 1190]

4
CDH6
CD8SP-CDH6-NOV710-(vL-vH)-Myc-z-P2A-K13-
SKOV3

Flag-T2A-PAC(051716-I05)[SEQ ID NO: 1016]

5
CDH7
CD8SP-CDH6-NOV712-(vL-vH)-Myc-z-P2A-K13-
SKOV3

Flag-T2A-PAC(051716-J05)[SEQ ID NO: 1017]

6
CDH17
CD8SP-CDH17-PTA001A4-(vL-vH)-Myc-z-P2A-K13-
LoVo

Flag-T2A-PAC(051716-M06)[SEQ ID NO: 1018]

7
CDH19
CD8SP-CDH19-4B10-(vL-vH)-Myc-z-P2A-K13-Flag-
MEL624

T2A-PAC(051716-U05)[SEQ ID NO: 1180]

8
CLEC5A
CD8SP-CLEC5A-3E12A2-(vL-vH)-Myc-z-P2A-K13-
Kasumi

Flag-T2A-PAC(051016-F06)[SEQ ID NO: 1022]

9
CSF2RA
CD8SP-CSF2RA-Ab1-(vL-vH)-Myc-z-P2A-K13-Flag-
THP1

T2A-PAC(051616-G01)[SEQ ID NO: 1041]

10
CSF2RA
CD8SP-CSF2RA-Ab6-(vL-vH)-Myc-z-P2A-K13-Flag-
THP1

T2A-PAC(051616-H05)[SEQ ID NO: 1040]

11
EGFR & CEA
CD8SP-EGFR1-vHH-Gly-Ser-Linker-CEA1-vHH-
Hela

Myc-z-P2A-K13-Flag-T2A-PAC(040716-O08)[SEQ

ID NO: 1049]

12
GD3
CD8SP-GD3-KM-641-(vL-vH)-Myc-z-P2A-K13-Flag-
MEL624

T2A-PAC(051016-D04)[SEQ ID NO: 1065]

13
GFRa4
CD8SP-GFRa4-P4-10-(vL-vH)-Myc-z-P2A-K13-Flag-
LAN5

T2A-PAC(051316-L02)[SEQ ID NO: 1067]

14
GFRa4
CD8SP-GFRa4-P4-10-(vL-vH)-Myc-z-P2A-K13-Flag-
LAN5, TT

T2A-PAC(051716-L05)[SEQ ID NO: 1067]

15
Her2
CD8SP-Her2-Hu4D5-(vL-vH)-Myc-z-P2A-K13-Flag-
MCF7

T2A-PAC(050516-I03)[SEQ ID NO: 1084]

16
IL11Ra
CD8SP-IL11Ra-8E2-Ts107-(vL-vH)-Myc-z-P2A-K13-
K562

Flag-T2A-PAC(050516-D01)[SEQ ID NO: 1099]

17
IL13Ra
CD8SP-IL13Ra2-Hu108-(vL-vH)-Myc-z-P2A-K13-
U87MG

F1ag-T2A-PAC(050516-F04)[SEQ ID NO: 1102]

18
LAMP1
CD8SP-LAMP1-humab1-2-(vL-vH)-Myc-z-P2A-K13-
L363, U266

Flag-T2A-PAC(051716-T05)[SEQ ID NO: 1104]

19
cMET-Her3
CD8SP-cMET-171-vHH-Gly-Ser-Linker-Her3-21F06-
U266; MCF7

vHH-Myc-z-P2A-K13-Flag-T2A-PAC(041116-

B05)[SEQ ID NO: 1116]

20
MPL
CD8SP-2-MPL-111-(vL-vH)-Myc-z-P2A-K13-Flag-
HEL

T2A-PAC(040716-M02)[SEQ ID NO: 1120]

21
NYBR1
CD8SP-NYBR1-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-
L363

PAC(051716-Q05)[SEQ ID NO: 1131]

22
Slea
CD8SP-SLea-5B1-(vL-vH)-Myc-z-P2A-K13-Flag-
LAN5

T2A-PAC(051716-X05)[SEQ ID NO: 1149]

23
TGFBetaR2
CD8SP-TGFBR2-Ab1-(vL-vH)-Myc-z-P2A-K13-Flag-
NALM6

T2A-PAC(051716-O06)[SEQ ID NO: 1158]

24
Tim1
CD8SP-TIM1-HVCR1-ARD5-(vL-vH)-Myc-z-P2A-
A549; SKOV3

K13-Flag-T2A-PAC(051716-P05)[SEQ ID NO: 1161]

25
TnAg
CD8SP-TnAg-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-
K562

PAC(051616-F05)[SEQ ID NO: 1162]

26
TROP2
CD8SP-TROP2-ARA47-HV3KV3-(vL-vH)-Myc-z-
PC3

P2A-K13-F1ag-T2A-PAC(051716-G05)[SEQ ID

NO: 1165]

27
CD23
CD8SP-CD23-p5E8-(vL-vH)-Myc-BBz-T2A-
L1236

PAC[SEQ ID NO: 1727]

27
CD19
CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-PAC(112014-
RAJI, NALM6

A13)[SEQ ID NO: 1467]

27
CD19
CD8SP-FMC63(vL-vH)-BBz-P2A-IgHSP-IL6-
RAJI

19A(vL-vH)-Flag-T2A-PAC(011315-H06)[SEQ ID

NO: 1762]

27
CD19
CD8SP-FMC63(vL-vH)-Myc-BBz-P2A-cFLIP-L-Flag-
RAJI, NALM6, Jeko1,

T2A-PAC(092215-A06)[SEQ ID NO: 1754]
MOLM13

27
CD19
CD8SP-FMC63-(vL-vH)-BBz-P2A-IgHSP-Fx06-Flag-
RAJI, Bv173, NALM6

T2A-PAC(012115-N04)[SEQ ID NO: 1764]

27
CD19
CD8SP-FMC63(vL-vH)-BBz-P2A-IgHSP-IL6R-
RAJI, NALM6, U266

M83(vL-vH)-Flag-T2A-PAC(011315-K04)[SEQ ID

NO: 1763]

27
CD19
CD8SP-FMC63(vL-vH)-BBz-P2A-IgHSP-IL6-
RAJI, NALM6

19A(vL-vH)-Flag-T2A-PAC(011315-H06)[SEQ ID

NO: 1762]

27
CD22
CD8SP-CD22-m971-(vL-vH)-Myc-BBz-T2A-
RAJI, NALM6

PAC(091515-A02)[SEQ ID NO: 1519]

27
CD324
CD8SP-CD324-hSC10-17-(vL-vH)-Myc-BBz-T2A-
MDAMB-231

PAC(052516-A07)[SEQ ID NO: 1555]

27
DLL3
CD8SP-DLL3-hSC16-56-(vL-vH)-Myc-BBz-T2A-
SKMEL31, SKMEL37,

PAC(052516-C07)[SEQ ID NO: 1585]
LAN5

27
DLL3
CD8SP-DLL3-hSC16-13-(vL-vH)-Myc-BBz-T2A-
LAN5, SKMEL31,

PAC(052516-D07)[SEQ ID NO: 1584]
SKMEL317

27
GCC
CD8SP-GCC-5F9-(vL-vH)-Myc-BBz-T2A-PAC[SEQ
HCT116

ID NO: 1728]

27
MPL
CD8SP-MPL-161-(vL-vH)-Myc-BBz-T2A-
HEL, RAJI-MPL

PAC(021015-R07)[SEQ ID NO: 1658]

27
MPL
CD8SP-2-MPL-111-(vL-vH)-Myc-BBz-T2A-
HEL

PAC[SEQ ID NO: 1660]

27
Muc1/MHC
CD8SP-Muc1-D6-M3B8-(vL-vH)-Myc-BBz-T2A-
SKOV3

class I
PAC(052316 A02)[SEQ ID NO: 1665]

27
PTK7
CD8SP-PTK76-10-2-(vL-vH)-Myc-BBz-T2A-
LAN5

PAC(052516-E07)[SEQ ID NO: 1684]

27
TSHR
CD8SP-TSHR-KB1-(vL-vH)-Myc-BBz-T2A-
RAJI

PAC(052616-E05)[SEQ ID NO: 1709]

27
Tyrosinase
CD8SP-Tyros-TA2-(vL-vH)-Myc-BBz-T2A-PAC[SEQ
MEL624

ID NO: 1714]

Use of PI3K Inhibitors to Expand T Cells Expressing Conventional CARs and Backbones 1-62

Human peripheral blood T cells will be isolated using CD3 magnetic beads and infected with lentiviruses expressing the CAR constructs (SEQ ID NO: 11 1614-1B05) targeting CD 19. Cells will be left unselected or selected with puromycin and expanded using the standard protocol described previously using CD3/CD28 beads and IL2 but in the absence or presence of dual PI3K/mTOR inhibitor PF-04691502 (0.10 μM to 0.5 μM). NSG mice (Jackson Lab) will be sub-lethally irradiated at a dose of 175 cGy. 24 hours post irradiation (day2), mice will be injected with 2.5×10⁴RAJI cells via tail-vein. On day 3, the mice (n=5 for each group) will be treated with 5 million T cells that had been infected with the indicated CAR encoding lentiviruses and expanded in the absence or presence of PF-04691502. Control mice (n=5) will be injected with 5 million uninfected T cells. Mice are given human IL2 (400 IU i.p.) on alternate days till the death of all mice in control group. The median survival of mice which received CAR-T cells expanded in the presence of PI3K/AKT inhibitor is expected to be higher than the mice which received CAR-T cells that had been expanded in the absence of PI3K/AKT inhibitors.

Use of IL7 Along with CAR-T Cells

The study will be conducted as described in the preceding example with the exception that starting 1 day after the infusion of CAR-T cells, mice will be administered exogenous recombinant human IL-7 at a dosage of 200 ng/mouse by intraperitoneal injection three times, while the control mice receive normal saline. The mice that receive IL-7 are expected to reject their tumor and survive longer than the control mice.

Use of Autologous CAR-T Cells for Adoptive Cell Therapy

CAR-T cells of the invention can be used for adoptive cell therapy. As an example, patients with relapsed Acute lymphocytic Leukemia, chronic lymphocytic leukemia, or high-risk intermediate grade B-cell lymphomas may receive immunotherapy with adoptively transferred autologous CAR-T cells targeting CD19. A leukapheresis product collected from each patient will undergo selection of CD3-positive T lymphocytes using the CliniMACS Prodigy® System from Miltenyi Biotec and following the manufacturer's recommendations. Cells will be transduced with clinical-grade CD8SP-CD19Bu12-(vL-vH)-Myc-BBz-T2A-PAC(082815-P08)[SEQ ID NO:1470]. Alternatively, clinical grade CD8SP-CD19Bu12-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC[SEQ ID NO:930] virus will be used. The selection and expansion of the CAR-T cells will occur in a closed system. After the resulting cell products has undergone quality control testing (including sterility and tumor specific cytotoxicity tests), they will be cryopreserved. Meanwhile, following leukapheresis, study participants will commence with lymphodepletive chemotherapy (30 mg/m²/day fludarabine plus 500 mg/m²/day cyclophosphamide×3 days). One day after completion of their lymphodepleting regimen, the previously stored CAR-T cell product will be transported, thawed and infused at the patient's bedside. The study participant may also receive CAR-transduced lymphocytes infused intravenously followed by high-dose (720,000 IU/kg) IL-2 (Aldesleukin; Prometheus, San Diego, CA) every 8 hours to tolerance. The dose of CAR-T product will vary from 1×10⁴CAR+ve CD3 cells/kg to 5×10⁹CAR+ve CD3 cells/kg as per the study protocol. The CAR-T product may be administered in a single infusion or split infusions. Research participants will be pre-medicated at least 30 minutes prior to T cell infusion with 15 mg/kg of acetaminophen P.O. (max. 650 mg) and diphenhydramine 0.5-1 mg/kg I.V. (max dose 50 mg). The study participant will optionally receive daily injections of human IL-2. Clinical and laboratory correlative follow-up studies will then be performed at the physician's discretion, and may include quantitative RT-PCR studies for the presence of CD19-expressing ALL/lymphoma cells and/or the adoptively transferred T cells; FDG-PET and/or CT scans; bone marrow examination for disease specific pathologic evaluation; lymph node biopsy; and/or long-term follow up per the guidelines set forth by the FDA's Biologic Response Modifiers Advisory Committee that apply to gene transfer studies. Essentially a similar approach will be used to treat other diseases using autologous immune cells (e.g., T cells) that have been engineered to express the conventional CARs of the invention or conventional CARs with accessory module (i.e. backbones 1-62) where the CAR targets an antigen or antigens expressed on the disease causing or disease-associated cells.

Use of Autologous T Cells Expressing Conventional CARs and Backbones 1-62 Targeting Multiple Antigens for Adoptive Cell Therapy

Patients with many different diseases, including infectious diseases (e.g., HIV1, EBB, CMV, HTLV1, etc), degenerative diseases (e.g., Alzheimer's disease), allergic diseases (e.g., chronic idiopathic urticarial) and multiple cancers will be enrolled in an IRB approved phase I clinical trial of immunotherapy with adoptively transferred autologous CAR-T cells coexpressing K13-vFLIP (backbone 1) targeting different disease-causing or disease-associated antigens. The CAR for different diseases will be selected based on the known expression of their target antigen in the disease-causing or disease-associated cells. Where possible, the expression of the CAR target on the disease causing or disease associated cells will be confirmed by binding with Antigen binding domain-GGS-NLuc fusion protein in which the antigen binding domain of the CAR is fused to non-secretory form of NLuc protein via a flexible linker. Alternatively, immunohistochemistry or flow cytometry using commercially available antibodies will be used to confirm the expression of the target antigen of the CAR on disease-causing or disease-associated cells. T cells will be collected from the subjects using leukopheresis, transduced with the appropriate lentivirus vectors and expanded ex vivo using CD3/CD28 beads in a closed system. After the resulting cell products have undergone quality control testing (including sterility and tumor specific cytotoxicity tests), they will be cryopreserved. CAR-T cell products will be administered to the subjects as described in the preceding example. Clinical and laboratory correlative follow-up studies can then be performed at the physician's discretion.

Use of an mTOR Inhibitor RAD001 in Combination with T Cells Expressing Conventional CARs and Backbones 1-62

The study is conducted as described in the preceding examples with the exception that starting 1 day after the infusion of CAR-T cells, study participants will be administered an mTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001, at a dosage that provides a target trough level 0.1 to 3 ng/ml, where the trough level” refers to the concentration of a drug in plasma just before the next dose, or the minimum drug concentration between two doses.

Use of Ibrutinib in Combination with T Cells Expressing Conventional CARs and Backbones 1-62

The study will be conducted as described in the preceding examples with the exception that starting 1 day after the infusion of CAR-T cells, study participants will be administered oral ibrutinib at dose of 140 mg/d to 420 mg/d. It is expected that the study participant receiving ibrutinib will have lower incidence of severe cytokine release syndrome as compared to participants who received CAR-T cells without ibrutinib.

CAR-T Cell Hepatic Arterial Infusion

In addition to intravenous infusion, T cells expressing the conventional CARs and backbones 1-62 described in this invention can be infused intra-arterially to provide high concentration of CAR-T cells in a local area or organ involved with a disease. In the following example, this approach is used in case of a patient with hepatic metastases from a gastrointestinal cancer which expresses Folate Receptor alpha (FR1). Essentially a similar approach can be used for intra-arterial infusion of T cells expressing conventional CARs and backbones 1-62 targeting other tumor antigens.

A mapping angiogram will be performed via a right common femoral artery approach at baseline. The gastroduodenal and right gastric arteries, in addition to other potential sources of extrahepatic perfusion, will be embolized with microcoils. The same arterial access procedure will be carried out for administration of T cells expressing the construct CD8SP-FR1-huMov19-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC[SEQ ID NO:1060]. The T cells will be collected from the patient on day 0 and will be infected with lentivirus encoding the construct CD8SP-FR1-huMov19-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC[SEQ ID NO:1060] and expanded as described in the previous examples. The CAR-T cells will be given in a dose escalating fashion on day 14 (10⁷CAR-T cells), day 28 (10⁸CAR-T cells) and day 44 (10⁹CAR-T cells). The CAR-T cells will be injected manually via a 60 cc syringe at a rate of <2 cc/second. The total volume of infusion will be approximately 100 cc. Angiography with calibrated contrast rate will be performed after the first infusion of 50 cc and at completion of the CAR-T infusion to confirm preserved arterial flow. Infusions will be delivered into the proper hepatic artery when possible. Certain patients may have aberrant hepatic arterial anatomy, where either the right or left hepatic artery does not arise from the proper hepatic artery. In such cases the dose of CAR-T cells will be split based upon lobar volume calculations. In such cases, split doses will be delivered separately into the right and left hepatic arteries to ensure proportionate CAR-T delivery to both hepatic lobes.

Intraperitoneal Administration of CAR-T Cells

CAR-T cells can also be administered intraperitoneally, essentially as described in Koneru M et al (Journal of Translational Medicine; 2015; 13:102). In the following example, this approach is used in patients with peritoneal involvement with ovarian cancer which expresses Folate Receptor alpha (FR1). Essentially a similar approach can be used for intra-peritoneal infusion of CAR-T cells targeting other tumor antigens.

A screening informed consent will be offered to patients with recurrent high-grade serous ovarian cancer to test their cancer for the expression of FR1. After expression of FR1 is confirmed by immunohistochemistry, then patients will have a leukapheresis product obtained from peripheral blood. Excess platelet and red blood cell contamination will be removed from the leukapheresis product and the product will be frozen. In the treatment phase of the study, the leukapheresis product will be thawed and washed. Subsequently, CD3+ T cells will be isolated from the thawed leukapheresis product by magnetic separation using CD3/CD28 beads. Activated T cells will be lentivirally transduced with the CD8SP-FR1-huMov19-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC[SEQ ID NO:1060] construct and further expanded using CD3/CD28 bead expansion protocol.

Patients with recurrent high-grade serous ovarian, primary peritoneal or fallopian tube carcinoma shown to express FR1 antigen confirmed by immunohistochemistry (IHC) analysis of banked (paraffin embedded) or freshly biopsied tumor will potentially be eligible for the study.

The phase I dose-escalation dosing will be used in the trial. Cohorts of 3-6 patients will be infused with escalating doses of modified T cells to establish the maximum tolerated dose (MTD). There will be four planned dose levels: 3×10⁵, 1×10⁶, 3×10⁶, and 1 ×10⁷CAR-T cells/kg. Cohorts I and II will be treated with 3×10⁵CAR-T cells/kg but patients in cohort II will also receive lymphodepleting cyclophosphamide. Cohorts II-V will receive escalating doses of the modified T cells following pretreatment with cyclophosphamide. Lymphodepleting cyclophosphamide dosed at 750 mg/m²will be administered 2-4 days prior to the initial T cell infusion. A standard 3+3 dose escalation schema will be followed.

An IP catheter will be placed prior to T cell infusion. Patients will be admitted to the inpatient unit of the hospital prior to their first infusion of CAR T cells and will remain hospitalized until at least 3 days after the second infusion of CAR T cells. The first cohort of patients to be treated, and the first patient treated in each subsequent cohort, will be admitted to the intensive care unit (ICU); subsequent patients may be admitted to the medical oncology inpatient service (subject to the clinical judgment of the treating physician).

Patients will receive a single dose of lymphodepleting cyclophosphamide (750 mg/m²IV) chemotherapy 2 to 4 days prior to initiating treatment with CAR-modified T cells. The transduced T cells will be quality tested for number, purity, viability, and sterility prior to infusion. All patients will receive 50% of the genetically modified T cell dose intravenously. Patients will be closely monitored for toxicities. One to 3 days later, the remaining dose of T cells will be administered as an IP infusion. At least 3 patients will be treated at dose level 1, with an accrual of no more than 2 patients per month within each dose level. All patients treated in the preceding cohort will be observed for a minimum of 4 weeks from the day of the initial T cell infusion before escalation to the next cohort occurs. Blood samples will be obtained from all patients prior to and following treatment to assess toxicity, therapeutic effects, and survival of the genetically modified T cells.

Use of CAR-T Cells for Intratumoral Injection

CAR-T cells can also be administered intra-tumorally, essentially as described in Brown C E, et al, Clin Cancer Res. 2015 September 15; 21(18): 4062-4072. In the following example, this approach will be used in case of patients with recurrent glioblastoma (GBM) which expresses IL13Ra2. Essentially a similar approach can be used for intra-tumoral injection of T cells expressing conventional CARs or conventional CARs expressing accessory modules (backbones 1-62) targeting other tumor antigens.

A pilot safety and feasibility study will be conducted to test CD8SP-IL13Ra2-Hu108-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC(050516-F04)[SEQ ID NO:1102] expressing T cells in recurrent GBM. All participating patients will be required to give written informed consent. The clinical protocol will be approved by the University of Southern California Institutional Review Board and conducted under an Investigational New Drug Application, and registered at ClinicalTrials.gov. Eligible patients will include adults (18-70 yrs) with recurrent or refractory unifocal supratentorial grade III or IV glioma whose tumors do not show communication with ventricles/CSF pathways and are amenable to resection. Participation in this trial will be independent of IL13Ra2 (or IL13Ra2) tumor antigen status. Patients will be enrolled following initial diagnosis of high-grade glioma (WHO grade III or IV), at which time they will undergo leukapheresis for collection of peripheral blood mononuclear cells (PBMC). These cells will be used to engineer T cells to express the construct CD8SP-IL13Ra2-Hu108-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC(050516-F04)[SEQ ID NO:1102] containing the puromycin resistance gene (PAC) following infection with the corresponding lentiviral vector as described in the previous examples. Alternatively, the CAR-T cells could be generated following infection with a retroviral vector or using sleeping beauty transposon or by transfection of IVT mRNA. Subsequently, the release tested therapeutic CAR-T cells will be cryopreserved and stored for later use. At the time of first recurrence of the tumor, the research participant will undergo resection of tumor along with placement of a Rickham reservoir/catheter. Concurrently, the therapeutic CAR-T cells will be thawed, re-expanded in vitro using CD3/CD28 beads based rapid expansion protocol. Following recovery from surgery and post baseline MR imaging, the CAR-T cells will be administered directly into the resection cavity via the indwelling catheter, essentially as described (Brown C E, et al, Clin Cancer Res. 2015 21(18): 4062-4072). Cells will be manually injected into the Rickham reservoir using a 21 gauge butterfly needle to deliver a 2 mL volume over 5-10 minutes, followed by 2 mL flush with preservative free normal saline over 5 minutes. The protocol treatment plan will specify an intra-patient dose escalation schedule with a target of 12 CAR T cell doses administered intracranially over a 5 week period comprised of weekly treatment cycles. During cycles 1, 2, 4 and 5, T cell infusions will be performed on days 1, 3 and 5 of the cycle week, and week 3 will be a rest cycle. For safety, in cycle 1 an intrapatient dose escalation strategy, with CAR T cell doses of 10⁷, 5×10⁷and 10⁸cells per infusion administered on days 1, 3 and 5 respectively, will be used and this will be followed by 9 additional CAR T cell infusions of 10⁸cells over 4 weeks. Imaging to assess response will be performed during the week 3 rest cycle and after week 5. The guidelines provided in the NCI Common Toxicity Criteria version 2.0 (https://ctep.ifo.nih.gov/1) will be followed for the monitoring of toxicity and adverse event reporting

Use of CAR-T Cells for Ex-Vivo Purging of Bone Marrow or Peripheral Blood Stem Cell Preparation Prior to Transplant

CAR T cells can be used to purge the bone marrow or peripheral blood stem cell preparation of cancer cells prior to stem cell transplant. In the following example, CD8SP-CS1-HuLuc64-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC[SEQ ID NO:1032] expressing T cells will be used to purge bone marrow or peripheral blood stem cells obtained from a patient with multiple myeloma prior to autologous stem cell (or bone marrow) transplant.

Patient will undergo leukopheresis to collect peripheral blood mononuclear cells (PBMC). T cells will be purified using CD3 beads. These cells will be used to engineer T cells to express the CD8SP-CS1-HuLuc64-(vL-vH)-Myc-z-P2A-K13-Flag-T2A-PAC[SEQ ID NO:1032] CAR following infection with the corresponding lentiviral vector as described in the previous examples. Subsequently, the release-tested therapeutic CAR-T cells will be cryopreserved and stored for later use or used fresh. Bone marrow cells and peripheral blood progenitor cell products will be collected from a patient with multiple myeloma following standard procedures. For mobilization of peripheral blood stem cells, patients will receive cyclophosphamide, 3 gm/m²followed by G-CSF, 10 μg/kg subcutaneously each day beginning 24 h after cyclophosphamide until pheresis is complete. Peripheral blood stem cells will be collected once the peripheral blood CD34+-cell count is 15 cells/μl. The collection goal will be to process three blood volumes per day until a minimum of 2.0 times 10⁶CD34+ cells/kg are reached after processing. The bone marrow and peripheral blood stem cell products will be optionally depleted of Red Blood Cells and/or enriched for CD34 expressing cells using CliniMACS Prodigy® System from Miltenyi Biotec and following the manufacturer's recommendations. The products will be used for ex-vivo purging fresh or cryopreserved. For purging, the bone marrow or peripheral blood stem cell products will be cocultured with thawed CAR-T cells at an effector to target ratio ranging from 5:1 to 30:1 for 4 to 24 hours in XVIVO medium (Lonza) supplanted with 100 IU recombinant human-IL2. Cells will be cultured at 37° C., in a 5% CO2 humidified incubator. At the end of the coculture period, an aliquot of the cells will be taken for sterility and quality testing (including measurement of CFU-GM and flow cytometry for CD34 and CD138 positive cells). The remaining sample will be administered intravenously to the patient who has previously received myeloablative chemotherapy (e.g., high dose Melphalan in two divided doses of 70 mg/m²for a total dose of 140 mg/m²).

REFERENCES

1. Bertin, J., et al. (1997), Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis, Proc Natl Acad Sci USA, 94(4), 1172-6.

2. Brentjens, R. J. (2011), Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817-28.

3. Burchat, A., D. W. Borhani, D. J. Calderwood, G. C. Hirst, B. Li, and R. F. Stachlewitz (2006), Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection, Bioorg Med Chem Lett, 16(1), 118-22.

4. Chaudhary, P. M., A. Jasmin, M. T. Eby, and L. Hood (1999), Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins, Oncogene, 18(42), 5738-46.

5. Chugh, P., H. Matta, S. Schamus, S. Zachariah, A. Kumar, J. A. Richardson, A. L. Smith, and P. M. Chaudhary (2005), Constitutive NF-kappaB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice, Proc Natl Acad Sci USA, 102(36), 12885-90.

6. Groger, M., et al. (2009), Peptide Bbeta (15-42) preserves endothelial barrier function in shock, PLoS ONE, 4(4), e5391.

7. Hu, S., C. Vincenz, M. Buller, and V. M. Dixit (1997), A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis, J Biol Chem, 272(15), 9621-4.

8. Jeang, K. T. (2001), Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B, Cytokine Growth Factor Rev, 12(2-3), 207-17.

9. Liu, L., M. T. Eby, N. Rathore, S. K. Sinha, A. Kumar, and P. M. Chaudhary (2002), The Human Herpes Virus 8-encoded Viral FLICE Inhibitory Protein Physically Associates with and Persistently Activates the Ikappa B Kinase Complex, J Biol Chem, 277(16), 13745-51.

10. Matta, H., V. Punj, S. Schamus, L. Mazzacurati, A. M. Chen, R. Song, T. Yang, and P. M. Chaudhary (2008), A nuclear role for Kaposi's sarcoma-associated herpesvirus-encoded K13 protein in gene regulation, Oncogene, 27(39), 5243-53.

11. Rapoport, A. P., et al. (2015), NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma, Nat Med, 21(8), 914-21.

12. Ren, T., W. Dong, Y. Takahashi, D. Xiang, Y. Yuan, X. Liu, T. P. Loughran, Jr., S. C. Sun, H. G. Wang, and H. Cheng (2012), HTLV-2 Tax immortalizes human CD4+ memory T lymphocytes by oncogenic activation and dysregulation of autophagy, J Biol Chem, 287(41), 34683-93.

13. Robbins, P. F., et al. (2015), A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response, Clin Cancer Res, 21(5), 1019-27.

14. Robek, M. D., and L. Ratner (1999), Immortalization of CD4(+) and CD8(+) T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone, J Virol, 73(6), 4856-65.

15. Roybal, K. T., L. J. Rupp, L. Morsut, W. J. Walker, K. A. McNally, J. S. Park, and W. A. Lim (2016), Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits, Cell, 164(4), 770-9.

16. Sadelain, M., R. Brentjens, and I. Riviere (2009), The promise and pitfalls of chimeric antigen receptors, Curr. Opin. Immunol., 21, 215-23.

17. Schade, A. E., G. L. Schieven, R. Townsend, A. M. Jankowska, V. Susulic, R. Zhang, H. Szpurka, and J. P. Maciejewski (2008), Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation, Blood, 111(3), 1366-77.

18. Sieburg, M., A. Tripp, J. W. Ma, and G. Feuer (2004), Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 tax oncoproteins modulate cell cycle progression and apoptosis, J Virol, 78(19), 10399-409.

19. Thome, M., et al. (1997), Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors, Nature, 386(6624), 517-21.

20. Turtle, C. J., M. Hudecek, M. C. Jensen, and S. R. Riddell (2012), Engineered T cells for anti-cancer therapy, Curr. Opin. Immunol., 24, 633-39.

21. Weichsel, R., et al. (2008), Profound inhibition of antigen-specific T-cell effector functions by dasatinib, Clin Cancer Res, 14(8), 2484-91.

22. Wu, C. Y., L. J. Rupp, K. T. Roybal, and W. A. Lim (2015), Synthetic biology approaches to engineer T cells, Curr Opin Immunol, 35, 123-30.

23. Wu, C. Y., K. T. Roybal, E. M. Puchner, J. Onuffer, and W. A. Lim (2015), Remote control of therapeutic T cells through a small molecule-gated chimeric receptor, Science, 350(6258), aab4077.

24. Zhan, J., B. Felder, A. R. Ellison, A. Winters, H. Salimi-Moosavi, S. Scully, J. R. Turk, and P. Wei (2013), Novel anti-c-Mpl monoclonal antibodies identified multiple differentially glycosylated human c-Mpl proteins in megakaryocytic cells but not in human solid tumors, Monoclonal antibodies in immunodiagnosis and immunotherapy, 32(3), 149-61.

The various methods and techniques described above provide a number of ways to carry out the application. Of course, it is to be understood that not necessarily all objectives or advantages described can be achieved in accordance with any particular embodiment described herein. Thus, for example, those skilled in the art will recognize that the methods can be performed in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other objectives or advantages as taught or suggested herein. A variety of alternatives are mentioned herein. It is to be understood that some preferred embodiments specifically include one, another, or several features, while others specifically exclude one, another, or several features, while still others mitigate a particular feature by inclusion of one, another, or several advantageous features.

Furthermore, the skilled artisan will recognize the applicability of various features from different embodiments. Similarly, the various elements, features and steps discussed above, as well as other known equivalents for each such element, feature or step, can be employed in various combinations by one of ordinary skill in this art to perform methods in accordance with the principles described herein. Among the various elements, features, and steps some will be specifically included and others specifically excluded in diverse embodiments.

Although the application has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the embodiments of the application extend beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and modifications and equivalents thereof.

Preferred embodiments of this application are described herein, including the best mode known to the inventors for carrying out the application. Variations on those preferred embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. It is contemplated that skilled artisans can employ such variations as appropriate, and the application can be practiced otherwise than specifically described herein. Accordingly, many embodiments of this application include all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the application unless otherwise indicated herein or otherwise clearly contradicted by context.

All patents, patent applications, publications of patent applications, and other material, such as articles, books, specifications, publications, documents, things, and/or the like, referenced herein are hereby incorporated herein by this reference in their entirety for all purposes, excepting any prosecution file history associated with same, any of same that is inconsistent with or in conflict with the present document, or any of same that may have a limiting affect as to the broadest scope of the claims now or later associated with the present document. By way of example, should there be any inconsistency or conflict between the description, definition, and/or the use of a term associated with any of the incorporated material and that associated with the present document, the description, definition, and/or the use of the term in the present document shall prevail.

It is to be understood that the embodiments of the application disclosed herein are illustrative of the principles of the embodiments of the application. Other modifications that can be employed can be within the scope of the application. Thus, by way of example, but not of limitation, alternative configurations of the embodiments of the application can be utilized in accordance with the teachings herein. Accordingly, embodiments of the present application are not limited to that precisely as shown and described.

Various embodiments of the invention are described above in the Detailed Description. While these descriptions directly describe the above embodiments, it is understood that those skilled in the art may conceive modifications and/or variations to the specific embodiments shown and described herein. Any such modifications or variations that fall within the purview of this description are intended to be included therein as well. Unless specifically noted, it is the intention of the inventors that the words and phrases in the specification and claims be given the ordinary and accustomed meanings to those of ordinary skill in the applicable art(s).

The foregoing description of various embodiments of the invention known to the applicant at this time of filing the application has been presented and is intended for the purposes of illustration and description. The present description is not intended to be exhaustive nor limit the invention to the precise form disclosed and many modifications and variations are possible in the light of the above teachings. The embodiments described serve to explain the principles of the invention and its practical application and to enable others skilled in the art to utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed for carrying out the invention.

While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that, based upon the teachings herein, changes and modifications may be made without departing from this invention and its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as are within the true spirit and scope of this invention.

The present application and invention further includes the subject matter of the following numbered clauses. [00794] 1. A chimeric antigen receptor comprising: an antigen-specific targeting domain; a hinge region; a transmembrane domain; and an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment or an antigen specific ligand.

2. The chimeric antigen receptor of clause 1, further comprising one or more co-stimulatory domains.

3. The chimeric antigen receptor of clause 1, wherein the antigen-specific targeting domain targets any one or more of MPL receptor, CD19, GRP-78, CD79b, Lym-1, Lym-2, FLT3 or combinations thereof.

4. The chimeric antigen receptor of clause 1, wherein the hinge region comprises any one or more of human CD8 hinge region, an Fc fragment of an antibody or a functional equivalent, fragment or derivative thereof, a hinge region of an antibody or a functional equivalent, fragment or derivative thereof, a CH2 region of an antibody, a CH3 region of an antibody, an artificial spacer sequence and combinations thereof.

5. The chimeric antigen receptor of clause 4, wherein the hinge region comprises any one or more of (i) a hinge, CH2 and CH3 region of IgG4, (ii) a hinge region of IgG4, (iii) a hinge and CH2 region of IgG4, (iv) a hinge region of CD8a, (v) a hinge, CH2 and CH3 region of IgG1, (vi) a hinge region of IgG1, (vi) a hinge and CH2 region of IgG1, or (vii) combinations thereof.

6. The chimeric antigen receptor of clause 1, wherein the transmembrane domain comprises any one or more of a transmembrane domain of a zeta chain of a T cell receptor complex, CD28, CD8a, and combinations thereof.

7. The chimeric antigen receptor of clause 2, wherein the co-stimulatory domain comprises a signaling domain from any one or more of CD28, CD137 (4-1BB), CD134 (OX40), Dap10, CD27, CD2, CD5, ICAM-1, LFA-1, Lck, TNFR-I, TNFR-II, Fas, CD30, CD40 and combinations thereof.

8. The chimeric antigen receptor of clause 1, wherein the intracellular signaling domain comprises a signaling domain of one or more of a human CD3 zeta chain, FcgRIII, FceRI, a cytoplasmic tail of a Fc receptor, an immunoreceptor tyrosine-based activation motif (ITAM) bearing cytoplasmic receptors, and combinations thereof.

9. The chimeric antigen receptor of clause 1, further coexpressed with scFv or vHH or bispecific antibody specific for cytokines or cytokine receptor.

10. The chimeric antigen receptor of clause 9, wherein the coexpressed cytokines or cytokine receptor are any one or more of IL-6, IL6R, IFNγ, TNFα or combinations thereof.

11. The chimeric antigen receptor of clause 1, further coexpressing the peptide FX06 so as to mitigate capillary leak associated with CAR therapy.

12. The chimeric antigen receptor of clause 1, further coexpressing a viral or cellular signaling protein to stimulate T cell activation, proliferation and/or to block T cell activation induced cell death.

13. The chimeric antigen receptor of clause 12, wherein the signaling protein is any one or more of vFLIP K13, vFLIP MC159, vFLIP MC160, vFLIP E8, HSV vFLIP, BHV vFLIP, Herpes virus Mecaca vFLIP, cFLIP/MRITα, cFLIP-p22, HTLV1 Tax, HTLV2 Tax, HTLV1-Tax RS mutant, HTLV2 Tax RS mutant, Tio, StpC, Tip or mutants or combinations thereof.

14. The chimeric antigen receptor of clause 12, wherein the signaling protein is expressed in a constitutive or inducible manner.

15. The chimeric antigen receptor of clause 12, where activity of the signaling protein is controlled at the post-translational level by administration of a compound.

16. The chimeric antigen receptor of clause 12, where the signaling protein is expressed in fusion with one or more copies of FKBP domain.

17. The chimeric antigen receptor clause 16, where the activity of the protein is controlled at the post-translational level by administration of therapeutically effective amount of a chemical compound that induces dimerization of the FKBP domain.

18. A chimeric antigen receptor of clauses 1 or 3, where the antigen specific targeting domain targeting MPL comprises a scFV fragment of 161, 175, 178, AB317, 12E10, or VB22 or human TPO or mouse TPO or mutants thereof.

19. A chimeric antigen receptor of clauses 1 or 3, where the antigen specific targeting domain targeting CD19 comprises a scFV fragment of CD19Bu12 or CD19MM or mutants thereof.

20. A chimeric antigen receptor of clauses 1 or 3, where the antigen specific targeting domain targeting CD79b comprises a scFV fragment of huMA79bv28 or CD79b-2F2 or mutants thereof.

21. A chimeric antigen receptor of clauses 1 or 3, wherein the antigen specific targeting domain targeting FLT3 comprises a scFV fragment of NC7 or mutants thereof.

22. A chimeric antigen receptor of clauses 1 or 3, wherein the antigen specific targeting domain targeting Lym1 antigen comprises a scFV fragment of Lym1 or mutants thereof.

23. A chimeric antigen receptor of clauses 1 or 3, wherein the antigen specific targeting domain targeting Lym2 antigen comprises a scFV fragment of Lym2 or mutants thereof.

24. A chimeric antigen receptor of clauses 1 or 3, wherein the antigen specific targeting domain targeting GRP-78 comprises a scFV fragment of GRP78-GC18 or mutants thereof.

25. A polynucleotide encoding the chimeric antigen receptor of any one of clauses 1, 12 and 18-24.

26. A polypeptide encoding the polynucleotide of clause 25.

27. A vector comprising the polynucleotide of clause 25.

28. A virus comprising the polynucleotide of clause 25.

29. The virus of clause 25, wherein the virus is a retrovirus, an adenovirus, an adeno-associated virus, a lentivirus, a pox virus or a herpes virus.

30. A genetically engineered cell, comprising the polynucleotide of clause 25 or the chimeric antigen receptor of clause 1.

31. The genetically engineered cell of clause 30, wherein the cell is a T-lymphocyte (T-cell).

32. The genetically engineered cell of clause 31, wherein the cell is a naïve T cells, a central memory T cells, an effector memory T cell, Treg or a combination thereof.

33. The genetically engineered cell of clause 21, wherein the cell is a natural killer (NK) cell, a hematopoietic stem cell (HSC), an embryonic stem cell, or a pluripotent stem cell.

34. A pharmaceutical composition comprising: any one or more of the chimeric antigen receptor of clause 1, the polynucleotide of clause 25, the polypeptide of clause 26, the vector of clause 27, the virus of clause 28, the genetically engineered cell of clause 30 and combination thereof; and a pharmaceutically acceptable carrier.

35. A method for treating cancer comprising: providing the composition of clause 34; and administering a therapeutically effective amount of the composition to the subject so as to treat cancer.

36. The method of clause 35, wherein the cancer is blood cancer.

37. The method of clause 36, wherein the blood cancer is any one or more of acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, lymphoma, multiple myleoma and acute lymphocytic leukemia.

38. A method of controlling the activity of T cells expressing the CAR of clause 1, comprising administering a therapeutically effective amount of an inhibitor of tyrosine kinases wherein the kinase are selected from the src family of kinases.

39. A method of treating CRS associated with treatment with CAR-T cells comprising administering a therapeutically effective amount of an inhibitor of tyrosine kinases wherein the kinase are selected from the src family of kinases.

40. A method of treating neurological complications associated with treatment with CAR-T cells comprising administering a therapeutically effective amount of an inhibitor of tyrosine kinases wherein the kinase are selected from the src family of kinases.

41. The method of clauses 38, 39 or 40, wherein the inhibitor inhibits the src kinase Lck.

42. The method of clause 41, wherein the inhibitor is Dasatinib.

43. The method of clause 41, wherein the inhibitor is Ponatinib.

44. The method of clause 41, wherein the inhibitor is A-770041.

45. A method of controlling the activity of T cells activated by a BiTE comprising administering a therapeutically effective amount of an inhibitor of tyrosine kinases wherein the kinase are selected from the src family of kinases.

46. A method of treating CRS caused by treatment with BiTE comprising administering a therapeutically effective amount of an inhibitor of tyrosine kinases wherein the kinase are selected from the src family of kinases.

47. A method of treating neurological complications caused by treatment with BiTE comprising administering a therapeutically effective amount of an inhibitor of tyrosine kinases wherein the kinase are selected from the src family of kinases.

48. The method of clauses 45, 46 or 47, wherein the BiTE is Blinatumomab (Blincyto).

49. The method clauses 45, 46 or 47, wherein the inhibitor inhibits the src kinase Lck.

50. The method of clause 49, wherein the inhibitor is Dasatinib.

51. The method of clause 49, wherein the inhibitor is Ponatinib.

52. The method of clause 49, wherein the inhibitor is A-770041.

53. A method of treating complications of CAR and BiTE comprising administering a therapeutically effective amount of an inhibitor of tyrosine kinases wherein the kinase are selected from the src family of kinases.

54. The method of clause 53, wherein the BiTE is Blinatumomab (Blincyto).

55. The method of clause 53, wherein the inhibitor inhibits the src kinase Lck.

56. The method of clause 55, wherein the inhibitor is Dasatinib.

57. The method of clause 55, wherein the inhibitor is Ponatinib.

58. The method of clause 55, wherein the inhibitor is A-77041.

59. A method of treating CRS, neurological complications and other complications of CAR-T cells and BiTE by administration of therapeutic effective amount of Avasimibe.

60. A method of immortalizing human peripheral blood mononuclear cells and T cells by expressing vFLIP K13 in the cells.

61. The method clause 60, wherein vFLIP K13 is expressed constitutively.

62. The method clause 60, wherein vFLIP K13 is expressed in a manner that allows control of its activity at the transcriptional or post-translational level.

63. The method clause 60, wherein vFLIP K13 is expressed in fusion with one or more domains of FKBP.

64. The method of clause 63, where FKBP-vFLIP-K13 fusion protein further comprises an N-terminal Myristoylation sequence.

65. The method of clause 64, wherein the activity of FKBP-vFLIP-K13 fusion protein is controlled by a chemical that induces dimerization of FKBP domain and activation of K13 induced NF-κB signaling.

66. The method of clause 65, wherein the peripheral blood mononuclear cells and/or T cells expressing K13 or FKBP-K13 fusion protein are administered to a patient.

67. The method of clause 65, wherein the peripheral blood mononuclear cells and/or T cells expressing K13 or FKBP-K13 fusion protein also co-express a chimeric antigen receptor, a native T cell receptor or an artificial T cell receptor.

68. A method of immortalizing human peripheral blood mononuclear cells and T cells by expressing HTLV2 Tax protein in the cells.

69. A method of immortalizing human peripheral blood mononuclear cells and T cells by expressing HTLV2 Tax RS mutant protein in the cells.

70. The method clauses 68 or 69, wherein the HTLV2 Tax and its RS mutants are expressed in fusion with one or more domains of FKBP.

71. A method of clause 70, wherein FKBP-Tax fusion proteins further comprises an N-terminal Myristoylation sequence.

72. The method of clause 71, wherein the activity of FKBP-Tax and FKBP-Tax-RS fusion proteins is controlled by a chemical that induces dimerization of FKBP domain and activation of Tax induced NF-kB signaling.

73. The method of clause 72, wherein the peripheral blood mononuclear cells and/or T cells expressing HTLV2 Tax HTLV2 Tax-RS mutant, FKBP-Tax, or FKBP-Tax-RS mutant proteins are administered to a patient.

74. The method of clause 72, wherein the peripheral blood mononuclear cells and/or T cells expressing HTLV-Tax or FKBP-Tax fusion protein further co-express a chimeric antigen receptor, a native T cell receptor or an artificial T cell receptor.

	Number	Date	Country
Parent	16089106	Sep 2018	US
Child	18525506		US

CHIMERIC ANTIGEN RECEPTORS TARGETING CANCER

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

CROSS-REFERENCE TO RELATED APPLICATIONS

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Provisional Applications (1)

Continuations (1)